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Abstract
Postpartum haemorrhage (PPH) is the main cause of maternal deaths worldwide. 
Despite the global effort to improve maternal health, developing countries are still far 
away from the proposed target of reducing maternal mortality. Therefore, a great 
deal of research is extensively going on globally to find out and improve appropriate 
treatment and technologies for low- resourced settings to prevent PPH and the work 
in this thesis on misoprostol was part of it.
Misoprostol is a uterotonic which can be given via different routes such as oral, 
rectal, vaginal and sublingual. Also, it is stable at ambient temperature and can be 
administered by non-skilled attendants. However, it has several adverse drug 
reactions but the increase in body temperature (fever) was the most common and 
irritating side effect. Therefore, reaching a balance between efficacy and safety was 
the overall aim of this thesis.
A systematic review was conducted to examine the incidence and the risk of fever 
after using misoprostol for prevention of PPH. Data showed that the occurrence of 
misoprostol induced fever was dose related and more with the sublingual route. Also, 
there was a variation in the incidence of fever in relation to the populations. To find 
out a low and effective dose of misoprostol with better adverse drug reaction profile, 
a randomised controlled trial was conducted to compare the effect of three different 
doses of sublingual misoprostol on the uterine activity. The choice of a suitable 
catheter to be used in this trial was done after conducting a validity study to compare 
two types of the catheters. The results of the trial showed that the three doses of 
misoprostol produced similar levels of uterine activity but the severity of fever was 
dose related. A genetic association with misoprostol induced fever was hypothesised 
as populations variations was documented in many RCTs and in the systematic 
review.
A pharmaco genetic study was carried out to examine the role of single nucleotides 
polymorphisms (SNPs) in two populations from Ecuador and Liverpool. There was 
an association between three SNPs in the prostaglandin transporters encoding genes 
and the increase in body temperature in the Ecuadorian population and this was not
23
reported in Liverpool population. Overall, while maintaining the efficacy of 
misoprostol, doses and routes can be optimised for the use in different populations to 
reduce the adverse drug reactions.
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Chapter 1. Literature review
This chapter will review the literature on misoprostol as a medication used for many 
obstetrics and gynaecological indications including the prevention and treatment of 
PPH. Finally, it will examine closely a common side effect of misoprostol: fever. 
First we will discuss drug-induced increases in body temperature in general and then 
highlight the mechanism and the molecular aspects of prostaglandin-induced fever 
and the possibility of investigating this issue by using pharmacogenetic approach. 
Also, it will explore the literature for up to date information about PPH including 
causes, prevention and treatment options
I. Misoprostol in obstetrics and gynaecology
1. Introduction
Misoprostol (15-deoxy-16-hydroxy-16-methyl PGEi) was developed in 1973 as a 
stable synthetic form of prostaglandin Ei analogue. It was originally developed for 
the treatment of gastric ulcers, using its anti-secretory properties. In addition, 
misoprostol has mucosal protective properties, which led to its use for the prevention 
of non-steroidal anti-inflammatory drug-induced peptic ulcers.
Prostaglandins have a potent effect on the female reproductive system. Misoprostol, 
being a prostaglandin analogue, is not different in this respect. It has become one of 
the most important drugs in obstetrics and gynaecology owing to its cervical ripening 
and uterotonic effects. However, its use in obstetrics and gynaecology is still off- 
label in many countries over the world and until recently, was not approved by the 
Food and Drug Administration (FDA) for use in pregnant women. In spring 2002, 
the FDA made a change to the misoprostol label: the statement that misoprostol is 
contraindicated in pregnancy was removed and a labour and delivery section was 
added.
In addition to the potent effect of misoprostol on uterine contractility and cervical 
ripening, misoprostol has the advantages of being cheap, widely available and stable 
at room temperature. This has made it suitable for use in developing countries and
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became a central focus of obstetrics and gynaecology research over the past two 
decades.
This section will review the structure and chemistry of misoprostol, 
pharmacokinetics, uses, doses and side effects of misoprostol use in obstetrics and 
gynaecology.
2. Structure and chemistry of misoprostol
The rapid metabolic degradation of natural prostaglandins promoted the development 
of analogues suitable for clinical use. The most clinically important analogue is 
misoprostol. Its structure differs from the natural prostaglandin E by the presence of 
a methyl ester at C-1 and a methyl group and hydroxyl group at C-16 rather than at 
C-15. The addition of a methyl group at C-16 and the movement of the hydroxyl 
group from C-15 to C-16 improves oral activity and the safety profile of the drug as 
well as increasing its duration of action whereas, the presence of methyl ester group 
at C-l increases the potency of its anti-secretory effect. Figure 1 shows the structure 
of natural prostaglandin Ei and misoprostol.
Misoprostol
Figure 1. The structure of misoprostol and naturally occurring prostaglandin (PGE()
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3. Misoprostol pharmacokinetics
Misoprostol is a prostaglandin Ei analogue. It has a molecular weight of 382.54, 
exists as a mixture of two diastereomers and is stabilised by a dispersion on hydroxyl- 
propyl-methylcellulose (Karim 1987). Misoprostol is rapidly de-esterified to 
misoprostol acid, the biologically active metabolite. As a result of this rapid 
metabolic conversion, plasma concentrations of misoprostol are usually undetectable 
(Schoenhard, Oppennann & Kohn 1985). However, the absorption and metabolism of 
misoprostol has been studied using the 17, 18-tritium-labeled compound (Karim 
1987). The absorption of misoprostol is rapid and extensive and most likely occurs in 
the stomach. Studies in many species including human found that the absorption of 
radioactivity takes place within 1.5 hours (Schoenhard, Oppennann & Kohn 1985). 
Plasma concentration of misoprostol acid reaches its peak in less than 30 minutes and 
its elimination half-life is 25-30 minutes after oral administration (Karim 1987).
Misoprostol acid is metabolised by beta oxidation to inactive dinor and tetranor 
metabolites (Figure 2, (Karim 1987). Less than 1% of the dose is excreted in urine as 
unchanged misoprostol and its acid metabolite. Around 80% of the total radioactivity 
is excreted in the urine and faeces with in the first 24 hours of drug administration 
(Schoenhard, Oppennann 8c Kohn 1985). The presence of radioactivity in the faeces 
is attributed to the biliary excretion of misoprostol but not to the unabsorbed drug. 
This shows that at least 88% of the oral radio-labelled misoprostol is absorbed (Karim 
1987).
The serum protein binding of radio-labelled misoprostol is 81-89% and was 
concentration-independent. There was no evidence that misoprostol is accumulated in 
red blood cells. Misoprostol has no effect on the hepatic mixed function oxidase 
(cytochrome P-450). Therefore, misoprostol does not affect the metabolism of other 
medicines that are metabolised by this enzyme system (Schoenhard, Oppennann & 
Kohn 1985). There was no accumulation in the plasma following multiple doses of 
misoprostol and steady state plasma concentrations were achieved within 2 days 
(Karim 1987).
28
L SC-29333; Misoprostol
n. SC-30695; Misoprostol Acid
m. SC-41947; CM nor Add MstaboUts
COOH
IV. SC-41411; Tatra nor Add MstsbolHs
COOH
Figure 2. Structure of misoprostol (I), its biologically active misoprostol acid (II), and 
inactive dinor (HI), and tetranor (IV) acid metabolites (From Karim A. 1987)
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4. Pharmacokinetic profiles of various routes of administration of 
misoprostol
Studying and understanding the pharmacokinetics properties of different routes of 
administration of misoprostol can help to define the appropriate doses and design the 
best regimens for different clinical applications. Misoprostol is rapidly absorbed and 
undergoes extensive first-pass metabolism (de-esterification) to produce misoprostol 
acid which is active clinically and detectable in plasma. The peak concentration (C 
max), time to peak concentration (T max) and the area under the serum concentration 
versus time curve (AUC) are the three pharmacokinetic properties which have been 
studied. C max represents how well the drug is being absorbed; T max reflects how 
rapidly the drug can be absorbed whereas the AUC indicates the total exposure to the 
drug (the bioavailability). The peak plasma concentration of misoprostol acid is 
approximately 30 minutes after the oral ingestion of misoprostol tablets and decrease 
rapidly thereafter. Food or antacids ingestion with misoprostol decreases its 
bioavailability. Metabolism of misoprostol takes place first in the liver. It does not 
induce the hepatic cytochrome enzyme P-450 enzyme system (Goldberg, Greenberg 
& Barney 2001) and less than 1% of its active metabolite is excreted in urine (Foote 
etal., 1995).
Misoprostol is commercially available as an oral tablet in 100 meg un-scored and 
200 meg scored tablets. However, other routes of administration including vaginal, 
rectal, buccal and sublingual have been extensively used for obstetrics and 
gynaecological indications.
4.1. Oral route
The pharmacokinetics properties of oral misoprostol have been studied and 
compared with other routes of administration. Following oral administration, 
misoprostol is rapidly absorbed from the gastrointestinal tract. After a single oral 
dose of 400 meg misoprostol, the plasma misoprostol levels increase rapidly and 
reach the highest level at about 30 minutes, decline rapidly by 120 minutes and 
remain low thereafter (Khan et al., 2004; Meckstroth et ah, 2006; Tang & Ho 2006; 
Tang et al., 2002); Figure 3).
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Therefore, the oral route might be most appropriate when a rapid action is required as 
in cases of cervical dilatation prior to surgical procedures.
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Figure 3. Mean plasma misoprostol acid concentration overtime after sublingual, oral, 
vaginal and moist vaginal misoprostol (Tang et al., 2002)
A slow -release (SR) form of oral misoprostol has been formulated (Chen et al., 
2000). Higher doses of the SR form of misoprostol are needed to reach adequate 
serum levels to provide an effect on uterine contractility, while lower doses have 
almost no effect. 800 meg of SR misoprostol has been studied and compared to 400 
meg of oral misoprostol (Fiala et al., 2005a). The SR form of misoprostol 
demonstrated a lower peak plasma level but a longer lasting elevated serum levels up 
to at least 12 hours in comparison to other routes of administration which suggested 
using SR misoprostol as an alternative to repeated administration of oral or vaginal 
misoprostol (Aronsson et al., 2007; Fiala et al., 2005a)(Figure 4).
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Figure 4. Mean Serum concentrations of MPA over time, (x) slow release;a sublingual, 
▲ , vaginal. Reproduced from (Aronsson, A., et al., 2007)
4.2. Vaginal route
Although misoprostol tablets were originally developed for oral use, they are also 
effective when administered vaginally. After placing a tablet in the vagina, the 
plasma concentration increase gradually reaching a maximum level after 70-80 
minutes (Figure 3). After this, it slowly declines with a still detectable drug level 
after 6 hours (Zieman et al., 1997). The bioavailability of vaginal misoprostol (area 
under the curve) is greater than for oral routes (Zieman et al., 1997) which might 
explain its effectiveness for stimulating uterine contraction, particularly for clinical 
indications where a longer duration of action is preferable, like medical abortion.
After vaginal administration it is not uncommon to find remnants of the tablets after 
some time. This indicates that absorption is variable and incomplete. Several 
attempts have been made to improve the absorption of vaginal misoprostol. Singh 
and his colleague used acetic acid to dissolve the tablets for women undergoing
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termination of pregnancy, but it did not make a difference (Singh et ah, 1999). The 
bioavailability of vaginal misoprostol was improved by adding water to the tablets 
and it was not significantly different from the sublingual route (Tang et ah, 2002). 
On the other hand, progressive decline in the peak plasma level of misoprostol acid 
was observed in women with significant vaginal bleeding (Tang et ah, 2009).
4.3. Sublingual route
The misoprostol tablet is very soluble when it is taken sublingually and is fully 
dissolved within 20 minutes. The time to peak concentration (T max) is about 30 
minutes which is the same for oral administration but significantly shorter than 
following vaginal route of a administration which takes 75 minutes (Tang et ah, 
2002). The sublingual route has the highest serum peak concentration (C max) of 
misoprostol acid compared to vaginal, wet vaginal and oral routes. The sublingual 
route seems to have a quick onset of action with high serum concentration (C max). 
Hence, it might be more useful in cases where rapid onset of action is required, such 
as postpartum haemorrhage or cervical priming.
After administration of 400 meg sublingual misoprostol, the achieved peak serum 
levels were significantly higher than those of oral and vaginal administration 
(Aronsson et ah, 2007). This may be explained by the avoidance of the first -pass 
effect by the liver as well as the rapid absorption through the sublingual mucosa. 
This might be a result of abundant blood supply under the tongue and a relatively 
neutral pH (Tang et ah, 2002).
The bioavailability of sublingual misoprostol at 6 and 12 horns, measured as (AUC 
360 and AUC 720) are significantly larger than that for vaginal or oral administration 
(Tang et al., 2002) (Aronsson et ah, 2007). The AUC 350 after oral and vaginal 
treatment are almost similar and constitute only 54% and 58% respectively of that 
after sublingual administration (Tang et ah, 2002). On the other hand, Zieman et al 
found that the bioavailability is greater for vaginal misoprostol than for oral 
administration (Zieman et ah, 1997). The differences in these studies’ finding can be 
explained by the variation in the vaginal absorption among different women.
33
4.4. Buccal route
In this route of administration, misoprostol tablet is placed between the cheek and the 
teeth to be absorbed through the buccal mucosa. The tablets dissolve more rapidly in 
the sublingual compartment than in the buccal mucosa, it takes more than 30 minutes 
when administered buccally (Tang, Gemzell-Danielsson & Ho 2007). The T max is 
about 75 minutes after buccal administration which is similar to that after vaginal 
treatment. The serum concentration curve after buccal administration is similar to the 
vaginal route and is clearly different from the sublingual route (Figure 5) 
(Meckstroth et ah, 2006). The structure of the buccal mucosa has more similarities to 
the vagina than the sublingual compartment, with a large surface area and thick 
epithelium. In contrast, the sublingual mucosa is thinner and more vascular 
(Meckstroth et ah, 2006). Therefore, buccal administration of misoprostol can be an 
alternative to the vaginal route particularly in cases of leakage or profuse bleeding.
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Figure 5. Mean serum levels of misoprostol acid in pg/mL for four epithelial routes of 
misoprostol administration over 5 hours. Error bars represent standard deviation 
(Meckstroth et ah, 2006)
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4.5. Rectal route
There are limited pharmacokinetics studies of rectal administration of misoprostol, 
and these give variable findings. Meckstroth and his colleagues found that serum 
misoprostol acid levels after rectal administration peaked at around 15 minutes, 
earlier than buccal and vaginal routes of administration, with rapid decline thereafter. 
The area under the curve (AUC) of misoprostol serum concentration after rectal 
treatment is only third of the vaginal route of treatment (Meckstroth et ah, 2006). In 
contrast, Khan and his colleagues found that plasma concentration peaked at between 
45-120 minutes (mean 71.7 minutes), then gradually declined. By 240 minutes, 
plasma concentration reached 46% of its maximum concentration. AUC240 of rectal 
misoprostol was not significantly different from the oral route whereas vaginal route 
AUC240 was the highest among the three routes (Khan et ah, 2004), Figure 6).
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Figure 6. Mean plasma concentrations of misoprostol acid over time with oral, rectal, 
and vaginal administration. (Error bars represent 1 standard deviation) (Khan et al., 
2004)
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5. Effects of misoprostol on the uterus and the cervix
5.1. Effect on the uterus
Studies on uterine contractility and misoprostol have shown that a sustained level, 
rather than high serum level, is required to develop and maintain regular and 
effective uterine contractions. However, studies have failed to determine the 
threshold level for uterine contractility. This is complicated by the increase in uterine 
sensitivity to prostaglandins with increasing gestation (Tang, Gemzell-Danielsson & 
Ho 2007).
Studies show that a single oral dose of misoprostol can increase uterine tone. In order 
to produce uterine contractions, however, a high sustained plasma level of 
misoprostol is required and this needs repeated doses of oral misoprostol (Aronsson, 
Bygdeman & Gemzell-Danielsson 2004). In contrast, single dose of vaginal 
misoprostol can develop uterine tone due to its prolonged action. Regular uterine 
contractions develop after 1-2 hours and last for at least 4 hours after a single dose 
(Danielsson et ah, 1999).
Larger doses of misoprostol will cause uterine tonus. This occurs more rapidly and 
more markedly after oral and sublingual misoprostol than following vaginal 
treatment. The mean time to maximum tonus is 8 and 11 minutes for oral and 
sublingual treatment respectively while after vaginal treatment, the maximum tonus 
is achieved after 20 minutes of administration. The uterine tonus ends after 1-2 hours 
of oral treatment while after vaginal administration it is slowly replaced with regular 
uterine contractions (Aronsson, Bygdeman & Gemzell-Danielsson 2004). This 
uterine activity is sustained for a longer time after vaginal treatment than after 
sublingual administration. The uterine contractions start to decrease after 4 hours of 
vaginal treatment compared to 3 hours following sublingual administration (Figure
7).
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Figure 7. Uterine activity was measured in Mentevideo Units (MU). The treatment 
groups were as follows: Vaginal (0.4 mg), oral (0.4 mg) and sublingual (0.2 and 0.4 mg). 
Significant differences between the means of the sublingual (0.4 mg) and oral group: 
*/><0.05; (Aronsson, Bygdeman & Gemzell-Danielsson 2004).
The uterine effect of buccal and rectal misoprostol has been studied by (Meckstroth 
et al., 2006). The uterine activity after buccal administration is very similar to 
vaginal route, even though the bioavailability was two times less. Rectal misoprostol 
has got the lowest bioavailability, the lowest uterine activity and the longest mean 
onset of activity (103 minutes) among other routes of administration (Figure 8).
38
2000 i
1800 -
-•—Vaginal Dry 
Vaginal Moist 
• x Buccal 
-a- Rectal
1600 -
D 1400 -
£» 1200 -
1000 •
800 -
600 -
400 -
. i-------
200 -
Time (minutes)
Figure 8. Mean uterine activity in Alexandria Units for four epithelial routes of 
misoprostol administration over five hours. Alexendria Units estimate area under the 
pressure across-time curve for uterine contractions. Error bars represent standard 
deviation. AU, Alexandria Units (Meckstroth et al., 2006)
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5.2. Effect on the cervix
Misoprostol also causes softening of the cervix. It is likely that this is due to a direct 
effect on the cervix as well as secondary to the misoprostol induced uterine 
contractions. The uterine cervix is composed mainly of fibroblast cells and fibrous 
connective tissue which is mainly glycosaminoglycans and collagens. Ripening the 
cervix is an active and complex biochemical process in which collagen is degraded 
through an increase in its solubility and collagenolytic activity (Aronsson et ah, 
2005). Disintegration and dissolution of the cervical collagen fibre may be seen in 
cervical biopsies 2-4 hours after administration of 600 meg vaginal misoprostol (El- 
Refaey et ah, 1994). The mechanism of cervical softening is described as being 
similar to an inflammatory reaction. The influx of inflammatory cells to the cervical 
stroma increases matrix metalloproteinases which lead to degradation of collagen 
and softening of the cervix (Aronsson et ah, 2005).
6. Misoprostol use in obstetrics and gynaecology
6.1. First trimester termination of pregnancy with misoprostol
In the last two decades, medical termination of pregnancy has become a safe 
alternative to surgical methods of termination in early pregnancy. Dilatation and 
curettage (D&C) was the only method used for safe abortion until the second half of 
the twentieth century, and in the 1960s, vacuum aspiration become the standard of 
care. Recently, however, the mifepristone / misoprostol regimen has become more 
widely available and considered to be the gold standard of early pregnancy 
termination (Faundes et al., 2007). A recent study shows that a single dose of vaginal 
misoprostol 800 meg provides a similar success rate to surgical methods of 
termination. In addition, side effects were fewer with misoprostol and this medical 
method of termination was well accepted (Prasad, Kumar & Divya 2008). Many 
studies have been conducted on the use of misoprostol alone for medical abortion. 
However, a direct comparison of regimens is often not possible due to the wide 
variety of inclusion criteria and dosage regimens.
Many publications have shown the effectiveness of vaginal doses of 800 meg of 
misoprostol repeated up to three times. This results in complete abortion in more
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than 60% of cases (Blanchard et al., 2005). Oral misoprostol is less effective than 
vaginal (El-Refaey & Templeton 1994). Therefore, for termination of pregnancy, 
misoprostol should be administer vaginally unless there are reasons to avoid it 
(Blanchard et al., 2005). However, sublingual treatment is a good alternative and 
may be considered as a second choice.
A randomized control trial comparing vaginal and sublingual routes of misoprostol 
has shown that the intervals between vaginal misoprostol doses can be as long as 12 
hours without significant effect on efficiency. On the other hand, sublingual 
misoprostol need more frequent administration, every 3 hours, to achieve a similar 
effectiveness to the vaginal route. However, it may cause more frequent 
gastrointestinal side effects, shivering and hyperthermia (von Hertzen et al., 2007). 
The recommended regimen is therefore 800 meg of vaginal misoprostol administered 
every 6 hours for a maximum of three doses (Faundes et al., 2007).
6.2. Misoprostol to treat early fetal demise in the first trimester
The usual treatment of early fetal demise is suction curettage. However, several 
studies have shown that medical treatment is a safe, effective and acceptable 
alternative (Gronlund et al., 2002; Trinder et al., 2006; Weeks & Danielsson 2006). 
A study comparing 800 meg of oral or vaginal misoprostol for treatment of early 
fetal loss showed that both methods were highly effective and acceptable. However, 
the mean time for expulsion was shorter in the vaginal group. It was 13.7 hours in the 
vaginal group versus 21.04 hours in the oral group (Ngoc et al., 2004). A study 
using a regimen of mifepristone in combination with misoprostol found that 800 meg 
sublingual misoprostol and 800 meg vaginal misoprostol were equally effective in 
inducing complete abortion, but a higher rate of side effects in the sublingual group 
(Tang et al., 2003). Lower doses of sublingual misoprostol have therefore been 
studied in an attempt to find an effective treatment with a low incidence of side 
effects. In a study of 50 women, a regimen of 600 meg of sublingual misoprostol 
every 3 hours for a maximum of three doses was 86% effective for treatment of 
missed abortion (Shaima, Singhal & Rani 2007). Therefore, the recommended 
treatment of early fetal demise is 800 meg vaginal misoprostol every 3 hours for a
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maximum of 2 doses or 600 meg of sublingual misoprostol every three hours 
repeated twice (Gemzell-Danielsson et al.5 2007).
6.3. Treatment of incomplete miscarriage with misoprostol
The use of misoprostol to manage incomplete miscarriage could reduce the cost of 
health care through saving in surgical provider training, anaesthesia, sterilisation, 
hospitalisation and surgical equipment. Misoprostol can be provided at primary 
health care facilities for a low cost which, making it a good option in low-resource 
countries. Furthermore, the less invasive nature of misoprostol treatment makes it 
very acceptable to women worldwide (Blum et ah, 2007b).
A regimen of a single dose of 600 meg misoprostol has been compared with manual 
vacuum aspiration (MVA) for management of incomplete miscamage. Both 
treatment options are effective with success rates of 91% to 96% respectively after 1- 
2 weeks of follow up (Bique et ah, 2007; Weeks et al., 2005). However, misoprostol 
is more acceptable to women than MVA (Shwekerela et al., 2007). The use of double 
doses of 600 meg of misoprostol increases the rate of side effects without clinical 
benefits (Phupong et al., 2004) (Blanchard et al., 2004).
There is now extensive evidence in the literature to support the use of misoprostol for 
treatment of incomplete abortion (Dao et al., 2007) . It has been suggested that it 
should now be considered the first line option for incomplete miscarriage (Gemzell- 
Danielsson, Fiala & Weeks 2007). The recommended regimen is a single dose of 600 
meg of oral misoprostol for women with incomplete miscarriage and uterine size 
equivalent to 12 weeks (Blum et al., 2007b).
6.4. Misoprostol for second trimester termination of pregnancy
Termination of early second trimester pregnancy can be performed by dilatation and 
curettage (D&C) or suction curettage, whereas termination performed late in second 
trimester requires cervical dilatation and fetal extraction or medical induction. 
Surgical procedures may result in severe complications include cervical laceration, 
uterine perforation and injuries to abdominal organs. Medical termination is 
potentially safer. Furthermore, it provides good histological specimens, a factor that 
is important if the termination is for fetal malformations. Medical termination is
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therefore recommended by WHO (WHO 2003) and RCOG (RCOG 2004) using 
mifepristone followed by a prostaglandin analogue.
Several studies have investigated the use of misoprostol for second trimester 
induction of labour (Bhattacharyya et ah, 2006; Carbonell et ah, 2008; Dickinson & 
Evans 2002; Feldman et ah, 2003; Herabutya, Chanrachakul & Punyavachira 2005; 
Pongsatha & Tongsong 2008; Tang et ah, 2004; Wong et ah, 2000). Women 
included in these studies have different duration of gestational age, received variable 
doses of misoprostol at different intervals and various route of administration. In 
addition to individual variations in women’s drug response, the uterus becomes more 
sensitive to misoprostol with increasing gestational age and with fetal death 
(Srisomboon & Pongpisuttinun 1998). Therefore, these studies are difficult to 
compare.
Most of studies have used the vaginal route. However, the regimens were extremely 
variable. Carbonell and his colleagues found that 600 meg of vaginal misoprostol 
given every 6 hours was as effective as 400 meg of misoprostol every 4 hours with 
fetus mean expulsion time of 10.7 hours in the first group and 11.5 hours in the 
second group and the difference was not statistically significant (Carbonell et ah, 
2008). A study conducted by Khazardoost et al (Khazardoost, Hantoushzadeh & 
Madani 2007) concluded that 200 meg of vaginal misoprostol every 6 hours up to 4 
doses was as effective as 400 meg misoprostol, and had less side effects. Even 
though women at earlier gestational age usually require larger doses for termination, 
women in this study responded well to as low doses as 200 meg of misoprostol, even 
though they were all under 16 weeks.
Dickinson and his colleagues conducted a randomised trial of 3 regimens of 
misoprostol for intra uterine fetal death at 14-30 weeks. They found that 400 meg 
vaginal misoprostol 6 hourly provided the optimal regimen, with a shorter delivery 
interval than 200 meg dose and had fewer side effects than the 600 meg dose 
(Dickinson & Evans 2002).
Even though uterine rupture is a serious complication of termination of pregnancy in 
the second trimester, several studies have reported safe use of misoprostol in women 
with scarred uterus (Rouzi 2003; Shammas & Momani 2006; Tarim et ah, 2005). All
43
these studies recommended a careful consideration of doses and intervals for women 
with a scarred uterus. Further studies are essential before using misoprostol as a 
standard method for second trimester termination of pregnancy with a previous 
caesarean section.
There are a variety of successful regimens reported in the literature. In balancing 
efficacy and side effects, a regimen of 400 meg vaginal misoprostol at 3 hours 
intervals for a maximum 5 doses is recommended (Ho et al., 2007). Higher doses 
may be needed for early second trimester abortion and lower doses may be sufficient 
to induce abortion later in the second trimester.
6.5. Misoprostol for intrauterine fetal death
There are a wide variety of clinically effective misoprostol regimens for induction of 
labour* following second and third trimester IUFDs. The doses vary from 50 to 400 
meg given every 3 to 12 hours by different routes of administration (Chittacharoen, 
Herabutya & Punyavachira 2003; Fadalla, Mirghani & Adam 2004; Nakintu 2001; 
Pongsatha & Tongsong 2004). A recent study comparing vaginal, oral and sublingual 
misoprostol found that the induction to abortion interval was significantly shorter in 
the sublingual group compared to the oral and vaginal routes. The doses were 100 
meg given 4 hourly for the three routes of misoprostol (Elhassan, Abubaker & Adam 
2008). Chittacharoen et al (Chittacharoen, Herabutya & Punyavachira 2003) reported 
that 400 meg of oral misoprostol given 4 hourly is more effective than 200 meg 
vaginal misoprostol administered every 12 hours, albeit with more side effects. On 
the other hand, many studies have recommended vaginal misoprostol for treatment of 
IUFD (Jain, Kuo & Mishell 1999; Khazardoost, Hantoushzadeh & Madani 2007; 
Srisomboon & Pongpisuttinun 1998). The required amount of misoprostol decreases 
with increasing gestational age and should be even less in women with IUFDs 
(Srisomboon & Pongpisuttinun 1998). Because of the risk of uterine rupture, it is 
recommended that women with scared uterus should receive lower doses of 
misoprostol and doubling of doses should not happen. Therefore, the recommended 
doses are variable according to the gestational age. From 13-17 weeks, 200 meg 
vaginal misoprostol is required 6 hourly with 4 doses in maximum, 100 meg vaginal 
misoprostol 6 hourly for a maximum of 4 doses is recommended for 18-26 weeks
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and 25-50 meg every 4 hours for a maximum of 6 doses is used for gestational age 
from 27-43 weeks. If the first dose does not produce effective contraction, the second 
dose could be doubled (Gomez Ponce de Leon, Wing & Fiala 2007).
6.6. Misoprostol for induction of labour with a live fetus
Induction of labour can be achieved by many medical and mechanical methods. 
Vaginal dinoprostone is the current gold standard method and is the drug of choice 
for cervical ripening and induction of labour (Weeks et ah, 2007). Misoprostol has 
been used for cervical ripening and induction of labour since 1987. Several studies 
have been conducted to find out the best routes and dosages to reach equilibrium 
between high doses which cause uterine hyperstimulation and low doses which might 
lead to induction failure. Over 100 randomised trials have been reviewed for The 
Cochrane Library. In the review for vaginal misoprostol for induction of labour, 
Hofmeyr and Gulmezoglu (Hofmeyr & Gulmezoglu 2003) found that 25 meg of 
vaginal misoprostol every 2 to 3 hours, 50 meg every 4 hours and 100 meg 6 to 12 
hourly are all more effective than dinoprostone and oxytocin for induction of labour, 
but rates of uterine hyperstimulation increased with high doses. Meconium stained 
liquor is also significantly associated with misoprostol usage. Whether it is due to 
uterine hyperstimulation or due to the direct effect of misoprostol on fetal bowel is 
still not proven.
Alfirevic and Weeks reviewed 41 trials to assess the effectiveness and safety of oral 
misoprostol for induction of labour with viable fetus. In comparison of vaginal 
misoprostol, 50 meg oral misoprostol every 4 to 6 hours seems to decrease the need 
for caesarean section in women with intact membrane. With no significant difference 
in uterine hyperstimulation and meconium stained liquor rates. The authors 
recommended a maximum of 50 meg of oral misoprostol for induction of labour 
(Alfirevic & Weeks 2006).
Titrated oral misoprostol can be made by dissolving one tablet (200 meg) into 200 ml 
of tap water. Hofmeyr and his colleagues (Hofmeyr et al., 2001a) used 20 meg of 
misoprostol every 2 hours while Cheng his colleagues (Cheng, Ming & Lee 2008) 
used 20 meg every 1 hour for 4 doses and adjusted it against individual uterine 
response. This regimen has associated with low incidence of uterine hyperstimulation
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and low caesarean section rate as well as shorter induction to labour interval than 
vaginal misoprostol. Therefore, 20 meg of oral misoprostol solution every 2 hours 
for a maximum of 12 doses has been recommended (Weeks et al., 2007). A 
systematic review of 9 studies with 2937 women concluded that low-dose oral 
misoprostol solution (20 meg) administered every 2 hours seems at least as effective 
as both vaginal dinoprostone and vaginal misoprostol, with lower rates of caesarean 
delivery and uterine hyperstimulation, respectively (Kundodyiwa, Alfirevic & Weeks 
2009).
Few studies have conducted to investigate the effect of buccal and sublingual 
misoprostol for induction of labour. More research is required to establish the 
effectiveness, safety and optimum dosage of buccal and sublingual misoprostol for 
induction and cervical ripening (Muzonzini & Hofmeyr 2004).
Women who have a history of a previous uterine scar are at increased risk of 
ruptured uterus when induced by misoprostol (Wing, Lovett & Paul 1998). The risk 
of uterine rupture with misoprostol was increased in women who attempting vaginal 
birth after caesarean section (VBAC) and who have not had a previous vaginal 
delivery (Smith et al., 2004). A trial of vaginal delivery after previous caesarean 
section has shown that uterine rupture occurred in 5.6% of patients who induced by 
misoprostol which is significantly higher when compared to 0.2% in those who did 
not (Plant, Schwartz & Lubarsky 1999). On the other hand, one study reported no 
uterine rupture in 48 women who had a history of caesarean section and were given 
misoprostol for induction (Choy-Hee & Raynor 2001). However, there is no enough 
evidence for the safety of misoprostol for induction with previous uterine scare 
(Plant, Schwartz & Lubarsky 1999). Therefore, the use of misoprostol is 
contraindicated in this situation.
The recommended doses for induction of labour are 25 meg vaginal misoprostol or 
50 meg of oral misoprostol every 4 hours for a maximum of 6 doses. Another option 
is 20 meg of oral misoprostol solution 2 hourly for a maximum of 12 doses (Weeks 
et al., 2007).
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6.7. Cervical priming with misoprostol before trailsceiwical procedures
Cervical priming means softening or dilating the cervix before transcervical 
procedures including surgical abortion, hysteroscopy, dilatation and curettage, 
insertion of intrauterine device and endometrial biopsy. Cervical priming can 
facilitate mechanical dilatation, shorten the operation time, reduce blood loss and 
decrease the frequency of complications (Fiala et ah, 2007) and can be achieved 
medically by prostaglandins analogues. Administration of misoprostol prior to 
transcervical procedures results in clinical and histochemical changes which involves 
the influx of inflammatory cells into the stroma. This degrades of the collagen 
leading to softening and dilatation of the cervix (El-Refaey et al., 1994).
Misoprostol has been used effectively for cervical priming in pregnant women. 
Studies show that both oral and vaginal misoprostol are useful for cervical priming 
prior to vacuum aspiration (Ngai et ah, 1999). The dose of 400 meg of vaginal 
misoprostol administrated 3 hours before the procedures is recommended as an 
optimal dose (Fong, Singh & Prasad 1998). The same regimens using either oral or 
sublingual misoprostol were as effective as the vaginal route (Ngai et ah, 1999; 
Tang, Mok & Ho 2004). Another study found that the vaginal route is more effective 
than oral misoprostol (Maclsaac et ah, 1999). 200 meg sublingual misoprostol 
administered 2 hours before suction curettage was as effective as 400 meg vaginal 
misoprostol 3 hours before that procedure with higher pain scores and similar 
patients’ satisfaction (Caliskan et ah, 2007). However, oral and sublingual routes 
have the advantages of being more convenient and more acceptable to women 
(Chong, Chua & Arulkumaran 1997; Tang, Mok & Ho 2004).
Misoprostol can also be used for cervical priming in non-pregnant women. Ngai and 
his colleagues investigated the effect of 400 meg oral misoprostol given 12 hours 
before the procedure on the cervix prior to hysteroscopy. Data showed that 
misoprostol was more effective than placebo in terms of significantly reducing the 
amount of force required for cervical dilatation and increasing the mean baseline 
cervical dilatation from 3.3 mm in the placebo group to 6.0 mm in the misoprostol 
group (Ngai et al., 1997). Misoprostol is also effective in cervical softening in 
nulliparous women. Administration of 400 meg of sublingual misoprostol has
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facilitated the insertion of intrauterine device in those women. The most common 
side effect associated with this regimen was shivering which could be reduced by 
using oral and vaginal routes (Saav et al., 2007).
Misoprostol has shown considerable effect on the uterine cervix in the 
premenopausal women. One thousand micrograms of vaginally self administered 
misoprostol the evening prior to operative hysteroscopy has shown a significant 
effect on cervical ripening in pre-menopausal women but no effect on the 
postmenopausal women. However, this dose was associated with lower abdominal 
pain and slight preoperative bleeding (Oppegaard et ah, 2007). Batukan et al 
investigated a dose of 400 meg vaginal versus 400 meg oral misoprostol in 
premeopausal women for cervical priming prior to operative hysterescopy. The 
vaginal route was more effective than the oral misoprostol in increasing the mean 
cervical width, shortening the time required for cervical dilatation and the duration of 
surgery. However, the vaginal misoprostol was associated with excessive fluid 
leakage and cervical softening (Batukan et al., 2008).
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Figure 9. Recommended doses of misoprostol. Recommendations from: Weeks, A. & 
Faundes, A. Misoprostol in obstetrics and gynaecology. Int J Gynaecol Obstet, 2007. 99 
SuppI 2: p. S156-9 (1. Termination of pregnancy or medical abortion; 2. Also known as 
missed or silent miscarriage; 3. Intrauterine fetal death; 4. Induction of labour with a live 
fetus; 5. Postpartum haemorrhage.
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6.8. Prevention of postpartum haemorrhage with misoprostol
PPH is the most preventable cause of maternal death. Providing cheap, stable and 
effective therapy for prevention of PPH is essential for reducing maternal mortality in 
low-resource countries. Several studies have now demonstrated the efficacy of 
misoprostol in preventing PPH. An initial trial comparing 500 meg of oral misoprostol 
to standard oxytotic regimen suggested that oral misoprostol was comparable to 
oxytotic drugs for prevention of postpartum haemorrhage (El-Refaey et ah, 2000). 
Another multicenter randomised controlled trial including 2058 women and 
comparing 600 meg of oral misoprostol to 1 ml intramuscular syntometrine found that 
misoprostol is comparable to syntometrine in the incidence of PPH, the mean blood 
loss and the fall in haemoglobin concentration (Ng et ah, 2001). However, a much 
larger WHO multicentre randomised trial showed that misoprostol is worse than 
oxytocin in hospital settings. This study showed a significant difference in the 
amount of blood loss and the need of additional uterotonics. In addition, misoprostol 
was associated with a significantly higher incidence of shivering and fever 
(Gulmezoglu et ah, 2001). Comparison of misoprostol with a placebo in rural settings 
shows that misoprostol is very effective in prevention of PPH.
A prospective single-blinded, randomised controlled trial was conducted in Nigeria in 
a quite poor standard care hospital where cold storage facilities are below standard, 
which compared to most rural health centres in Nigeria. 864 women received either 
400 meg of oral misoprostol or 500 meg of intramuscular methylergometrine. Those 
given oral misoprostol had significantly lower rates of PPH although prolonged third 
stage of labour (>15 min) and need for manual removal of placenta were more in the 
misoprostol group (Enakpene et ah, 2007). This result could be explained by poor 
cold storage for the methylergometrine. Therefore, misoprostol could be a good 
alternative to methylergometrine in poor resource setting. A randomised double blind 
placebo controlled trial; undertaken in 661 women in primary health centre in Guinea- 
Bissau showed that 600 meg sublingual misoprostol reduced the frequency of severe 
PPH > 1000 ml; (Hoj et ah, 2005). Another placebo randomised controlled trial 
included 1620 women in primary health centres in rural India and found that 600 meg 
oral misoprostol reduced acute and severe bleeding postpartum by 50% compared
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with placebo (Derman et ah, 2006). A trial conducted in 26 villages in rural Gambia 
with 52 traditional birth attendants (TBAs) to compare 600 meg of oral misoprostol to 
placebo and 4 tablets of 0.5 mg ergometrine found that misoprostol group had lower 
incidence of blood loss and mean drop in Hb was significantly lower in the 
misoprostol group (Walraven et ah, 2005).
To determine the feasibility of implementing community based distribution of 
misoprostol for prevention of PPH within the government health system, a recent 
study was conducted in a remote setting in Nepal. This study showed that the overall 
coverage of uterotonics among women with vaginal birth increased from 11.6% to 
74.2% (OR 25.0, 95% Cl 15.6^40.1). Regarding the safety, none of the women 
reported taking it before the delivery and the maternal mortality rate was lower in the 
women who used misoprostol (10 deaths among 13,969, giving a mortality ratio of 72 
per 100,000) compared to the estimated national rate of 281 per 100,000 (95% Cl 
178-384) and to the non-users of misoprostol (292 per 100,000; i.e. 35 deaths among 
12,031 births; (Rajbhandari et ah, 2010). A systematic review of randomised 
controlled trials with a total of 28,138 women to assess the effects of prophylactic 
misoprostol in the third stage of labour concluded that injectable uterotonic drugs are 
more effective than misoprostol (Villar et ah, 2002). A recent Cochrane systematic 
review comparing prostaglandins for prevention of PPH concluded that a dose of 600 
meg oral or sublingual misoprostol shows promising results in reducing blood loss 
postpartum compared to placebo. The authors recommended further research to find 
out the optimal route with a minimum effective dose of misoprostol for routine use for 
prevention of PPH to reduce the side effects which are dose related (Gulmezoglu et 
ah, 2007). Based on the above evidence the WHO recommended the use of oxytocin 
rather than 600 meg of oral misoprostol for prevention of PPH (WHO 2007). In 
addition, expert group recommended single doses of 600 meg of oral or sublingual 
misoprostol for the prevention of PPH when injectable uterotonic drugs are not 
available and this dose should not be repeated for 2 hours (Weeks & Faundes 2007).
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6.9. Treatment of postpartum haemorrhage with misoprostol
The treatment of PPH is based mainly on the administration of uterotonic drugs, with 
parenteral oxytocin and ergometrine being the most commonly used agents. However, 
they are not widely available, require refrigeration and relatively expensive (Blum et 
ah, 2007a). Small observational study shows that misoprostol is highly effective in 
treatment of PPH. This study conducted to assess the efficacy of rectal misoprostol as 
a second line treatment of primary PPH by comparing it to methylergonovine maleate. 
The doses of misoprostol were ranging from 800 to 1000 meg. This results showed no 
significant difference between the two groups in the need for blood transfusion, the 
need for third line medical therapy and surgical intervention (Baruah & Colin 2008). 
However, this study has some limitations including small sample size and it was a 
retrospective one and subjected to selection bias.
Two small randomised controlled trials found that misoprostol is associated with 
reduction in blood loss and recommended that misoprostol should be available to 
women who do not have access to the conventional uterotonic drugs, oxytocin and 
ergometrine (Hofmeyr et ah, 2004; Walraven et ah, 2004).
The need for more stable, less expensive and easily administered drugs has turned the 
attention toward misoprostol and therefore, parachute approach were used in some 
countries to implement policies based on good science without randomised controlled 
trials especially in poor setting with high maternal mortality, when a simple 
intervention can save lives (Potts et al., 2006). Nigeria was the first who approves 
misoprostol for treatment of PPH (Jadesimi & Okonofua 2006) followed by Uganda 
and Ethiopia . This happened as a result of increasing evidence supporting its use in 
low resource sitting, where oxytotic drugs are not available.
Since the Cochrane review of treatment of PPH which was published in 2007 and 
updated in 2009, 3 large multi-centre double blind, randomised trials were published 
in the Lancet (2010). These trials investigated and compared the misoprostol to 
oxytocin in three different scenarios. Their data provided strong evidence that 
misoprostol is inferior to oxytocin when used after physiological management of the 
third stage of labour and equivalent to oxytocin after AMTSL. Also, the data showed
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that misoprostol was not as effective as placebo when used as an adjunct to standard 
uterotonics for treatment of PPH.
The first trial compared 800 meg sublingual misoprostol to 40 IU intravenous 
oxytocin for the treatment of PPH in women who had not exposed to oxytocin in 
labour. The study involved 9348 subjects from three different populations in Ecuador, 
Egypt and Vietnam. 978 (10%) of them were diagnosed with PPEI and received the 
study treatments. The results showed that the cessation of active bleeding within 20 
minutes was achieved in 440 out of 488 women who received misoprostol (90%) and 
in 468 out of 490 women who was treated by oxytocin (96%) and (RR 1.78, 95% Cl 
0.91-0.98). Also, additional blood loss of > 300 ml after treatment occurred in 30% of 
the women who managed with misoprostol and in 17% in women who received 
oxytocin (RR 1.78, 95% Cl (1.40-2.26), whilist additional loss of 1000 ml after 
treatment occurred in 1 or less of the women in the both study arms (RR 1,67, 95% Cl 
1.40-6.96, P=0.36). Although data provided evidence that oxytocin is significantly 
better than misoprostol for PPH treatment, the authors still recommended the use of 
misoprostol as a first line treatment of PPH in setting where oxytocin is not feasible 
(Winikoff et al., 2010).
The second trial examined and compared the 800 meg sublingual misoprostol 40 IU 
oxytocin given in a litre of intravenous solution over 15 minutes for the treatment of 
PPH after AMTSL with oxytocin. This trial included 31055 women and 809 (3%) 
were diagnosed with PPH after exposed to prophylactic oxytocin. The active bleeding 
was controlled within 20 minutes in 363 (89%) women managed with misoprostol and 
in 360 (90%) of women given oxytocin [RR 0.99, 95% Cl (0.95-1.04)]. The incidence 
of additional blood loss of > 300 ml after treatment was higher in the misoprostol 
group (34%) vs. (31%) in the oxytocin group (RR 1.12, 95% Cl 0.92-1.37), whilst 
blood loss > lOOOmls after treatment occurred in 11 (3%) women managed with 
misoprostol and in 3 (1%) of women given oxytocin (RR 3.62, 95% Cl 1.02-12.86). 
These finding suggested that 800 meg sublingual misoprostol is a possible alternative 
to 40 IU intravenous oxytocin for the management of PPH after AMTSL. However, 
misoprostol administration was significant associated with more side effects than with
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oxytocin. The incidence of shivering were (37% vs. 15%) and fever were (22% vs. 
15%) for misoprostol and oxytocin respectively (Blum et ah, 2010).
The third study explored the possibility of using misoprostol in addition to 
conventional injectable uterotonics to treat PPH. The study compared 600 meg 
sublingual misoprostol with placebo. The finding showed no significant difference 
between the two treatment groups in the proportion of blood loss of > 500 ml within 
60 minutes [100/705 (14%) vs, 100/717 (14%)]. As the other two trials, the incidence 
of adverse drug reactions were more in the misoprostol group compared to no 
treatment. Therefore, this study does not support the use of misoprostol in addition to 
other uterotonics for the treatment of PPH. The rate of shivering was 65% and 32% 
and the frequency of fever > 38°C was 43% and 15% respectively (Widmer et al, 
2010).
This strong evidence clearly showed that misoprostol is inferior to oxytocin for the 
treatment of PPH when used after physiological management of the third stage of 
labour and it was equivalent to oxytocin after AMTSL. Also, evidence showed that 
misoprostol was as effective as placebo in conjunction to standard uterotonics for 
treatment of PPH. Therefore, these trials confinned that oxytocin is still the first line 
for the treatment of PPH in hospital sitting and where it is available and misoprostol is 
the first choice of treatment where injectable uterotonics are not available particularly 
in poor and remote areas.
7. Cost-effectiveness of misoprostol for prevention and treatment of 
PPH
One of the main targets to help reducing maternal mortality in the developing world is 
producing an affordable medicine for the management of PPH. An observational 
study that traditional birth attencence (TBAs) administered 1000 meg of misoprostol 
rectally when PPH occurred helped to prevent 1647 cases of severe PPH. It was 
estimated that this saved $ 115.335 in the cost of referral, IV therapy and transfusions 
per 10,000 births (Bradley et al., 2007). The cost-effectiveness of 600 meg of 
misoprostol for the prevention of PPH and reducing maternal mortality was 
investigated in an observational study conducted in rural India. Administration of
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misoprostol by TBAs after the delivery resulted in a 38% (95% Cl 5%-73%) decrease 
in the maternal deaths. The cost effectiveness estimate of US$ 1401 for each life 
saved was favourably compared to other public health intervention. For instant, the 
cost-effectiveness of improving comprehensive emergency obstetric care per life 
saved is US$10,532 (Sutherland & Bishai 2009), which is more expensive than 
misoprostol and unaffordable to the developing counties with the highest rates of 
maternal mortalities.
A recent study modelled the cost-effectiveness of standard management plus 800 meg 
sublingual misoprostol for treatment of PPH and the standard management plus 600 
meg oral misoprostol for prevention of PPH versus the standard management alone in 
rural India. For example, in one region with 3,888,000 home births and with an MMR 
of 440, the total cost of the misoprostol treatment package would have been $ 
1,644,181. Each year, they estimate that this intervention would save the lives of 2994 
women who would have died because of PPH (Sutherland et ah, 2010) making a cost 
of around $ 550 per life saved. Large scale implementation of misoprostol for 
prevention and treatment of PPH requires careful consideration of cost, efficacy and 
safety in the low resource settings where illiteracy and poverty are common.
8. Side effects of misoprostol
8.1. Chills and /or fever
Chills are fairly common in association with the use of misoprostol but are transient. 
Hyperthermia can be severe (Chong, Chua & Arulkumaran 1997) with high doses, 
shorter intervals and particularly with oral and sublingual routes. (More details in 
Chapter 4, the systematic review of misoprostol induced fever).
8.2. Gastrointestinal side effects
Nausea, vomiting and diarrhoea are quite common adverse reactions of misoprostol 
intake. About 35% of women will experience gastrointestinal side effects (Gomez 
Ponce de Leon, Wing & Fiala 2007). If there is significant vomiting, anti-emetic can 
be offered and it usually resolves in 2 to 6 hours. Diarrhoea is the major side effect 
and it is usually mild and self-limiting within a day. The gastrointestinal side effects
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are more common with oral and sublingual administration (Tang, Gemzell-Danielsson 
& Ho 2007).
8.3. Uterine hyperstimulation and rupture
Hyperstimulation may occur as a result of using too high doses as well as with the 
recommended dosage of misoprostol. Several studies show a greater incidence of 
uterine hypercontractility with misoprostol compared with oxytocin. The incidence of 
hyperstimulation with misoprostol is 4-12% which is similar to the rate after induction 
with dinoprostone (Alfirevic & Weeks 2006; Hofmeyr & Gulmezoglu 2003).
Uterine rupture is another concern with the use of misoprostol. However, it is rare in 
the first trimester termination of pregnancy. Kim and his colleagues have reported a 
case of uterine rupture with misoprostol at 8 weeks gestation (Kim et ah, 2005). The 
most cases of uterine rupture took place during induction of labour in the third 
trimester and associated with a previous uterine scar (Plant, Schwartz & Lubarsky 
1999).
8.4. Abdominal cramps
Abdominal cramps usually develop with in the first few hours and may start as early 
as 10 minutes. The pain can be stronger than that of a regular period. NSAIDs can be 
given for pain relief without affecting the effectiveness of misoprostol (Fiala et ah, 
2005b). More analgesia is required in younger women, with advanced pregnancies 
and with multiple doses of misoprostol whereas women with previous live birth were 
significantly less likely to require analgesia (Hamoda et ah, 2004).
8.5. Fetal abnormalities
The risk of fetal malformation after use of misoprostol is low. The estimated risk is 
about 1% among exposed fetus (Tang, Gemzell-Danielsson & Ho 2007). Multiple 
congenital abnormalities have been reported after unsuccessful use of misoprostol for 
termination. The association between misoprostol at abortifacient doses and some 
congenital malformation might indicate a real teratogenic effect of misoprostol (Orioli 
& Castilla 2000). The association between Mobius syndrome (congenital facial
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paralysis with or without limb defects) and exposure to misoprostol has been reported 
by Pastuszak et al (Pastuszak et ah, 1998).
8.6. Skin rash
Administration of misoprostol occasionally leads to development of skin rash which 
resolve within several hours (Blum et ah, 2007b).
Table 1. Systemic, local and teratogenic adverse drug reaction for misoprostol
Multiple congenital 
abnormalities Mobius 
syndrome (congenital facial 
paralysis with or without 
limb defect)
Uterine hyperstimulation 
and rupture
Abdominal cramps
Gastrointestina; side effects 
(nausea, vomiting, 
diaahoea)
Chills and/ or fever
(Tang, Gemzell-Danielsson 
& Ho 2007)
(Gomez Ponce de Leon, 
Wing & Fiala 2007)
(Hofmeyr & Gulmezoglu 
2003)
Incidence: 4-12%
Estimated risk 1%
Incidence: 35%
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II. Prostaglandin-induced fever
1. Introduction
Misoprostol, which is a prostaglandin analogue, has similar side effects to 
prostaglandins, which were mentioned in the previous section. The most common side 
effect is pyrexia (fever). Although drug-induced increase in body temperature (such as 
malignant hyperthermia) has been extensively reported and examined in the literature, 
the mechanism of misoprostol-induced fever has not yet been studied. Therefore, this 
section will discuss prostaglandins-induced fever in terms of its mechanism and its 
molecular aspects. This section will also give an overview of phannacogenetics and 
adverse drug reactions.
2. Fever, hyperthermia and hyperpyrexia
Although the terms hyperthermia (un-regulated elevation of body temperature) and 
hyperpyrexia (fever with an extreme elevation of body temperature, >41.5°C) are 
sometimes used synonymously, they are actually different in terms of both 
mechanism and treatment. Hyperpyrexia results when a pathogen, insult or drug cause 
the hypothalamus to increase its core temperature set-point in a regulated manner, 
whereas hyperthermia is a process by which stress, extreme heat and drugs increase 
the body’s metabolic state, increase heat production and/or decrease heat loss without 
impairment of the temperature set-point in the hypothalamus. This results in un­
regulated increase in body temperature, making it particularly dangerous (Howard 
1993). Therefore, antipyretics can be used to treat fever by reducing the elevated set- 
point in the hypothalamus (Hadad, Weinbroum & Ben-Abraham 2003). During 
hyperthermia, skin blood flow increases which in turn, leads to heat loss through the 
evaporation of water (sweating). In contrast, with hyperpyrexia, febrile people do not 
sweat but rather shiver to increase metabolic heat production to the new set-point in 
the hypothalamus (Roth et ah, 2006). The existence of a common mediator of fever 
was postulated as it can be produced by many types of administered substances 
peripherally ranging from organic and inorganic compounds, and microbial and 
mammalian proteins (Conti et al., 2004).
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3. Aetiology of increased body temperature
Increased body temperature or fever is the most common clinical symptom and can be 
a presentation in a vast array of illnesses and conditions. Table 2 summarises some of 
the causes of increased body temperature (Laupland 2009).
Table 2. Most common causes of fever (adapted from Laupland 2009)
Infectious diseases
(bacterial, fungal, viral and protozoa)
Influenza, malaria, measles, infectious
mononucleosis, typhoid fever, yellow fever
Neoplastic diseases Leukaemia, lymphomas, kidney cancer
Rheumatic diseases Rheumatic arthritis, rheumatic fever
Immunological and collagen diseases Sarcoidosis, lupus erythematosus
Metabolic and inherited diseases Gout, prophyria, Familial Mediterranean fever
Hematologic causes Transfusion reactions, pulmonary embolism,
deep vein thrombosis
Inflammations Boils, abscess, wound infection
Tissue destruction Crush syndrome, infarction, haemolysis,
surgery
Environmental causes Heatstroke
Drug-induced fever Succinylcholine, cocaine, amphetamine,
misoprostol
Endocrine diseases Thyrotoxicosis, pheochromocytoma, and
adrenal crisis
Fever of unknown origin
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4. Molecular aspects of drug-induced increase in body temperature
Drugs can increase body temperature through several mechanisms. Some drugs can 
cause hyperthermia such as malignant hyperthermia, produced by succinylcholine and 
some drugs may cause hyperpyrexia, such as prostaglandin-induced fever. The 
mechanisms of drug-induced increase in body temperature, however, are 
multifactorial and incompletely understood. They are mainly classified into five 
categories: hypersensitivity reactions, directly drug-induced, altered thermoregulation, 
direct drug’s pharmacological action and idiosyncratic reactions (Johnson & Cunlia 
1996).
Thermoregulation is simply the balance between heat loss and heat gain. It uses both 
central and peripheral mechanisms to maintain the body’s temperature within tightly 
controlled limits. Severe and fatal conditions can result from failure of the 
thermoregulation system. There are various mechanisms of drug-induced fever which 
alter the balance between heat production and heat loss, involving many structures, 
from the hypothalamus down to the brain stem and spinal cord (Boulant 2000). The 
preoptic region neurons near the rostral hypothalamus are very sensitive to changes in 
core temperature and receive inputs from the skin and spinal chemoreceptors. Both 
central and peripheral information are integrated in the preoptic region to adjust the 
core temperature at a pre-defined set-point. This is achieved by regulating regional 
and cutaneous blood flow, hormonal response, sweating and shivering (Hadad, 
Weinbroum & Ben-Abraham 2003). The mechanism of hyperthermia may result from 
increased basal metabolic activity, absorption of heat from the environment and 
increased muscle activity. In addition, the preoptic region communicates with lower 
brain stem areas via the median forebrain bundle pathway passing through the lateral 
hypothalamus. This pathway for preoptic efferent signals control skin blood flow 
(Kanosue, Yanase-Fujiwara & Hosono 1994) and shivering (Kanosue et ah, 1994). 
This section shows the difference between these two types of drug-induced increase in 
the body temperature, including the mechanism, the molecular and the genetic 
aspects.
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4.1. Molecular aspects of drug-induced hyperthermia
Drug-induced hyperthermia is defined as hyperthermia which develops following 
drug administration and which disappears after cessation of drug administration, 
providing that no other causes of fever are evident (Mackowiak & LeMaistre 1987). It 
is mainly diagnosed by exclusion. There are five well-known syndromes of drug- 
induced hyperthermia: malignant hyperthermia, anticholinergic poisoning, serotonin 
syndrome, neuroleptic malignant syndrome, and sympathomimetics poisoning (Table 
3). The symptoms can vary from simple elevation in body temperature to life- 
threatening conditions (Hadad, Weinbroum & Ben-Abraham 2003).
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Table 3. Hyperthermic syndromes, their causative agents and mechanisms of heat 
production (Reproduced from Halloran and Bernard 2004)
Hyperthermic
syndrome
Causative drugs Mechanisms of heat production
Malignant hyperthermia Anesthetic gases: Halothane, effeurage, 
isoflurane, methoxyflurane, cyclopropane, 
diethyl ether, ethylene.
Muscle relaxant: succinylcholine, 
decamethonium, gallamine.
Dysfunction calcium channels of skeletal 
muscle permit uncontrolled release of Ca : 
into the cells. This results in high 
production of ATP in the mitochondria, 
leading to muscle contraction and 
increased metabolism and consequently 
increased heat production.
Anticholenergic poisoning Antihistamines, atropine, belladonna 
alkaloida, benztropine, carbamazepine, 
chlorpheniramine, clozapine, 
diphenyhdramine, doxylamine, 
disopyramide, glutethimide, glycopyrrolate, 
hydroxyzine, hyoscyamine, meclizine 
orphenadrine, phenothiazines, 
procainamide, quinidine, quinine, tricyclic 
antidepressants.
Hyperthermia is due to central and 
peripheral muscarinic receptors blockade. 
Central blockade is due to drugs 
permeable to the BBB and leads to seizers 
and coma. Peripherally, it interferes with 
cutaneous heat loss by impairing sweat 
gland function.
Serotonin syndrome L-tryptophan, amphetamines, cocaine, 
Ecstasy, fenfluramine, mescaline, psilocin, 
L-dopa/carbidopa, lithium, lysergic acid 
diethylamine, selective serotonin uptake 
inhibitors, tricyclic antidepressants, 
meperidine, dexamethorphan, monamine 
oxidase inhibitors.
It alters the levels of serotonin and 
dopamine in the CNS. Heat production is 
due to agitation, tremor and muscle 
rigidity.
Neuroleptic malignant 
syndrome
Neuroleptics: phenothiazines, 
butyrophenones, thioxanthenes.
Tricyclic antidepressants
Monoamine oxidase inhibitors
Benzodiazepines
Drugs alter the central hypothalamic 
regulation by elevated serotonin and 
decreased dopamine, causing muscle 
rigidity and increased heat production.
Sym pat horn imetics 
syndrome
Cocaine, ecstasy, amphetamines, 
methamphetamines.
Heat production involves central and 
peripheral disturbances in 
thermoregulation. They impair cutaneous 
heat loss through vasoconstriction, 
increased muscle activity and rigidity. It 
can increase non-shivering thermogenesis 
through increased hepatic metabolism.
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4.1.1. Malignant hyperthermia
One of the well-described syndromes of drug-induced fever is malignant 
hyperthermia (MH). MH is an autosomal dominant pharmacogenetic clinical disorder 
characterised by hypermetabolic state and skeletal muscle rigidity after exposure to 
inhalational anaesthetic gases and succinylcholine (Ording 1989). It was first 
described by Denborough and his colleagues who found an autosomal dominant 
pattern in deaths of patient’s relatives upon exposure to anaesthetics agents 
(Denborough et ah, 1962).
4.1.2. Pathophysiology of malignant hyperthermia
This hypermetabolic syndrome is caused by an abnormal, sudden and progressive 
release of calcium ions from the sacroplasmic reticulum to the sarcoplasm 
(myoplasm). The release of calcium ions in the skeletal muscle leads to actin and 
myocin interaction which results in muscle contraction. The release of the calcium 
takes place via the calcium release channel. Muscle relaxation occurs when the 
calcium returns to the sacroplasmic reticulum through the membrane adenosine 
triphosphatase (ATPase) pump (McCarthy 2004).
During malignant hyperthermia episodes, calcium transport is mediated by the 
ryanoidine receptor, isoform l(RYRl), a Ca+2 release channel. It is located in the 
membrane of the sarcoplasmic reticulum and is directly affected by depolarisation via 
the transverse tubule system which causes change in the dihydropyridine calcium 
channel (DHP), the voltage sensor of the skeletal Ca+2 release channel. A defect in the 
ryanoidine receptor allows abnormal calcium release when exposed to anaesthetic 
gases. The mechanism by which anaesthetic gases cause and initiate abnormal 
calcium release is unknown (Figure 10) (Litman & Rosenberg 2005).
Uncontrolled calcium release induces skeletal muscle contraction, activates 
glycogenolysis and oxidative phosphorylation cycle and increases cell metabolism. 
Sustained hypermetabolism results in heat production, excessive lactate production, 
high oxygen consumption and increased CO2 production followed by ATP depletion. 
This presents as acidosis, hypercapnia and hypoxia (Eyer & Zilker 2007; Jurkat-Rott, 
McCarthy & Lehmann-Horn 2000). If untreated, continuous myocyte death and
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rhabdomyolysis results in leakage of calcium, potassium, creatinine phosphokinase 
and myoglobin into the circulation. This result in arrythemias, disseminated 
intravascular coagulation, pulmonary and cerebral oedema, end-organ failure and 
death (McCarthy 2004; Rosenberg et ah, 2007).
Figure 10. Mechanisms and consequences of uncontrolled calcium release in the skeletal 
muscles. L-type calcium channel also called dihydropyridine receptor (DHP-R), 
transverse tubule (T-Tubule), (RYRO the calcium release channel also called ryanodine 
receptor, sarcoplasmic reticulum (SR). Reproduced from (Litman & Rosenberg 2005)
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4.1.3. Genetic background of MH
Over 100 mutations have been identified for the RYR-1 gene which lies on the 
chromosome 19ql3.1. However, this gene is not always abnormal in families who are 
affected by MH. RYR-1 protein (the calcium release channel protein) has a tetrameric 
structure which bridges the gap between sacroplasmic reticulum and the t-tubulin in 
skeletal muscle and acts as a calcium release channel. The human RYR-1 gene 
contains 106 exons, and the 5038 amino acid proteins in the N-terminal domain form 
a large foot region that contains most of the ligand binding sites. A fifth of the 
molecules in the C-terminal form the trans-membrane calcium channel (McCarthy, 
Quane & Lynch 2000).
The majority of RYR-1 mutations are clustered within three regions: the amino acid 
residues 35 to 614 in the N-terminus, amino acids 2163 to 2456 within the 
sacroplasmic reticulum membrane and amino acids 4214 to 4806 in the C-tenninus 
(Jurkat-Rott, McCarthy & Lehmann-Horn 2000). Screening of the entire coding 
region of the RYR-1 genes showed 31 mutations; 16 of them were novel and some of 
them were located outside the main three regions. All the 31 mutations were localised 
in 23 exons out of the 106 exons of RYR1 gene (Galli et al., 2006).
In addition to RYR-1 gene mutation, at least other five mutations have been 
discovered in association with MH, but only one gene has been identified (Table 4). 
The CANCA1S or CACNL1A3 gene, that encoding for the alpha subunit of the DHP 
channel (DHPR), is the second gene discovered with mutation associated with MH 
(Rosenberg et ah, 2007). The mutations and chromosomal locations are shown in 
Table 6 (Greenbaum, Weigl & Pras 2007).
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Table 4. Loci, chromosomal location and genes involved in malignant hyperthermia 
(Greenbaum, Weigl & Pras 2007)
Locus Chromosomal location Gene
MHS1 19ql3.1 RYR1
MHS2 17ql 1.3-q24 Unidentified
MHS3 7q21-q22 Unidentified
MHS4 3ql3.1 Unidentified
MHS5 lq32 CANCA1S
MHS6 5p Unidentified
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4.2. Molecular aspects of hyperpyrexia (fever)
The pyrogenic effect of a pathogen or a chemical product may occur through several 
mechanisms and involves many immunological and physiological products. Cytokines 
and prostaglandins both contribute to the mechanism of fever. This section shows the 
role of cytokines and prostaglandins in the development of fever.
4.2.1. Role of cytokines in the mechanism of fever
Cytokines are members of the class of immunopolypeptides produced mainly by 
mononuclear phagocytes as a result of their activation by invading pathogens and/or 
their products. These molecules can be synthesised and mediate their action peripheral 
in the immune system and they can also be released in the circulation and transported 
to mediate their effect in the central nervous system.
Several cytokines have been investigated for their pyrogenic effect. Interleukin 1 beta 
(ILl-p), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-a) are considered 
to be endogenous pyrogens (Conti et al.5 2004). A large amount of evidence supports 
the role of inflammatory cytokines in the manifestation of the febrile response. These 
cytokines appear in the circulation in response to injection of lipopolysacharides 
(LPS) at the same time the fever develops. TNF-a is the first cytokine that appears in 
the circulation (Jansky et al., 1995), followed by traces of IL-1 (Jansky et al., 1995) 
and a significant amount of IL-6 (Roth et ah, 1993). Levels of IL-6 show the best 
correlation with changes in the body temperature.
Systemic injection of individual cytokines can induce fever. This was proved for IL-1 
(Anforth et al., 1998), IL-6 (Blatteis et al., 1990) and TNF-a (Goldbach et al., 1996). 
Neutralising or antagonising the biological activity of cytokines, such as treatment 
with IL-1 receptor antagonist (Luheshi et al., 1996), a TNF-a neutralising receptor 
(Roth et al., 1998) or IL-6 neutralising IL-6 antibodies (Cartmell et al., 2000), resulted 
in attenuation of febrile response to LPS. Furthermore, experiments in cytokines 
deficient knockout (KO) mice (Leon 2002), particularly IL-1, showed that LPS- 
induced fever is reduced but not abolished completely (Kozak et al., 1995). This 
means that IL-1 contributes to but is not essential for the febrile response to LPS. 
Moderate LPS-induced fever was completely eliminated in IL-6 KO mice (Kozak et
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al., 1998). This suggested that the expression of IL-6 receptor is essential for the 
response to fever (Chai et al,, 1996). This large body of evidence supports the view 
that appearance of exogenous pathogen in a host causes fever via formation of 
endogenous pyrogens (cytokines) which mediate their action in the brain.
Cytokines are large hydrophilic peptides with a molecular weight of 15-25 kd. 
Therefore, they cannot pass the relatively impermeable blood-brain barrier to 
stimulate the hypothalamic thermoregulatory structures. Three mechanisms have been 
proposed for the mechanism of immune-to- brain signalling through circulating 
cytokines. First, cytokines may reach their site of action through gaps in the tight 
blood-brain barrier which are known are as the circumventricular organs (CVOs). 
Alternatively, they may interact with their receptors on the endothelial cells or 
perivascular cells or may pass the blood-brain barrier by active transport system (Roth 
et al., 2006).
CVOs are so named because they are positioned at distinct sites around the margin of 
the ventricular system of the brain and they have dense vascularisation, lack a blood- 
brain barrier and are in contact with the cerebroventricular system. CVOs have a 
sensory subgroup which includes the organum vasculosum of the laminae terminalis 
(OVLT), the subfornical organ (SFO) and the area postrema (AP). The sensory CVOs 
are directly exposed to the circulating molecules which they may be able to sense via 
specific receptors (Roth et al., 2004). The OVLT is a very important structure because 
of its location in close proximity to the preoptic area in the anterior hypothalamus 
which is considered as a major pyrogenic zone of the brain. The role of the OVLT in 
the mechanism of fever has been investigated in studies on brain lesions. Large 
lesions that included the OVLT prevented the development of fever after systemic 
injections of LPS (Blatteis et al., 1983). There is evidence that the OVLT acts as a 
sensor for circulating endogenous pyrogens. This evidence includes the presence of 
IL-1 (Ericsson et al., 1995), IL-6 (Vallieres & Rivest 1997) and TNF-a (Nadeau & 
Rivest 1999) receptors in the OVLT cells. Also, neurons in the OVLT change their 
firing rate in response to the cytokines (Shibata & Blatteis 1991) (Figure 11).
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Furthermore, the entire brain endothelium is a target for the circulating cytokines. 
Endothelial brain cells express IL-1 and TNF-a receptors. IL-1 receptor type 1 is 
predominantly expressed in the venules but not in the arterioles (Konsman et al., 
2004), and IL-6 glycoprotein receptor is expressed in the endothelial brain cells under 
inflammatory conditions (Vallieres & Rivest 1997). The final activation of the brain 
endothelial and perivascular cells results in the appearance of enzymes that are 
responsible for the formation of prostaglandin E2, which is regarded as the principal 
mediator for fever (Cao et al., 2001).
PVH
EP3R DMH
Spinal cord
•Artery vasoconstriction
•Activation of brown
adipose tissue (BAT)
Figure 11. Model shows the role of the preoptic area (MnPO, OVLT/VMPO) in the 
hyperthermic response. (MnPO - median preoptic area; OVLT - organum vasculosum 
of the lamina terminalis; VMPO - ventromedical preoptic nucleus; DMH - dorsomedial 
hypothalamus; RPa - raphe pallidus nucleus). Reproduced from Lazarus (2006)
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4.2.2. Role of prostaglandin E2 in the mechanism of fever
Prostaglandin E2 is a derivative of arachidonic acid which is produced from 
diacylglycerol and phospholipid by phospholipase C or phospholipase A2. 
Arachidonic acid is converted to prostaglandin H2 (PGH2) by PGH2 synthase (COX-1 
or 2 and peroxidise). PGH2 is isomerised to PGE2 by prostaglandin synthetase (PGES) 
(Ivanov & Romanovsky 2004).
PGE2 is considered as the key fever mediator in the brain and as the agent that is 
ultimately in charge of the upward shift of the thermoregulatory set-point. This 
information was supported by some evidence. Firstly, injection of prostaglandin into 
the PGE2 sensitive site within the preoptic nucleus in the hypothalamus stimulates the 
febrile response (Scammell et ah, 1996). Secondly, PGE2 levels increase in the brain 
and in the blood in accordance with the changes in the body temperature. Thirdly, 
systemic administration of drugs that block prostaglandin synthesis pathway inhibits 
fever effectively. The latter was confirmed by systemic treatment with prostaglandin 
synthesis inhibitors such as cycloxygenase (COX) inhibitor (diclofenac) or COX-2 
inhibitor (meloxicam) which resulted in effective attenuation of EPS-induced fever in 
rats (Ivanov & Romanovsky 2004).
Many enzymes responsible for PGE2 formations are induced and up-regulated in 
response to exogenous and endogenous pyrogens. COX-2 and PGES-1 are inducible 
enzymes that are regulated by a transcription factor (NK-kB), which is activated by 
EPS, IL-1 or TNF-a.(Turrin & Rivest 2004). The expression of these enzymes is up- 
regulated by pyrogenic cytokines in EPS-induced fever to increase production of 
PGE2 in the brain and their expression increases predominantly by endothelial brain 
cells and perivascular cells. Systemic administration of EPS causes strong expression 
of COX-2 in the OVLT and SFO (Roth et ah, 2006). Studies of KO mice deficient in 
either COX-2 or mPGES-1 showed that febrile response is depressed and therefore, 
the synthesis of these enzymes is critical for formation of PGE2 during fever.
PGE2 mediates its effect via prostaglandin receptor subtype EPS. Studies in KO mice 
suggested that response to EPS-induced fever is strongly impaired in mice deficient in 
this receptor. PGE2 activates EPS receptors and stimulates the thermogenesis via
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activation of the descending neuronal pathway that affects the thermoregulatory set- 
point in the hypothalamus (Ushikubi et ah, 1998).
5. Molecular aspects of prostaglandin-induced hyperpyrexia (fever)
Prostaglandins can be part of the mechanism of hyperpyrexia due to other pathogens 
and also they can produce fever as a result of their direct effect on the 
thermoregulatory set-point in the hypothalamus. Therefore, some prostaglandin drugs 
can cause fever as an unwanted drug reaction. For instance, shivering and fever have 
been reported in several studies investigating the pharmacological effects of 
misoprostol in different obstetric and gynaecological indications (Bugalho et ah, 
2001; Zuberi et ah, 2008). The effect of prostaglandin drugs on the human 
physiological and immunological processes takes place through the prostaglandins 
pathway, including prostaglandin transport, effect on the cells (target) and the drug 
metabolism.
5.1. Prostaglandin receptors involved in prostaglandin-induced fever
5.1.1. Prostaglandin transporter (PGT)
Rapid penetration of PGs cannot be achieved by rapid diffusion alone because cell 
membrane is not permeable to prostaglandins (Bito & Baroody 1975) and there is 
evidence for the need and presence of carrier-mediated PG transport across the plasma 
membrane. PGT is the first discovered and the best characterised transporter. It is 
widely expressed in various peripheral tissues and in the brain of several mammalian 
species and humans (Schuster 2002). It is localised on the cell membrane and 
facilitates PG transport in the apical to basolateral direction. The two most specific 
trans-membrane carriers of PGE2 are PG transporter (PGT, OATP) (Kanai et ah, 
1995) and multi-specific organic anion transporters (MOAT, ABCC4) (Nishio et al., 
2000).
71
5.1.2. Prostaglandin receptors (EP)
The four EP receptor subtypes differ in their structure, ligand-binding affinity and 
signal transduction pathway. PG binding sites are mainly in the plasma membrane and 
sacroplasmic reticulum (Hamon et al., 1993). EP1 receptors are responsible for 
contraction of smooth muscle in several tissues including the respiratory tract, the 
gastrointestinal tract, vas deferens, iris smooth muscles and myometrium. EPS 
receptors are involved in mediating contraction of the myometrium, inhibition of the 
gastric secretion, lipolysis in adipose tissue, modulation of neurotransmitter release 
and sodium and water reabsorption in kidney tubules (Negishi, Sugimoto & Ichikawa 
1995).
EP2 and EP4 receptors are widely distributed in smooth muscle and mediate 
relaxation of trachea and ileum circular muscles and vasodilatation of blood vessels. 
These receptors are highly expressed in ileum followed by thymus, lung, spleen, heart 
and uterus (Lebel et ah, 2004). However, the EP2 receptor is not as widely distributed 
as the other EP receptors (Sugimoto & Narumiya 2007). EPS receptor mRNA is 
highly expressed in the kidney and uterus and also expressed in stomach, thymus, 
spleen, lung and brain. It is also the most abundant EP subtype in the brain and 
neurons (Sugimoto et ah, 1994). EP2 and EP4 receptors are the only two types of 
PGE2 receptors expressed by human monocytes. EP2 and EP4 receptors mediate their 
action via coupling to G proteins of the Gs subclass which increases the intracellular 
level of cyclic adenosine monophosphate (cAMP) (Panzer & Uguccioni 2004).
EP1 and EPS receptors are classified as excitatory, whereas EP2 and EP4 are thought 
to be inhibitory. The inhibitory effect of EP2 is mediated through the activation of 
adenylate cyclase and increased levels of intracellular cAMP, while EP4 receptors 
stimulate adenylate cyclase via G proteins (Negishi, Sugimoto & Ichikawa 1995). 
The stimulatory effect of EP1 and EPS receptors involves phospholipase C (PLC) 
activation and mobilisation of calcium from intracellular stores via enhancing inositol 
1,4,5-trisphosphate (InsPS) production and also by stimulating calcium influx through 
the cell membrane (Coleman, Smith & Narumiya 1994). In addition, EPS receptors 
mediate its myometrial stimulatory effect by inhibiting cAMP production. Uterine
72
contraction takes place as a result of increasing intracellular calcium level, which 
leads to myosin light chain kinase activation. On the other hand, relaxation of uterine 
muscles is promoted by cyclic nucleotides (cAMP and cGMP), which decreases the 
affinity of myosin light kinase for calcium-calmodulin complex and by stimulating a 
mechanism to decrease intracellular calcium levels (Asboth et al, 1996). EPS 
receptors are the most widely expressed in the uterine body. The expression of EPS 
receptor mRNA is reduced in early pregnancy compared to the non-pregnant uterus. 
The effect of misoprostol at term may also involve different PGE2 receptors, 
particularly EP2 which is more abundant in the lower uterine segment than EPS 
receptors (Lyons et al., 2003). EPS receptors are further subdivided into rEPSct and 
rEPSp. The receptor rEPSa causes myometrial contraction by inhibiting cAMP 
formation whereas rEPSP receptors act through calcium mobilisation. High doses of 
misoprostol produce rapid expression of rEPSa and rEPSp receptor mRNA in the 
myometrium, but do not change the level of their expression in the cervix, which 
appeal's to be low (Lyons et al., 2003).
In the nervous system, the EPS receptor is highly expressed in the dorsal root ganglion 
and brain regions such as preoptic area (POA), hypothalamus, hippocampus, 
maxillary body, locus coeruleus and raphe nuclei (Coleman, Smith & Narumiya 
1994). Oka and his colleagues mapped the EP receptors distribution in the brain by in 
situ hybridisation for their mRNA. They found that EPS is mainly localised to the 
MnPO (median preoptic nucleus) which appears at the dorsal levels of an inverted Y- 
shaped structure capping the OVLT (Oka et al., 2000). Apart from EPS receptors, EP4 
receptors are expressed in the VMPO (ventromedical preoptic nucleus) and the lateral 
OVLT and also located in the MnPO (Figure 11) (Lazarus 2006).
Gamma-aminobutyric acid receptor (GABA receptors) and drenergic, beta, receptor 
(ADRB1, 2, 3) will be discussed later with the mechanism of prostaglandin induced 
fever. Table 5 shows summary of the receptors that may involve in the prostaglandin 
pathway.
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Table 5. Summary of different receptors that involved in the prostaglandins pathway, 
including prostaglandin transport and function
Prostaglandin 
transporter receptors
Prostaglandin target 
receptors
Organic anion transporter 
family, member
Prostaglandin E receptor
(PTGER.1,2,3,4)
(influx transporter)
(OATP2A1, OATP1B1)
ATP-binding cassette, sub­
family C, member 4
Gamma-aminobutyric acid 
receptor
(efflux transporter) (GABA)A
(ABCC4)
Adrenergic, beta, receptor
(ADRB1,2,3)
Adrenergic, beta, receptor 
kinase 1
(ADRBK1)
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5.1.3. Misoprostol and prostaglandins receptors
Misoprostol binds to PGEi and PGE2 receptor through its four stereoisomers. Only 
one isomer is responsible for the receptor-mediated activity, whereas the other three 
isomers are inactive. Misoprostol is more stable in vivo and has a longer elimination 
half-life than naturally occurring prostaglandins (Shield 1995). Prostanoid receptors 
have been classified further to DP, EP, FP, IP and TP (Kennedy et al., 1982). The 
variable effects of prostaglandins (PG) are explained by the presence of G-protein 
coupled receptors which are classified into four subtypes of EP receptors (PGE2): 
EP1, EP2, EP3 and EP4. Misoprostol is structurally related to PGEi. It has clear EP2 
agonist activity, weak EP1 receptor affinity, but potent and selective EPS activity 
(Coleman, Smith & Narumiya 1994). Prostanoid sub-family and its relation with 
misoprostol is shown in Figure 12.
Misoprostol and prostaglandin receptors 
Prostanoid receptors sub family
1--------- — 1 — 1 -------------1--------------------- 1
EP 1-4 mm DP m FP Jj ip 8 tp
EP3 (rEP3a & 
rEP3p)
EP4
Weak affinity to 
misoprostol
Clear misoprostol 
agonist activity
Potent and selective 
misoprostol activity
High affinity to 
misoprostol
Expressed in 
many tissue as 
RT, GIT, blood 
vessels, uterus 
and CNS
Figure 12. Misoprostol and prostaglandins receptors target (RT - respiratory tract), 
(GIT - gastrointestinal tract), (CNS - central nervous system)
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6. Mechanisms of prostaglandin-induced fever
PGE2 is considered as a principal mediator of fever in the brain and a key 
intermediate in the sequence of events leading to fever. Therefore, it is essential to 
understand the mechanism of fever in general and the important role of prostaglandins 
as a mediator of fever due to other pyrogens and also as substance inducing fever.
The thermogenic activity of prostaglandin E has been recognised in humans after 
increasing its application in reproductive medicine. The administration of PGE and its 
analogues by different routes and at variable doses provoked thermal side effects. It 
was reported early (1978) that the incidence of elevated body temperature was 53%, 
shivering was 93% and subjective coldness was 100% (Dingfelder & Brenner 1978). 
A recent randomised controlled trial has confirmed that shivering and pyrexia are the 
most common side effects of 600 meg oral misoprostol. The incidence of shivering 
and pyrexia were 44% and 38% respectively (Hofmeyr et ah, 2001b).
Prostaglandin (E-type) has been assumed as a principal mediator of fever in the brain 
(Boulant 2000; Kanosue, Yanase-Fujiwara & Hosono 1994; Kanosue et ak, 1994) and 
it circulates as albumin-bound. Once it is dissociated from albumin at the blood-brain 
barrier (BBB), it is carried into the brain by prostaglandin transporters (PGTs) and 
organic anion transporting polypeptide subtype 2 (Oatp2) expressed at the BBB 
(Taogoshi et ah, 2005). Many studies have been conducted to investigate the role of 
prostaglandin El in the production of fever in cats and rabbits (Feldberg & Gupta 
1973; Feldberg & Saxena 1971; Stitt 1973). Microinjection of PGE] into the anterior 
hypothalamus of unanaesthetised cats raised the core body temperature. On the other 
hand, even the injection of a larger amount of PGEi into the posterior hypothalamus 
did not affect the temperature (Feldberg & Saxena 1971). The same conclusion has 
been drawn by Stitt (1973) when the same experiment was conducted on rabbits. The 
site where PGEI acts to produce fever is the same as the site where pyrogens produce 
their thermogenic effect (Stitt 1985). This would support the idea that PGEi is a 
mediator of pyrogen-induced fever. Furthermore, PGEi febrile effect is not an all or 
none response. It is in a dose-responsive manner, like in pyrogenic fever. Both 
pyrogen and PGEi cause an elevation of the thermoregulatory set-point in the 
hypothalamus (thermostat) resulting in cold feeling, increased heart rate, muscle tone
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and shivering. The change in the temperature due to prostaglandin and pyrogen is a 
regulated one. While pyrogen is regarded as a precursor of PGEi in the brain tissue, 
PGEi is one step closer to the production of fever. Therefore, the onset of PGEi fever 
is more rapid than pyrogen (Stitt 1973).
PGE2 is a powerful mediator of pyrogen-induced fever in the brain and mainly in the 
POA. The evidence showed increased levels of PGE2 in the cerebrospinal fluid after 
pyrogen-induced fever (Sirko, Bishai & Coceani 1989). The injection of PGE2 into 
(OVLT) and (POA) induce elevation of the core body temperature and its effect is 
mainly mediated through EP1 and EP3 receptors (Oka 2004).
EP2, EP2/EP3 agonists produce a gradual rise in body temperature, whereas the effect 
of EP1 agonist was not significant. EP3 agonist showed marked febrile response, 
suggesting the significant role of EP3 receptor in mediating febrile response. This 
response has been reported after injection of prostanoid receptor (EP1, EP2, EP3 
subtypes) agonists into the lateral ventricles of prepubertal pigs which produced dose- 
related increase in body temperature (Parrott & Vellucci 1996). In addition, a study 
of EP receptor knockout mice showed lack of a febrile response to PGE2 in EP3 
receptors gene-deleted mice which indicate the crucial role of EP3 receptors in 
producing fever (Lazarus et al., 2007; Ushikubi et ah, 1998). Also, EP3 receptors KO 
mice showed a profound hypothermia, with decrease in body temperature up to 6°C 
(Oka et al., 2003). This shows that EP3 receptors are important to prevent a drop in 
temperature which occurs as a result of EP4 receptors’ response to PGS. On the other 
hand, PEI receptor-deficient mice showed mild and partial suppression of the febrile 
response. This indicates that all EP receptors are involved in the thermoregulatory 
effect of PGE2 and each receptor may have a different role (Oka, Oka & Saper 2003).
The preoptic area (POA) is considered as the sole region that can sense PGE series- 
induced fever. PGEs produce their thermogenic effects mainly through PE3 receptor- 
containing neurons in the somatodendritic portion of POA, specifically in the MnPO 
and MPO subregions. These neurons have direct input to DMH, LH, DH and RPa and 
so mediated their sympathetic thermogenesis (Nakamura et al., 2002). However, little 
information is available about the molecular events of PE3 activation in the preoptic 
neuron. Many studies suggested that GABA and GABAa receptors are essential for
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prostaglandin-induced febrile response in the POA. Microinjection of a GABAa 
receptor antagonist, bicuculline and gabazine into the POA area unilaterally, either 
contraleteral or epsilateral to the site of PGE2 injections, results in complete blockade 
of the PGE2.induced thermogenesis (Osaka 2008a). This finding indicates that the 
tonic GABAergic transmission to POA neurons has a role in the full expression of 
PGE2induced fever. In normal situations (in the absence of PGE2), EP3-expressing 
neurons produce a strong GABAergic tonic inhibition on fever-mediated raphe 
pallidus neurons (rRPa) and DMPI neurons. PGE2 suppresses the GABAergic activity 
of EP3-expressing neurons, resulting in disinhibition and activation of the rRPa and 
DMH neurons, leading to thermogenesis (Nakamura et al., 2005). The above 
mentioned mechanism of prostaglandin-induced fever is summarised and simplified in 
Figure (13).
PGE2-EP3 signalling may produce the GABA inhibition through changing the 
GABAa channels properties. It may affect the sensitivity of these channels to GABA 
or the response of the POA neurons to GABA. EPS receptor binds to G i/0 proteins in 
the POA neurons and results in attenuation of gabr gene expression. It has been 
demonstrated that PGE2-EP3 signalling rapidly decreases the expression of GABAa 
gene. As a result of the reduced number of GABAa receptors, the EP3-expressing 
neurons could become insensitive to the inhibition from GABA and mediated PGE2. 
induced fever (Tsuchiya et ah, 2008).
On the contrary, other studies have defined a region adjacent to the OVLT (peri- 
OVLT) in the ventromedial POA as the main site for the PGE-induced febrile 
response (Ranels & Griffin 2003; Stitt 1991). The same GABAergic effect in the 
DHM and RPa has been proved to take place in the peri-OVLT region (Osaka 2008b). 
Variation in these studies’ findings can be attributed to the different microinjection 
technique, chemicals used for injection and more to the interrelation of neurons in 
these very adjacent areas in the hypothalamus.
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PGE-EP3 signalling inhibits GABA ergic inhibition by:
1. Changing the GABA a channels properties
2. Rapidly decrease the expression of GABR gene —► | N- 
of GABAa receptors —> EP3-expressing neurons 
become insensitive to the inhibition from GABA —>
PG-induced hyperpyrexia
Figure 13. Summary of the mechanism of prostaglandin-induced fever as described in 
Nakamura et al. 2005
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Prostaglandins hyperpyrexia can also be produced by non-shivering thermogenesis via 
stimulating brown adipose tissue (BAT). The significant role of BAT in PGEi.induced 
fever is confirmed in rats (Fyda, Cooper & Veale 1991). BAT, which is mainly 
localised in the interscapular region, is under control of the peripheral sympathetic 
nervous system (Foster, Depocas & Zaror-Behrens 1982; Foster, Depocas & Zuker 
1982). PGS acts through the central nervous system to modify the sympathetic 
outflow to BAT. This is confirmed after intracerebroventricular (ICY) injection of 
PGE]> which results in increasing the sympathetic tone in the nerves innervating the 
BAT (Monda, Amaro & De Luca 1994). PGE2 is also involved in the non-shivering 
thermogenesis mechanism (Figure 19) and is considered as a potent stimulant for 
BAT thermo genesis. The injection of PGE2 into the anterior hypothalamic preoptic 
area (POAH) can produce a rapid and sustained increase in BAT and core temperature 
via increasing BAT thermogenesis through sympathetic drive from the VMH to BAT 
(Amir & Schiavetto 1990). BAT heat production is under sympathetic nervous system 
control through sympathetic norepinephrine stimulation of B-adrenergic receptors on 
the brown adipocytes membrane. Inhibition of the B-adrenegic receptor by 
propranolol or pre-treatment with sympathetic ganglionic blocker chlorisondamine 
chloride completely prevented the increase in the BAT and core temperature induced 
by PGE2 injection to the POAH (Amir & Schiavetto 1990). The thermoregulatory 
signals from intra-POAH injections of PGE2 can be mimicked by the signals produced 
by cold stimuli or cooling of intra-POAH (Imai-Matsumura & Nakayama 1987). 
These signals involve inhibition of warm-sensitive neurons and stimulation of cold- 
sensitive neurons in the POAH, resulting in increasing the thermoregulatory set-point 
in the hypothalamus (Satinoff 1978).
7. Pharmacogenetics and adverse drug reactions
Individuals’ variations in response to medications may be caused, at least in part, by 
differences in their genetic profile. Pharmacogenetics and pharmacogenomics are 
often used interchangeably to describe the genetic approach to explain the individual’s 
drug response. According to The European Agency for the Evaluation of Medical 
Products’ position paper on terminology (EMEA 2002), the term pharmacogenetics is 
defined as the study of inter-individual variations in DNA sequence related to drug
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response, whereas pharmacogenomics is used to describe the study of the variability 
of the expression of individual genes relevant to disease susceptibility as well as drug 
response at cellular, individual or population level. Phannacogenomic research 
strategies involve isolation and evaluation of the genetic polymorphisms in 
individuals and the establishment of definitive relationships between these genetic 
variations and drug responses (McLeod & Evans 2001).
The most common sequence variations in the human genome are single nucleotide 
polymorphisms (SNPs, pronounced snips), where one base pair in the DNA sequence 
is replaced with another (e.g. C to T). It has been estimated that there are 
approximately 10 million SNPs in the human genome, but only approximately 60,000 
are located in the coding regions of genes, and only half of these affect the amino acid 
sequence of the protein produced (Risch 2000; Sachidanandam et ah, 2001). 
However, SNPs do not have to be located in the coding sequence to have an effect on 
disease. SNPs in promoter (Klerkx et ah, 2003; Lin et al., 2003), intron (Tokuhiro et 
ah, 2003), splice site (Betticher et ah, 1995) and intragenetic regions (Helms et al., 
2003) have been associated with disease or susceptibility to disease (Crawford & 
Nickerson 2005). A SNP can be isolated individually or identified by looking at 
groups of genes that are known to be inherited together (haplotype). The width of 
research can be varied from the entire genome to a candidate gene approach.
7.1. Genome-wide method
The genome-wide method is a comprehensive but expensive method using SNP arrays 
(GWA). It is a hypothesis-fiee method and can reveal unexpected SNPs related to 
drag function or adverse reactions. It does not rely on the current knowledge of the 
mechanism of action and drug metabolism (Kooloos et al, 2009).
GWA is normally designed as a case-control study to compare the DNA of the two 
large groups of participants. One is a group of people affected by the disease or a 
particular drug adverse reaction and the other is a group of healthy individuals who 
are not affected. Each individual is genotyped for the majority of the common known 
SNPs. It may include genotyping several millions of SNPs. For each of these SNPs it 
is then investigated if the allele frequency is significantly different between the case
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and the control groups. In such setups, the odd ratio (OR) of interest is the odds of 
disease (the probability that the disease is present compared with the probability that it 
is absent) in exposed versus non-exposed individuals. In the context of GWA studies, 
OR is the proportion of individuals in the case group having a specific allele to the 
proportion of individuals in the control group having the same allele. If the allele 
frequency in the case group is much higher than in the control group, the OR will be 
greater than 1. The significance of the OR is calculated using P values from chi- 
squared test. Finding ORs that are significantly different from 1 is the objective of the 
GWA study because this shows that a SNP is associated with disease (Clarke et ah, 
2011). In addition to the association calculations, it is important to take into account 
the presence of several confounding factors which affect the results, such as age, sex 
and the genetic variations with different geographical populations and ethnical 
backgrounds. Controlling for the genetic and geographical variations is called 
‘population stratification’. This will show if the disease or the positive results are due 
to the underlying structure of the population and not due to a disease-associated locus 
(Freedman et ah, 2004).
GWA studies have several limitations. The common problems are insufficient sample 
size, control of multiple testing and population stratifications. GWA methods and 
platforms do not provide a complete coverage of all the chromosomes and 
chromosomal regions. If the platforms camiot sufficiently capture the variation in 
these genes, some of the causative variants that influence the phenotype may fail to be 
identified. Also, the coverage of SNPs is incomplete, particularly those with low 
minor allele frequency (MAF) (e.g. MAF<0.05). Many pharmacogenomic association 
studies have relatively small sample sizes compared to the disease-associated studies. 
To overcome the issue of small sample size, detecting the causative SNP may require 
coverage of the SNP on the GWA’s platform, sequencing of the gene, or imputing to 
the 1000 Genomes dataset. If the causative gene is poorly interrogated on the genome­
wide platform, it is more likely to miss important associations. The search for 
causative variation may require combining several methods to adequately survey all 
the genetic variation in pharmacogenes. This includes genome-wide study, candidate 
gene and imputation into sequence data (e.g. 1000 Genomes) (Gamazon, Skol &
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Perera 2012). Also, GWA studies are expensive and may be replaced by complete 
genome sequencing as their price is rapidly decreasing.
7.2. Candidate gene method
A candidate gene is a gene of known biological action involved in the physiological 
or pathological process under investigation. Candidate gene studies focus on the genes 
that are involved in the mechanism of the disease or drugs. Candidate gene study is 
conducted on population-based samples from affected and unaffected people (a case- 
control study). There are some problems with candidate gene studies as significant 
findings in some studies have not been replicated and also the current knowledge is 
insufficient to rely on them for selection and prediction (Tabor, Risch & Myers 2002).
7.2.1. Selecting candidate genes
Candidate gene selection involves an extensive literature search regarding the 
mechanism of action of a particular drug function, such as genes encoding for 
transporters and genes encoding target receptors and genes encoding for receptors that 
are involved in drug metabolism (Kooloos et al., 2009). Also, the search involves 
published studies of the phenotype of interest and the examined candidate genes. It is 
important to consider the reason for selecting a particular gene in these studies before 
selecting it for genotyping. In addition, linkage studies may provide information about 
genomic regions, population characteristics and phenotypic definition (Tabor, Risch 
& Myers 2002).
7.2.2. Prioritising polymorphism (SNP selection)
It is not practical or statistically feasible to genotype and test all SNPs in the genome 
for association with phenotypes. Therefore, it is important to carefully select a limited 
number of SNPs to genotype from the considerable number that is often available in a 
particular candidate gene. Polymorphisms that affect the function of protein 
expression and synthesis are desirable as they are most likely to affect the risk of 
phenotype.
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Information about the location and type of the sequence variants in a gene can be used 
to prioritise polymorphisms. It involves selection of SNPs with high probability to 
detect. It includes SNPs in the genetic regions with functional characteristics such as 
synonymous or promoter or untranslated regions. SNPs in the non-coding regions like 
introns could have indirect effect on transcription regulatory proteins. In the NCBI 
database, specific regions within each gene were investigated. There are four 
subdivisions, unknown, 3' and 5' near gene, introns and exons. The latter also were 
subdivided into synonymous, non-synonymous, 3' UTR and 5' UTR subgroups (Table 
6).
SNPs with low minor allele frequency (MAP) have a low chance of being detected 
and need large sample size to achieve a statistically significant association. SNPs 
causing amino acid alteration (non-synonymous SNPs) and effects on gene expression 
have been extensively studied. On the other hand, SNPs located within non-coding 
regions remain poorly identified. If a SNP has a predicted significant effect, it is 
favourable to include it in the association studies (Tabor, Risch & Myers 2002).
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Table 6. Priorities for single-nucleotide-polymorphism selection reproduced from 
Tabor, Risch & Myers 2002
Type of variant 
Predicted Location Functional effect
Frequency 
in genome
relative risk
of phenotype
Nonsense
| Coding 
i sequence
Premature 
termination of 
amino-acid 
sequence
Very low Very high
Missense
non-synonymous
(non-conservative)
Coding
sequence
Changes an amino 
acid in protein to 
one with different 
properties
Low
Moderate to 
very high, 
depending on 
location
Missense/non-
synonymous
(conservative)
Coding
sequence
Changes an amino 
acid in protein to 
one with similar 
properties
Low
Low to very 
high, depending 
on location
Sense/synonymous
Coding
sequence
Does not change the 
amino acid in the 
protein — but can 
alter splicing
Medium Low to high
Promoter/regulaton
region Promoter, 5' 
UTR, 3'
UTR
Does not change the 
amino acid, but can 
affect the level, 
location or timing of 
gene expression.
Low to 
medium Low to high
Intronie
Deep within 
introns
No known function, 
but might affect 
expression or 
mRNA stability
Medium Very low
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7.2.3. Linkage disequilibrium among SNPs
Another important consideration in selecting SNPs for an association study is whether 
there is significant linkage disequilibrium in the candidate gene. Linkage 
disequilibrium is the non-random association of alleles at two or more loci, not 
necessarily on the same chromosome. In other words, linkage disequilibrium is the 
occurrence of some combinations of alleles or genetic markers in a population more 
often or less often than would be expected from a random formation. The degree of 
LD between alleles at two loci can be described with the correlation coefficient (r2). 
An r of 1 indicates full linkage, which means there is no loss of power when using a 
tag SNP instead of directly genotyping the direct SNP associated with the drug 
reaction. LD blocks (including tagged SNPs) can be relocated using the metric D\ 
which is closely related to r2 and gives information about the recombination 
breakpoints of chromosomes (Kooloos et ah, 2009). It is also important to search for 
tag SNPs and particularly those in linkage disequilibrium.. Tag SNPs usually occur in 
haploblock or subregions, and SNPs in different haploblocks or from different genes 
are in LD. To limit the cost and effort of association study, taking tag SNPs in accoimt 
is very important (Kooloos et al., 2009).
Misoprostol-induced fever is a common and well-known side effect. The mechanism 
of misoprostol-induced fever has not been investigated solely. However, many studies 
examined the mechanism of prostaglandin-induced fever in animal models. The 
pharmacogenetics may provide an explanation of the presence of misoprostol-induced 
fever in certain populations and not in others. This will be investigated in a candidate 
gene association study in Chapter 4.
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III. Postpartum haemorrhage
1. Introduction
Although PPH is considered to be the most avoidable cause of maternal death, and in 
spite of the global effort to improve maternal health, developing countries are still far 
away from the Millennium Development Goal 5 (MDG5). This aimed to reduce the 
global maternal mortality ratio by three quarters between 1990 and 2015, but only a 
5% decline in the maternal mortality ratio was achieved between 1990 and 2005. 
Global maternal mortality has, however, declined from 409,100 (uncertainty interval 
382,900-437,900) in 1990 to 273,500 (256,300-291,700) deaths in 2011 (Lozano et 
al., 2011). In addition to death, PPH also is an important cause of maternal morbidity, 
causing hypovolaemic shock, disseminated intravascular coagulation (DIG), hepatic 
failure, renal failure and adult respiratory distress syndrome (Boimar 2000).
There are several factors that contribute to the high maternal morbidity and mortality 
from PPH in resource-poor sittings. Women in developing countries are more likely to 
have severe anaemia during pregnancy, have other serious diseases like malaria and 
AIDS, and experience difficulties in accessing the health services due to geographical 
and social factors. Moreover, even if the women can reach the health facilities still 
they may face difficulties due to a lack of adequate medical supplies including blood 
products. For example, in Uganda, 97% of health facilities that expected to be able to 
offer emergency obstetrics care had shortages in the basic services (Mbonye et al., 
2007). A great deal of effort has been put into the identification of women at risk of 
PPH on the basis of historical and clinical factors. However, more PPH occurs in 
women without risk factors than in women who have identifiable risk factors. It is 
recommended, therefore, that all women during child birth should have access to PPH 
management, as it often occurs without warning (WHO 2007).
This section, will give an overview of PPH and its management, starting with the 
definition, incidence and prevalence and it will highlight the main aetiologies and risk 
factors of PPH before it turning to details of strategies for its prevention and 
management.
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1.1. Definition of PPH
Although most clinicians have observed PPH, a globally accepted definition is still 
elusive. The most common definition of PPH is a blood loss greater than 500 ml in 
the first 24 hours, with more than 1000 ml classified as severe PPH (SPPH). 
Nonetheless, these cut-offs may be not clinically significant because healthy pregnant 
woman can tolerate blood loss up to 1000 ml before showing any symptoms or fall in 
haemoglobin (Hofmeyr & Mohlala 2001). The majority of pregnant women are 
young and healthy, with a body physiology well adapted to the anticipation of blood 
loss. This occurs through blood volume expanding by around 50% and the red blood 
cell volume increasing by 32% (Pritchard 1965).
The amount of blood loss at delivery usually incorrectly estimated (Stafford et al., 
2008). Using standard measures to estimate blood loss can improve the accuracy of 
estimating blood loss, but this approach is not feasible to be applied worldwide. 
Furthermore, a recent randomised trial has shown that an accurate assessment of 
blood loss does not assist with management (Zhang et al., 2010). Therefore, another 
definition of PPH can be used to overcome any mistaken numerical assessment; this is 
the amount of excessive bleeding that results in signs and symptoms of hypovolaemia 
(Rajan & Wing 2010). There is another diagnostic criteria for PPH. It includes a 
hematocrit drop of greater than 10% or bleeding that necessitates blood transfusion or 
that results in signs and symptoms of hypovolaemia (Combs, Murphy & Laros 1991b)
. The Royal College of Obstetricians and Gynaecologists (RCOG) recommended that 
a primary PPH with an estimated blood loss of 500-1000 ml and no signs and 
symptoms of shock should prompt basic measures of monitoring and readiness of 
resuscitation. This includes close monitoring, intravenous access, Rill blood count, 
and group and screen. However, an estimated blood loss of more than 1000 ml (or a 
smaller loss associated with clinical signs of shock, tachycardia, hypotension, 
tachypnoea, oliguria or delayed peripheral capillary filling) prompts full measures to 
resuscitate, monitor and arrest the bleeding (RCOG 2009).
PPH is divided into two types. Early PPH (primary) occurs within the first 24 hours 
after delivery and late PPH (secondary) occurs after 24 hours postpartum but before 6
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weeks. The causes of early and late PPH are naturally different. However, most of 
maternal deaths due to PPH occur immediately after delivery due to acute blood loss.
1.2. Epidemiology of PPH
Reports of the incidence of PPPI vary widely due to the use of different diagnostic 
criteria, flowever, it is estimated at between 4 and 6%. A systematic review of 
databases from 1997 to 2006 has been performed to assess the global incidence of 
PPH (Carroli et al., 2008). The definitions of PPH is a blood loss > 500 ml and SPPH 
as > 1000 ml blood loss were used as inclusion criteria for studies investigated PPH. 
On the whole 224 datasets were included in the final analysis. The finding illustrated 
an overall prevalence for blood loss of over 500 ml of 6.09% [95% confidence 
intervals (Cl), 6.06-6.11] of all deliveries. The rate was 10.6% when blood loss was 
measured objectively. For SPPH (loss over 1000 ml), the prevalence was 1.86% (95% 
Cl, 1.82-1.90), but 3.04% (95% Cl, 2.90-3.17) when the blood loss was measured 
objectively (Carroli et al., 2008). Interestingly, this extensive systematic review found 
that PPH was more common in the rural than urban areas. On the other hand, there 
was no difference in SPPH rate between these settings. They also found a wide 
discrepancy between the developing and developed countries with the highest 
incidence in Africa (10.45%) which the authors attributed to a lack of skilled birth 
attendance and a scarcity of facilities to provide a satisfactory management during 
labour.
The PPH rates in individual studies vary greatly. For example, a study of 1620 women 
from rural India with low risk pregnancies found that the rate of measured PPH of 
over 500 ml was 9.2% (Geller et al., 2008). In a study where PPH was defined as 
estimated blood loss > 1000 ml, a need for blood transfusion or presence of sign and 
symptoms of hemodynamic instability found that the incidence of PPH was 5.2% of 
women who delivered vaginally (Magann et al., 2005). In a case-control study of 
9598 vaginal deliveries, the PPH defined as a haematocrit drop of 10 points or more 
found that the rate of PPH was 3.9% (Combs, Murphy & Laros 1991b) . In another 
study of women delivered by caesarean section using the same definition of PPH, 
PPH occurred in 196 of 3052 women, producing a rate of 6.4% (Combs, Murphy & 
Laros 1991a).
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The rate of PPH is significantly reduced by the administration of prophylactic 
oxytocin during the third stage of labour as part of the active management of the third 
stage of labour (AMTSL). Recently 2 large studies in which blood loss was measured 
in 40,000 women delivering vaginally with view to randomising those who had blood 
loss of over 700 ml to receive 800 meg sublingual misoprostol or 40 IU oxytocin 
intravenous. In 9348 women who did not receive prophylactic oxytocin during 
vaginal delivery, 978 (10%) cases were diagnosed with PPH (Winikoff et ah, 2010). 
In contrast, PPH complicated the delivery of 809 (3%) of 31,055 women who 
received oxytocin as a prophylaxis during labour (Blum et al., 2010). Whilst women 
in these studies were not randomly allocated to receive oxytocin prophylaxis or not, 
the data does clearly demonstrate the association of oxytocin prophylaxis with lower 
PPH rates.
Very few studies have investigated the rate of secondary PPH. A retrospective study 
of 123 women presented with secondary PPH over a three-year period found that 
secondary PPH complicated less than 1% of deliveries. This was associated with a 
history of primary PPH and retained placenta, and resulted in considerable maternal 
morbidity (Hoveyda & MacKenzie 2001).
1.3. Trends in PPH rates
Even though there is little literature available on studies reporting PPH trends, it does 
appear to be an overall increase in rate of PPH over time. A retrospective study of 
over 750,000 women was conducted to examine the effect of changes in risk factors 
and their relationship to rising in PPH rate over the period Rom 1994 to 2002 in 
Australia. It found that the reported rate of PPH increased from 4.7% to 6.1%. This 
increase was not related to changes in the risk factors of the women over time, but the 
authors suggest that it might be explained by changes in the management and 
reporting of PPH (Ford et al., 2007b). Similarly, a population- based study in New 
South Wales in Australia included more than 52,000 women and found that the rate of 
PPH increased from 8.3% to 10,7% Rom 1994 to 2002. This change was not 
associated with changes in the risk factors. However, there was a 6-fold increase in 
the use of blood transRision for the management of PPH over the same period 
(Cameron et al, 2006).
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A retrospective cohort study was conducted in Canada to investigate the trends in 
PPH between 1991 and 2004. The study found an increase in PPH rates from 4.1% to 
5.1%, a change that was associated with a 73% increase in the hysterectomy rate. This 
increase in PPH was explained by a 34% increase in uterine atony over that period. 
The cause of the increased rate of atonic PPH remains unclear (Joseph et al., 2007).
The rate of manual removal of placenta in the United Kingdom has considerably 
increased from a mean of 0.66% in the 1920s to 2.34% in the 1980s and this might 
have an effect on the rates of PPH. The authors postulated that this increase might 
occur as a result of increased rates of labour induction, premature birth and pregnancy 
termination with time (Cheung et al., 2011).
1.4. Recurrence of PPH
Previous history of PPH is considered as a significant risk factor for PPH in 
subsequent pregnancies. A population-based study was conducted in Australia to 
investigate the occurrence and recurrence of PPH in 125,295 women from 1994 to 
2002 (Ford et al., 2007a) . Among the women studied, 5.8% had a PPH in their first 
pregnancy and 14.8% of these women had PPH in their second consecutive 
pregnancy, which represents a 3-fold increased risk of PPH (RR 3.3, 95% Cl 3.1-3.5). 
The rate of PPH in a third consecutive pregnancy in women who had a PPH in their 
first two consecutive pregnancies was 21.7%. Furthermore, the rate of PPH in the 
third pregnancy of women who had a PPH in their first pregnancy and second 
uncomplicated pregnancy was 10.2%. Therefore, women with history of PPH in 
previous pregnancy are at increased risk of PPH in a subsequent pregnancy.
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2. Physiology of the third stage of labour
To understand the pathophysiology and aetiology of PPH, it is important to know the 
mechanical, physiological and coagulative events of the third stage of labour.
2.1. Mechanical events of the third stage of labour
The biomechanical events which lead to the delivery of placenta and membranes 
starts in the first stage of labour, where detachment of the membranes begins and 
slowly progresses upwards from the internal os. Dining the second stage of labour, 
when the baby’s trunk is delivered, the uterine muscles undergo a very powerful 
contraction. The uterus is reduced in size and volume as the uterine muscle shortens. 
This process is known as retraction. The latter may be facilitated by the special 
arrangement of uterine muscle fibres. The outer longitudinal muscle cells are 
generally arranged in the long axis of the uterus and the inner circular muscle cells are 
arranged concentrically around the longitudinal axis (Garfield & Yallampalli 1994). 
The decrease in uterine size and volume and tight compression of the placenta causes 
a reduction in the placental site surface area. The compression of the placenta also 
forces the placental blood back into the sinuses in the decidua basalis. The placenta 
attempts to force blood against the high resistance in the uterine sinuses produced by 
the strong myometrial contraction. As result, the sinuses become congested and 
rupture. The blood that escapes from the ruptured sinuses tears the fine septae of the 
spongy layer of the decidua basalis. Consequently, the placenta shear off (Khan & El- 
Refaey 2006).
Real-time ultrasonographic imaging studies during the third stage of labour were 
performed to investigate the mechanism of placental delivery. One study reported that 
normal third stage of labour occurs in four phases (Herman et ah, 1993). It started 
with a ‘latent phase’, characterised by thin placenta site wall and thick placental free 
wall. This is followed by the ‘contraction phase’ where the retro-placental 
myometrium increases in thickness from < 1 cm to > 2 cm. When it achieves its foil 
thickness the placenta completes its separation and detaches - this is the ‘detachment 
phase’. Failure of the retro-placental myometrium contraction may cause 
dysfunctional labour and retained placenta (Weeks 2003). With a sliding movement.
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the placenta comes out during the ‘expulsion phase’. Interestingly, neither the latent 
phase nor the contraction phase was associated with presence of retroplacental 
haematoma formation.
There are two classical methods of placental delivery which result in different 
bleeding patterns. In the Schultze method, separation and descend occur in the central 
part of the placenta followed by the rest. The Matthew Duncan method is 
characterised by detachment of the placenta edges leading to the entire organ sliding 
down and out of the uterus sideways. There is however little relevance of this; 
distinction of the placental separation method appeal's to be clinically irrelevant and 
clinicians are incapable of predicting or changing the method of separation (Khan & 
El-Refaey 2006).
A similar classification of the mechanisms of placental separation and expulsion was 
reported using continuous real time ultrasound during the third stage of labour. 
Monophasic separation of the placenta, in which placental detachment occurred 
simultaneously, was uncommon. The most common type of placental separation was 
(down-up separation) where the process started at the lower pole. It rarely began from 
the upper pole (up-down separation). In cases of a fundal placenta, the separation was 
considered multiphasic but it began from either the posterior or anterior pole with the 
fundal part separating last (bipolar separation) (Herman et ah, 2002) . The up-down 
separation was more common in women who had previous caesarean section, 
probably due to impaired lower uterine segment contractility (Mo & Rogers 2008).
Another study using real time B mode ultrasound described placental separation in 
three types. In Type I, which occurred in 53% of the cases, placental separation from 
its bed occurred smoothly and slides out immediately, usually one or two contractions 
after the delivery of the baby. This type was characterised by the least blood loss and 
the shortest duration of the third stage of labour. Placental separation in Type II 
started at the marginal site and gradually progress with each recurring contraction. 
With this type, the bleeding tended to be greater and the time to placental separation 
tended to be longer. In Type III, separation of the placenta began at the central part 
with formation of retroplacental clots resulting in an increase in placental size. The 
blood loss and the duration of the third stage was generally moderate (Goto 1984).
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The contraction and retraction of the interlacing myometrial fibres plays a vital role in 
PPH control. When the placenta is separated from the uterine wall it leaves about 300 
square centimetres with may be 100 tom arteries which had been delivering around 
500 ml of blood per minute to the placenta (Hytten 1995). This massive trauma 
requires both a physical compression of the blood vessels by the myometrial 
contraction, as well as vessel blockage by haemostasis. Uterine muscles compress the 
maternal radial arteries and veins of the placental bed, resulting in an obliteration of 
their lumina. Moreover, the strong myometrial contraction helps haemostasis by 
opposing the uterine walls firmly against one another and producing direct pressure 
on the placental site (Khan & El-Refaey 2006). Control of postpartum bleeding 
requires complete integration between the endocrine and coagulation systems.
2.2. Endocrine mechanisms of the third stage of labour
Similar to all muscular activity, uterine contractility requires both electrical and 
hormonal stimuli. Intrinsic activity of the uterine muscle may be mediated via stretch 
receptors which may involve both neural and neurohormonal mechanisms. There are 
two classes of natural honnones linked to the third stage uterine activity, namely 
oxytocin and prostaglandins.
2.2.1. Oxytocin
There is a large amount of clinical experience with therapeutic oxytocin in the 
induction of labour and prevention of PPH. However, the role of oxytocin in the 
mechanism of the third stage of labour is not well understood. Oxytocin is a 
nonapeptide hormone released by the posterior pituitary gland which acts on the 
female reproductive system to cause increased uterine contractions. It was the first 
peptide to be chemically synthesised to produce a biological active form. The 
oxytocin receptor is highly expressed in the endothelium, placenta, amnion and 
decidua. There is a strong increase in the density of oxytocin receptor in early labour. 
Its level rises up to 200 times that in the non-pregnant state (Gimpl & Fahrenholz 
2001). A clear physiological relationship between oxytocin and the third stage of 
labour event has not yet been elucidated for many reasons. Firstly, oxytocin can be 
synthesised locally in a paracrine system operating in the amnion, chorion and
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decidua. Therefore, a simple oxytocin assay is unreliable to reflect the exact 
concentrations of the hormone at the myometrium. Furthermore, there is no 
relationship between oxytocin plasma levels and the density of oxytocin receptors. 
Finally, the high activity of oxytocinase degrades the oxytocin before it reaches the 
target tissues. This also explains the non significant increase in plasma oxytocin 
concentration during labour (Gimpl & Fahrenholz 2001),
During labour, oxytocin is released in short duration discrete pulses (Fuchs et ah, 
1991). Thornton and his colleagues found that the oxytocin pulse does not occur at the 
same time as the uterine contraction. Some women with a completely normal third 
stage of labour do not experience an increase in oxytocin levels after the delivery of 
the baby. In addition, it is not necessary to have an oxytocin pulse in order to deliver 
the placenta (Thornton, Davison & Baylis 1988).
2.2.2. Prostaglandins
Prostaglandins are found in most tissue and organs including decidua, fetal 
membranes and placenta. They are involved in uterine contraction through paracrine 
and autocrine signals. Prostaglandins augment oxytocin induced contraction. Studies 
also suggest that prostaglandins increase the expression of the oxytocin receptors 
(Chan, Berezin & Daniel 1988). The presence of prostaglandins in maternal blood 
during labour is of interest because the sensitivity of uterine tissue to prostaglandins 
increases with the progress of gestation until it reaches a maximum at term. 
Prostaglandin is detected in the blood of women during labour before each uterine 
contraction, but very little is present at the end of the contraction. This indicate that 
prostaglandin is not released because of the contraction (Karim 1968).
The localisation of prostaglandin receptors in the tissue is important. The contraction 
promoting receptors EP1 and EP3 are found in the fundus while relaxation promoting 
receptors (EP2 and EP4) are more abundant in the cervix to facilitate the passage of 
the fetus during delivery (Olson 2003). It has been observed that large amount of 
prostaglandins are released during the third stage of labour. Plasma levels of 
prostaglandin F2a reach a maximum level and started to decline within 10 minutes of 
placental separation, and return to pre-labour levels within 2 to 3 hours. This rapid
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decline of plasma levels suggests that prostaglandin is mainly produced by cells at the 
placental site and fetal membranes. The latter is known to be the most important 
source of prostaglandins (Noort et ah, 1989). This reflects the active role of 
prostaglandins in ensuring the haemostasis after labour.
2.3. Mechanism of coagulation
Coagulation at the placental site has an important role in the prevention of PPH. 
Around the time of delivery many changes both in the coagulation factors and 
fibrinolysis agents take place. There is consumption of platelets and blood coagulation 
factors including fibrinogen by clot formation and haemostasis at the placental site. 
This causes a decrease in the peripheral plasma fibrinogen levels. In a study 
performed by Bomiar and his colleagues, samples of uterine vein blood were obtained 
during caesarean sections. They found that the time of placental separation was 
accompanied by a striking activation of the local clotting mechanism and a sharp 
increase in factor VIII (Bonnar et ah, 1970). In the peripheral circulation, there was a 
rapid increase in the clotting factors VIII and V and a decrease in plasma fibrinogen. 
Within one hour of delivery, fibrinolytic activity returns to its non-pregnant levels, 
and there is an increase in the level of fibrin/fibrinogen degradation products. In early 
puerperimn, changes promoting coagulation take place. This includes an increase in 
the fibrinogen level and a swift increase in platelet count. The level of factor VIII 
remains high (Bonnar, McNicol & Douglas 1970). These changes may explain the 
increased susceptibility to thromboembolic complications during puerperimn.
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3. Aetiology and risk factors of PPH
The causes of PPH can be classified into 6 main categories (Table 7):
3.1. Uterine atony
The most common cause of PPH is the failure of uterus to contract (uterine atony). 
This pathology is responsible for 75-90% of primary PPH (Koh, Devendra & Tan 
2009). Uterine atony occurs when the relaxed myometrium fails to contract and 
constrict the blood vessels. At term, about 600 ml of blood enters the uteroplacental 
circulation every minute (Rajan & Wing 2010). Therefore, over a short time of 
myometrial relaxation can lead to fatal haemorrhage. There are many risk factors 
associated with PPH (Table 7). However, uterine atony may occur in women without 
any risk factors. About 26% of women who underwent hysterectomy had no 
identifiable risk factors (Clark et al., 1984). In the UK, uterine atony was responsible 
for 53% of peripartum hysterectomy between February 2005 and February 2006 
(Knight & Ukoss 2007). Although the most common risk factor is a previous history 
of PPH, there are many other important associated risk factors. Also, there may be 
more than one cause for the PPH and each cause requires a different treatment. 
Therefore, clinicians should be aware of all the risk factors so that they are able to 
anticipate and manage PPH in line with their own unit’s protocol.
Uterine atony may occur as a result of uterine over-distension caused by 
polyhydramnios, multiple pregnancies or fetal macrosomia. Labour related problems 
such as a prolonged first or second stage of labour may also lead to uterine atony, but 
uterine dysfunction before onset of labour might result in a delay in all the three 
stages of labour, leading to PPH. Very rapid labour either natural or caused by 
induction or augmentation is thought to cause strong uterine contractions. These may 
lead to myometrial acidosis and contractile failure (Quenby et al., 2004).
Chorioaminonitis also impairs uterine contraction during the first and second stages of 
labour. This results in prolonged labour, which is a risk factor of PPH. Other risk 
factors may also include history of antepartum haemorrhage (placental abruption or 
praevia), obesity and an age of > 35 years (Breathnach & Geary 2009).
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Table 7. Factors associated with postpartum haemorrhage (Oyelese & Ananth 2010)
Uterine atony Retained placenta and clots
Labour-related causes: Coagulation disorders
Induction of labour Disseminated intravascular coagulopathy
Oxytocin use Placental abruption
Precipitated labour Liver dysfunction
Prolonged labour Amniotic fluid embolism
Chorioaminonitis Intrauterine fetal demise
Uterine overdistension Thrombocytopenia
Multiple pregnancies Inherited bleeding dysfunction
Polyhydramnios eg, von Willebrand disease
Placental abruption with large 
intrauterine clot
Anticoagulant therapy
Uterine inversion
Fetal macrosomia
Anaesthesias
General anaesthesia with inhaled agents
Genital tract trauma Implantation of the placenta into the lower
Iatrogenic
uterine segment
Caesarean delivery
Placenta praevia
Forceps delivery
Placenta accreta
Vacuum delivery
Episiotomy
Spontaneous
Genital tract lacerations
Uterine rupture
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3.2. Genital tract trauma
Traumatic causes of PPH, including genital tract laceration, uterine rupture and 
uterine inversion, account for about 20% of all primary PPH. Generally, if PPH is not 
due to uterine atony, genital tract trauma is likely to be the cause of severe bleeding. 
Trauma may result from laceration of the cervix, vagina sidewall, perineum and 
episiotomy, or from uterine rupture. Genital tract trauma could also be iatrogenic 
during caesarean delivery or instrumental delivery such as forceps or vacuum. These 
are risks for genital tract trauma and PPH should be highly anticipated.
3.3. Retained placenta and clots
Retained placenta or placental fragments, either as disrupted portions or more rarely a 
succenturiate lobe, may cause inadequate uterine contraction. Retained products of 
conception may act as a physical or endocrine block against strong uterine contraction 
which constricts the blood vessels at the placental bed. However, most cases of 
retained placenta are due to dysfunctional postpartum myometrial contraction 
(Oyelese & Ananth 2010).
3.4. Coagulation disorders
Both inherited and acquired coagulation defects are associated with excessive blood 
loss postpartum. Disseminated intravascular coagulation associated with abruption 
placenta (Figure 14), retained dead fetus, amniotic fluid embolism, excessive blood 
loss and massive blood transfusion may all lead to PPH. Other coagulation disorders 
such as thrombocytopenia, von Willebrand’s disease and anticoagulant drugs also 
may cause massive blood loss postpartum.
99
Revealed haemorrhage
Concealed haemorrhage
Figure 14. Abruptio placenta (premature separation of placenta). Two types of 
bleeding, revealed and concealed haemorrhage (Baker & Kenny 2011) (Obstetrics by 
Ten Teachers, 19,h edition)
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3.5. Uterine inversion
Uterine inversion is rare but life threatening condition. It occurs secondary to 
excessive cord traction during the delivery of the placenta. The resulting PPH is likely 
to be caused by a failure of the myometrium to contract and compress the blood 
vessels. The amount of shock may be inappropriate for the amount of blood loss. 
However, this cause of PPH can be fatal if not recognised and treated appropriately 
and quickly.
3.6. Implantation of the placenta into the lower uterine segment
The anatomical and physiological limitations of the lower uterine segment cause 
ineffective uterine contraction to prevent PPH after separation of the placenta from its 
bed. Implantation of the placenta in the lower segment (placenta praevia) makes 
haemorrhage much more likely (Figure 15). If the placenta invades the myometrium 
(placenta accreta), there is no clear cleavage line and attempts of removal can cause 
tearing of the placenta. The remaining fragments and opened sinuses will lead to 
severe haemorrhage.
Minor placenta praevia Major placenta praevia
Figure 15. Placenta praevia (a) minor placenta praevia (b) major placenta praevia 
(Baker & Kenny 2011) (Obstetrics by Ten Teachers, 19,h edition)
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4. Management of Postpartum Haemorrhage
The majority of PPH occurs in women who do not have well-known risk factors. 
Therefore, the first step in reducing maternal morbidity and mortality of PPH is to 
provide preventive management for all women during labour. Each woman should be 
assessed for the likelihood of developing PPPI before labour and staff need to be 
prepared to manage women who develop PPH. Appropriate precautions should be 
taken for all women who are at risk.
4.1. Prevention of Postpartum Haemorrhage
Methods for prevention of PPH have been developed and introduced to the 
intrapartum care to reduce maternal morbidity and mortality due to PPH. It mainly 
involves the active management of the third stage of labour (AMTSL), the main 
component of which is the use of uterotonics such as oxytocin, ergot alkaloids, 
prostaglandins and misoprostol.
4.1.1. Active versus expectant management of the third sage of labour
Third stage of labour or ‘placental stage’ is defined as the time from the delivery of 
the fetus until the delivery of the placenta and fetal membranes. The correct 
management of the third stage of labour plays an important role in the prevention of 
PPH. The physiological or the expectant management of the third stage of labour 
involves spontaneous delivery of placenta with maternal pushing efforts whereas 
active management involves a utrotonic plus other activities such as uterine massage, 
early cord clamping and cutting, or controlled traction on the umbilical cord and 
administration of uterotonics. This depends on different organisations’ 
recommendations (Table 8). It is advised that for the first two hours after delivery, 
the uterus should be palpated to check that the uterus is well contracted with massage 
being performed as needed, making sure that the uterus does not become soft 
(relaxed) after stopping the massage (FIGO/ICM 2004a; Hofmeyr, Abdel-Aleem & 
Abdel-Aleem 2008).
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Table 8. Recommendations for active management of third stage of labour (AMTSL) 
according to the organisation; CCT (controlled cord traction); FIGO, International 
Federation of Gynaecology and Obstetrics; ICM, International Confederation of 
Midwives; WHO, the World Health Organization; RCOG, Royal College of Obstetrics 
and Gynaecology; NICE, the National Institute for Health and Clinical Excellence; 
SOGC, The Society of Obstetricians and Gynaecologists of Canada
Organisation Oxytocin Cord
clamping
Time of 
oxytocin
CCT Uterine
massage
Placental
cord
drainage
FIGO & ICM
(FIGO/ICM
2004b)
Yes Within one
minute
after
delivery of 
baby
Yes Yes
After
placental
delivery
RCOG
(RCOG 2009)
Yes - 5 IU or
10 IU by
intramuscular
injection
Early cord 
clamping 
only when 
indicated
NICE Yes 10IU Early — Yes — —
(NICE 2007) IM
WHO
(WHO 2009)
Yes Late (at 
around 3 
minutes)
Within 1
minute
after
delivery of 
baby
Yes Yes
SOGC
(Leduc et al., 
2010)
Yes 10 IU
IM
Delayed After
delivery of 
the anterior 
shoulder
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Initial trials of AMTSL found that the incidence of PPH was lower in actively 
managed women. The Bristol third stage trial compared active and expectant 
management in 1695 women. It found that expectant management was associated 
with a three times higher likelihood of PPH compared to the active management (OR 
3.1, 95% Cl 2.3-4.2) (Prendiville et al., 1988). The most recent Cochrane systematic 
review compared active versus expectant management of labour concluded that 
AMTSL in hospitals with mixed levels of PPH risk reduces the risk of PPH > 1000 ml 
(risk ratio (RR) 0.34, 95% Cl 0.14 to 0.87), three studies, 4636 women and the 
incidence of blood transfusion. In the subgroup of women at low risk of excessive 
bleeding, there were similar findings (average RR 0.31, 95% Cl 0.05 to 2.17, two 
studies, 2941 women), except there was no significant difference identified between 
groups for severe haemorrhage or maternal Hb less than 9 g/dl (at 24 to 72 hours). 
The review concluded that the active management also increases the risk of side 
effects such as postnatal hypertension, after pains and return to hospital due to 
bleeding. The trials included in this review used syntometrine or ergometrine in their 
intervention aim which could explain the occurrence of theses adverse outcomes. The 
AMTSL is also associated with a reduction in the birth weight which may reflect a 
reduction in the neonate blood volume due to early cord clamping (Begley et al., 
2011).
The components of the AMTSL have been investigated to find out the effect of 
different practice on the reduction of postpartum blood loss and the possible adverse 
effects. These included the timing of administration of the uterotonics and the timing 
of cord clamping, uterine message and whether to apply cord traction for placental 
delivery or not. The administration of uterotonic prior to placental delivery raised the 
concerns that this could inhibit the delivery of the placenta. Available data propose 
that immediate administration of uterotonics does not lead to greater need for manual 
removal of placenta (Rajan & Wing 2010). However, the impact of early 
administration on blood loss remains uncertain. There was no difference in the 
incidence of PPH between women who had oxytocin immediately after the delivery 
and who had oxytocin after the delivery of placenta [56/745 (7.5%) vs. 72/741 (9.7%), 
P=0.15] (Jackson et al., 2001). Another small trial found that the rate of PPH was 
lower in the group who received oxytocin after the delivery of the placenta compared
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to those women who received oxytocin after the delivery of the anterior shoulder 
[0/24 (0%) vs. 4/27 (14.8%), P=0.05]. However, the trial was terminated early at this 
small sample size due to lack of resources and this may make it under powered (Huh, 
Chelmow & Malone 2004). The most recent Cochrane review of the timing of 
prophylactic uterotonics found that timing of the administration of oxytocin either 
before or after the expulsion of the placenta did not have any significant effect on the 
rate of PPH, length of the third stage of labour and the rate of placental retention 
(Soltani, Hutchon & Poulose 2010). This review included a small number of trials and 
investigated only intravenous infusion of the oxytocin. Therefore, it recommended 
further studies to examine different routes of administration and different maternal 
and neonatal outcomes.
Only one study addressed the subject of the uterine massage. The 200 subjects were 
randomised to receive routine active management of labour (oxytocin 10 IU I.V. or 
I.M, immediate cord clamping and controlled cord traction) with uterine massage 
every 10 minutes for the first 60 minutes or active management without uterine 
massage. The trial demonstrated a significant reduction in blood loss by 78 ml and 80 
% reduction in the need for additional uterotonics in the massage group compared to 
the non-massage group. There was no significant reduction in the rate of PPH (4/98 
(5%) vs., 8/102 (7%) (Abdel-Aleem et al., 2006). A larger study is needed to confirm 
the finding and to show the effect of uterine massage in settings where injectable 
uterotonics are available. This would be of great importance in low resource setting 
where PPH is the main cause of maternal mortality.
Early umbilical cord clamping after birth is one component of the triad that makes up 
the original description of the active management of labour. However, the latest 
Cochrane review suggested that delayed cord clamping seems not to increase the 
incidence of PPPI and may be beneficial to the baby in terms of promoting better iron 
stores, although fewer infants in the early cord clamping group require phototherapy 
for jaundice compared to the late cord clamping group (RR 0.59, 95% Cl 0.38-0.92) 
(McDonald & Middleton 2008). A recent study to investigate the effects of delayed 
umbilical cord clamping compared with early clamping on infant iron status at 4 
months of age in a European setting showed a 45% (95% Cl 23-71%) higher mean
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ferritin concentration (117 jxg/L v 81 |ug/L, P<0.001) and a lower prevalence of iron 
deficiency (1 (0.6%) v 10 (5.7%), P=0.01) (Andersson et al, 2011).
Another concern in the protocol of the management of the third stage of labour is the 
risk of uterine inversion with cord traction by untrained attendants. Therefore, the 
current WHO statement on PPH recommended that skilled birth attendants should 
offer AMTSL to all women; it does not advocate active management by non skilled 
attendants (WHO 2007). The International Federation of Gynaecologists and 
Obstetricians (FIGO) and International Confederation of Midwives (ICM) joint 
statement in 2003 stated that active management should be routinely offered to all 
women in the third stage of labour providing that all birth attendants should have the 
knowledge and the proper facilities to perform the active management safely 
(FIGO/ICM 2004a). According to this statement, the active management of labour 
consists of the use of uterotonics (preferably oxytocin), controlled cord traction and 
uterine massage. However, a recent multicentre randomised controlled trial showed 
that omission of controlled cord traction has very little effect on the risk of severe 
haemorrhage (Guhnezoglu et al., 2012).
Until recently, the individual components of the third stage of labour had not been 
examined extensively in research. Therefore, there has been confusion about the 
optimal management protocol. A survey of European policies of the management of 
the third stage of labour revealed a considerable variation within and between 
countries in the choice and timing of the uterotonic administration as well as cord 
clamping (Winter et al., 2007). More research is needed to examine the effect of each 
component of the third stage of labour and the proper uterotonics for the active 
management in the developing countries where the potential risk of PPH is high.
4.1.2. Oxytocin for the third stage of labour
Oxytocin is a naturally occurring uterotonic produced by the posterior lobe of the 
pituitary gland. It was synthesised in 1953 by Du Vigneaud and colleagues (Du 
Vigneaud, Ressler & Trippett 1953). Its mode of action involves the stimulation of the 
upper uterine segment to contract in a rhythmic manner. Oxytocin has a rapid onset of 
action and short half life (mean 3 minutes) when given IV. Therefore, a continuous
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infusion is needed to maintain uterine contraction. By contrast, use of the 
intramuscular route results in a slower onset of action (3-7 minutes) but a longer 
duration of action (up to 60 minutes). Oxytocin has anti-diuretic effect; therefore, 
prolonged infusion can cause water intoxication particularly if given in large volume 
of electrolyte-free solution. Bolus intravenous should be used with caution as 
oxytocin results in relaxation of vascular smooth muscles and may cause profound 
hypotension (ACOG 2006; Breathnach & Geary 2009).
A Cochrane review included over 3000 women in seven trials with considerable 
variation in the doses and the route of administration found a clear benefit of the use 
of oxytocin in the third stage of labour compared to no uterotonic. Oxytocin use was 
associated with a lower incidence of PPH > 500 ml (RR 0.5, 95% Cl 0.43-0.95) and 
> 1000 ml (RR 0.61, 95% Cl 0.44-0.87) and less need for therapeutic uterotonics (RR 
0.5, 95% Cl 0.39-0.64) (Cotter, Ness & Tolosa 2001). Compared to ergot alkaloids, 
there was no difference in the rate of PPH > 500 ml and the need of additional 
uterotonics between these two uterotonics. However, oxytocin administration was 
associated with less frequent manual removal of placenta (RR 0.57, 95% Cl 0.41- 
0.79) and less raised blood pressure (RR 0.53, 95% Cl 0.19- 1.52), compared to ergot 
alkaloids (Cotter, Ness & Tolosa 2001).
A new delivery system of oxytocin using a prefilled oxytocin injection (Uniject) is of 
great importance in the prevention of PPH particularly in less developed countries. A 
study conducted in Angola found that Uniject showed marked reduction in the rate of 
blood loss > 500 ml compared to no treatment [316/782 (40.4%) vs. 67/814 (8.2%), 
PO.OOl] (Strand et ah, 2005). The midwives in a study conducted in Indonesia found 
the device easier and more practical than the traditional way using needle, syringe and 
ampule (Tsu et ah, 2003). These trials finding suggest that the introduction of the 
Uniject may facilitate the application of the AMTSL in the developing countries 
particularly in places with high incidence of HIV and viral hepatitis.
4.1.3. Ergot alkaloids for the third stage of labour
Ergometrine results in prolonged and sustained uterine contractions in both the upper 
and the lower uterine segments via an increase in the calcium influx which in turn
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activates the uterine smooth muscles to contract in a tetanic manner. The onset of 
action is 2-5 minutes after intramuscular injection of the standard dose (0,25 mg of 
ergometrine). It is mean plasma half life is 30 minutes and the clinical effect continues 
for 3 hours. The administration is mainly by intramuscular route, although oral and 
intravenous routes are also possible. Ergot alkaloids mediate its action via stimulation 
of the a-adrenergic receptors which can results in vasoconstriction and cause 
hypertension. Therefore, it is contraindicated in women with hypertension, pre­
eclampsia, heart disease, migraine, Raynaud’s syndrome and peripheral vascular 
disease. The most commonly reported side effects are nausea, vomiting, headache, 
dizziness and increased blood pressure (Breathnach & Geary 2009).
For the AMTSL, ergot alkaloids were compared to no uterotonic agent in a systematic 
review for the Cochrane collaboration. Parenteral administration of ergot alkaloids 
significantly decreased the mean blood loss and the risk of PPH > 500 ml (RR 0.38, 
95% Cl 0.21-0.69). On the other hand, the treated women had elevated blood pressure 
(RR 2.60, 95% Cl 1.03-6.57), vomiting (RR 11.81, 95% Cl 1.78- 78.28) and after 
pain requiring analgesia (RR 2.53, 95% Cl 1.34-4.78) (Liabsuetrakul et ah, 2007). 
Most studies used intramuscular ergometrine. However, the one study that used the 
intravenous route reported that 0.5 mg intravenous ergometrine was associated with a 
significant increase in the incidence of manual removal of placenta (3%) compared to 
the physiological management of the third stage of labour (0.1%) (Begley 1990). The 
one trial that examined the oral route showed no significant benefit of ergot alkaloid 
over placebo and concluded therefore that oral ergometrine is not an alternative to 
oxytocin in the management of the third stage of labour (De Groot 1996). Overall the 
evidence suggests that although ergometrine is effective at PPH prophylaxis, oxytocin 
is much better tolerated.
Syntometrine® is one of the most widely used uterotonics in the UK. It is 
combination of 5 IU oxytocin and 0.5 mg ergometrine. It has both the advantages of 
the oxytocin rapid onset of action and the sustained uterine contractility provided by 
the ergometrine. The Cochrane review of the prophylactic use of syntometrine versus 
oxytocin found that the syntometrine reduced the occurrence of PPH > 500 ml [OR 
0.82, 95% Cl 0.71 to 0.95] but not of PPH > 1000 ml (OR 0.78, 95% Cl 0.59-1.04).
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Syntometrine was associated with significantly more risk of side effects such as 
hypertension [OR 2.81 (95% 1.17 to 6.73)] and vomiting (OR 4.92, 95% Cl 4.03- 
6.00) (McDonald, Abbott & Higgins 2004). Therefore, although oxytocin would 
appear to be marginally less effective than syntometrine, it is generally recommended 
as first line treatment due to its low rate of side effects and greater stability to light 
and heat.
4.1.4. Oxytocin agonist
Carbetocin is a synthetic long acting analogue of the natural human oxytocin. It binds 
to the oxytocin receptor on the uterine muscle and produce rhythmic contraction by 
releasing calcium ions. Carbetocin was produced by modifying the oxytocin molecule 
and this prolonged its half life and reduced its enzymatic degradation. Carbetocin has 
a similar rapid onset of action, the same side effect profile as oxytocin, and can be 
administered intramuscularly or intravenously. Intravenous carbetocin has a half life 
of approximately 40 minutes (Sweeney et ah, 1990). The uterine effects of the 
intramuscular injection persist for approximately 120 minutes and for the intravenous 
injection for about 60 minutes (Hunter, Schulz & Wassenaar 1992). The optimal dose 
of carbetocin is 100 meg intravenous or intramuscular (van Dongen et ah, 1998). The 
efficacy of carbetocin in the AMTSL has been investigated after vaginal and after 
caesarean delivery. A randomised, double blind, placebo controlled trial found that 
single intramuscular injection of 100 meg carbetocin was more likely to prevent PPH 
in high risk women than a 2 hour intravenous infusion of 10 IU oxytocin. The main 
difference was observed in the need of additional interventions either additional 
uterotonic or uterine massage. An additional intervention was required in 44.6% of 
the women who received carbetocin and in 63.6% of women who were managed with 
oxytocin (P<0.025). However, no significant differences were observed for other 
efficacy variables which included change in haemoglobin and haematocrit over the 
initial 24 hours postpartum, estimated blood loss, uterine tone and the amount and 
type of lochia (Boucher et ah, 2004). Another RCT which investigated the efficacy of 
intramuscular carbetocin (100 meg) versus intramuscular syntometrine in the 
prevention of PPH did not demonstrate a significant difference between the two 
treatment arms in tenns of reduction in the haemoglobin level, need for additional
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uterotonics, rate of PPH > 500 ml and the incidence of retained placenta (Leung et al., 
2006). The use of carbetocin was associated with lower rates of nausea, vomiting and 
increased blood pressure, but a higher incidence of maternal tachycardia (Leung et ah, 
2006). Carbetocin is currently approved in 23 countries as single intravenous injection 
for the prevention of uterine atony after caesarean section under epidural or spinal 
anaesthesia (Peters & Duvekot 2009; Rath 2009). Data from 2 RCTs were evaluated 
in Cochrane meta-analysis to determine the efficacy of carbetocin in caesarean 
delivery. The risk of PPH > 500 ml was not significantly decreased in the women who 
were treated with carbetocin compared with the oxytocin group (RR 0.71, 95% Cl 
(0.14-3.35). However, carbetocin significantly decreased the need for additional 
uterotonics (RR 0.44, 95% Cl (0.25-0.78) and uterine massage (RR 0.38, 95% Cl 
(0.18-0.8) compared with oxytocin. This review concluded that most of the outcomes 
were extracted from a single trial and the available data on carbetocin has several 
limitations as most of the trials did not use blood loss as a primary outcome (Su, 
Chong & Samuel 2007). Therefore, that evidence of carbetocin superiority over the 
currently available uterotonic is not yet proven and it remains outside of most 
international PPH guidelines.
4.1.5. Prostaglandins E and F for the third stage of labour
Prostaglandins play a major role in producing uterine contractions. The exogenous 
administration of different types of prostaglandin has been investigated for prevention 
and treatment of PPH. Many prostaglandins and its analogues have been available for 
these indications. They include prostaglandin F2a (dinoprost) and its analogue 
(carboprost), prostaglandin E2 analogue (dinoprostone, sulprostone) and prostaglandin 
Ei analogues (misoprostol and gemeprost). This section will focus on all the above 
mentioned prostaglandins except misoprostol which will be described in the following 
section as extensive research has been conducted to find out the effectiveness of 
misoprostol in the AMTSL particularly in the developing world.
Prostaglandin F2a and prostaglandin E are mainly used for the treatment of PPH and 
the data of their application for PPH prophylaxis is very limited. Ten small trials 
involving injectable prostaglandins have been evaluated in the Cochrane review for 
prostaglandins for preventing PPH. When compared with no uterotonic, injectable
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prostaglandins had less mean blood loss and also it has less blood loss and shorter 
duration of the third stage of labour compared to conventional uterotonics 
(Gulmezoglu et ah, 2007). However, a higher incidence of abdominal pain, vomiting 
and diarrhoea has been reported with the injectable prostaglandins. The use of one 
prostaglandin E2 analogue (sulprostone) was associated with cardiac arrest in 3 
women and it was therefore voluntarily withdrawn by the manufactures (Sharma & 
El-Refaey 2003). Overall, injectable prostaglandins appear to be superior to placebo 
but were not preferable to conventional uterotonics in the management of the third 
stage of labour (Gulmezoglu et ah, 2007).
4.1.6. Misoprostol for the third stage of labour
Overall, Misoprostol appears to be less effective than conventional uterotonics. But, it 
is clear that misoprostol is better than placebo for AMTSL. Data from studies about 
misoprostol for PPH is difficult to interpret as most of them were un-blinded and 
subjective measurement of blood loss is difficult and inaccurate. More details was 
mentioned in the first section of this chapter.
4.2. Treatment of Postpartum Haemorrhage
The management of PPH should be started antepartum and intrapartum. The 
likelihood of a woman developing PPH should be assessed carefully and appropriate 
precautions should be taken in women who are at risk. All women at risk should have 
intravenous access and have appropriate uterotonics and blood products available.
A systematic approach should be taken when managing women presenting with heavy 
bleeding after delivery. The women should be assessed carefully to find out the cause 
of bleeding and they should be resuscitated if develop signs and symptoms of 
haemorrhagic shock. The first action should be to call for help and to alert an 
experienced obstetrician, followed by resuscitation of the patient, assessment of the 
uterine tone and rule out the possibility of retained products of conception, genital 
tract trauma and coagulopathy (commonly known as the 4Ts: tone, tissue, trauma, 
thrombin). Bladder evacuation and keeping a catheter in place is very important as a 
distended bladder could be the only cause of uterine atony and PPH. The second line
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of treatment, if atony persists is bimanual uterine compression (Figure 16) which 
should be applied and additional uterotonics administered immediately. If bleeding 
persists despite this, exploration under anaesthesia should be done before transition to 
surgical management (RCOG 2009).
Figure 16. Bimanual uterine massage for management of uterine atony (Anderson & 
Etches 2007)
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4.2.1. Medical treatment of PPH
The first line medical treatment of uterine atony involves administration of oxytocin 
or ergometrine as a bolus doses. Despite extensive and extended use of injectable 
uterotonics over the last few decades, there were no clinical trials comparing oxytocin 
and ergometrine as first line therapies for treatment of uterine atony. Although both 
agents seem to be equally effective, oxytocin is more widely used as it has fewer side 
effects and can be easily used in women with hypertension and preeclampsia. On the 
other hand, intravenous administration of 5 IU oxytocin can result in profound 
hypotension due decrease in the resistance of vascular smooth muscles (Figure 17) 
(Weeks 2010). Therefore, it is recommended to use 5 IU oxytocin as slow intravenous 
injection and replace it with a continuous infusion of 20 IU oxytocin in 500 ml 
crystalloid solution to maintain uterine contraction if bleeding persists. Ergometrine 
can be administered as 0.25 mg intramuscular injection. It is contraindicated in 
women with hypertension and causes nausea, vomiting and dizziness.
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Figure 17. Systemic vascular resistance, mean arterial pressure and cardiac output 
represented as means (95% confidence intervals) vs. time (seconds). Arrow indicates 
timing of 5 unit oxytocin bolus (from Weeks 2010 with permission)
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Carboprost (PGF2a) is considered as the second line for the management of PPH in a 
uterus unresponsive to oxytocin or ergometrine. However, there were no trials 
comparing it with other uterotonics. It has a longer duration of action than 
dinoprostone (PGE2). Carboprost can be given as a deep intramuscular or direct 
intramyometerial injection. The latter route has a rapid onset of action and can be 
achieved under direct vision dining caesarean section, transabdominally or 
transvaginally. The peak plasma concentration of the intramuscular route is achieved 
at 15 minutes and at less than 5 minutes for the intramyometerial injection. It is 
available in single dose vials of 0.25 mg. The dose can be repeated every 15 minutes 
up to a maximum of 2 mg (8 doses) (Breathnach & Geary 2009).
Misoprostol is generally recommended as the last line of management of uterine atony 
in hospital sittings and in the presence of other injectable uterotonics. Also, 
misoprostol could be an appropriate alternative when parenteral prostaglandin is not 
available or when it is contraindicated (usually astlnna). The authors of the latest 
Cochrane review for treatment of PPH concluded that the available evidence was not 
enough to support the use of misoprostol instead of oxytocin and ergometrine as a 
first line treatment of PPH (Mousa & Alfirevic 2007). The use of misoprostol for 
treatment of PPH was discussed in more details in Section I.
4.2.2. Fluid and blood product for treatment of PPH
While investigating the aetiology of PPH and treating the cause, resuscitation and 
volume replacement should immediately take place. Rapid infusion with colloid- 
crystalloid solutions should be started. The haematologist and blood transfusion 
laboratory should be notified. Anaesthesia should be also notified to be ready for 
siugical interventions once needed. Baseline investigation should be ordered such as 
complete blood count as well as prothrombin time (PT) and partial thromboplastin 
time (PTT) (RCOG 2009).
4.2.3. Uterine tamponade
There are several methods based on tamponade to terminate uterine bleeding. These 
methods can include the most basic methods of uterine backing using long gauze
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placed in the uterine cavity, or inserting a condom attached to the end of Foley 
catheter, a technique that is particularly useful in the developing countries. The one 
disadvantage of these devices is that they may mask uterine bleeding by blocking the 
outflow tract. Therefore, it is important to note the fundal levels at the time of packing 
(Rajan & Wing 2010).
A more developed balloon device such as Sengstaken-Blakemore tube, Rusch 
balloon and Bakri balloon have been used in Europe (Figure 18, (Georgiou 2009). 
These methods, except the Rusch balloon, have the advantage of providing an outflow 
tract for the continuous bleeding (Majumdar et al., 2010). The effectiveness of 
ditterent tamponade methods has only been described in cases series since 
randomised controlled trials are unlikely to be conducted as the cases which need 
uterine tamponade is relatively rare. Uterine balloons have proved very popular with 
reported a success rate of 81% for the Sengstaken-Blackemore tube (Doumouchtsis et 
al., 2008) and 59% success for Rusch balloon (Majumdar et al., 2010). Therefore, 
uterine balloon tamponade is considered as important weapon in the treatment of 
PPH.
Figure 18. Distal component of tamponade balloons (Georgiou 2009)
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4.2.4. Uterine compression and selective pelvic vessels embolisation
If bleeding continues despite all the above measures, operative intervention should 
follow quickly. This involves exploratory laparotomy via a midline vertical incision. 
Many compression methods have been described to control the uterine bleeding such 
as B-Lynch technique and through- and through square sutures. Some clinicians go 
immediately for hysterectomy as a life-saving procedure. The surgical management 
depends mainly on the health facilities and the experience of surgeons where the cases 
of PPH are treated. The B-Lynch suture was first described in 1997 by Christopher B- 
Lynch and modified techniques have evolved later (B-Lynch et ah, 1997). The 
efficacy of uterine compression suture is high as demonstrated in several systematic 
reviews of cases series of women with severe PPH (Fotopoulou & Dudenhausen 
2010; Ouahba et ah, 2007).
Vascular embolisation technique can also be applied in haemodynamically stable 
patients with continued bleeding in centres with good facilities and trained personnel. 
It is a less invasive intervention and involves insertion of a catheter into the femoral 
artery to the aorta then to the uterine arteries. A success rate of 95-100% has been 
reported (Hansch et ah, 1999; Vegas et ah, 2006; Winograd 2008). Therefore, this 
technique is highly recommended as first line before surgical intervention. However, 
the facility to perform this technique is not widely available even in the developed 
countries.
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5. Postpartum intrauterine pressure measurements of myometrial 
activity
Intrauterine pressure (IUP) measurements were introduced into clinical practice 
mainly to study uterine activity during labour. It assisted in the diagnoses of various 
labour dysfunctions such as obstructed labour, arrested labour and uterine 
hyperstimulation particularly during the induction of labour using uterotonics.The 
intrauterine pressure measurements have also been used extensively in research to 
investigate the uterine activity at different stages of the female reproductive life. This 
included studies of the uterine muscle activity during menstruation to investigate 
dysmenorrhoea (Lumsden, Kelly & Baird 1983; Milsom & Andersch 1985), studies 
of uterine stimulation during different procedures and stages of assisted reproduction 
(Bulletti & De Ziegler 2005) and research into uterine activity during the third stage 
of labour to explore the causes and treatment of uterine atony (Chong et ah, 2001).
5.1. History of intrauterine pressure measurements
The current methods of intrauterine pressure measurements came after more than a 
century of evolving and improving techniques for this purpose. The first recording of 
intrauterine pressure was done by Heimicius in 1889. The catheter was a large balloon 
connected to a manometer by an electroplated catheter. The insertion of this large 
balloon required anaesthesia and produced marked uterine irritability. Therefore, 
efforts were directed to decrease the balloon size. In 1893, Westermark developed a 
smaller balloon tipped cannula which made the insertion easier and produced more 
accurate information (Smith 1984).
Although many modifications were applied to methods of the uterine measurements 
after this, the balloon tipped catheters remained the standard until the concept of the 
intrauterine pressure transducer was introduced in 1944. By moving the pressure 
sensor into the uterus, the inaccuracies caused by the transmission of the pressure 
wave to an external manometer was avoided. In 1962, improvements were made to 
the transducer which became more sensitive and well tolerated by the patients, and no 
longer severely restricted the woman’s position and movement. By the early 1970’s,
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micro-transducers were developed and were being used for the evaluation of the 
uterine pressure during labour (Smith 1984).
5.1.1. Units for evaluating uterine activity
For the assessment of uterine muscle activity, we need to know how strong the 
contractions are, how frequent they are and how long they last. Therefore, ideally one 
would have one measurement or unit to describe all three factors which would provide 
a clear idea about the nature and the quality of the uterine contractions during labour. 
Several units have been introduced to assess uterine contractions such as Montevideo 
unit (MVU), Alexandria units (AU), area under the uterine pressure curve, active 
pressure integral (API), and mean active pressure (MAY). Although each method has 
its advantages and disadvantages, all have been used in practice and in research. The 
MVU is calculated by measuring the peak intrauterine pressure during the contraction 
and multiply them by the number of the contraction over 10 minutes. Many authors 
have pointed out that the MVU ignores the contribution of the duration of contractions 
and is also insensitive to the shape of the contractions. Although the Alexandria unit 
included the duration of the uterine contraction in its formula, it has not gained 
popularity. The use of ‘area under the uterine pressure curves’ takes into account the 
frequency, intensity and duration of the uterine contraction. However, it fails to 
differentiate between the active contraction and baseline tone. API is an integral of 
active pressure which is the intrauterine pressure minus the baseline pressure over a 
period of 15 minutes. Dividing the active pressure integral by the number of seconds 
in 15 minutes (900 sec) gives the mean of active pressure (MAP) (Phillips & Calder 
1987).
5.2. Current methods of IUP measurement (Types of catheters)
There are different types of the intrauterine pressure catheters with variable shapes 
and design. Some of the catheters have a transducer at the tip (e.g. the Intran catheter) 
and some have a sensor at the tip connected to an external transducer (e.g. the Koala 
catheter; Figure 19 ; (Dowdle 1997). The catheter with a pressure transducer at the tip 
was introduced to overcome the disadvantages of the fluid filled polythene catheter 
which may cause uterine perforation. Partial blockage of the system with vernix or
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blood clots also commonly leads to an underestimation of the uterine activity. This 
could result in clinicians giving an excessive amount of oxytocin and causing uterine 
hyperstimulation. Also, an increased incidence of endometritis has been reported 
(Steer et ah, 1978). It has also been shown that transducer-tipped IUP catheters may 
artifactually elevate the basal uterine tone reading due to the physical mechanics 
inherent in the tipped transducer catheter. This may result in difficulties in the 
management of dysfunctional labour, augment or induced labour and in the diagnosis 
of abruptio placenta (Ross & Walton 1994).
Figure 19. Koala catheter tip (left) as compared to the catheters with transducers at 
their tips: the Intran Plus (center) and SoftTrans (right) (Dowdle 1997)
The recently produced intrauterine pressure catheter with a sensor at the tip and an 
external transducer (Koala) shows some advantages over the catheter tip transducer 
(Intran). These include an easier insertion which occurs because the catheter has a 
softer, smaller catheter tip and a flexible body. It also gives a more accurate 
measurement as it has multiple holes to transmit all the amniotic pressure to the 
transducer. Also, unlike the transducer tipped catheters, the accuracy of the
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measurements are not affected by changes in the temperature from body to room 
temperature, contact pressure or force as the transducer is located outside the body. It 
is also easier to set up and easier to zero while it is in-utero as the transducer is 
connected to an external reusable connector (Dowdle 1997).
The most recent development of the IUPC was the addition of a sensing membrane to 
the tip of the external transducer catheter. This new catheter was produced by clinical 
innovations and is known as the Koala IUP-5000E catheter (Figure 20). It employs 
air-coupling technology from a distally mounted flexible balloon that communicates 
through a sealed micro-tube to an externally located electronic reusable transducer in 
the monitor cable and connector. The purpose of this is to eliminate the direct tissue 
contact force erro.
Figure 20. Koala IUP-5000E catheter (Clinical innovations)
5.3. The reliability studies of IUP catheters
Several studies have been conducted to investigate the reliability of lUPs during 
different stages of labour. Some of the studies used an in vitro uterine model to mimic 
several conditions during labour whereas others conducted the reliability test in a real 
situation during labour. One study used an in vitro uterine model to test the reliability 
of two catheters from Utah Medical. One was the sensor tipped transducer catheter 
and the other was fluid-filled catheter with an external transducer. In this model
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several situations were introduced such as kinking of the catheter tip, using thick fluid 
to simulate thick meconium and using petroleum jelly on the catheter tip to simulate 
vernix obstruction. Both types of catheter showed satisfactory recording of the 
intrauterine pressure except when in the presence of simulated thick meconium. The 
study showed a significant decrease in peak pressures in fluid-filled catheter series at 
all pressure levels compared with the sensor-tip catheter series. Flushing of the fluid- 
filled catheter resulted in non-significant difference in the resting and peak pressures 
and the pressure waveforms between both types of catheters. Therefore, in presence of 
thick meconium it is advised to use a sensor-tip catheter to avoid the need for 
continuous flushing of the fluid-filled catheter (Devoe, Smith & Stoker 1993).
The transducer tipped catheter has been evaluated during the first and the third stages 
of labour. During the first stage of labour, the intrauterine pressure transducer-tipped 
catheter was evaluated clinically in 100 patients. In the study, the clinicians were able 
to successfully insert the catheter 95% of the time and there were no significant 
maternal or fetal complications. The time required for insertion was short and could 
be done without assistance. This type of catheter also needed few or no ongoing 
maintenance (Strong & Paul 1989). The accuracy of tip transducer catheter was 
investigated by introducing two catheters into the same amniotic fluid pocket and 
introducing two catheters into two different pockets. The study found that the 
information on the cumulative intrauterine pressure was reliable whenever the 
catheter’s tip was located in the uterus (Chua et al., 1992).
Another study compared the IUP recorded from 3 different types of catheter during 
the first stage of labour. This included conventional fluid-filled catheter (Soft-Trans), 
catheter tip transducer (Intran plus) and external transducer catheter (Koala). The data 
showed a significant difference between Koala and the other catheters in ease of 
insertion and use and in level of clinical accuracy. However, it showed no significant 
difference between the catheters in safety during insertion, signal zeroing and signal 
drift (Dowdle 1997). The reliability of the air-charged coupled Koala catheter was 
compared with an electronic pressure transducer tipped catheter (Intran) during 
labour. Both catheters were bound together at their tips and introduced into the uterus. 
The data showed similar mean baseline tone, peak pressures, contractions frequency
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and duration during labour. However, there was no reliability study for koala catheter 
during the third stage of labour (Dowdle 2003).
During the third stage of labour, the reliability of the transducer tipped catheter was 
evaluated at different locations in the uterus using two catheters tied together and two 
separate catheters. Whether the catheters were separate or tied, the comparison of 
individual active pressure readings revealed good agreement and the cumulative 
active pressure was very similar in each catheter in the same uterus (Chua et al., 
1998). In these studies there was no gold standard to enable an assessment of 
accuracy.
Intrauterine pressure catheters have a wide range of applications in practice and 
research. Clinically, they are mainly utilised to assess the strength of uterine 
contractions during the first stage of labour and can help to diagnose labour 
dysfunction due to inappropriate uterine contractions’ strength and frequency 
(Bakker, Van Rijswijk & van Geijn 2007).
In research, intrauterine pressure catheters have been used to study the uterine activity 
during menstruation to investigate the causes of dysmenorrhoea and also to explore 
uterine contraction during IVF procedures. Research into drugs’ effect on uterine 
activity either dining labour or postpartum, has utilised the intrauterine pressure 
catheters to measure this effect postpartum as it does not involve the fetus. Even 
though calcium channel blockers such as nifedipine and isradipine are mainly used in 
obstetrics to inhibit uterine contraction in preterm labour, many studies have 
investigated the relaxant effect of these drugs on uterine contraction during the third 
stage of labour (Ingemarsson et al., 1989).
Research into PPH has used intrauterine pressure catheters to measure uterine 
contractions during the third stage of labour. Early studies showed that medications 
such as oxytocin, ergometrine and prostaglandins all have a strong contractile effect 
on the uterine muscle. Intrauterine pressure catheters were widely used to investigate 
the effect of these medications and to compare different doses and routes for 
prevention and treatment of PPH.
123
Chapter 2
The risk of fever after administration of misoprostol 
for prevention of postpartum haemorrhage: 
systematic review and meta-analysis
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1. Introduction
Misoprostol, a PGEi analogue, has been recommended as an alternative to parental 
uterotonics for the management of PPH because of its potency, ease of administration, 
stability at ambient temperature and cost effectiveness (Mousa & Alfirevic 2007). 
However, elevated body temperatures after its use in relatively high doses for PPPI 
have raised concerns about its safety (Hofmeyr & Gulmezoglu 2008). Identification of 
the correct dosage is however difficult and recommended misoprostol dosages vary 
widely according to the route of administration, indication and gestation (Elati & 
Weeks 2009). Finding the appropriate dosage for PPH management has proved 
particularly controversial due to the relative lack of efficacy of misoprostol compared 
with oxytocin (Gulmezoglu et al., 2001). This has led practitioners to use the 
maximum tolerated dose for PPH management.
The most commonly reported side effect of misoprostol is shivering, which is 
commonly followed by an increase in the body temperature. However, these side 
effects are not severe, are transient (resolving within 12 hours or less) and have not 
been associated with any lasting effect on health (Gulmezoglu et al., 2001; Hofmeyr 
et al., 2001b). The thermogenic activity of prostaglandin E was recognised in the 
human with the increasing use of high doses in reproductive medicine. 
Pharmacokinetic studies show that the sublingual and oral routes achieve higher and 
more rapid maximum plasma concentrations than the vaginal and rectal routes (Khan 
et ah, 2004; Tang et al., 2002; Zieman et ah, 1997). They would therefore be expected 
to be associated with a higher incidence of shivering and fever compared to the other 
routes.
The use of misoprostol for the prevention and treatment of PPH appears to be a 
particular problem with respect to the thermogenic side effects. In early studies of 
misoprostol a woman developed severe pyrexia with a rectal temperature of 41.9°C 
after ingestion of 800 meg oral misoprostol (Chong, Chua & Arulkumaran 1997). A 
PPH treatment trial of 244 women also reported three women with a temperature 
above 40.0°C following 1000 meg misoprostol (administered as 200 meg oral, 400 
meg sublingual and 400 meg rectal) (Hofineyr et ah, 2004). The most two recent
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randomised controlled trials have confirmed that shivering and pyrexia are the most 
common side effects of 800 meg sublingual misoprostol (Blum et al., 2010; Winikoff 
et ah, 2010). Data from these trials showed that the incidence of shivering was 43%, 
with 34% reporting fever. In one hospital in Ecuador the incidence of high fever > 
40.0°C was 35.6% (Durocher et al., 2010). Fortunately, all cases made full recovery 
after management with cold compresses and antipyretics.
The effectiveness and safety of misoprostol are equally important for the clinician and 
for their patients. However, most of the studies which investigated misoprostol for the 
management of PPH have focused on the effectiveness of treatment and have paid 
little attention to the associated side effects. Although experience has shown that the 
misoprostol-related fever is not life-threatening, it would be better for patients’ 
comfort, providers’ acceptance and drug compliance if a lower effective dose could be 
found that minimises the rate of this side effect. In this chapter, we have therefore 
reviewed the incidence and risk of fever associated with the use of misoprostol for the 
prevention of PPH.
2. Objectives
To assess the incidence and risk of fever associated with the use of misoprostol for the 
prevention of PPH and examine how they vary with different doses and routes of 
administration.
3. Criteria for considering studies for this review
There is now a vast amount of literature on misoprostol use in the third stage of 
labour. Fever is, however, a very specific complication whose detection will be 
markedly increased if specifically sought in those using misoprostol, either through a 
questionnaire or through direct measurement. This is most likely to be done in the 
context of a randomised trial and we therefore focused our review on data from these 
studies only as a way of reducing reporting bias (Loke, Price & Herxheimer 2008; 
McIntosh, Woolacott & Bagnall 2004). Studies in which misoprostol was used for 
PPH treatment were excluded as haematological instability and blood loss could affect 
the thermoregulatory response of the body to misoprostol.
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All misoprostol arms from randomised controlled trials were included in the analysis 
of the incidence of fever and grouped by route and dose. In the meta-analysis of fever 
risk, the ideal comparator would be a placebo. Given the evidence in favour of PPH 
prophylaxis, however, most researchers believe it to be unethical to use a no-treatment 
control. Placebo-controlled misoprostol trials for PPH prevention are therefore rare. In 
view of this, all the studies of misoprostol for PPH prevention have been retained for 
the risk meta-analysis, including studies that compare misoprostol with oxytocin, 
ergometrine and other misoprostol regimens. This is justified as fever is not a reported 
side effect of any of these therapies (Begley 1990; Prendiville et al., 1988).
2.1. Types of studies
All randomised clinical trials using misoprostol in at least one of their intervention 
arms for the prevention of PPH up to 20 July 2010.
2.2. Types of participants
The participants were women during the third stage of labour taking part in 
randomised trials in which prophylactic misoprostol was studied for the prevention of 
PPH.
2.3. Types of interventions
Misoprostol administered by any route or dose in one or more of the treatment arms 
and placebo or any other uterotonic in the control arm.
2.4. Types of outcome measures
The primary outcomes are the frequency of fever (authors’ definitions) in the 
misoprostol group and its risk ratio compared to controls. Definitions of ‘fever5 vary 
considerably and so if the analysis were to be restricted to any particular cut-off, the 
number of trials to be included would be greatly reduced. It is therefore, considered 
justified to use ‘fever’ as an outcome and not a more specific cut-off.
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4. Search strategy for identification of studies
In this narrowly focused review, the search in Cochrane CENTRAL, Scopus, Embase, 
Web of Knowledge and PubMed for randomised clinical trials was conducted using 
different free text terms including: misoprostol, third stage of labour (or labor), and 
postpartum haemorrhage (or hemorrhage). The search was limited to randomised 
clinical trials in humans without language restriction.
5. Methods for the randomised clinical trials
5.1. Studies selection
All potential studies identified as a result of the search strategy were assessed 
independently for inclusion by 2 reviewers (Anisa Elati & Andrew Weeks).
5.2. Data extraction and management
We developed a data extraction form based on the CONSORT statement for better 
reporting of harms in randomised trials (loannidis et ah, 2004) (Appendix A.l) One 
reviewer extracted the data from the included studies and the second reviewer 
checked the extracted data. Discrepancies were resolved through discussion. 
StatsDirect Software and Review Manager 5 were used for data management, analysis 
and production of Forest plots.
5.3. Appraisal of study quality and data abstraction
We excluded non-randomised trials, those which used misoprostol for treatment of 
PPH, and trials which had not recorded the rate of fever. The validity of each 
remaining study was assessed by two reviewers working independently to determine 
the adequacy of randomisation and concealment of allocation, blinding and extent of 
loss to follow up according to the following criteria:
(1) Selection bias (randomisation and allocation concealment)
(A) Adequate concealment of allocation: such as telephone randomisation, 
consecutively numbered sealed opaque envelopes;
(B) Unclear whether adequate concealment of allocation: such as list or table
128
used, sealed envelopes, or study does not report any concealment approach;
(C) Inadequate concealment of allocation: such as open list of random number 
tables, use of case record numbers, dates of birth or days of the week.
(2) Attrition bias (loss of participants, e.g. withdrawals, dropouts, protocol 
deviations)
(A) less than 5% loss of participants;
(B) 5% to 9.9% of loss of participants;
(C) 10% to 19.9% loss of participants;
(D) More than 20% loss of participants.
(3) Performance bias (blinding of participants, researchers and outcome 
assessment)
(1) blinding of participants (yes/no/unclear);
(2) blinding of caregiver (yes/no/unclear);
(3) blinding of outcome assessment (yes/no/unclear).
5.4. Measures of treatment effect and assessment of heterogeneity
Tests of heterogeneity were applied between trials, using the P statistic. In the 
absence of significant heterogeneity (exceeding 50%), fixed-effects meta-analysis was 
used for combining data. When there were high levels of heterogeneity, a random- 
effects meta-analysis was used to obtain the overall summary statistic. In this group, 
sensitivity analysis was also carried out to explore the effects of trial quality. This 
involved analysis based on the rating of selection and attrition bias. Studies of less 
than ‘A5 quality for these outcomes were excluded from the analysis in order to assess 
for any substantive difference to the overall result. The test for heterogeneity between 
the subgroups was used to explore the dosage effects. Heterogeneity was also 
explored by examination of year of publication. This is because postpartum fever is 
very prone to reporting bias, and it might be expected that reports of fever in early 
studies might lead to increased detection in later studies. Fever rates in the control 
groups were also explored as high reported fever rates might reflect population 
differences in peri-partum infection or in predisposition to fever, and may not occur 
simply as a result of the misoprostol.
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7. Statistical analysis
Two main analyses were conducted. In the first, the incidence of fever was presented 
as the rate of fever in women who received misoprostol via different routes. Pre­
specified subgroups were the doses of misoprostol. The data was summarised as an 
overall incidence for each route using StatsDirect software.
In the second analysis, the risk ratio of fever in studies comparing misoprostol to 
controls were combined in a formal meta-analysis and presented as risk ratios (RRs) 
with 95% confidence intervals (CIs) using Review Manager 5. In this second analysis, 
the following subgroup analyses were included:
I. The risk of fever with misoprostol versus placebo
1. 600 meg oral misoprostol
2. 600 meg sublingual misoprostol
II. The risk of fever with misoprostol versus oxytocin
1. 400 meg oral misoprostol
2. 500 meg oral misoprostol
3. 600 meg oral misoprostol
3. 800 meg oral misoprostol
4. 400 meg sublingual misoprostol
5. 600 meg sublingual misoprostol
6. 500 meg rectal misoprostol
7. 600 meg rectal misoprostol
8. 800 meg rectal misoprostol
III. The risk of fever with misoprostol versus methyl ergometrine
1. 200 meg oral misoprostol
2. 400 meg oral misoprostol
3. 600 meg oral misoprostol
4. 400 meg sublingual misoprostol
5. 600 meg sublingual misoprostol
IV. The risk of fever with misoprostol versus combined oxytocin/ergometrine
1. 400 meg oral misoprostol.
2. 600 meg oral misoprostol
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V. The risk of fever with misoprostol compared to misoprostol of other doses and 
routes
1. 600 meg versus 400 meg sublingual
2. 600 meg versus 400 meg oral
3. 600 meg versus 400 meg rectal
8. Results
8.1. Description of the identified studies
For this review 231 studies were initially identified. After exclusion, 33 trials were 
included in the review and 28 were excluded (Figure 1).
8.1.1. Excluded studies
159 studies were excluded initially because the misoprostol was not being used for the 
management of the third stage of labour. A further 28 trials were excluded on closer 
examination: 2 trials were subgroup analyses for other trials included in the review, in 
5 trials the misoprostol was used for treatment of PPH, 2 RCTs were excluded 
because misoprostol was mixed with other uterotonics in the treatment aim, one RCT 
has herb in the control arm (Miller 2009) and 19 trials did not provide data on the 
incidence of fever.
8.1.2. Included studies
We included 33 studies in the review, containing 38478 women. All of them were 
included in the assessment of the incidence of fever. We further excluded 3 RCTs in 
the meta-analysis of the risk of fever because the control group was a herb in 1 RCT 
and was mixed uterotonics in 2 RCTs.
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Figure 1. Flow diagram of the randomised clinical trials included in the review
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8.2. Methodological quality of the included studies
8.2.1. Selection bias and attrition
All the included studies were randomised trials and 8 out of the 33 included studies 
were multicentre randomised controlled trials. 27 (out of 33) studies used adequate 
methods of allocation and concealment and 24 of the 33 reported loss of participants < 
5%. For detailed description of the included trials see Appendix A.2.
8.2.2. Quality of reporting of fever
Five of the 33 trials had no clear definition of the side effect under investigation 
(Miller 2009; Patted 2009; Vimala 2006; Lokugamage 2001; El-Refaey 2000). The 
method of fever assessment was not clearly reported in 6 (Cook 1999; Garg 2005; 
Hofmeyr 2001; Miller 2009; Verma 2006; Naser 2009).
8.2.3. Performance bias (blinding)
Of the 33 included studies, only 19 trials were blinded. However, both blinded and 
open trials were included in the meta-analysis because the blinding was not possible 
in many good quality trials as they compared tablets and injection. This could be a 
source of bias if fever is not monitored systematically for all the participants, as the 
clinician who is aware of the fever as a common side effect of misoprostol may seek 
the complication more actively in women who had misoprostol.
8.3. Outcomes
8.3.1. Incidence of misoprostol induced fever
The incidence of fever was pooled according to the route of administration and the 
dose. There were 7 studies reporting fever with the sublingual misoprostol with a 
pooled incidence of 15% (95% Cl 10-22, I2 = 79.3%). The incidence was 12% (95% 
Cl 7-18, F = 58%) in the 400 meg subgroup and 23% (95% Cl 19-28) in the 600 meg 
subgroup. The overall I2 of 79.3% suggests a dosage effect (Figure 2).
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Proportion meta-analysis plot [random effects]
Singh 2009 0.12 (0.06, 0.22)
Vimala 2004 0 07(0.02, 0.16)
Vimala 2006 0.16 (0.07, 0 29)
Vaid 2009 0.20(0.11, 0.31)
Verma 2006 0.06(0.02, 0.13)
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0.23 (0.19, 0.28)
Figure 2. Pooled incidence of fever with sublingual misoprostol
134
The rate of fever with oral misoprostol was reported in 22 trials and the pooled 
incidence was 8.9% (95% Cl 6.7,-11.4; I2 = 95%. The incidence was 6% (95% Cl 2.2- 
12.6) in the 200 meg subgroup (1 RCT), 7.5% (95% Cl 5-10.5, I2 = 85.8% in the 400 
meg subgroup and 10.6% (95% Cl 6.6 -15.4, I2 = 97.2% in the 600 meg subgroup 
(Figure 3) and for the 800 meg the incidence was 11.4 (95% Cl 7.4-16.5) (1 RCT). 
The overall heterogeneity suggesting dosage effects between the subgroups.
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Figure 3. Pooled incidence of fever with oral misoprostol
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The incidence of fever with rectal misoprostol was pooled from seven trials and gave 
a figure of 3.95% (95% Cl 1.4-10.1; I2 (inconsistency) = 91%. The incidence was 
1.34% (95% Cl 0.02-4.7) in the 400 meg subgroup, 4.0% (95% Cl 2.3-6.5) in the 500 
meg subgroup, 2.0% (95% Cl 0.5-4.4) in the 600 meg subgroup and 10.4% (95% Cl 
0.8-28.7) in the 800 meg subgroup (Figure 4).
Proportion meta-analysis plot [random effects]
400 meg
0.0134 (0.0002,0.0471)
500 meg
600 meg
800 meg
0.104(0.008, 0.287)
Figure 4. Pooled incidence of fever with rectal misoprostol
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8.3.1.1. Exploring heterogeneity
The heterogeneity was explored through the dosage subgroups (see above). In 
addition further analyses were undertaken to explore the effect of date of publication 
(a potential increase in reporting the adverse drug reaction with time) and the ethnicity 
of participants.
8. 3.1.2. Year of study publication
Although there is a change in route of misoprostol used over time with sublingual 
misoprostol becoming more popular after 2004 there were no particular trends over 
time. The incidence of fever in Figure 5 is shown according to year and route.
42 30%
c 10%
♦ oral
■ Sublingual
▲ Rectal
Year of publication
Figure 5. The incidence of fever with different routes of misoprostol according to the 
year of study publication
137
8.3.1.3. Ethnicity
The incidence of fever in single centre study (25 RCTs) was compared in the 
countries in which the study was conducted (breakdown of the incidence of fever 
according to participants’ ethnicity was not provided in any of the studys’ report). 
There were 2 studies in which the incidence of fever was far higher than the others: 
these were the studies using oral misoprostol conducted in Belgium and South Africa 
(Figure 6).
o>o
O
V«->co
s
Mean incidence of fever according to the 
population and the route of adminstration
■ oral
■ rectal
■ Sublingual
Figure 6. Incidence of fever with different routes of misoprostol according to the 
population
138
8.3.2. Risk of misoprostol induced fever compared to control groups
8.3.2.1. Risk of fever with misoprostol compared to that w ith placebo
There were only two studies comparing 600 meg oral misoprostol with placebo 
which reported data on fever (Figure 7). The risk ratio (RR) of fever was 5.24 
(95% Cl 3.28-8.38). The risk of fever with 600 meg sublingual misoprostol versus 
placebo was reported in only one study. The risk ratio was 7.11 (95% Cl 3.85- 
13.12). The overall risk ratio of all 3 studies was 5.83 (95% Cl 4.18-8.13). There 
was no overall heterogeneity or heterogeneity between these subgroups.
Of interest is the variation of the absolute risk between the studies. Although very 
homogenous results are found in the meta-analysis, the incidence of fever varies 
greatly between the groups with 38% in the Hofmeyr study, 24% in the Hoj study 
and 4.2% in the Patted study. The risk ratio is similar in the 3 studies however due 
to the large variation in the incidence of fever in the placebo groups (Hofmeyr 
6.1%, Hoj 3.3% and Patted 1.1%).
misoprotol Placebo Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl
6.1.1 600 meg oral
Hofmeyr 2001 114 299 18 294 49.8% 6.23 [3.89, 9.97] -m-
Patted 2009 34 812 9 808 20.8% 3.76 [1.81, 7.79] —■—
Subtotal (95% Cl) 1111 1102 70.6% 5.24 [3.28, 8.38] ♦
Total events 148 27
Heterogeneity: Tau2 = 0.03; Chi2 1.30, df = 1 (P = 0.25) ; I2 = 23%
Test for overall effect: Z = 6.91 (P < 0.00001)
6.1.2 600 meg sublingual
Haj 2005 78 330 11 331 29.4% 7.11 [3.85, 13.12]
Subtotal (95% Cl) 330 331 29.4% 7.11 [3.85, 13.12]
Total events 78 11
Heterogeneity: Not applicable
Test for overall effect: Z = 6.28 (P < 0.00001)
Total (95% Cl) 1441 1433 100.0%
Total events 226 38
Heterogeneity: Tau2 = 0.00; Chi2= 1.88, df = 2 (P = 0.39); I2 = 0% 
Test for overall effect: Z = 10.41 (P < 0.00001)
Test for suborouo differences: Chi2 = 0.60. df = 1 (P = 0.44). I2 = 0%
5.83 [4.18, 8.13] ♦
0.01
H---------- ---------- 1---------- 1
0.1 1 10 100 
Placebo Misoprostol
Figure 7. The risk ratio of fever w ith misoprostol versus Placebo
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8.3.2.2. Risk of fever with misoprostol compared to that with oxytocin
Nineteen trials reported fever data in studies of misoprostol where oxytocin was the 
control (Figure 8). The risk ratio in the oral 400 meg subgroup was 4.19 (95% Cl 
1.37-12.77,12 = 85%). Four studies reported the incidence of fever with 600 meg oral 
misoprostol and the overall risk ratio was 4.22 (95% Cl 2.12-8.38; I2 = 60%). One 
study reported fever with 800 meg oral misoprostol and this had a high relative risk 
(RR 50.62, Cl 3.10-827.06).
For the sublingual route, there were 2 RCTs which reported fever as a side effect with 
400 meg sublingual misoprostol. The overall risk ratio was 5.67 (95% Cl 1.48- 
21.71). The one study of 600 meg sublingual misoprostol (Singh 2009) showed a risk 
ratio of 19 (95% Cl 1.13-320.67).
Only one study reported data on fever with 500 meg rectal misoprostol (RR 2.74, 95% 
Cl 1.08-6.93) and one with 600 meg rectal misoprostol (RR 5.00, 95% Cl (0.24- 
102.8). Two studies reported data on fever with 800 meg rectal misoprostol and gave 
a risk ratio of 6.9 (95% Cl 0.52-91.94).
The overall risk ratio of fever with different doses and routes of misoprostol when 
compared to oxytocin was 4.94 (95% Cl 2.77-8.8). There was a large amount of 
heterogeneity (78%) but the test for subgroup differences was I2= 0% (P=0.56) which 
shows no heterogeneity between the subgroups of doses and routes of misoprostol. All 
the heterogeneity was within the subgroups.
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Study or Subgroup
Misoprostol Oxytocin
Events Total Events Total Weight
Risk Ratio
M-H, Random, 95% Cl
6.2.1 400 meg oral
Baskett 2007 39 311 1 311 4.5% 39.00 [5.39, 282 10]
Cook 1999 57 371 37 383 9.6% 1.59 [1.08, 2.35]
Kundodyiwa 2001 18 243 1 256 4.4% 18.96 [2.55, 140.96]
Lumbiganon 1999 4 195 6 199 6.7% 0.68 [0.19, 2.37]
Walley 2000 12 176 5 152 7.6% 2.07 [0.75, 5.75]
Zachariah 2006 48 730 4 617 7.6% 10.14 [3.68, 27.97]
Subtotal (95% Cl) 2026 1918 40.3% 4.19 [1.37, 12.77]
Total events 178 54
Heterogeneity: Tau2 = 1.50; Chi2 =■ 33.45, df = 5 (P< 0.00001); I2 =85%
Test for overall effect: Z = 2.52 (P = 0.01)
6.2.3 600 meg oral
Caliskan 2003 16 404 5 384 7.6% 3 04 [1.13, 8.22]
Gulmezoglu 2001 559 9198 78 9205 9.8% 7.17 [5.67, 9.07]
Lumbiganon 1999 15 199 6 200 7.9% 2.51 [1.00, 6.34]
Oboro 2003 3 247 1 249 3.9% 3.02 [0.32, 28.88]
Subtotal (95% Cl) 10048 10038 29.2% 4.22 [2.12, 8.38]
Total events 593 90
Heterogeneity: Tau2 = 0.27; Chi2 = 7.44, df = 3 (P = 0.06); I 2 = 60%
Test for overall effect: Z = 4.11 (P < 0.0001)
6.2.4 800 meg oral
Parsons 2006 24 211 0 218 2.9% 50.62 [3.10, 827.06]
Subtotal (95% Cl) 211 218 2.9% 50.62 [3.10, 827.06]
Total events 24 0
Heterogeneity: Not applicable
Test for overall effect: Z = 2.75 (P = 0.006)
6.2.5 400 meg sublingual
Singh 2009 9 75 0 75 2.9% 19.00 [1.13, 320.67]
Vimala 2004 4 60 0 60 2.8% 9.00 [0.50, 163.58]
Vimala 2006 8 50 2 50 5.9% 4.00 [0.89, 17.91]
Subtotal (95% Cl) 185 185 11.5% 6.11 [1.83, 20.37]
Total events 21 2
Heterogeneity: Tau2 = 0.00; Chi2 = 1.08, df = 2 (P = 0.58); I II o
Test for overall effect: Z = 2.94 (P = 0.003)
6.2.6 600 meg sublingual
Singh 2009 9 75 0 75 2.9% 19.00 [1.13, 320.67]
Subtotal (95% Cl) 75 75 2.9% 19.00 [1.13,320.67]
Total events 9 0
Heterogeneity: Not applicable
Test for overall effect: Z = 2.04 (P = 0.04)
6.2.7 800 meg rectal
Nasr2009 48 257 2 257 6.2% 24.00 [5.90, 97.70]
Parsons 2007 8 200 4 209 7.0% 2 09 [0.64, 6.83]
Subtotal (95% Cl) 457 466 13.2% 6.90 [0.52, 91.94]
Total events 56 6
Heterogeneity: Tau2 = 3.05; Chi2 = 7.95, df = 1 (P = 0.005); I2 = 87%
Test for overall effect. Z = 1.46 (P = 0.14)
Total (95% Cl) 13022 12920 100.0% 5.01 [2.85, 8.82]
Total events 881 152
Heterogeneity: Tau2 = 0.83; Chi2 = 82.10, df ■= 16 (P < 0.00001); I2 = 81%
Test for overall effect: Z = 5.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.97. df = 5 (P = 0.55), I2 = 0%
Risk Ratio
M-H, Random, 95% Cl
+
■>
H------------------------ 1------------ 1
0.1 1 10 100 
Oxytocin Misoprostol
Figure 8. The risk ratio of fever with misoprostol versus oxytocin
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8.3.23. Risk of fever with misoprostol compared to that with methyl ergometrine
The risk ratio of fever in the only study in which 200 meg oral misoprostol was 
compared to methyl ergometrine was 13 (95% Cl 0.74-227.72) (Figure 9). Two 
studies reported data on fever with 400 meg oral misoprostol and the risk ratio was 
3.75 (95% Cl 2.31-6.09). Also, two studies showed data on fever with 600 meg oral 
misoprostol (RR 6.28, 95% Cl 2.32-16.96).
In considering the risk of fever for the sublingual route versus methyl ergometrine, 4 
studies reported the risk of fever with 400 meg sublingual misoprostol. The risk ratio 
was 10.29 (95% Cl 3.17-33.46). Only one study gave data on fever with 600 meg 
sublingual misoprostol (RR 33, 95% Cl 2.02-540.22).
The overall risk ratio of fever with different doses and route of misoprostol versus 
methyl ergometrine was 4.97 (3.47-7.14). The overall heterogeneity was 0% and the 
test for subgroup differences (I2) was about 22.6% with p value of 0.27, which 
suggested no heterogeneity within or between the subgroups.
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misoprotol Methyl ergometrine
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl
6.3.1 200 oral
Chhabra 2008 6 100 0 100 1.6% 13.00 [0.74, 227.72]
Subtotal (95% Cl)
Total events 6
100
0
100 1.6% 13.00 [0.74, 227.72]
Heterogeneity: Not applicable 
Test for overall effect: Z = 1.76 (P = 0.08)
6.3.2 400 meg oral
Enakpene 2007 31 432 7 432 20.0% 4.43 [1.97, 9.95]
Zachariah 2006 48 730 13 676 35.8% 3.42 [1.87, 6.25]
Subtotal (95% Cl) 
Total events 79
1162
20
1108 55.8% 3.75 [2.31,6.09]
Heterogeneity: Tau2 = 0.00; Chi2 == 0.25, df = 1 (P = 0.62); I
£oII
Test for overall effect: Z = 5.35 (P < 0.00001)
6.3.3 600 meg oral
Amant 1999 34 100 3 100 9.9% 11.33 [3.60, 35.70]
Garg 2005 29 100 7 100 21.6% 4.14 [1.90, 9.01]
Subtotal (95% Cl)
Total events 63
200
10
200 31.5% 6.28 [2.32, 16.96]
Heterogeneity: Tau2 = 0.28; Chi2 == 2.12, df = 1 (P = 0.15); 1I2 = 53%
Test for overall effect: Z = 3.62 (P = 0.0003)
6.3.4 400 meg sublingual
Singh 2009 9 75 0 75 1.6% 19.00 [1.13, 320.67]
Vaid 2009 13 66 1 67 3.2% 13.20 [1.78, 98.04]
Verma 2006 6 100 1 100 3.0% 6.00 [0.74, 48.94]
Vimala 2004 4 60 0 60 1.6% 9.00 [0.50, 163.58]
Subtotal (95% Cl)
Total events 32
301
2
302 9.4% 10.29 [3.17, 33.46]
Heterogeneity: Tau2 = 0.00; Chi2 == 0.52, df = 3 (P = 0.92); 1 2 = 0%
Test for overall effect: Z = 3.88 (P = 0.0001)
6.3.5 600 meg sublingual
Singh 2009 16 75 0 75 1.7% 33.00 [2.02, 540.22]
Subtotal (95% Cl)
Total events 16
75
0
75 1.7% 33.00 [2.02, 540.22]
Heterogeneity: Not applicable
Test for overall effect: Z = 2.45 (P = 0.01)
Total (95% Cl) 1838 1785 100.0% 4.97 [3.47,7.14]
Total events 196 32
Heterogeneity: Tau2 = 0.00; Chi2 = 8.44, df = 9 (P = 0.49); I 2 = 0% I
Risk Ratio
M-H, Random. 95% Cl
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi’ = 5.17, df = 4 (P = 0.27), I2 = 22.6%
0.01 0.1 1 10 
Methyl ergometrine Misoprostol
Figure 9. The risk ratio of fever with misoprostol versus methyl ergometrine
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S.3.2.4. Risk of fever with misoprostol compared to that with syntometrine"
There were two studies reported data on fever with 400 meg oral misoprostol and the 
risk ratio was 3.13 (95% Cl 0.4-24.66) (Figure 10). The risk ratio with 600 meg 
sublingual misoprostol was 6.73 (95% Cl 3.78-11.98). The overall risk for 
misoprostol in studies in which it was compared with syntometrine was 4.04 (95% Cl 
1.06-15.48). The test for subgroup differences (I2) was 0%, (P=0.04) which suggested 
no dosage effect.
misoprotol syntometrine Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl
6.4.1 400 meg oral
Cook 1999 57 371 37 383 43.5% 1.59 [1.08, 2.35]
Ng 2007 7 178 0 177 14.8% 14.92 [0.86, 259.21]
Subtotal (95% Cl) 549 560 58.3% 3.13 [0.40, 24.66]
Total events 64 37
Heterogeneity: Tau2 = 1.55; Chi2 == 2.44, df = 1 (P = 0.12); 1I2 = 59%
Test for overall effect: Z = 1.08 (P = 0.28)
6.4.2 600 meg oral
Ng 2001 87 1026 13 1032 41.7% 6.73 [3.78, 11.98]
Subtotal (95% Cl) 1026 1032 41.7% 6.73 [3.78, 11.98]
Total events 87 13
Heterogeneity: Not applicable
Test for overall effect: Z = 6.48 (P < 0.00001)
Risk Ratio
M-H, Random, 95% Cl
Total (95% Cl) 1575 1592 100.0%
Total events 151 50
Heterogeneity: Tau2= 1.04; Chi2 = 19.28, df = 2 (P < 0.0001); l2= 90% 
Test for overall effect: Z = 2.04 (P = 0.04)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 = 0%
4.04 [1.06, 15.48]
I-------------- 1-------------- -------------- 1—
0.01 0.1 1 10 
Syntometrine Misoprotol
----- 1
100
Figure 10. Risk of fever with different doses and routes of misoprostol versus 
syntometrine for prevention of PPH
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S.3.2.5. Risk of fever with misoprostol compared to that with misoprostol of 
other doses or routes
Three studies compared high to low doses of misoprostol (Figure 11). Singh 2009 
compared 600 meg and 400 meg sublingual misoprostol (RR 1.78, 95% Cl 0.84- 
3.77). Lumbiganon 1999 compared 600 meg to 400 meg oral misoprostol (RR 3.73, 
95% Cl 1.26-11.04) and Khan compared 600 meg and 400 meg rectal misoprostol 
(RR 0.49, 95% Cl 0.05-5.36). The overall risk ratio favours the lower doses with RR 
2.13, 95% Cl 1.19-3.81).
High Low Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl
6.1.1 600 meg versus 400 meg sublingual misoprostol
Singh 2009 16 75 9 75 59.9% 1.78 [0.84, 3.77]
Subtotal (95% Cl) 75 75 59.9% 1.78 [0.84,3.77]
Total events 16 9
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
6.1.2 600 meg versus 400 meg oral misoprostol
Lumbiganon 1999 15 199 4 198 26.7% 3.73 [1.26, 11.04]
Subtotal (95% Cl) 199 198 26.7% 3.73 [1.26, 11.04]
Total events 15 4
Heterogeneity: Not applicable
Test for overall effect: Z = 2.38 (P = 0.02)
-----■-----
6.1.3 600 meg rectal versus 400 meg rectal misoprostol
Khan 2003 1 92 2 91 13.4% 0.49 [0.05, 5.36] -------------■—
Subtotal (95% Cl) 92 91 13.4% 0.49(0.05,5.36] —
Total events 1 2
Heterogeneity: Not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% Cl) 366 364 100.0% 2.13 [1.19,3.81]
Total events 32 15
Heterogeneity: Chi2 - 2.69, df - 2 (P = 0.26); I2 = 26% •------------ 1------------0 010 'Test for overall effect: Z = 2.54 (P = 0.01) Low
Test for subgroup differences: Chi2 = 2.68, df = 2 (P = 0.26), I2 = 25.3%
------------1------------ 1
10 100
High
Figure 11. Risk of fever with misoprostol compared to that with misoprostol of other 
doses or routes
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9. Discussion
The review has shown that the incidence of misoprostol induced fever was route 
related as the incidence with sublingual misoprostol was higher than oral and the latter 
was higher than the rectal. Also, the frequency of fever was dose related. The overall 
risk of fever was 5 times higher with misoprostol compared to placebo or any other 
uterotonics.
The overall incidence of fever by different routes of misoprostol showed the highest 
incidence with sublingual route (15%) followed by the oral route (11.4%) and the 
rectal route rate (4%). This might be explained by the pharmacokinetics and the 
pharmacodynamics properties of different routes of misoprostol. The difference in the 
rate of fever with different doses and routes of misoprostol is also consistent with the 
direct comparison of misoprostol in this review. The comparison was between 600 
meg oral, 400 meg rectal and 600 meg rectal misoprostol and the incidence of fever 
was 9%, 2% and 1% respectively (Khan & El-Refaey 2003). Three recent studies that 
were published too late for inclusion in this review. One pharmacodynamic study 
showed that the rates of fever over 39°C in sublingual doses of 200, 400 and 600 meg 
were 8.3%, 8.3% and 45.4% (Elati et al., 2011). The other two RCTs also showed low 
incidence of fever >38 °C with 400 meg sublingual misoprostol which was 6% 
(Fawole et al, 2011) and 2.3% (Chaudhuri, Biswas & Mandal 2012).This data all 
supports the notion that there is both a dosage and route effect on the incidence of 
fever with misoprostol. Sublingual routes achieve a higher peak concentration 
compared to the other routes of administration as a result of its rapid absorption 
through the sublingual mucosa and the avoidance of the first pass metabolism via the 
liver (Tang, Gemzell-Danielsson & Ho 2007).
Interestingly however, there is no clear dosage or route effect seen in the studies of 
risk ratio. This fact points to wide variation in the incidence of fever in the control 
arms of the studies as well as the misoprostol arm. This is best demonstrated in the 
placebo controlled studies where the wide variation in incidence in the misoprostol 
arms of the 3 studies are cancelled out by equally wide variations in the incidence in 
the placebo arm leading to a homogenous finding in which the risk ratio was around 5 
in all the studies. The reason for the wide variation in postnatal fever in the reported
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studies is not known but may be occur as a result of clinical factors such as pre- 
partum infection, multiple vaginal examinations with prolonged labour and prolonged 
rupture of membranes. Reported rates of fever may also vary according to whether the 
temperature is systematically and regularly measured post-delivery, self-reported, or 
simply retrospectively collected from case notes after the event. Given that in many 
settings temperature is not routinely measured in the immediate postnatal period and 
midwives may not formally record the symptom if it settles spontaneously, the latter 
methods may grossly underestimate the incidence of this side effect. To provide 
accurate data about the risk of fever, we recommend systematic collection and 
reporting of postnatal temperature in future randomised controlled trials.
An alternative explanation for the different rates of fever between studies could be a 
genetic variation in participants’ predisposition to side effects. Apost hoc analysis of 
a clinical trials for treatment of postpartum haemorrhage using 800 meg sublingual 
misoprostol showed that the incidence of fever (> 40.0 °C) was 35.6% in Ecuador 
compared to women from other populations who has lower incidence of fever.lt was 
less than 3% in Turkey and Egypt (Durocher et ah, 2010). Genotyping of DNA from 
women who have misoprostol induced fever may help the identification of variant 
genotypes with the highest predictive value for the development of chills and/ or fever 
in women treated with misoprostol. Misoprostol has a similar mechanism of fever 
production as PGE2, which is a key fever mediator in the brain and ultimately in 
charge of the upward shift of the thermoregulatory set-point. Several genes are 
involved in the mechanism of action of prostaglandins including genes involved in the 
expression of prostaglandins receptors (PTGER1,2,3,4) and prostaglandin transporters 
(SLC02A1, SLCOIBI & ABCC4) in the brain (Oka, Oka & Saper 2003). There are 
also other genes which are involved in the expression of separate receptors that 
mediate the prostaglandin action such as gamma-aminobutyric acid receptor genes 
(GABRG2 & GABRA2; (Osaka 2008a) and adrenergic beta receptors genes 
(ADRB1,2,3 & ADRBK1; (Amir & Schiavetto 1990). Genetic polymorphisms in 
these genes may affect the response to misoprostol and the susceptibility of women to 
misoprostol-induced fever. Genetic studies were conducted to explore this possibility 
and this will be in shown in detail in Chapter 4.
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Systematic reviews of adverse effects can be broad or narrow in scope. Broad scope 
reviews examine all the adverse effects associated with a particular therapy while a 
narrowly focused review examines a known or common side effect in detail (Loke, 
Price & Herxheimer 2007). This review is of the latter variety and examines the 
incidence and risk of fever as a commonly observed side effect of misoprostol. 
McIntosh and her colleagues studied the assessment of harmful effects in systematic 
reviews and concluded that systematic reviews of adverse effects were more likely to 
produce appropriate information if they addressed a focused question. They also 
suggested developing quality assessment methods for the trials of harmful effects to 
be used in these reviews (McIntosh, Woolacott & Bagnall 2004).
The decision on types of studies to include in the review depends mainly on the focus 
of the research question. Data on rare or new side effects of an intervention are 
unlikely to be found in reports from RCTs and may require the examination of all 
studies from a wide selection of studies types such as cohort, case-control, 
observational, randomised control trials and case series reports. In contrast, data on 
well recognised and easily detectable side effects may be available from RCTs (Loke, 
Price 8c Herxheimer 2007). This narrowly focused review evaluates fever which is 
common side effect of misoprostol. We therefore included only randomised control 
trials.
The reporting of harms in RCTs is often inadequate and receives less attention than 
the reporting of efficacy and effectiveness. In this review we had to exclude 19 trials 
because of lack of information about fever. Ideally the assessment of quality of trials 
to be included in the review of adverse effects should concentrate on how precise the 
methods were used to detect fever and how good the reporting was (loannidis et ah, 
2004). We assume that the method for examination of fever is by using the 
thermometer as a measurement tool. However, many studies might not mention this 
assuming it is already known practice for the measurement of fever and others may 
rely on participants5 self reports. This is unclear in many study reports and may have 
been a contributing factor to the inconsistency in rates.
Inconsistency in terminology can also lead to difficulties when searching for studies 
for systematic reviews and lead to the missing of some important trials. Therefore, in
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our search terms we did not include fever or hyperthermia as search terms, but instead 
searched for all the trials that using misoprostol for postpartum haemorrhage and then 
examined all of them to find reports of fever as a side effect.
10. Conclusion
The incidence of fever with misoprostol is related to both its dosage and route with 
the highest incidences found in the high dose sublingual route. However, this is not 
the only influence on postnatal fever. There appear also to be effects related to genetic 
variation between ethnic groups and intra-partum clinical factors. Further research is 
required to find out the low and best effective dose for prevention of PPH with the 
best adverse drug reaction profile.
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Chapter 3
The effect of misoprostol on postpartum contractions: 
a randomised comparison of three sublingual doses
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1. Introduction
PPH is the leading cause of maternal mortality in the developing world and is 
responsible for about 25% of all maternal deaths worldwide (Khan et al., 2006). The 
most common cause of PPH is the failure of the uterus to contract after child birth 
(atonic PPH) and AMTSL is recommended to prevent it (NICE 2007; WHO 2007). 
This involves, as a minimum, the administration of a uterotonic drug at delivery and 
controlled cord traction. Oxytocin is recommended as the first line oxytocic for the 
prevention of PPH (FIGO/ICM 2004a; WHO 2007). However, oxytocin requires 
refrigeration because it is unstable when exposed to high ambient temperatures. 
Furthermore, this drug must be given parenterally which requires a skilled birth 
attendant and a continuous supply of sterile syringes and needles. Both of these are 
frequently unavailable in low resource settings. About 99% of maternal deaths occur 
in low resource settings where there are poor transportation systems, a lack of skilled 
birth attendance and emergency obstetrics services (McCormick et ak, 2002). Hence, 
a major objective for reducing maternal deaths in poor areas is to find low-cost and 
effective ways to prevent and control PPH.
Misoprostol is orally active prostaglandin analogue with uterotonic effects, and is an 
option for PPH prevention in low resource settings due to its thermo-stability, cost 
effectiveness and ease of administration. There have been at least 36 trials that have 
studied misoprostol for PPH prevention using doses of between 200 and 1000 meg 
and a variety of routes including oral, vaginal, sublingual and rectal (Gulmezoglu et 
ak, 2007). It is, however, as yet unclear which gives the best balance of efficacy and 
safety. Given the relative ineffectiveness of misoprostol for PPH, the tendency has 
been to use high doses of misoprostol. There are however potential dangers to this. 
Shivering and pyrexia are commonly reported side effects, and hyperpyrexia of over 
40°C has been reported, reaching an incidence of 36% in some population groups 
(Winikoff et al., 2010). A recent systematic review recommends further research to 
find out the optimal route and minimum effective dose of misoprostol for routine use 
for the prevention of PPH (Hofmeyr et ak, 2009). The authors suggest that the 
sublingual route is likely to be the most suitable owing to its rapid uptake, prolonged 
duration of action and greater bioavailability.
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Early studies showed that medications such as oxytocin, ergometrine and 
prostaglandins all have a strong contractile effect on uterine muscle. Intrauterine 
pressure catheters were widely utilized to investigate the effect of these medications 
and to compare different doses and routes for prevention and treatment of PPH 
(Chong et ah, 2001; Chong et ah, 2004).
Intrauterine pressure (IUP) measurements were mainly introduced to clinical practice 
in order to study uterine activity during labour. They assisted in the diagnosis of 
labour dysfunctions such as obstructed labour, arrested labour and uterine 
hyperstimulation, particularly during induction of labour using uterotonics. The 
intrauterine pressure measurements were used extensively in research to investigate 
uterine activity at different stages of the female reproductive life. For instance, 
intrauterine pressure catheters were used in studies of uterine muscle activity during 
menstruation to investigate dysmenorrhoea (Lumsden, Kelly & Baird 1983; Milsom 
& Andersch 1985), and uterine stimulation during different procedures in various 
stages of assisted reproduction (Bulletti & De Ziegler 2005). They were also used in 
research into uterine activity during the third stage of labour to explore the causes and 
treatment of uterine atony (Chong et al., 2001).
The current methods of intrauterine pressure measurement came after more than a 
century of evolving and improving techniques for this purpose. There are many types 
of intrauterine pressure catheters (IUPC) (Figur 1). However, the most common types 
are the external transducer catheters and the tip transducer catheters. Catheters with a 
tip sensor but external transducer (e.g Koala) show some advantages over the catheter 
tip transducer (e.g Intran). It has a softer, smaller catheter tip and flexible body and is 
therefore easier to insert. Also, the accuracy of the measurements are not be affected 
by changes in the temperature from body to room temperature. It is also easier to set 
up and easier to zero while it is in-ntero as the transducer is connected to an external 
reusable cable (Dowdle 1997). The tip sensors are of various types. There is a 
pinpoint tip sensor with a membrane sensitive to the surrounding pressure produced 
by a column of the amniotic fluid. The other type of tip sensors is a sensing 
membrane, or balloon on the tip of the catheter. It employs the air-coupling 
technology from a distally mounted flexible balloon (sensing membrane) that
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communicates through a sealed micro-tube to the externally located electronic 
reusable transducer in the monitor cable and connector (Figure 1). This type of 
catheter was produced by Clinical Innovations and is known as Koala IUP-5000E 
catheter.
Sensor and transducer at 
the tip (SoftTrans ) on the 
left and (Intan Plus) on the 
right.
0
l
Tip guide and balloon 
sensor near the tip and 
external transducer fixed 
to the reusable cable 
connected to the feto- 
matemal monitor (Koala 
IPC 5000E).
n
Tip guide and sensor at 
the tip and external 
transducer fixed to the 
reusable cable connected 
to the feto-matemal 
monitor (Koala IPC 
5000C).
Figure 1. Types of the catheters according to the position of the sensors and the 
transducers
When the temperature sensitive transducer is placed at the tip of the catheter, the 
change from room to body temperature affects the monitoring baseline. The thermal 
effects combined with other sensitivities can alter the intrauterine reading by 8 
mmHg. The presence of the transducer outside the uterus provides accurate re-zeroing 
just by disconnecting the catheter from the cable transducer and pressing the zero 
button on the fetal monitor. A true zero can be only obtained when the transducer is 
exposed to the atmospheric pressure (Anonymous 2009). To our knowledge there has 
been no studies that has used the external transducer catheter (Koala) to evaluate the 
treatment effect of uterotonics during the third stage of labour.
The reliability of the air-charged coupled Koala catheter has been compared with an 
electronic pressure transducer tipped catheter (Intran) during the first stage of labour
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(Dowdle 1997; Dowdle 2003). Both catheters were bound together at their tips and 
introduced into the uterus (Dowdle 2003). The data showed a similar mean baseline 
tone, peak pressures, contractions frequency and duration during labour. However, 
neither reliability nor validity studies have been performed for the Koala catheter 
during the third stage of labour.
This chapter describes an in vitro study to examine the validity of an IUPC with an 
external transducer (Koala External IPC 5000E) and a catheter tipped transducer 
(Intran pluse IUP-500). This will enable an appropriate choice of catheter in the 
clinical trial to examine the uterine activity during the third stage of labour after 
administering different doses of sublingual misoprostol to prevent PPH.
2. Objectives and hypothesis
This study therefore was devised
1. To examine and compare the validity of the pressure values that given by Koala 
and Intran plus Catheters to find the best to be used in the clinical trial of comparing 
the IUP after three sublingual doses of misoprostol.
2. To compare the effects of three sublingual misoprostol doses using the 
measurements of postpartum intrauterine pressure as a surrogate endpoint to evaluate 
the uterine activity of these uterotonics
3. To compare the side effects associated with each treatment.
Data from a small cohort of women given intramuscular oxytocin prophylaxis are also 
shown for comparison with the misoprostol data.
We hypothesised that low doses of misoprostol produce a similar strength of 
myometrial contraction to high doses.
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3. Materials and methods
3.1. The validity of the intrauterine pressure catheters
Two types of intrauterine pressure catheters were investigated. They are the Intran 
plus IUP-500 (Utah Medical Products, Utah, Inc, USA) which has a silicone 
diaphragm transducer on its tip, and the Koala External IPC 5000E (Clinical 
Innovations, Utah, USA) which has a sensing membrane near its tip. This 
communicates through a sealed micro-tube to an electronic transducer located in the 
reusable catheters (Figure 2). The procedure was carried out by two observers using 
three different methods.
Figure 2. Intran plus IUP-500 (left) and Koala External IPC 5000E (right)
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1. Testing accuracy in air with varying air pressures:
We measured the pressure inside a calibrator (Latitude® calibrator. Clinical 
Innovations, Utah, USA) (Figure 3). This represents the ideal situation for the intra 
uterine catheter to measure the pressure correctly. Both the Intran plus and the Koala 
External catheters were inserted into the calibrator until both sensors were inside and 
sealed into the end of tube. Each was connected to a feto-matemal monitor (General 
Electric, GE 250 series CX). The first observer pumped the tube with series of 
predetermined pressures between 0 and 120 mmHg (the maximum pressure in the 
calibrator pressure gauge). The second observer remained blind to the tube pressure 
but recorded the values of the pressure from the electronic tocograph on the two feto- 
matemal machines. The pressure values were selected at random within each range 
using a random number generator programme on (http://www.random.org) and then 
arranged in a random order using the same software. The pressure was selected in 
three categories (0-40, 41-80 and 81-120 mmHg). This ensured that the two catheters 
were tested at various levels of pressures and included multiple measurements. A total 
of 40 different measurements for each catheter were made available for the final 
analysis.
Figure 3. LatitudeK calibrator with the two catheters inside
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2. Testing accuracy in water with varying fluid pressures:
The second method attempted to mimic the situation in a fluid filled cavity. A rubber 
balloon filled with 5 ml of water was fixed around each catheter tip (Figure 4) and 
surrounded by a pressure cuff. Each catheter was connected to a feto-matemal 
monitor (General Electric, GE 250 series CX). Approximately 5 mis of tap water was 
put into the balloon around the catheters and a sphygmomanometer cuff placed 
around the balloon. The pressure exerted by the sphygmomanometer should be 
transmitted through the fluid to the catheters and then to the feto-matemal monitors. 
The pressure values measured by the monitors were compared to the actual pressure 
exerted by the sphygmomanometer (Gold standard). The first observer pumped the 
cuff to a predetermined pressure between 0 and 200 mmHg and shielded the 
sphygmomanometer dial from the first observer. The pressure values were selected at 
random within each range using a random number generator programme on 
(http://www.random.org) and then arranged in a random order using the same 
software. The pressure was tested in four categories (0-50, 51-100, 101-150 and 151- 
200 mmHg). This ensured that the two catheters were tested at various levels of 
pressures and included multiple measurements. A total of 80 different measurements 
for each catheter were made available for the final analysis.
Figure 4. Intran pluse IUP-500 (below) and Koala External IPC 5000E (above), each 
w ithin balloon fdled with 5 ml of water
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3. Testing accuracy in simulated (wet) postpartum uterine activity:
The validity of the two catheters was tested in an open but wet system designed to 
mimic the postpartum uterus using wet tissue surrounding the catheters’ tips. Two 
catheters were fixed 1 cm apart using adhesive tape. The two catheters’ tips were 
wrapped with wet tissue and which was moistened after each measurement (as water 
was squeezed out of the tissue each time the pressure was applied). This is similar to 
the postpartum uterus where there is a little amount of fluid (blood) that is squeezed 
out and yet produced again between each contraction (Figure 5).
Figure 5. Intran pluse IUP-500 and Koala External IPC 5000E, within wet tissue
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To avoid bias, the second observer, who read and recorded the measurements from the 
two machines, was blind to the true measurements. The data was collected on two 
identical forms shown below. The first observer filled the column of true pressure 
values on one copy while the second observer filled the columns for the pressure 
values on measured by the two feto-maternal monitors on a second copy. At the end 
of the experiment, the two data forms were combined onto one form.
Sphygmomanometer/
Calibrator (True)
Koala Intran
1
2
3
4
5
....80
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3.2. Randomised clinical trial
3.2.1. The study population and location
The study population was made up of women who gave birth at Zliten Teaching 
Hospital (in Zliten, Libya) between July and December 2009. This is a government 
funded, secondary referral hospital serving a population of 200,000 people with 4,500 
deliveries per year. Prior to the study, a small pilot study was conducted in a nearby 
teaching hospital (in Misurata) in order to test and improve the study equipment and 
methodology which was employed for data acquisition.
Inclusion criteria
• Age more than 18 years old
• Women who have had spontaneous vaginal delivery
• Women with gestational age >34 weeks
• Women who give an informed written consent
Exclusion criteria
• Women with history of PPH
• Women with history of APH
• Women with previous caesarean section
• Women with 5 or more previous deliveries at over 28 weeks
• Women who have PROM
• Women with anaemia (Hb <1 Og/dl)
• Women who have given birth to a baby of birth weight > 4.0 Kgs
• Women who have induced or augmented labour with any uterotonic drugs
• Women with multiple pregnancies
• Women with polyhydramnios
• Women with pre eclampsia
• Women with infection
• Women who do not give a written consent
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3.2.2. The study procedures
3.2.2.I. The pilot study
To my knowledge, our research methods, units of measurement and the summary 
measures (MYU) have not been used in previous studies looking at the intrauterine 
pressure postpartum as a parameter. Therefore, a pilot study was conduct before the 
original study in order to give more information about the nature and the 
characteristics of the postpartum intrauterine pressure. Also, the pilot study was 
conducted to explore the practicalities of the catheters, equipment setup and the data 
acquisition. The findings of this pilot study used to calculate the sample size for the 
final study.
10 participants were recruited according to the above mentioned inclusion and 
exclusion criteria. Intrauterine pressure catheter was inserted through the cervix 
immediately after the delivery of the placenta and held in place using the supplied 
adhesive pad against the mother’s thigh. Initially, up to 5 women received 10 units of 
intramuscular oxytocin and the equipment and study instruments tested. Once 
consistent readings are being obtained, a further 5 participants received 600 meg 
moistened sublingual misoprostol. The intrauterine pressure was continuously 
recorded over 120 minutes. Vital signs, pulse, blood pressure and temperature were 
measured at before treatment and at 30, 60, 90 and 120 minutes.
At the end of this small pilot study, the study was transferred to Zliten Teaching 
Hospital and the ethical approval was amended accordingly. During the trial set up 
period for the main study at this new site (pilot data analysis, recalculation of samples 
sizes and development of the randomisation schedule and envelopes), 14 women were 
recruited to an observational study at Zliten where women were treated with oxytocin 
alone. Once all the study instruments were in place, the main randomised study 
commenced and women entering the delivery suite at the times when the researcher 
was present (usually working hours during the week) were invited to participate.
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S.2.2.2. Randomisation and concealment
A commercial randomisation programme was used to produce a random list of 
allocations to 3 doses of misoprostol (www.sealedenvelope.com). The allocations 
were written on cards and placed in consecutively numbered sealed opaque envelopes 
by staff not involved in the study. Blinding was not possible since the treatment was 
provided by the researcher who was available at the time of the delivery to carry out 
the final selection of women and collection of data.
3.2.2.3. The main study procedure
Women who met the inclusion criteria were invited to participate in the randomised 
study. After reading the patient information sheet (Appendix B.l), an informed 
consent was obtained (Appendix B.2.). Furthermore, women who gave birth to babies 
of over 4 kg were also not randomised. To enable this, the baby was weighed 
immediately after delivery. So, when the birth weight was 4 kg or less, the 
randomisation envelope was then opened and the study drug administered. In all cases 
the drug was administered within a minute of birth.
The delivery of the baby was left entirely to the midwives. Routine practice is to give 
the uterotonic at the delivery of the anterior shoulder and deliver the placenta using 
controlled cord traction. Once the baby is delivered, the cord is cut and the baby 
weighed immediately. All babies are then transferred to the neonatal unit for 2 hours 
of observation, even if the birth and immediate neonatal period were completely 
normal. Once the woman is transferred to the postnatal ward (after 2 hours of 
observation on labour ward), the baby rejoins her and she is then able to start 
breastfeeding. This routine was not changed for women in the study except that the 
study drug was given by the researcher immediately after the baby was weighed 
(which occurred within seconds of delivery) rather than at delivery. For women 
receiving misoprostol, the oxytocin was omitted.
Once the woman was determined to be eligible, the next successive treatment 
envelope was opened and the designated treatment given. We randomly allocated the 
eligible women to 200 meg, 400 meg or 600 meg sublingual misoprostol (Cytotec; 
Pfizer, Italy). The tablets were moistened with tap water prior to being placed under
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the tongue. At the same time, an ‘under-buttocks drape with fluid collecting pouch’ 
(Kimberly-Clark, Kent, UK) was placed under the woman’s buttocks for collection of 
any blood over the next 120 minutes. Immediately after placental delivery, an 
intrauterine catheter (Koala External Balloon Catheter IPC-5000E, Clinical 
Innovations, Utah, Figure 6) was inserted manually through the cervix into the uterine 
cavity until the tip of the catheter could be felt to touch the fundus. The catheter was 
secured in place with tape to the mother’s thigh and connected to a Corometrics 118 
maternal / fetal monitor (Corometrics Medical Systems Inc, Texas, USA). The uterine 
activity was recorded and saved over the next 120 minutes. A researcher was with the 
women throughout the 2 hours of observation to record maternal temperature, pulse, 
and blood pressure before labour, immediately after the delivery and then at 30, 60, 90 
and 120 minutes .The women were closely observed for any side effects experienced 
(Appendix B.3. Case Report Form).
Figure 6, Koala External Balloon Catheter IPC-5000E, Clinical Innovations, Utah
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3.2.3. The study outcomes
a) Primary
The primary outcome was the intrauterine pressure over the first 10 minutes after the 
delivery of the baby. The slight differences in time during which the pressure was 
measured in the first 10 postnatal minutes (the catheter was only inserted after 
placental expulsion) meant that the Montevideo units (MVU) measurement had to be 
adjusted for the first reading. This was done by adding together the uterine pressures 
collected in the first 10 minutes from delivery of the baby, dividing it by the length of 
minutes during which the measurements were taken (to get MVU per minute) and 
then multiplying by 10.
b) Secondary
The secondary outcomes include:
• Change in the intrauterine pressure from 20 to 120 minutes using MVU.
• Side effects of treatment (Fuse, blood pressure and temperature at 30. 60. 90 
and 120 minutes)
• Measured blood loss in the 120 minutes after delivery
• Additional use of other uterotonic drugs to treat patients who might develop 
PPH.
3.2.4. Ethical consideration and consent
The study was approved by University of Liverpool Ethics Committee 
(RETH000237) and accepted by the local hospital committees in Zliten and Misurata 
Teaching Hospitals.
All subjects were informed of the nature and purpose of the study, its requirements 
and possible hazards, and their right to withdraw at any time from the study without 
prejudice and without jeopardy to any future medical care at the study site. 
Participants had the purpose of the study explained and received appropriate written 
information. All subjects were offered adequate opportunity to ask the investigator or 
nominated designee about any aspect of the study. The consent sought on admission
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to the labour word. Each participant agreed to co-operate in all aspects of the study 
and gave informed written consent to the investigator for participation. They asked to 
sign three informed consent forms, one for the investigator and one for the hospital 
and one to themselves.
3.2.5. Safety Assessment
The safety of the women in this study is of high importance. Participants recruited had 
no invasive procedures unless the responsible clinician felt it will not affect woman’s 
health.
Where any woman diagnosed with PPH during her participation in the study, 
treatment of PPH was started inunediately as follows,
• Uterine massage (‘rubbing up the fundus) to stimulate contractions
• Ensure bladder is empty (Foley catheter, leave in-situ)
• Syntocinon 10 units by slow IV injection
• Ergometrine 0.5 mg by slow IV injection
• Syntocinon infusion (30 units in 500 mis Hartmann’s at 125 mis / hr)
• Misoprostol 600 meg in case of continued bleeding
Any side effects or complications that developed during the study were treated and 
reported and recorded in the serious adverse events form.
3.2.6. Direct Access to Source Data and Documents
All information obtained as a result of the study were kept confidential and there were 
no disclosure to any third party other than the Ethics Committee. Records identifying 
the participant will be kept confidential and, to the extent permitted by the applicable 
laws and/ or regulations, will not be made publicly available.
Documents relating to the study that contained personal data that may disclose the 
identity will remain with the investigator and will not provide any personal data that 
may identify the participant to any third party at any time during the study.
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4. Statistical analysis
a. The validity study
To test the validity of the Koala External IPC 5000E and Intran pluse IUP-500 
intrauterine pressure catheters, the pressure recorded by each catheter was compared 
with the true pressure exerted by the sphygmomanometer or the Latitude calibrator 
using limits of agreement (LOA) (Bland & Altman 1986). The narrower the LOA of a 
catheter, the better the measurement of the intrauterine pressure.
b. RCT
The difference in means of the primary outcome was calculated using one way 
ANOVA. The intrauterine pressures from 20 to 120 minutes postpartum were 
secondary outcomes. Repeated measures of longitudinal data analysis (repeated 
measures ANOVA) were used to compare the effect of the study treatments over 120 
minutes of observation. Other mean comparisons were done using the one way 
ANOVA with multiple comparisons Bonferroni test. The incidence of shivering and 
fever and other side effects among the three misoprostol group were compared using 
Chi square test with Yates’ correction and Fisher exact test as appropriate. Statistical 
analysis was performed using Excel and PASW Statistics 17. The difference between 
the 4 groups’ parameters was taken as statistically significant when P values were less 
than 0.05. Based on the primary outcomes (mean intrauterine pressure over the first 
10 minutes) and to detect a significant difference (P=0.05, two-sided) at 0.8 power 
with 50% effect size, we needed a sample size of 12 in each group. The calculation 
was done by G*Power 3.0.10 software.
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5. Results
5.1. Results of the validity study
1. a. Limits of agreement of Intran catheter versus the calibrator
The mean difference in pressure values recorded by the Intran catheter and the 
pressure exerted by the calibrator was 0.75 mmHg (95% Cl 1.1 -0.42). The limits of 
agreement were -1.4 to 2.9.
The plot in Figure 7 shows graphically that the difference in individual pressure 
values obtained by the Intran catheter and that produced by the calibrator. The range 
of pressure values was only 4.3 mmHg.
3.00".
1.00-
-1.00-
-3.00-
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Average
Figure 7. Difference against mean of pressure data of Intran pluse IUP-500 catheter 
and the Latitude calibrator
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l.b. Limits of agreement of Koala catheter versus the calibrator
The mean difference in pressure values recorded by Koala and the pressure exerted by 
the calibrator was 2.1 mmHg (95% Cl 1.26-2.94). The limits of agreement were -3.2 
and 7.4 mmHg.
Figure 8 shows graphically the difference in the pressure values obtained by Koala 
and the actual pressure values produced by the calibrator. The range of the difference 
was 10.6 mmHg. The scatter plot of the raw data showed that the pressure measured 
by the Intran catheter is more correlated with the true pressure exerted by the 
calibrator than the Koala catheter (Figure 9).
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Figure 8. Difference against mean of pressure data of Koala External IPC 5000E 
catheter and the Latitude calibrator
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Calibrator pressure
■ Koala 
♦ Intran
Figure 9. Scatter plot for the raw data for the pressures measured by the Intran and 
Koala catheters and the Calibrator
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2. a. Limits of agreements for Intran (within balloon filled with water) versus 
sphygmomanometer
The mean difference in pressure values recorded by the Intran catheter within a 
balloon tilled with water and the pressure exerted by the sphygmomanometer was 
84.5 mmHg (95% Cl 74-95). The upper and lower limits of agreements were 178.5 
and -9.5 respectively.
Figure 10 shows that the range of the limits of agreement was 188 mm Hg.
170.00-
120.00-
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Figure 10 . Difference against mean of pressure data of Intran pluse IUP-500 catheter 
(within balloon filled with water) versus sphygmomanometer
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2. b. Limits of agreements for Koala (within balloon filled with water) versus 
sphygmomanometer
Figure 10 illustrates the mean pressure difference between the Koala catheter within a 
balloon filled of water and the sphygmomanometer. The mean difference was 62 
mmHg (95% Cl 55.1-68.9). The upper and lower limits of agreement were 123.9 and 
0.1 mmHg respectively.
Although the range of the difference is wide, at 123.8 mmHg, this difference was less 
than in the Intran catheter (188 mmHg). Neither catheters pressure showed a good 
correlation with the pressure exerted by the sphygmomanometer. However, the Koala 
catheter was slightly better than the Intran catheter (Figure 11). Furthermore, there is a 
clear and direct correlation between pressure and error as can be seen on the 
correlation graph (Figure 12) and the limits of agreement graphs (Figure 10 & 11).
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Figure 11. Difference against mean of pressure data of Koala External IPC 5000E 
catheter (within balloon fiUed with water) versus sphygmomanometer
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Figure 12. Scatter plot for the raw data for the pressure measurement of Intan and 
Koala catheters within balloon filled with water
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3. a. Limits of agreements for Intran within wet tissue versus 
sphygmomanometer
As shown in Figure 13, the mean difference in pressure recorded by Intran catheter 
within wet tissue and the actual pressure exerted by the sphygmomanometer was 80.2 
(95% Cl 65.1-95.3). The Limits of agreements were -15.4 and 175.9 mmHg giving a 
range of 191.3.
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Figure 13. Difference against mean of pressure data of Intran pluse IUP-500 catheter 
(within wet tissue) versus sphygmomanometer
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3. b. Limits of agreements for Koala within wet tissue versus 
sphygmomanometer
The mean difference in pressure values recorded by Koala catheter and the 
sphygmomanometer was 41.0 mmHg (95% Cl 50.8-31.2). The limits of agreement 
were 19.8 and 101.8 mmHg.
As can be seen in Figure 14, the range of the limits of agreement is 121.6 mmHg. 
However, it is less than the range of difference recorded by the Intran catheter (191.3).
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Figure 14. Difference against mean of pressure data of Koala External IPC 
5000E catheter (within wet tissue) versus sphygmomanometer
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Niether catheters' pressure measurements within the wet tissue showed a good 
correlation with the pressure exerted by the sphygmomanometer. However, the Koala 
catheter was better than the Intran catheter (Figure 15).
Sphygmomanometer pressure (mmHg)
♦ Intran 
■ Koala
Figure 15. Scatter plot for the raw data for the pressure measurement of Intan and 
Koala catheters within wet tissue
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5.2. Results of the randomised trials
227 were eligible to participate in the study after applying the primary selection 
criteria and informed about the study. 178 women were excluded because they had 
induced or augmented labour, caesarean section and instrumental delivery. 49 women 
were eligible and participated in the study (Figure 16).
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14 women sequentially 
allocated to receive 10 IU 
IM oxytocin
35 women were randomly allocated 
after SVD
Withdrawals
49 women were eligible
12 women 
completed the 
study
12 women 
completed the 
study
14 women 
completed the 
study
11 women 
completed the 
study
11 women 
allocated to 
receive 600 meg 
misoprostol SL
12 women 
allocated to 
receive 400 meg 
misoprostol SL
12 women 
allocated to 
receive 200 meg 
misoprostol SL
178 women were excluded 
because they had induced or 
augmented labour, caesarean 
section, instrumental delivery.
227 women were eligible to 
participate in the study after 
applying the primary selection 
criteria and informed about the 
study.
Figure 16. Flow diagram of the progress of the study
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5.2.1. Basic Characteristics of the study population
A total ot 35 women were randomised out of a planned sample of 36. The study was 
curtailed before the planned finish when I had to return to the UK. The randomised 
women were compared to a cohort of 14 women treated with oxytocin prior to the 
start of the randomised study. The age, parity, gestational age and baby’s birth weight 
was similar in the four groups (Table 1).
Table 1. Basic characteristics of four treatment groups presented as mean ± SD
Medication Given 10 IU
Oxytocin
200 meg SL 
misoprotol
400 meg SL 
misoprostol
600 meg SL 
misoprotol
No of women 
recruited
14 12 12 11
Parity (n/%)
0 2(14%) 0 1 (8.3%) 1 (9%)
1 4 (28.5%) 3 (25%) 3 (25%) 2(18%)
2 4 (28.5%) 5(41.5%) 4 (33.3%) 5 (45%)
>2 4 (28.5%) 4 (28.5%) 4 (28.5%) 3 (27.3%)
Age (Years) 28.5 ±6.2 28 .1 ±5.4 27 ±3.3 26.3 ±3.7
Gestational age 
(weeks)
40.2 ± 1.4 40.1 ± 1.1 40.3 ± 0.8 41 ± 1.1
Birth weight (gin) 3350 ±0 364 3458 ± 0 262 3595 ± 0 397 3522 ±0 337
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5.2.2. Effect of oxytocin and three sublingual doses of misoprostol on the 
intrauterine pressure
All three doses of sublingual misoprostol showed a rapid increase in uterine activity 
with a peak at 40 minutes followed by a gradual decrease over the following 80 
minutes (Figure 17). Throughout the time of observation, there was no significant 
difference between the intrauterine pressure in the three misoprostol dosage groups 
(P=0.8).
The uterine pressure in those receiving oxytocin was highest in the immediate 
postpartum period and declined gradually after 40 minutes of administration. In the 
first ten minutes, intra uterine pressure of the three misoprostol groups was 
significantly lower than that of the oxytocin group (P=0.008). Conversely, the uterine 
pressure over the period from 50 to 120 minutes was significantly higher in the three 
misoprostol groups than in the oxytocin group (P=0.008).
----- OxytocinlOiulM
----- Miso200mcgSL
----- Miso400mcgSL
----- MisoGOOmcgSL
1000-
800-
o 400-
Minutes
Figure 17. Mean postpartum uterine pressure in the different treatment groups. Data is 
presented as Montevideo units (±SEM). The data in the first 10 minutes is adjusted to 
correct for the timing of placental delivery (MVU per minute).
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5.2.3. Side effects of oxytocin and misoprostol
All the women were closely observed for side effects. As shown in Table 2, women 
who received intramuscular oxytocin reported no side effects. In the misoprostol 
groups, the two most commonly reported side effects were shivering and 
hyperpyrexia, and a dose-related rise in the body temperature was observed. The 
incidence of severe hyperpyrexia (>39°C) was higher in the 600 meg misoprostol 
group than the 200 meg and 400 meg misoprostol groups, but this was not statistically 
significant (P=0.1; Figure 4). Most of the women were not aware of the fever, but 
complained of coldness and marked shivering. All women in the 400 meg and 600 
meg groups had shivering compared to 75% of the women in the 200 meg 
misoprostol. The differences were statistically significant (P=0.04).
Table 2. Incidence of side effects in the different treatment groups. Number (%)
Medication Given
10 IU
Oxytocin
200 meg SL
misoprotol
400 meg SL
misoprostol
600 meg SL
misoprotol
No of women
recruited 14 12 12 11
Temperature >39 C 0 1 (8.3%) 1 (8.3%) 5 (45%)
Chills / shivering 0 9 (75%) 12(100%) 11 (100%)
Coldness 0 9 (75%) 12(100%) 11 (100%)
Abdominal pain 0 0 2(16.6%) 0
Nausea & vomiting 0 0 2(16.6%) 1 (9%)
Skin rash 0 0 0 1 (9%)
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Figure 18. The incidence of fever in 10 IU oxytocin IM, 200 meg, 400 meg, 600 meg 
sublingual misoprostol
5.2.4. Blood loss
The blood loss was under 500 ml in all women and was normally distributed. The 
lowest mean blood loss (±SD) was observed in women who received 10 IU oxytocin 
(193±35 ml), followed by those who received 200 meg SL misoprostol (239 ± 46 ml), 
600 meg SL misoprostol (275 ± 62 ml) and 400 meg SL misoprostol (299 ± 60 ml). 
The difterence was statistically significant between oxytocin and 400 meg 
misoprostol (P<0.001), oxytocin and 600 meg misoprostol (P<0.001) and also 
between the three misoprostol groups (P=0.04). Howevere, the study was not powered 
to detect difterence in blood loss. None of the women received additional uterotonics 
or blood transfusion.
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5.2.5. Additional analysis of the study data (post-hoc)
This additional analysis was carried out to analyse in depth and separately the role of 
uterine strength and uterine frequency in the mechanism of cease postpartum 
bleeding.
5.2.5.1. Effect of different treatments on uterine contraction strength
The intrauterine pressure was considered here to measure the strength of the uterine 
contractions. The graph shows the mean intrauterine pressure for the 4 treatment 
groups (Figure 19). Over the first 20 minutes post partum, all the investigated 
treatments showed non-significant difference of the intrauterine pressure (P>0.05). 
Thereafter, the mean intrauterine pressure of the three different sublingual misoprostol 
doses (200 meg, 400 meg and 600 meg) was higher than the IUP of the 10 IU 
oxytocin (P<0.05).
E 120
c 100
----- Oxy 10 IU
200 meg SL misoprostol 
—• 400 meg SL misoprostol 
1 600 meg SL misoprostol
Minutes
Figure 19. Mean intrauterine pressure in different treatment groups (10 IU oxytocin, 
200 meg, 400 meg, 600 meg sublingual misoprostol)
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S.2.5.2. Effect of different treatments on uterine contraction frequency
Figure 20 shows the mean frequency of uterine contractions in the different treatment 
groups over 120 minutes. Oxytocin had a significant effect on the uterine contraction 
frequency compared to the three sublingual doses of misoprostol over the first 10 
minutes postpartum (P<0.05). Over the next 30 minutes, there was non-significant 
difference in the uterine contraction frequencies between the treatments (P>0.05). 
T hereafter, misoprostol had a higher frequency of uterine contractions compared to 
oxytocin (P< 0.05).
Minutes
------Oxy
" 200 meg SL misoprostol
""" 400 meg SL misoprostol
600 meg SL misoprostol
Figure 20. Mean uterine contraction frequency in different treatment groups (10 IIJ 
oxytocin, 200 meg, 400 meg, 600 meg sublingual misoprostol)
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6. Discussion
This study was conducted to find out whether high dose misoprostol offered any 
significant improvements in postpartum uterine pressure over low dose misoprostol, 
and to compare the adverse drug reactions associated with each treatment. We also 
had concurrently collected data on intrauterine pressures following oxytocin, and this 
allowed us to compare the IUP produced by these two types of uterotonics. For the 
measurements of IUP postpartum, we examined the validity of two types of IUP 
catheters to choose the best of them for the trial.
The validity experiment has shown that both the tip transducer (Intran) and external 
transducer (Koala) catheters are valid and sensitive to changes in the surrounding 
pressure when they are tested inside the calibrator. The limits of agreement were very 
close and the differences were not clinically significant for either type of catheter. 
This clearly demonstrates that both catheters are working effectively when they are 
tested in an optimum situation. The closed system in which they are surrounded by air 
transmits the pressure equally and consistently to the membrane in the tip transducer 
of the Intran catheter and to the balloon sensors on the tip of the Koala catheter.
Neither catheter is designed to measure the pressure exerted by a flat surface as occurs 
for intrauterine pressure postpartum - they are mainly produced to measure the intra­
partum intrauterine pressure in the amniotic cavity. Therefore, some inconsistency 
and inaccuracy in the pressure values was expected when using them within the wet 
tissue. But it should be accurate in a fluid filled cavity when using the balloon filled 
with water. However, that was also similarly inconsistent and inaccurate. This may 
be due to lack of sensitivity in the balloon wall as it is flexible and so the pressure was 
not transmitted correctly from the sphygmomanometer cuff to the water to the 
sensors. The limits of agreement of both types of catheters were very wide and the 
difference was significant. This may show that using these catheters in a suboptimum 
situation will cany a high risk of inaccuracy. However, there are no catheters 
specifically designed for the measurement of intrauterine pressure postpartum and the 
methods we used in trying to mimic the third stage of labour may not be the optimum. 
On the other hand, the wide variability in the results of both catheters may be related
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to the fact that they are not designed to work outside a fluid cavity. Conducting this 
experiment in vivo would be the best method. However, this was not possible as there 
is no way of knowing the ‘true’ postpartum pressure.
There was an in vivo study conducted to test the reliability of the Gaeltec catheter-tip 
pressure transducer for the measurement of intrauterine pres sme in the third stage of 
labour (Chua et al., 1998). This study compared the reliability when two catheters 
were connected together and when they were inserted independently into the uterus. 
Comparison of pressure reading from both catheters revealed good agreement whether 
they were tied together or were separate. This means that the Gaeltec catheter-tip 
pressure transducer is reliable in detecting the uterine pressure at any site in the 
uterus. But their accuracy was not demonstrated and given that the sensor membrane 
was at the end of a narrow channel, it was likely to be very low. Therefore, in our 
experiment we tried to find a different type of catheter to use for the measurement of 
intrauterine pressure postpartum. Koala catheter was a good candidate as it has two 
inches balloon of sensing membrane surrounding its tip, which provides a wide area 
to be in contact with the uterine wall compared to a pin-point membrane at the tip of 
the Intran catheter. In our two methods to mimic the postpartum situation, the the 
accuracy of the Koala was better than that of the Intran, but was still poor.
The reliability of a clinical test means a consistency in the measurements produced by 
that test at different time points by the same observer (intra-observer reliability) and 
the consistency of the measurements between two observers (inter-observer 
reliability). However, all the measurements may be not accurate when compare with 
the true state which may be obtained by using a reference standard or “gold standard” 
(Khan & Chien 2001). When the accuracy is poor, it is not valuable to measure inter 
or intra observer reliability.
In the randomised trial, we utilised the Koala External Balloon senor system (Dowdle 
1997; Dowdle 2003) for the measurement of the uterine activity (Figure 6). The mean 
intrauterine pressure over 120 minutes for the intramuscular oxytocin and the three 
doses of sublingual misoprostol were shown in Figure 17. The difference seen in 
speed of onset of action can be explained both by their differing pharmacokinetics and 
by their different routes of administration. The absorption of misoprostol is affected
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by mouth dryness and any surrounding fluid, (Singh et ah, 1999; Tang et ah, 2002) 
but we standardised for this by moistened the tablets with tap water before placing 
them under the tongue. The pharmacokinetics may explain our observation of stronger 
and more frequent initial uterine contractions with intramuscular oxytocin than with 
sublingual misoprostol. The peak of uterine contraction for oxytocin was within the 
first 10 minutes post administration whereas for sublingual misoprostol it was only 
achieved after 30 to 40 minutes. This mirrors their plasma concentrations in the 
previous studies (Tang et ah, 2002; Weeks 2006).
Most uterine bleeding occurs immediately after placental separation (Hytten 1995). At 
this time the mean intrauterine pressure of intramuscular oxytocin was significantly 
higher than with the three sublingual misoprostol doses. Even though the effective 
action of sublingual misoprostol started late, it caused high uterine contractions 
maintained over a considerable period. This may help to prevent steady moderate 
bleeding which may be unobserved until serious hypodynamic manifestations occur.
Very few studies have examined the effect of misoprostol on the uterine activity 
during the third stage of labour using measurement of intrauterine pressure as an 
indicator. Chong and collegaues using a Galtec tipped catheter, found no difference in 
postpartum uterine pressures between oral misoprostol and intramuscular 
syntometrine (Chong et ah, 2001).
The mean intrauterine pressure of the three different doses of sublingual misoprostol 
was not significantly different over the two hours observation period. This is 
consistent with previous research findings. For example, in one previous study there 
was no difference seen in intrauterine pressure measurements with 5 different doses of 
oral misoprostol, although again this used a Galtec tipped catheter (Chong et ah, 
2001). Furthermore, randomised control trials found that both 600 meg sublingual 
and 400 meg oral misoprostol were more effective than placebo for prevention of PPH 
(Hofineyr et ah, 1998; Hoj et ah, 2005) and a meta-analysis in which an indirect 
comparison was made between the 400 and 600 meg oral doses concluded that the 
two were likely to be equally effective (Hofineyr & Gulmezoglu 2008). As a result of 
side effects associated with high doses of sublingual misoprostol, some researchers 
have therefore argued that the dosage of misoprostol should be reduced from the 600
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and 800 meg doses in common usage today. Our research findings give further 
weight to that argument.
The most commonly observed side effects in this study were shivering and fever. 
Around half of the women who had 600 meg had a temperature >39°C whereas the 
incidence for women who received 400 meg and 200 meg was around 8%. Most of 
the women were not aware of the increase in their body temperature, but complained 
of coldness and intolerable shivering (all women in the 400 meg and 600 meg groups 
had shivering). Although there appeared to be clinical differences in the incidence of 
fever between high and low doses, the difference was not statistically significant as 
the study was not powered enough to detect differences in incidence of side effects. 
Shivering and fever have been reported in most of the studies using misoprostol for 
different indications and with variable routes and doses. In a recent multicentre 
randomised control trial using 800 meg sublingual misoprostol for treatment of PPH, 
the overall incidence of fever (>40°C) was 14%. However, the incidence of fever 
varied between different populations with the highest incidence in Ecuador (36%) and 
the lowest (0%) in Egypt (Winikoff et al., 2006; Winikoff et al., 2010). In our study, 
the incidence of side effects appeared to be dose-related. Prostaglandins are the 
principal mediator of fever in the brain and can pass the blood brain barrier to the 
thermoregulation centres in the hypothalamus, causing elevation of the 
thermoregulatory set-point. In order to increase the body temperature to the new set- 
point, there are increases in heart rate, muscle tone and shivering (Boulant 2000; 
Kanosue, Yanase-Fujiwara & Hosono 1994; Kanosue et al., 1994).
Clinical trials have shown that oxytocin prophylaxis is more effective than oral 
misoprostol for the prevention of blood loss over 1000 mis (Gulmezoglu et al., 2001). 
Given that most blood is lost around the time of placental expulsion during the first 10 
postpartum minutes, it is not surprising that oxytocin is the more effective 
prophylactic (Weeks 2006). It is only after the first 50 minutes that the uterine 
contraction strength was higher in the misoprostol groups. However, although the 
effect of misoprostol is delayed, it should be eventually as effective as oxytocin in 
preventing massive blood loss through atony. There is evidence for this from the 
Cochrane review in which there are significant differences between oxytocin and
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misoprostol in blood loss over 500 mis and 1000 mis, but no difference in need for 
blood transfusion (Gulmezoglu et al, 2007).
We acknowledge that this study recruited only low risk women in whom the chance 
of developing an atonic PPH was small. However, even in a study which included 
high risk women, the majority of women would not develop an atonic PPH - and this 
is the very group for which the intervention is designed. However, the area of interest 
in this study is the comparison between drug dosages and, as such, it is important to 
have as homogeneous group of women as possible. This was best achieved through 
the use of a low risk group. Furthermore, it was considered by the ethical committee 
to be inappropriate to expose women at risk to misoprostol which has been shown to 
be less effective for prophylaxis than oxytocin.
7. Post -hoc discussion
During the immediate 10 minutes postpartum, oxytocin produced similar uterine 
pressure (uterine contraction strength) as the three different doses of misoprostol. But, 
it produced more frequent contractions. This may explain the superiority of oxytocin 
for management of PPH. The results also prove that strength of the uterine 
contractions and its frequency are both essential to cease bleeding postpartum 
particularly during the immediate postpartum period and maintain gradual uterine 
involution thereafter.
Measurement of the uterine pressure is not very reliable as the intrauterine pressure 
catheters are mainly devised to work in the amniotic cavity. The use of intrauterine 
pressure as a surrogate to measure the effect of uterotonics on the uterine muscle 
could only help to detect differences between the treatment groups providing 
standardising the method for each treatment arm. Uterine contractions and its 
frequency can be detected easily and correctly either clinically or by intrauterine 
catheters. In this study we found that the trend of the effect of the treatment groups’ 
on uterine frequency (Figure 20) is similar to the trend of the effect measured using 
MVU which involves both uterine pressure and frequency (Figure 17). This may 
suggest the possibility of using the uterine frequency as a valid parameter to measure
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the effect of uterotonics on the myometrium rather than the unreliable intrauterine 
pressure measurements.
8. Conclusion
Both Intran and Koala catheters measurements appear- to be accurate in an optimum 
situation. However, both catheters showed wide range of limits of agreement when 
used in situations that mimic the intrauterine space both antenatally and postpartum. 
The Koala catheter was however more accurate. The Koala catheter was therefore 
chosen in our study for comparing the effect of different doses of sublingual 
misoprostol on the intrauterine pressure postpartum.
Our results showed that 200, 400 and 600 meg doses of sublingual misoprostol 
produced similar levels of IUP, but that the severity of side effects was dose related. 
These findings suggest that lower doses of misoprostol may be as effective as high 
doses. Clinical applications of low doses of sublingual misoprostol for prevention of 
PPH should be further explored by large randomised trials comparing the 
effectiveness and the safety of low doses of sublingual misoprostol.
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Chapter 4
Candidate gene association study of misoprostol-
induced fever
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1. Introduction
Although misoprostol has been demonstrated as a safe and effective alternative 
treatment option for PPH, concerns remain about its side effects profile. Chills and 
fever are considered as the commonest adverse drug reactions in some populations. In 
several studies, misoprostol has been associated with fever greater than 40.0°C when 
used for the management of PPH. One case in particular - which called the medical 
community’s attention to alarming complication - involved a reported peak 
temperature of 41.9°C following administration of 800 meg oral misoprostol 
prophylaxis (Chong, Chua & Arulkumaran 1997).
A PPH treatment trial in South Africa reported three women with temperature above 
40.0°C following 1000 meg misoprostol (administered 200 meg oral, 400 meg 
sublingual and 400 meg rectal) (Hofmeyr et al., 2004). More recently, one hospital in 
Quito, Ecuador, documented a higher-than-expected rate of elevated body temperature 
(> 40.0°C) in which 35% of all women receiving misoprostol treatment (800 meg 
sublingually) experienced high fever, compared with 0-10% in the eight hospitals 
following the same treatment protocol (Winikoff et al., 2006). All of these cases 
resolved with anti-pyretic treatment and cool compresses within several hours and 
without complications. Nonetheless, it is unclear why some women develop high 
body temperature while others do not and why most high fevers occurred in Ecuador. 
Hence, the possibility of a genetic cause might answer this question as individuals’ 
variations in response to medications may be caused, at least in part, by differences in 
their genetic profile. Pharmacogenetic is a study of the genetic basis of differences in 
drug response between individuals. It can involve studying DNA sequence related to 
drug response or by investigating the variability of the expression of individual genes 
relevant to disease susceptibility as well as drug response at cellular, individual or 
population level (EMEA 2002).
Pharmacogenomic research strategies involve identification and evaluation of genetic 
polymorphisms in individuals and the establishment of definitive relationships 
between these genetic variations and drug responses (McLeod & Evans 2001). To 
investigate why misoprostol-induced fever was clustered in Quito, Ecuador,
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environmental factors such as Quito’s high attitude, and patient characteristics such as 
genetic make-up of participants, have been considered. Misoprostol has been used in 
other high altitude settings for PPH (e.g. Pakistan) (Mobeen et ah, 2011); however, 
similar trends in elevated body temperature have not been reported as the incidence of 
fever was 4%. We therefore hypothesise that some women may be more susceptible 
to experiencing elevated body temperature than others due to genetic predisposition, 
which may affect the response to misoprostol and the susceptibility of women to 
adverse drug reactions.
The effectiveness of misoprostol is well established in preventing PPH after vaginal 
delivery (Derman et ah, 2006; Enakpene et ah, 2007) and has been evaluated in 
several trials, including two large multi-centred RCTs, for its potential as an 
alternative therapy option for PPH . Findings from the two recently conducted RCTs 
have demonstrated that 800 meg of misoprostol, when given sublingually, is similar in 
effectiveness to IV oxytocin in controlling excessive postpartum bleeding (Blum et 
ah, 2010; Winikoff et ah, 2010). Anecdotal evidence also suggests that misoprostol is 
widely used off-label by health care providers for PPH and other reproductive health 
indications. To date, there has been no evidence that use of misoprostol for this 
indication poses undue risks to women (Abdel-Aleem, El-Nashar & Abdel-Aleem 
2001; Adekanmi et ah, 2001; Gulmezoglu et ah, 2004; Hofmeyr et ah, 2001a; Kulier 
et ah, 2004; Lokugamage et ah, 2001; Ng et ah, 2001; O'Brien et ah, 1998; Oboro, 
Tabowei & Bosah 2003; Ozan et ah, 2000). The research ethics committees at the 
University of Liverpool and in Ecuador approved the study.
The aim of this study was to identify the genetic factors involved in the development 
of misoprostol-induced fever in women using misoprostol in different populations. 
We studied misoprostol-induced fever in two populations: one in Ecuador, where 
misoprostol was given for treatment of PPH, and in Liverpool, United Kingdom, 
where women were administered misoprostol for termination of pregnancy (TOP).
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2. Study design and participants
2.1. Ecuador population
The Ecuadorian population was part of a clinical trial which was designed for the 
assessment of fever after misoprostol administration for the treatment of primary 
PPH.
The clinical trial was designed to investigate whether a lower, 600 meg dose of 
sublingual misoprostol, compared to the previously used 800 meg, will reduce the 
incidence of elevated body temperature (> 40°C) associated with misoprostol. The 
study design also sought to document the acceptability of 600 meg sublingual 
misoprostol for PPH treatment. In addition, blood samples were collected to 
investigate whether some women are more susceptible to experiencing high fever 
following misoprostol administration, and whether genetic factors are responsible for 
misoprostol-induced fever.
2.1.1. Description of research and samples collection
The trial has evaluated side effects after misoprostol as a first-line treatment for PPH 
due to suspected uterine atony. Women who were given oxytocin prophylactically 
during the third stage of labour were consented and had their postpartum blood loss 
measured following vaginal delivery (Appendix C. 1. Patient information sheet and 
consent form). Women diagnosed with PPH that the clinical care team deemed would 
benefit from uterotonic therapy to control their excessive bleeding were enrolled in 
the study and were given the study treatment. The treatment regimen consisted of 
three 200 meg (600 meg) tablets of misoprostol given sublingually. Delivery 
attendants documented the occurrence of any side effects experienced following PPH 
treatment. Body temperature was measured systematically using an oral mercury 
thermometer at 60 minutes and 90 minutes for all women given 600 meg of 
sublingual misoprostol (Appendix C. 2. Blood sample/case review form). Women 
who had body temperature measuring > 40.0°C were closely observed and had their 
body temperature measured and documented every half-hour until fever subsided 
(measuring below 38.0°C). All women had a blood sample collected (one sample of 9
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ml) by venepuncture conducted under aseptic technique. The blood samples were 
stored at the hospital in Ecuador at -20°C and sent to the University of Liverpool in 
the UK for genotypic analysis to determine whether genetic factors are responsible for 
misoprostol-induced elevated body temperature. All samples were identified only by a 
code number, and could not be traceable to any individual participant.
2.1.2. Population and research location
Ecuador (Isidro Ayora Maternity Hospital)
Isidro Ayora is located in Ecuador’s capital city, Quito, and attends roughly 11,000 
births per year. As a large, public hospital, they often receive referrals; however, they 
are also linked with two local hospitals (Eugenio Espejo and Red Cross Hospital) to 
which they refer highly complicated obstetric cases for intensive care. Misoprostol is 
used regularly in Isidro Ayora for a variety of indications, including intrauterine fetal 
death (IUFD), treatment of incomplete abortion, treatment of PPH (when standard 
oxytocics fail), and cervical ripening.
Sample size calculation
Systematic measurement of elevated body temperature following misoprostol 
treatment served as the primary outcome measure. Any elevated body temperature 
measuring greater than or equal to 40.0 °C was categorized as a ‘high fever.’ We 
hypothesize that significantly fewer women will experience high fever following a 
600 meg regimen of sublingual misoprostol, compared to a previously documented 
rate of 36% following 800 meg in Quito, Ecuador. It is a hypothesized that a lower 
dose of misoprostol will reduce the rate of high fever by 50% in this setting. To 
detect a one-sided difference of 50% or less, with 80% power at the alpha=0.05 level, 
a maximum of 75 cases of PPH was required.
A PPH rate of 30% was previously documented in this setting via objective 
assessment of postpartum blood loss among patients not given oxytocin 
prophylactically during the third stage of labour. The study hospital now routinely 
practices the active management of third stage of labour, which has been shown to 
reduce the rate of PPH by 60-75%. We therefore expect to document a rate of PPH 
between 8% and 12%. Assuming a 10% incidence of PPH in this setting, the samples
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that were needed to be enrol approximately 750 delivering women. From the 750 
women, 50 women had PPH and treated with 600 meg sublingual misoprostol.
2.1.3. Eligibility criteria
All women presenting for vaginal delivery and who receive oxytocin prophylactically 
dining the third stage of labour were eligible for participation. Informed consent was 
obtained upon presentation at the hospital. However, only women experiencing PPH 
and for whom uterine atony is a suspected cause were enrolled in the trial. If the 
provider felt that the woman, at presentation to the delivery ward, was too far 
advanced in her labour to give appropriate informed consent, or if she was unable to 
give informed consent for another reason such as mental impairment, she was not 
eligible for enrolment. Additional inclusion and exclusion criteria are described 
below.
Women’s willingness to participate in the trial, to have their blood drawn, to respond 
to a short questionnaire to document their background characteristics and to assess 
acceptability of the drug regimen were also criteria for eligibility. If, at any point, the 
woman indicated that she no longer wished to participate in the study, she was no 
longer considered a participant.
2.1.4. Inclusion criteria
Women delivering vaginally and experiencing primary PPH due to suspected uterine 
atony were enrolled in the trial. Primary PPH was defined either through visual 
estimation by the provider, or as blood loss > 700 ml using a calibrated receptacle 
(whichever occurred first).
2.1.5. Exclusion criteria
Women were excluded from participation if they had a known allergy to misoprostol 
or other prostaglandins, were not given oxytocin during the third stage of labour- 
and/or underwent a caesarean section during the current delivery.
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2.1.6. Ethical considerations
Ethical approval was sought from the Research and Ethics Committee in Hospital 
Gineco-Obstetrico Isidro Ayora, Quito, Ecuador. In addition, approval for the study 
was sought from the Liverpool University Ethics Committee where the blood samples 
were to be analysed. The potential risks for women who participated in the trial were 
the possible side effects of misoprostol, including chills, fever, shivering, painful 
uterine contractions and gastrointestinal upset. These side effects have previously 
been shown to be clinically mild and transient. Misoprostol does not increase blood 
pressure and is better tolerated than other oxytocics in terms of nausea, headache and 
dizziness; however, transient shivering and pyrexia are more common with 
misoprostol than oxytocin. Reports of misoprostol-induced fevers greater than 40.0°C 
have been documented following regimens for treating PPH (Hofmeyr et al, 2004; 
Winikoff et ah, 2006). Secondary effects associated with misoprostol, including high 
fevers, have been transient, easy to manage, non-life threatening, and have not 
resulted in prolonged hospitalisation. There may also be some minor, but short-lived 
discomfort from having a blood test. There is a small chance of bruising and an even 
smaller chance of infection at the site of the blood draw.
A second risk involved in the trial was the possibility that misoprostol is not as 
effective as oxytocin in treating PPH, meaning that women given misoprostol may 
have required additional treatment. Based on recent evidence, among women who 
receive oxytocin dining the third stage of labour and go on to experience PPH, 
treatment with 800 meg of sublingual misoprostol was similar in effectiveness to IV 
oxytocin for managing PPH (Blum et al, 2010; Winikoff et ah, 2010). To date, 
however, there is no evidence on how effective a 600 meg dose of sublingual 
misoprostol for treatment of PPH will be. All women were under continuous 
monitoring by a member of the study team. Women who experienced uncontrolled 
haemorrhages subsequently received the standard of care for treatment of PPH at the 
study hospital. The hospital has access to all necessary interventions, including gold 
standard uterotonics, to prevent severe morbidity or mortality resulting from PPH.
The potential benefits to study participants included the possibility that misoprostol 
will effectively stop excessive postpartum bleeding and reduce the risk of severe
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haemorrhage, the need for transfusion, hysterectomy and death. As described above, 
recent evidence, comparing 800 meg regimen of sublingual misoprostol to 40 IU IV 
oxytocin among women receiving oxytocin prophylactically dining the third stage of 
labour, shows that these treatments effectively stop bleeding in 9 out of 10 women. In 
fact, many dose reduction studies on misoprostol use for other reproductive health 
indications have demonstrated that lower doses of misoprostol achieved similar 
results (Carbonell et ah, 2008; Khazardoost, Hantoushzadeh & Madani 2007; Sharma, 
Singhal & Rani 2007). The women had also their blood loss monitored closely to 
ensure timely treatment for their condition.
The genotypic analysis using the blood samples may also provide us with valuable 
information that would allow us to develop a way to predict which women are more 
susceptible to misoprostol-induced side effects and therefore develop better treatment 
strategies for future patients.
2.2. Liverpool population
107 women were recruited from the Liverpool Women’s Hospital termination of 
pregnancy clinic (Bedford Clinic). The participants had their treatment according to 
the recommended protocol for TOP in the department (Figure 1).
Sample size calculation
Systematic measurement of elevated body temperature following misoprostol 
treatment served as the primary outcome measure. Any elevated body temperature 
measuring greater than or equal to 40.0 °C will be categorized as a ‘high fever.’ We 
hypothesize that 15% of women will experience fever following 800 pg regimen of 
misoprostol for termination of pregnancy, compared to a previously documented rate 
of 36% following 800 pg in Quito, Ecuador. If we hypothesise that 60% of women 
who attend Termination of Pregnancy clinic (N=6 0/week) will agree to participate in 
our study and that 6 patients/week may experience increased body temperature above 
38°C after receiving misoprostol. It is therefore, plausible to plan recruitment of 200 
cases within 1 year'. To identify these 200 cases and with incidence of 15% of fever in 
this population, we need to recruit about 1333 women.
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2.2.1. Research description and samples collection
All women’s temperature was measured before and during treatment at 1, 2 and 4 
horns after the treatment. Every woman who developed fever after treatment were 
considered as a case of misoprostol-induced fever, providing that she was free of 
these symptoms before taking misoprostol.
The blood sample was obtained by venepuncture and 4-5 ml of blood was collected in 
a tube containing ethylenediaminetetraacetic acid (EDTA). Then, samples were stored 
at -20°C freezer in the Bedford Clinic and transferred to the Department of Molecular1 
and Clinical Pharmacology at the University of Liverpool for deoxyribonucleic acid 
(DNA) extraction and genotyping. The designated people taking the sample were 
familiar with venepuncture and a septic technique.
2.2.2. Inclusion criteria
The participant women were above 18 years old, had misoprostol for the management 
of TOP and gave an informed consent (Appendix C. 3. Patient information sheet and 
consent form).
2.2.3. Exclusion criteria
Any woman younger than 18 years old was not approached by the study researchers 
for participation in the study for ethical reasons. Also, women with chronic illness and 
using regular medication were excluded. Women with baseline temperature above 
37.0°C and any women who had chills and/or fever dining the last 24 hours before 
admission for TOP were also excluded.
2.2.4. Withdrawal of subjects
Women were free to withdraw from the study at any time should they wish.
2.2.5. Ethical considerations
The study participants were identified by local TOP staff at the Liverpool Women’s 
Hospital and they received detailed written information. All subjects were informed of
198
the nature and purpose of the study, its requirements and possible hazards, and their 
right to withdraw at any time from the study without prejudice and without jeopardy 
to any future medical care at the study site. All subjects had given adequate 
opportunity to ask the investigator or nominated designee about any aspect of the 
study. Each participant agreed to co-operate in all aspects of the study and gave 
informed written consent to the investigator for participation. They were asked to sign 
three consent forms: one for the investigator, one for the case notes and one for 
participants. The blood samples were collected from the patient under aseptic 
technique. Samples for genotypic analysis were coded and stored in a locked freezer 
in the Department of Molecular and Clinical Pharmacology at the University of 
Liverpool. These samples were used for the genetic analysis related to this study and 
will not be used for any other genotypic analysis for any other reasons without the 
further permission of the Ethics Committee. After collection of clinical data, the 
coded samples were anonymised, and could not be traceable to any individual subject. 
Genotypic data was kept by the Molecular' and Clinical Pharmacology at the 
University of Liverpool (under secure conditions) and information will not be 
routinely disclosed to any third party in any event.
The study was conducted in compliance with the guidelines of the Declaration of 
Helsinki on biomedical research involving human volunteers (Hong Kong revision, 
1989 and the 48th General assembly, Somerset West, Republic of South Africa, 
October 1996, updated in October 2000) and International Conference on 
Harmonisation of technical requirements for registration of pharmaceuticals for 
human use - Good Clinical Practice guidelines (ICH-GCP guidelines).
Changes to the protocol were made available to the Ethics Committee by means of a 
formal written protocol amendment and submitted for approval by the Research 
Ethics Committee. The timing of taking the blood samples had to be changed to the 
time of consultation rather than the time of admission and to where the women had 
their blood taken for other necessary investigations as part of their routine care. 
Therefore, women were not exposed to another needle puncture. This facilitated the 
recruitment of participants because some women were not happy to have another 
venepuncture during admission.
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2.2.6. Safety Assessment
The safety of the women in this study was of high importance. Participants recruited 
were not exposed to the procedure of taking blood unless the responsible clinician 
agreed this would not affect the women’s health.
2.3. Data management
All case report forms (CRT) (Appendix C. 4. Case Report Form) were filled out by 
personnel administering the study procedures in a clear, legible maimer. Any changes 
or corrections were made by drawing a line through the data to be changed, entering 
the correct information, and signing (or initialling) and dating the change. Every 
effort was made to have the CRFs completed and signed as soon as possible following 
blood sample collection. All the study documents were available to the Ethics 
Committee for inspection on request.
All information obtained as a result of the study is considered confidential and 
disclosure to any third party other than the Ethics Committee is prohibited. Records 
identifying the participant were kept confidential.
Documents relating to the study that contained personal data that may have disclosed 
the identity remained with the investigator in a locked filing cabinet. Participant 
confidentiality was further assured by anonymising samples at the end of the study 
and data was not traceable back to any individual patient.
2.4. Outcome measures for the genetic study
Systematic measurement of elevated body temperature following misoprostol 
treatment is the primary outcome measure. The secondary outcome is the 
identification of variant genotypes with the highest predictive value for the 
development of chills and/or fever in women treated with misoprostol.
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Counselling & giving the information 
sheet
Assessment of gestational age: USG/PV
obtaining blood sample from women who 
signed the informed consent
Figure 1. Flow chart for the study procedure incorporated into the Bedford Clinic 
protocol for termination of pregnancy
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3. Materials and Methods
3.1. DNA extraction and quantification
3.1.1. DNA extraction
DNA was extracted from all the samples from Liverpool and Ecuador using 
Chemagen extraction instrument (PerkinElmer chemagen Technologic GmbH, 
Germany) (Figure 2). This technology is built around the paramagnetic beads 
chemistry based on polyvinyl alcohol (M-PVA magnetic beads). The latter is 
subsequently carboxylated for the easy binding of nucleic acids. Their high magnetite 
content permits a rapid separation process. The beads have a polydisperse size 
distribution.
The DNA extraction takes place in two steps. The first step is the lysis step where the 
protease and the lysis buffer work together to break down the cell and the nuclear 
membranes to release the DNA into the surrounding solution. The second step is the 
elution of DNA, where the magnetic beads bind to the DNA helped by the binding 
buffer. Then, both bind to the magnetic rods and go through several washes in the 
washing buffers over the racks until the DNA is released in the elution buffer.
Figure 2. Chemagen extraction machine
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4-5 ml blood samples were collected in tubes containing (EDTA) and stored at -20°C 
in the freezer. The samples were allowed to thaw at room temperature. Chemagen was 
loaded with rods covers in rack one and empty tubes in racks 2-8. Blood samples, 
lysis buffer and protease enzyme were added to the tubes in rack 2. The rod mixed the 
contents and allowed the protease to break down the cell membranes and the nuclear 
membranes to release the DNA into the surrounding solution. Thereafter, 19.5 ml of 
binding buffer and 500 pi of magnetic beads were added to the solution. The beads 
bound to the DNA and then bound to the magnetic rods and were taken through a 
series of washes through the racks until the DNA was released into the elution buffer 
in rack 8. Magnetic beads were discarded into rack 7. DNA samples were collected 
and stored at -4°C for further quantification of the DNA concentration and quality.
3.1.3. DNA quantification
Concentration and quality of the collected DNA samples were measured using the 
Thenno Scientific NanoDrop 8000 spectrophotometer. This technology is based on 
the sample retention system which captures the sample between an array of upper and 
lower optical surfaces. The samples are held in place by the surface tension only and 
form a column in between the two surfaces. A spectral measurement and 
quantification of each sample is made based on the tightly controlled path length 
(Figure 3).
-
Figure 3. Thermo Scientific NanoDrop 8000 spectrophotometer
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After switching on the machine, the water was added to the each pedestal. Then the 
system was blanked to ensure that the elution buffer in which DNA was suspended 
did not interfere with the quantification of the samples. Once blanked, 1.5 pi of the 
samples were added to the appropriate pedestal in the direction A-H.
1 he result of the DNA quantification displayed as curve represents the absorbance 
against the wave length as can be seen in Figure 4. The concentration of the DNA is 
given in ng/pl and the purity of the DNA is given for the quality ratios. These are 
measures to the purity of the DNA and used to determine if any contamination is 
present. The ratio of 260/280 around 1.8 and for the ratio 260/230 2 and 2.2 
approximately indicated good DNA quality.
Figure 4. The result of the DNA quantification displayed as a curve represents the 
absorbance against the wave length
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3.2. Candidate gene approach
3.2.1. Bioinformatics gene and SNPs selection
For the genetic analysis, the candidate gene selection was done through searching 
individual genes and genome-wide association studies (GWAS), from the literature 
and through the pathway analysis from publically accessible databases, for genes that 
are involved in the mechanism of action, function and metabolism of misoprostol. 15 
genes were explored (Table 1).
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Table 1. Candidate genes for misoprostol-induced fever
Chr - chromosome, q- long arm of the chromosome, p- short arm of the 
chromosome
The candidate Group Name Location Role in fever
genes production
HPGD Prostaglandin 15- Chr4: 1) Inactivation of
metabolism hydroxyprostaglandin q34.1 - pge2
dehydrogenase [NAD+]; q34.1 catabolising
NAD+-dependent 15- enzymes in other
hydroxyprostaglandin tissues but not in
dehydrogenase; the brain increase
prostaglandin the blood-brain
dehydrogenase 1; short gradient of PGE2
chain and this
dehydrogenase/reductase mechanism likely
family 36C, member 1 facilitates 
penetration of 
PGE2 into the 
brain and 
prevents its 
elimination from 
the brain (Ivanov, 
Scheck &
Romanovsky
2003).
CR Prostaglandin 15- 2) As above
metabolism hydroxyprostaglandin (Ivanov, Scheck
NB, dehydrogenase; & Romanovsky
There are
CBR 1,3,4
NADPH-dependent 
carbonyl reductase 1; 
carbonyl reductase 
(NADPH); carbonyl 
reductase (NADPH) 1; 
carbonyl reductase 
[NADPH] 1; 
prostaglandin 9- 
ketoreductase; 
prostaglandin-E(2) 9- 
reductase; short chain 
dehyd rogenase/red uctase 
family 21C, member 1
2003).
PGT Prostaglandin solute can ier organic chr3: Down regulation of PGT
anion transporter family, and MOAT in the lung
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Alternate
symbols:
OATP2A1,
PGT,
SLC02A1
transport member 2A1
(member of OATP 
family)
q22.1
q22.2
OATP-C
Alternate
symbols: LST-
1, LST1,
MGC133282,
OATP-C,
OATP1B1,
OATP2,
OATPC,
SLC21A6
SLCOIBI
Prostaglandin
transport
solute carrier organic 
anion transporter family, 
member 1B1
chr!2:
p!2.2 -
p!2.1
ABCC4 Prostaglandin ATP-binding cassette, chrl3:
transport sub-family C q32.1 -
Alternate
symbols:
ABCC4,
AF071202.1,
EST170205,
MOAT-B,
MOATB,
MRP4
(CFTR/MRP), member
4
q32.1
PTGER1 Prostaglandin prostaglandin E receptor chrl9:
Alternate 
symbols: EP1
target 1 (subtype EP1), 42kDa p!3.12 - 
pl3.12
PTGER2 Prostaglandin prostaglandin E receptor chr!4:
Alternate 
symbols: EP2
target 2 (subtype EP2), 53kDa
q22.1 
q22.1
PTGER3 Prostaglandin
target
prostaglandin E receptor
3 (subtype EP3
chrl:
p31.1 -
and liver but not in the 
brain would increase 
blood-brain gradient and 
likely facilitate 
penetration of PGE2 into 
the CNS and prevent its 
elimination from the 
brain (Ivanov, Scheck & 
Romanovsky 2003). 
OATP-A strongly 
expressed in the brain 
(Tamai et al., 2000)
Expressed at the BBB
Expressed mainly in the 
liver (Tamai et al., 2000).
Down regulation of PGT 
and MOAT in the lung 
and liver but not in the 
brain would increases 
blood to brain gradient 
and likely to facilitate 
penetration of PGE2 into 
the CNS and prevent its 
elimination from the 
brain (Ivanov, Scheck & 
Romanovsky 2003).
Weak affinity to 
misoprostol
Clear misoprostol agonist 
activity
Potent and selective 
misoprostol activity
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Alternate 
symbols: EP3, 
EP3-I, EP3-II, 
EP3-II1, EP3- 
IV, EP3e, 
MGC141828, 
IMGC141829, 
MGC2730
EP3 (rEP3a & rEP3p) p31.1 PE3 is
1. Highly expressed in 
the brain regions 
such, raphi nuclei 
(Rpa), hypothalamus 
preoptic area (POA) 
and median preoptic 
nucleus (MnPO) 
(Nakamura et al., 
2002)
2. PGE-EP3 signalling 
inhibits GABAergic 
inhibition by 
changing the GABAa 
channels properties.
It may affect the 
sensitivity of these 
channels to GABA or 
the response of the 
POA neurons to 
GABA (Nakamura et 
al., 2005).
3. EP3 receptor binds to 
G i/0 proteins in the 
POA neurons and 
results in attenuation 
of gabr gene 
expression (Osaka 
2008a, 2008b; 
Tsuchiya et al.,
2008).
PTGER4
Alternate 
symbols: EP4, 
EP4R, 
MGC126583
Prostaglandin
target
GABR (2 
genes)
Prostaglandin
target
GABRG2,
GABRA2
prostaglandin E receptor 
4 (subtype EP4)
gamma-aminobutyric 
acid (GABA)a receptor.
chr5:
p!3.1
p!3.l
Chr 5, 
q34
Chr 4, 
pl2
High affinity to 
misoprostol
PE4
It is mainly expressed in 
the ventromedial preoptic 
nucleus (VMPN) and also 
located in the MnPO 
(hypothalamus)
GABAA
1. GABA and GABAa 
are essential for PGs 
to induce febrile 
response in the POA 
(Osaka 2008a).
2. PGE-EP3-signalling 
inhibits GABAergic
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ADRB1
Alternate
symbols:
ADRB1R,
B1AR,
BETA1AR,
RHR
ADRB2
Alternate
symbols:
ADRB2R,
ADRBR,
B2AR, BAR,
BETA2AR
Prostaglandin
target
adrenergic, beta-1-, 
receptor
chrlO:
Prostaglandin adrenergic, beta-2-, 
target receptor, surface
q32 - q32
inhibition by rapidly 
decreasing the 
expression of gabr 
gene —> | N^_of 
GABAa receptors 
—> EP3-expressing 
neurons become 
insensitive to the 
inhibition from 
GABA -► PG 
induced 
hyperthermia 
(Nakamura et ah, 
2005; Osaka 2008a, 
2008b; Tsuchiya et 
ah, 2008).
BAT heat production 
(non-shivering 
thermogenesis) is under 
sympathetic nervous 
system control through 
sympathetic 
norepinephrine 
stimulation of B- 
adrenergic receptors on 
the brown adipocytes 
membrane. Inhibition of 
the B-adrenegic receptor 
by propranolol or pre­
treatment with 
sympathetic ganglionic 
blocker chlorisondamine 
chloride completely 
prevented the increase in 
the BAT and core 
temperature induced by 
PGE2 injection to the 
POAH (Amir & 
Schiavetto 1990).
As above
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ADRB3
Alternate
symbols:
BETA3AR,
FLJ99960
Prostaglandin
target
adrenergic, beta-3-, 
receptor
chr8 :
pi 1.23 - 
pi 1.23
As above
ADRBK1 Prostaglandin adrenergic, beta, chrl 1 : As above
target receptor kinase 1 q!3.2 -
Alternate q!3.2
symbols: 
BARK1, 
BETA-ARK 1, 
FLJ16718, 
GRK2
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3.2.2. Criteria for the selection of SNPs
After candidate genes have been selected, SNPs selection in candidate genes was 
performed by searching the literature for reported SNPs, from the SNPs database 
(dbSNP) and from HapMap. We searched the HapMap for tagging SNPs selection as 
well. The SNP search within these genes was performed using the SNP database of 
the NCBI ('http://www.ncbi.nlm.nih.gov/SNPT
• The first step of SNPs selection was based on the following criteria:
Genetic region, types of SNPs and minor alleles frequency (MAP): from SNPs 
database (dbSNP), we selected all potentially functional SNPs in the exons, 3 UTR 
and 5' UTR regions with minor allele frequency not < (0.05) = 5%. Potentially 
functional SNPs (missense) are the SNPs which result in production of a different 
amino acid. A total of 62 potentially functional SNPs in the 15 genes were 
identified and available for the selection procedure.
• The secondary selection involved the identification of the 62 SNPs in the literature 
and their association with different diseases or drugs’ response. The criteria for 
selection were identification of SNPs with positive association with a disease or 
drug response. Accordingly, we identified 13 SNPs from the previously selected 62 
SNPs.
• The third selection of SNPs was based on identification of tagging SNPs and 
linkage disequilibrium. We searched HapMap database (http://www.hanmap.orgl 
for tagging SNPs and we selected SNP pairs with linkage disequilibrium (LD) of 1. 
Tagging SNPs are representative SNPs in a gene region with high LD (the non- 
random association of alleles at two or more loci). (For more information, see 
Chapter 1, section 3). Through these selection criteria, we identified 15 tagger 
SNPs with high LD.
Combination of the functional SNPs from dbSNP and tagging SNPs from HapMap 
resulted in a selection of 54 SNPs representing 15 candidate genes (Table 2).
Sequenom assay design was carried out using genotyping tools software from 
mysequenom website https://www.mvseauenom.com/Tools. These tools help to 
design amplification and extension primers and to design and validate multiplexed
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assays. Through this tool we designed 4 plexes. Two of them had 33 SNPs, 
representing all the candidate genes except PTGER1 (Figure 5). Primers wfere ordered 
from Metabion (http://www.metabion.com).
Functional SNPs
(62 SNPs)
Tagging SNPs
(15 SNPs)
Selection of 2 plexes
(33 SNPs)
Sequanom design
(54 SNPs)
Figure 5. SNPs selection procedure, the combination of the functional SNPs from dbSNP 
and tagging SNPs from HapMap followed by the sequenom assay design resulted in the 
final number of SNPs genotyped in our patients (33 SNPs)
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Table 2. The selected genes and its functional SNPs, tagging SNPs and examples of their 
association with some diseases and drugs’ response
Gene
CBR3
(PG
metabolism)
HPGD
(PG
metabolism)
Prostaglandin
transported
(OATP2A1)
(SLC02A1)
SNPs Studied SNPs Disease SNPs Tagger SNPs/
identified 
from SNPs Papers/year
studied positive
association Linkage
data base of publication
P value
disequilibrium
rs8133052 (Bains et al.. Naturally +ve rs8133052
2010) occurring 
variants of P<0.05
human CBR3
alter
Anthracycline in 
vitro metabolism
1
rs 16993929
rs 1056892 (Blanco et al., Anthracycline- -ve rs879894
2008) related
congestive heart 
failure after
childhood cancer
rs45439401
rs2555660
rs9312555 (Frank et al.. Colorectal -ve
2011) cancer risk
rs8752 (Frank et al., Colorectal +ve P=0.009
2011) cancer risk
rs2253270 rs2253170
rs2253170 rs2253170
213
OATP-C
(SLCOIBI)
Prostaglandin
transported
ABCC4/MRP
4
Prostaglandin
transporter
rs2306283
rsl 1045819 
rs4149056
rs34671512 
rs4149085 
rs4149087 
rsl 1045891 
rs4149088
(Nozawa et al., 
2005)
(Nozawa et al., 
2005)
(Takane 2011)
(Niemi, Pasanen 
& Neuvonen 
2011)
Hepatic uptake +ve P<0.05 
of irinotecan
Hepatic uptake +ve P<0.05 
of irinotecan
Decreased intake 
of anti-cancer +ve 
drug SN-38 from 
the systemic 
circulation, 
leading to an 
increase in its 
plasma 
concentration 
and enhancing 
the risk of 
neutropenia
Associated with 
statin-induced
adverse drug +ve P<0.05 
reactions
rs2417963
rsl 1045825 
rsl 1045879
rs4149087 
rsl 1045825 
rs4149087
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PTGER1
PTGER2 
(prostaglandi 
n target)
rs7249305
rs28364035
rsl353411
rsl254598
rs708502
rs4148551
rs3742106 (Rodriguez- 
Novoa et al., 
2009)
Kidney tubular 
necrosis in HIV 
patients treated 
with tenofovir
-ve rs3742106
rs3765534 (Ban et al., 
2010)
Thiopurine 
sensitivity in
Japanese patients 
with
inflammatory 
bowel disease
+ve
P=0.036
rs3765534
(Krishnamurthy 
et al., 2008)
Transporter-
mediated
protection
against
thiopurine-
induced
hematopoietic
toxicity
+ve
P<0.05
rs2274407 (Izzedine et al., 
2006)
No Association 
between ABCC4 
Gene Haplotypes 
and Tenofovir- 
induced 
proximal 
tubulopathy
-ve
r-l-' h'
(Park et al. 
2007)
(Kim et al., 
2007)
(Park et al., 
2007)
(Park et al., 
2007)
Asthma in the
Korean
population
Aspirin-
intolerant asthma
Asthma in the
Korean
population
Asthma in the
Korean
population
+ve P=0.002
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PTGER3 rs5697 rs3819783
(prostaglandi 
n target)
PTGER4 rs 16870224 (Kim et al., Aspirin- -ve rs 16870224
(prostaglandi 
n target)
2007) intolerant asthma
GABRG2
■■
(prostaglandi 
n target)
rs418210 
rs424740 (Pham et al., Anxiety 
2009) spectrum
disorders
-ve
GABRA2
(prostaglandi 
n target)
(Agravval et al., Nicotine +ve P=0.008
2008) dependence
(Haughey et al.. Acute effects of
2008) alcohol +ve P<0.05
(Agrawal et al.. Alcohol
2006) dependence and
drug dependence +ve
P=0.009
ADRB1
(prostaglandi 
n target)
rs279860
rs 1801252 (Leu et al.. Carotid intima- -ve
2011) medial thickness
(Bengtsson et Hypertension,
al., 2010) and Obstructive +ve P=0.042
Sleep Apnoea
Exercise
(Leineweber et capacity and -ve
survival in
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al., 2010) patients with
end-stage heart 
failure
Predicts
Flecainide action
(Nia et al., in patients with +ve P=0.03
2010) atrial fibrillation
Association with
atrial fibrillation +ve P<0.05
(Nicoulina et 
al., 2010)
(Johnson et al.. Hypertension +ve
2011) P=4.7xlO'10
Mortality in 
Carvedilol- +ve RR=2.3
treated chronic 
heart-failure 
patients
(Bengtsson et Hypertension, 
al., 2010) and obstructive -ve
sleep Apnoea
Exercise
capacity and 
survival in
patients with "ve 
end-stage heart 
failure
Left ventricular +veP=0.001 
(Hakalahti et al., hypertrophy 
2010)
(Leineweber et 
al., 2010)
(Petersen et al., 
2011)
(Baudhuin 
al., 2010)
(Nia et 
2010)
et
al.,
Response to.
Carvedilol or
Metoprolol
therapy in
Patients With
chronic heart
failure
Predicts
Flecainide action
in patients with
atrial fibrillation
+ve P=0.01
+ve P=0.03
rs 1801253
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Cardiovascular 
disease in
(Poon et al., patients with -ve
2010) diabetic
nephropathy
rs 1801704
'
rs 1801704
ADRB2 rs 1042711
(prostaglandi rs 1042713 (Leineweber et Exercise -ve rs 1042713
n target) al., 2010) capacity and
survival in
patients with
end-stage heart
failure
(Pereira, Risk of obesity
Mingroni-Netto in Japanese -ve
& Yamada
2011)
(Schiirks et al., Migraine in -ve
2009) women
rs 1042714 (Petersen et al., Mortality in -ve
2011) Carved ilol-
treated chronic
heart-failure
patients
Carotid intima- -ve
(Leu et al.. medial thickness
2011)
Exercise
(Leineweber et capacity and
al., 2010) survival in
patients with -ve
end-stage heart
failure
Migraine in
(Schiirks et al., women
2009) -ve
rs34434657
ADRB3 rs3 5646917
(prostaglandi rs4999
n target)
rs4998
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(Wang et ah. Gout in Chinese +ve
2011) male population P=0.027
(Tahara, Osaki 
& Kishimoto
BMI reduction -ve
2010)
(Yamakita et ah, Weight changes +ve
2010) in obese
Japanese Men
P=0.002
Cardiac disease
(Wang et ah, in type 2 +ve
2010) diabetes P=0.002
Type 2 diabetes 
and metabolic
(Cruz et ah. syndrome from +ve P=0.001
2010) Mexico City
Cardiovascular 
risk markers +ve P<0.05
(Fan et 
2010)
ah.
Hyperuricemia 
risk in a
(MorelHo et ah. population from +ve
2010) southern Spain P=0.017
BMI and obesity
(Marvelle et ah, +ve P<0.05
2008)
Metabolic
(Dunajska et ah. syndrome in
2008) postmenopausal -ve
women
rs4994
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3.3. Method for SNPs genotyping
3.3.1. Principle of SNPs genotyping using the Sequenom Mass ARRAY iPLEX 
Platform
The Sequenom Mass ARRAY system (Figure 6) is based on the technology of Matrix 
Assisted Laser Desorption/Ionisation-Time-of-Flight Mass Spectrometry (MALDI- 
TOF MS). Mass spectrometry is used to identify the SNP alleles based on the distinct 
mass of the extended primer. The primer’s mass indicates the sequence and, 
consequently, the alleles present at the polymorphic site of interest. The Sequenom 
(Spectro Typer) software automatically translates the mass of the observed primers 
into a genotype for each reaction.
Figure 6. Matrix Assisted Laser Desorption/Ionisation-Time-of- Flight Mass 
Spectrometry (MALDI-TOF MS)
Brief description of the process of Mass ARRAY genotyping
This section briefly describes the process of Mass ARRAY genotyping and for 
detailed description refers to the Protocol (Appendix C.5). Figure 7 shows a summary 
of the process of genotyping using MassARRAY system (MALDI-TOF MS).
Prior to the procedure, the DNA samples are diluted to 20 ng/ml using IxTE (Tris- 
EDTA) buffer. The DNA samples need to be amplified by PCR prior to performing 
the extension reaction of the SNPs of interest.
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PCR setuo and amplification
Adding reagents (SAP enzyme solution) 
using
Matrix Liquid Handler
SAP treatment to neutralise 
unincorporated dNTPs
Adding (iPLEX reaction mix) using 
Matrix Liquid Handler
Primer Extension Reaction
Primer Extension reaction
Resin Cleanup
Nanodispensing iPLEX reaction products 
on The SpectroCHIP
Detection of primer extension products by
MALDI-TOF MS
Report Generation (SpectroTYPER)
Figure 7. Process of Genotyping using Mass ARRAY system (MALDI-TOF MS)
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PCR setup and amplification
This step includes amplifying a selected fragment of genomic DNA for genotyping on 
the Mass ARRAY platform. The goal of multiplex PCR is to amplify many loci of 
DNA with minimal nonspecific by-products. The purified amplicons are used as 
templates for the primer extension reaction.
The PCR mix, which contains PCR buffer, MgCl2, dNTP mix, primer mix, and Hot 
Star Taq, undergoes thermal cycling (PCR reaction). Multiplexed assays for the 
master mix (PCR primers, extension primers) as shown in Appendix C. 6.
SAP reaction cleanup
Treatment with sin-imp alkaline phosphatase (SAP) is performed to remove the 
remaining, non-incorporated dNTPs from amplification products. This takes place by 
cleaving the phosphate groups from the 5' termini of the non-incorporated dNTPs. 
This procedure is performed by using the Matrix Liquid Handler robot. Incubation of 
the reaction is at 37°C for 40 minutes and is then followed by incubation at 86°C for 
20 minutes to inactivate SAP enzyme on thermal cycler.
Primer Extension Reaction
Primer Extension Reaction or iPLEX Reaction is a method for detecting single base 
polymorphisms or small insertion/deletion polymorphisms in amplified DNA. The 
primer extension reaction cocktail which contains iPLEX buffer, iPLEX-Termination 
mix, Primer mix and iPLEX enzyme are added to the amplification products. The 
addition of the iPLEX reaction is performed using Matrix Liquid Handler. During the 
iPLEX reaction, the primer is extended by one mass-modified dideoxynucleotide 
terminator of an oligonucleotide primer which anneals immediately upstream of the 
polymorphic site of interest. The primer extension is performed by thermal cycling.
Primer Extension Reaction resin cleanup
The cleanup step is essential to optimise mass spectrometry analysis of the extended 
reaction products. The cationic resin helps to remove salts such as Na+, K+ and Mg2+
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ions. The presence of these ions can result in high background noise in the mass 
spectra.
Nanodispensing iPLEX reaction products on the SpectroCHIP
The extended/desalted iPLEX reaction products are dispensed from 384-well 
microtiter plate on 384-sample SpectroCHIP. A small volume of the iPLEX products 
(25 nl) is arrayed onto the existing matrix spots on the silica chip and this allows for 
precise incorporation of oligonucleotides with the appropriate matrix for MALDI- 
TOF.
Detection of primer extension products by mass spectrometry
The extended primer products are detected using Mass ARRAY spectrometer and 
Sequenom real-time detection software.
In the mass spectrometer, once the laser beam is fired at the chip, the matrix made of 
crystallised molecules is ionised and part of its charge is transferred to the analyte 
molecules, which become ionised as well. The matrix molecules have several roles: 1) 
to absorb most of the laser energy, 2) to protect the analyte molecules from being 
destroyed by direct laser and 3) to prevent ion fragmentation (soft ionisation). The 
rapidly expanding matrix plume carries some of the analyte into the vacuum with it 
and this aids the sample ionisation process. The vaporised and ionised sample 
molecules are transferred electrostatically into time-of-flight mass spectrometer where 
they are separated from the matrix ions and individually detected based on their mass 
to charge ratio (m/z) and analysed by the software. Ion detection at the end of the tube 
is based on its flight time as molecules with large mass transfer slower than molecules 
with small mass. Flight time is proportional to the square root of its m/z. Therefore, 
the unique mass values of the extended primer allow discrimination between two 
alleles and identification of the SNPs (Figure 8).
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Figure 8. Cluster plot of low mass allele vs. high mass allele for chosen assay 
Spectrum of a chosen assay shows analyte signals, genotypes and mass range
224
3.4. Statistical analysis
Statistical analysis of incidence means ±SD were performed by Excel. Continuous 
data analysis in respect to genotypes and its association with body temperature in 
women on misoprostol (phenotype) was assessed using analysis of variance 
(ANOVA) with correction of multiple comparisons using Benfrroni method in SPSS 
statistics 19. The difference was taken as statistically significant when P values were 
less than 0.05.
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4. Results
4.1. Clinical data result 
4.1.2. Ecuador population
4.1.2.1. Characteristics of the study Ecuadorian population
766 women were enrolled in the study and screened for the diagnosis of PPH. 50 
women were included who were treated for PPH with 600 meg sublingual 
misoprostol. Table 3 shows the characteristics of the included population.
Table 3. Mean of women’s age, number of live births and BMI in the Ecuadorian 
population
Characteristics Mean ± SD
Age
Number of live births
BMI
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4.1.2.2. Ethnicity of the included Ecuadorian population
The study population included 5 different ethnic groups from Ecuador. The most 
common ethnic group was Mestizo, which means mixed population from indigenous 
and Europeans. This group represents 44 women with incidence of 88% of the 
included population (Table 4).
Table 4. Incidence of different ethnic groups in the Ecuadorian population (Mestizo: 
Indigenous and European) (Mulato: mixed white and black)
Ethnicity Number Percentage (%)
Indigenous
Black
Mestizo
Mulato
White
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4.I.2.3. Frequency and incidence of side effects after treatment with 600 meg 
sublingual misoprostol in Ecuadorian population
As illustrated in Table 5, the commonest side effect was chills or shivering with an 
incidence of 96%, followed by the fever, which occurred in 90 % of the population.
Table 5. Frequency and incidence of different side effects after treatment of Ecuadorian 
women with 600 meg sublingual misoprostol for PPH
Side effects Incidence (%)
Nausea
Vomiting
Diarrhoea
Chills/Shivering
■
Fever >37.6 °C
Fainting
Others
Headache
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4.1.2.4. Incidence of different categories of body temperature in the Ecuadorian 
population
Body temperature measurements from the 50 women who were treated for PPH were 
classified to 4 categories. Body temperature < 37.6°C occurred in 4 women, which 
represents 8% of the population under study; body temperature from 37.6°C to 39°C 
was reported in 33 (66%) of the population; body temperature of 39.1°C to 39.9°C 
was observed in 8 (16%) of the treated women; and body temperature >40°C was 
recorded in 5 (10%) of the population (Figure 9)
Incidence of fever in women treated with 
misoprostol for PPH in Ecuador
Figure 9. Incidence of different categories of fever in Ecuadorian women treated with 
misoprostol for PPH
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4.1.2.5. Number of women in different fever categories in different ethnic groups 
Ecuadorian population
The commonest fever category was the second (37.60C-39°C), which represents 
about 72% of the participant women with fever (46 women), followed by the third 
category (39.10C-39.9°C), which accounts for 17.4% of the febrile women. All 
women with high fever > 40°C were from the mestizo population and they represent 
11.9% of the febrile women population (Table 6).
Table 6. Number of women in different fever categories in Ecuador population 
according to the ethnic groups
Fever Category Indigenous Black Mestizo Mulato white Total
<37.6 °C (No 
fever)
3 4
3760C-390C 1 29 1 2 33/46
72%
39.10C-39.9°C 7 1 8/46
17.4%
> 40 °C 5 5/46
10.8%
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4.2.2. Liverpool population
4.2.2.1. Characteristics of Liverpool population
107 women who were seeking (TOP) were recruited for the study and they received 
800 meg vaginal misoprostol. 93 of the recruited women had complete data about 
fever and had their blood samples collected for the genetic analysis. Therefore, we 
included only these women in the statistical analysis of data. Table 7 shows the 
characteristics of the included population.
Table 7. Means and SD for gravidity, parity and BMI of the Liverpool population
Characteristics Mean ± SI)
Gravidity
Parity
BMI
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4.2.2.2. Ethnicity of the included Liverpool population
The study population included 7 different ethnic groups. The commonest ethnic group 
was White British and it represented about 85% of the total population. Other ethnic 
groups were very rare with not more than 3 individuals in each group (Table 8).
Table 8. Incidence of the different ethnic groups in Liverpool population
Ethnicity Number Percentage (%)
White ■
Black MHHH■
Other Ethnic II
Background imi
Other Mixed ii
Background ■
Indian ■
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4.2.2.3. Frequency and incidence of side effects after treatment with 800 meg 
vaginal misoprostol in Liverpool population
The commonest side effect was abdominal cramps (77.7%), followed by feeling of 
coldness (55.3%), whereas fever is the least common side effect and occurred in 8.8% 
of the treated women. The figures for other side effects are illustrated in Table 9.
Table 9. Incidence of side
Liverpool
effects of misoprostol in the participant women from
Side effects Number Incidence (%)
Coldness 52 55.3
Chills and/or shivering 30 31.9
Fever > 37.6 °C 8 8.8
Nausea and vomiting 36 38.3
Diarrhoea 19 20.2
233
4.2.2.4. Incidence of different categories of body temperature in Liverpool 
population
Body temperature measurements from the 91 women who underwent TOP were 
classified into 3 categories. Body temperature > 37.6°C was considered a diagnosis of 
fever and less than this figure was considered as no fever. Women with body 
temperature > 37.6°C represented around 9% of the total population (Figure 10).
Incidence of fever in women who treated 
with misoprostol for TOP
100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
< 37.6°C 37.6-39°C >39°C
Figure 10. Incidence of different categories of body temperature in Liverpool population
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4.2.2.S. Incidence of fever according to ethnicity
All women who were diagnosed with fever (body temperature > 37.6°C) were White. 
None of the other ethnic groups had fever.
4.2. Results of the SNPs genotyping
Genotyping quality control
Genotyping was performed in 143 subjects (50 Ecuadorian and 93 Liverpool women) 
for 33 known SNPs in 14 genes. Our overall genotyping sample success rate (call 
rate) was 90%. All the SNPs were genotyped and included in the final data analysis.
Call rate= Precent of gynotypes with calls other than low propability or no call out of 
the total number of possible calls
4.2.1. Ecuador population
4.2.1.1. The association between genotypes and body temperature
The genotype and phenotype data were used to determine if there was any association 
between the mean temperature and its genotype. There was an association between 2 
SNPs (rs4149085 and rs4149087) in the prostaglandin transporter (SLC01B1) 
(P=0.027 and P=0.005) respectively. Also, there was an association between the 
mean temperature and SNP (rsl 14869610) in prostaglandin transporter (SLC02A1) 
with P=0.017 (Table 10 and Figures 11, 12 & 13).
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Table 10. Allelic frequencies and genotype frequencies for the selected SNPs in 14 genes 
and their mean temperature in Ecuadorian women treated with misoprostol for 
treatment of PPH
Gene dbSNP Location Allele Allelic
Frequency
Genotype Count
(%)
mean
temperature 
(°C) (SD)
P
value
INCBI
/MAP
SLCOIBI rs 11045825 Chrl2 T 0.97 TT 47 (94) 38.8 (±0.8) 0.23 0.086
Intron C 0.03 CT 3(6) 38.2 (±0.9)
rs 11045879 Chrl2
Intron
C 0.195 CC 1 (2) 38.7 (0) 0.643 0.26
T 0.805 TC 17(35) 38.97 (±1.0)
TT 31 (63) 38.7 (±0.8)
rs4149085 Chrl2 C 0.01 CT 1 (2) 40.7 (0) 0.027 0.123
3'UTR T 0.99 TT 47 (98) 38.74 (±0.8)
rs4149087 Chrl2 G 0.35 GG 7(14) 39.6 (±0.9) 0.005 0.48
3’UTR T 0.65 GT 21 (42) 38.4 (±0.7)
TT 22 (44) 38.8 (±0.8)
rs34671512 Chrl2 A 0.99 AA 48 (98) 38.8 (±0.9) 0.367 0.56
missense C 0.01 CA 1(2) 38.0 (0)
SLCG2A1/ rs34550074 Chr3 A 0.306 AA 6(14.6) 38.8 (±0.9) 0.5 0.28
OATP2A1 missense G 0.694 GA 13(32) 39.0 (±0.9)
GG 22 (53.4) 38.6 (±0.8)
rsl 13569514 Chr3 C 0.265 CC 4 (11) 38.47 (±0.9) 0.756 0.33
5'UTR T 0.735 CT 11(31) 38.8 (±0.9)
TT 21 (58) 38.8 (±0.8)
rs6439448 Ch43 A 0.342 AA 6(13) 39.4 (±1.0) 0.08 0.25
intron C 0.658 CA 20 (42.5) 38.57(±0.8)
CC 21 (44.5) 38.75(±0.7)
rs72978388 Chr3 T 0.99 TT 49 (98) 38.8 (±0.8) 0.135 0.052
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ABCC4/ rs2274407 Chrl3 A 0.073 AA 1 (2.1) 38.7(0) 0.99
MRP4
missense
C 0.916 CA 5 (10.4) 38.8 (±0.6)
T 0.011 TC 1 (2.1) 39(0)
CC 40 (85.4) 38.8 (±0.9)
ABBCC4/ rs3742106 Chrl3 A 0.48 AA 12(25) 38.9 (±0.7) 0.86
MR 3'UTR C 0.52 CA 22 (46) 38.76 (±0.9)
CC 14 (29) 38.76 (±0.9)
rs4148551 Chrl3 A 0.48 AA 12 (25) 38.9 (±0.7) 0.864
3'UTR G 0.52 GA 22 (46) 38.7 (±0.9)
GG 14(29) 38.7 (±0.8)
rs34559063 Chrl3 A 0.53 AA 16(34.7) 38.66 (±0.9) 0.51
3'UTR G 0.47 GA 17(37) 38.88(±0.8)
GG 13 (28.3) 39.04 (±0.8)
rs3765534 Chrl3 C 0.95 CC 42 (88) 38.67 (±0.8) 0.24
missense T 0.05 CT 5(10) 39.18 (±1.0)
TT 1(2) 39.7 (0)
rs4148553 Chrl3 A 0.27 AA 4(10.3) 39.7 (±1.0) 0.065
3'UTR G 0.73 AG 13(33.3) 38.8 (±0.6)
GG 22 (56.4) 38.6 (±0.9)
PTGER2 rsl7197 Chrl4 C 0.235 CC 4(8) 38.97 (±0.4) 0.91
3' UTR T 0.765 TC 15(31) 38.75 (±0.8)
TT 30(61) 38.79 (±0.9)
rs708502 A 0.25 AA 5(10) 38.8 (±0.4) 0.96
G 0.75 AG 15(30) 38.7 (±0.8)
GG 29 (60) 38.7 (±0.9)
0.07
0.16
0.39
0.48
0.424
0.061
0.42
0.28
0.28
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rs4998
rs211035
rs2253170
0.07
0.93
ChrM A 0.97 AA 45 (94) 38.8 (±0.8) 0.285 0.05
3’UTR G 0.03 TA 3(6) 38.2 (±0.5)
Chrl C 0.255 CC 4 (8.9) 39.025 (±1.0) 0.646 0.244
Intron T 0.745 CT 15(33.3) 38.62 (±0.7)
TT 26 (57.8) 38.86 (±0.9)
Chr5 A 0.12 AG 11 (24) 38.77 (±0.9) 0.74 0.133
3'UTR G 0.88 GG 34 (76) 38.87 (±0.8)
ChrlO C 0.97 CC 31(97) 38.65 (±0.9) 0.415 0.294
missense G 0.03 GG 1(3) 37.9 (0)
Chr5 C 0.965 CC 42 (93) 38.87 (±0.9) 0.228 0.24
missense G 0.035 GC 3(7) 38.23 (±1.2)
Chr8 C 0.02 CG 2(4) 38.2 (±0.4) 0.34 0.095
3'UTR G 0.98 GG 47 (96) 38.8 (±0.9)
AG
GG
6(14.3) 39.06 (±0.9)
36 (85.7) 38.65 (±0.8)
A 0.065 AA 1 (3.2)
G 0.935 AG 2 (6.5)
GG 28 (90.3)
37.5 (0)
39.9 (±1.34)
Chr5 A 0.417 AA 3 (8.3) 39.1 (±0.87)
Intron C 0.583 CA 24 (66.7) 38.8 (±0.96)
CC 9(25) 38.9 (±0.59)
0.866 0.38
0.259 0.20
0.12 0.05
Rs45439401 C 0.315 CC 7 (16) 39.16 (±0.7) 0.4
T 0.685 TC 14(31) 38.6 (±0.8)
TT 24 (53) 38.7 (±0.9)
CBR3 rs879894 Chr21 A 0.177 AA 3 (6.2) 38.96 (±0.8) 0.9
Intron C 0.823 CA 11 (23) 38.86 (±0.7)
CC 34 (70.8) 38.77 (±0.9)
Individual Value Plot of Temperature
©39.6
38.9238
rs4149087
Figure 11. Individual plot of temperature showing the mean temperature in each 
genotype for rs4149087 in the prostaglandin transporter gene SLCOIBI (P=0.005)
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Individual Value Plot of Temperature vs rs4149085
S 39-
rs4149085
Figure 12. Individual plot of temperature showing the mean temperature in each 
genotype for rs4149085 in the prostaglandin transporter gene SLCOIBI (P=0.027)
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Individual Value Plot of Temperature vs rs!14869610
rsll4869610
Figure 13. Individual plot of temperature showing the mean temperature in each 
genotype for rsll4869610 in the prostaglandin transporter gene SLC02A1 (P=0.017)
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4.2.1.2. Comparison of Ecuadorian population with other Hispanic/Latino 
populations
As can be seen in Figure 14 from a genome-wide patterns study of Hispanic/Latino 
population, the Ecuadorian population (light green) showed similar genetic profile to 
Colombian (yellow) and Mexican (light blue) populations. The comparison of minor 
allele frequency (MAF) of these populations with this study Ecuadorian population is 
shown in fable 11. The MAF is actually the second most frequent allele value.
RCA of autosomal SNPs
-0.02 -001 0.00 0 01 0.02 0.03
Principal Component 1 (9.15%)
Hispanic/Latino Populations
• Mexico • Puerto Rico
• Ecuador • Dominican Republic
Colombian African American
Figure 14. Principal component analysis results of the Hispanic/Latino individuals. 
Adapted from Bryc et al. 2010
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Table 11. Allelic frequency of SNPs with positive association with misoprostol-induced 
fever (rs4149087) in this study Ecuadorian population and in twenty Ecuadorian and 
twenty-six Colombian populations (healthy volunteers) from a study of genome-wide 
patterns of population structure and admixture among Hispanic/Latino populations 
(Bryc et al. 2010)
Population (Number) MAP
rs4149087
Ecuadorian (20)
(Bryc et al., 2010)
0=0.4
Colombian (26)
(Bryc et al., 2010)
G=0.36
Our study population
(Ecuador) (50)
0=0.35
Caucasian (North America) 
(NCBI)
0=0.36
MAF/global NCBI 0=0.47
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4.2.2. Liverpool population
4.2.2.1. The association between genotypes and body temperature
The genotype and phenotype data was used to determine if there was any association 
between the mean temperature and its genotype. There was no genetic association 
with mean temperature in the Liverpool population treated with misoprostol for TOP 
(Table 12).
Table 12. Allelic frequencies and genotype frequencies for the selected SNPs in 14 genes 
and their mean temperature in Liverpool women treated with misoprostol for TOP
Gene dbSNP ID Location Allele Frequency
(%)
Genotype Frequency
N (%)
Mean
temperature 
(°C) (SD)
P
value
NCBI
/
MAF
(%)
SLCOIBI rs 11045825 Chrl2 C 15.5 CC 1 (1) 36.4 (0) 0.24 8.6
T 84.5
Intron CT 26 (29) 36.7 (±0.8)
TT 70 (63) 36.9 (±0.5)
rs 11045879 Chrl2 C 16 CC 1 (1.2) 36.0 (0) 0.86 26
T 84
Intron TT 58(69) 36.84 (±0.6)
TC 25 (29.8) 36.8 (±0.6)
rs4149085 Chrl2 C 0.5 CT 1(1) 37.3 (0) 0.4 12.3
T 99.5
3' UTR TT 84 (99) 36.8 (±0.6)
rs4149087 Chrl2 G 40 GG 14(16.3) 36.7 (±0.7) 0.5 48
T 60
3'UTR GT 41 (47.7) 36.8 (±0.6)
TT 31 (36) 36.9 (±0.5)
rs34671512 Chr 12 A 93.5 AA 80 (87) 36.8 (±0.7) 0.5 5.6
C 6.5
Missense CA 12(13) 37.0 (±0.5)
SLCG2A1 rs34550074 Chr3 A 13.8 AA 4 (5.5) 36.6 (±0.5) 0.6 28
G 86.2
/OATP2A1 Missense GG 57 (78) 36.9 (±0.5)
GA 12(16.5) 36.8 (±0.7)
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rs 114869610 Chr3 A 97 AA 82 (94.3) I! 36.8 (±0.6) 0.16 ?
C 3
3’UTR CA 5 (5.7) 37.2 (±0.18)
rs 113569514 Chr3 
5'UTR
rs6439448 Chr3 
Intron
rs72978388 Chr3
3' UTR
18
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99
1
ABCC4/ rs2274407 Chrl3 A
C
MRP4 Missense T
rs3742106 Chrl3 A
3'UTR C
rs4148551 Chrl3 A
G
3' UTR
rs34559063 Chrl3 A
G
3' UTR
rs3765534 Chrl3 1 C
missense T
rs4148553 Chrl3 A
G
3'UTR
CC
CT
TT
TT
TA
5(6)
20 (24) 
59 (70)
36.7 (±0.5) 0.4
36.8 (±0.8)
36.9 (±0.6)
91(98) 
2(2)
6.7 AA 1(1.4)
89.3
4 CC 60 (80)
AC 8(10.6)
TC 6(8)
51.5 AA 26 (30)
48.5
CC 24 (27)
CA 38 (43)
50 AA 25 (30)
50
GG 25(30)
GA 35 (40)
40.5 AA 25 (27)
59.5
GG 42 (46)
GA 25 (27)
1.5 CC 90 (97)
98.5
CT 2(3)
44 AA 17(22.3)
56
AG 33 (43.4)
GG 26 (34.3)
36.9 (±0.6) 0.4
37.3 (±0.3)
37.2 (0) 0.7
36.8 (±0.6)
37.0 (±0.9)
36.7 (±0.7)
36.8 (±0.5) 0.1
37.0 (±0.5)
36.7 (±0.7)
36.8 (±0.5) 0.09
37.1 (±0.5)
36.7 (±0.7)
37.1 (±0.5) 0.3
36.7 (±0.5)
36.8 (±0.8)
36.8 (±0.6) Jlo.7 
36.7 (±1.8)
36.87 (±0.4) 0.9
36.89 (±0.7)
36.95 (±0.7)
33
A 76.4 AA 5 (5.4) 36.7 (±0.6) 0.5 0.25
C 80.6
CC 61 (66.3) 36.9 (±0.6)
CA 26 (28.3) 36.8 (±0.7)
5.2
16
39
48
42.4
6.1
42
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PTGER2 rs45461592 Chii4 A 69.7 AA 86 (93.5) 36.8 (±0.7) 0.4 5
T 3.3
3’ UTR TA 6 (6.5) 37.1 (±0.3)
rs708502 - A 21 AA 4(5) 36.7 (±1.4) 0.9 28
G 79
AG 26 (32) 36.8 (±0.7)
GG 51 (63) 36.9 (±0.5)
Jrsl7197 Chrl4 1 C 14 CC |3 (3.5) 1136.3 (±1.3) 1 0.22 28
T 86
3'UTR TT 64 (75.3) 36.8 (±0.5)
TC 18(21.2) 36.7 (±0.7)
PTGER3 rs3819783 Chrl C 24.4 CC 4 (4.4) 36.8 (±0.5) 0.055 0.244
T 75.6
Intron CT 36 (40) 36.6 (±0.7)
TT 50 (55.6) 37.0 (±0.6)
PTGER4 |rs 16870224 Chr5 A 19.6 AA |1(1.5) l| 37.4 (0) 0.6 13.3
G 80.4
3'UTR AG 25 (36.2) 36.8 (±0.7)
GG 43 (62.3) 36.7 (±0.7)
ADRB1 rs 1801253 ChrlO C 91.65 CC 45 (83.3) 37.02 0.06 29.4
G 8.35 36.7
Missense CG 9(16.7)
ADRB2 |rs 1042714 Chr5 C 52 CC |24 (34) || 37.0 (±0.6) | 0.2 24
G 48
Missense GG 21 (30) 36.9 (±0.7)
GC 26 (36) 36.7 (±0.6)
ADRB3 rs4998 Chr8 C 0.5 CG 1(1) 36.7 (0) 0.76 9.5
G 99.5
3’UTR GG 89 (99) 36.9 (±0.6)
GABRG2 Irs211014 Chr5 A 29 AA |4(6) || 36.6 (±0.5) 0.6 38
C 71
Intron CC 32 (48) 36.8 (±0.5)
CA 31 (46) 36.9 (±0.7)
rs211035 Chr5 A 28.5 AA 9(12) 37.0 (±0.4) 0.5 20
G 71.5
Missense AG 25 (33) 36.8 (±0.5)
GG 42 (55) 36.8 (±0.7)
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IIPGD rs2253170
rs45439401
Chr4 A 10 > O 12(20) 37.0 (±0.3) 0.2 5
G 90
GG 49 (80) 36.8 (±0.7)
- C 23.5 CC 4(5) 36.7 (±0.3) 0.5 ?
T 76.5
TT 46 (58) 36.8 (±0.6)
TC 29 (37) 36.9 (±0.6)
CBR3 rs879894 Chr21
Intron
A
C
36
64
AA
CC
CA
15(16)
40 (44)
36 (40)
36.9 (±0.7)
37.0 (±0.5)
36.8 (±0.6)
0.4 0.39
ADRBK1 rs 114509093 Chr4 C 0.7 CT 1(1.4) 37.3 (±0) 0.47 0.084
T 99.3
TT 68 (98.6) 36.9 (±0.6)
4.2.2.2. The association between genotypes and increase in temperature with 
misoprostol
In the Liverpool population, the baseline temperature was less than normal in many 
women. Therefore, to overcome the possibility of false effect of this low baseline 
temperature on the final result of women’s temperature after treatment with 
misoprostol, we examined the association of genetic polymorphisms with the change 
in temperature from the baseline. However, there was no association between the 
SNPs under investigation and change in the temperature in women who were treated 
with misoprostol in Liverpool.
4.3.3. Chills and/or shivering
We related the occurrence of chills and/or shivering to the genetic outcomes. There 
was no significant association between genetic polymorphisms under study and chills 
and/or shivering after treatment with misoprostol in the Ecuador and Liverpool 
populations.
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5. Discussion
To our knowledge, this is the first study to examine the association between SNPs and 
the development of fever in women treated with misoprostol in two different 
populations predominantly were population from Liverpool and from Ecuador.
This study showed variations in the clinical data between these two populations. The 
incidence of fever > 37.6°C in the Ecuador population was 90%, whereas in Liverpool 
population the incidence was about 9%. Moreover, 10% of the Ecuadorian population 
had fever higher than 40°C. The most common ethnicity in Ecuador population was 
Mestizo and in the Liverpool population it was White British. Variation in the 
incidence of fever was observed in different populations. Many studies have reported 
fever as a side effect of misoprostol, particularly in the treatment of PPH. A post hoc 
analysis study to explore the triggers of high fever in Ecuadorian women who were 
treated with misoprostol showed that 58 of 163 (35.6%) experienced fever >40°C 
(Durocher et al., 2010). Also, our study of the effect of misoprostol on postpartum 
contractions, which was conducted on a Libyan population, showed that 45% of the 
women had fever higher than 39°C (Elati et al., 2011). On the other hand, populations 
from Egypt, Turkey and Vietnam showed an incidence of high fever of less than 3% 
(Durocher et al., 2010). Hence, the genetic effect hypothesis has arisen.
Low incidence of fever in the Liverpool population may be explained by the 
difference in the route and dose of misoprostol and the gestational age during the 
treatment. High incidence of high fever was mainly reported in the postpartum period 
and with the sublingual route (Winikoff et al., 2010). However, the Liverpool 
population had vaginal misoprostol during the first trimester for TOP. A low 
incidence of fever (<3%) was also observed in a recent study in Ecuador for treatment 
of incomplete miscarriage using 600 meg oral misoprostol (Montesinos et al., 2011). 
This may be explained by the increase in the production of prostaglandin during 
labour. In placenta, the PG synthase expression profile favours production of PGE2 
with high levels of PG transporters and catabolic PG dehydrogenase suggesting rapid 
PG turnover. Choriodecidua is primed for PGE2 production whereas myometrium 
from non-pregnant women has lower levels of prostaglandin synthases than pregnant
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myometrium (Phillips et al., 2011). Therefore, administration of misoprostol during 
the third stage of labour is adding to the endogenous prostaglandins and the overall 
level of prostaglandin is high compared to the levels in the first trimester. This 
increasing level of prostaglandins may contribute to the increasing incidence of 
temperature during the early postpartum period. On the other hand, low rates of fever 
were observed in some populations during the postpartum period and therefore, 
genetic polymorphisms may also have a role in the body response to misoprostol and 
the susceptibility of women to fever.
This study examined 33 SNPs in 14 genes related to prostaglandin’s pathway. Two 
genes were involved in prostaglandin metabolism receptors, three prostaglandin 
transporters and 9 prostaglandin target genes. Two polymorphisms in the 
prostaglandin transporter SLC01B1 (rs4149087 and rs4149085) were associated with 
misoprostol-induced fever in the Ecuador population. Also, there was a polymorphism 
(rs 114869610) in SLC02A1 transporter gene associated with misoprostol-induced 
fever. Genetic polymorphisms in prostaglandin transporters were found to be 
associated with different diseases’ susceptibility and drug responses. For instance, the 
polymorphism rs4149056 in SLCOIBI is associated with decreased intake of anti­
cancer drug SN-38 from the systemic circulation, leading to an increase in its plasma 
concentration and enhancing the risk of neutropenia (Takane 2011). This SNP is also 
associated with statin-induced adverse drug reactions. It reduces the uptake of 
simvastatin acid into the hepatocytes (where it inhibits cholesterol synthesis) and 
results in an increase in its plasma concentration and enhancing the risk of myopathy 
(Niemi, Pasanen & Neuvonen 2011). However, the SNPs we found to be associated 
with misoprostol-induced fever in the Ecuador population have not been shown before 
to be associated with any drugs’ side effects.
The allelic frequency of SLCOIBI (rs4149087) in healthy Ecuadorian population was 
0.4 (Bryc et al., 2010)1 which is very close to the allelic frequency in our population 
of Ecuadorian women who were treated with misoprostol for PPH (0.35).While we 
had a small sample size, it can be representative of the Ecuadorian population. Also, 
the allelic frequency of SLCOIBI (rs4149087) in a healthy Colombian population is
1 Genotype data from 100 Hispanic/Latinos deposited in the gene expression omnibus (GEO) series record GSE21248.
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almost similar to the allelic frequency in our population, which was (0.36) (Bryc et 
al., 2010)1. Therefore, the result of this study may suggest that misoprostol-induced 
fever may also occur in Colombian women if they were treated with misoprostol.
The finding of this study may contribute to the previous suggestion of the hypothesis 
of misoprostol-induced fever. In normal situations (in the absence of PGE2), EP3- 
expressing neurons produce a strong GABAergic tonic inhibition on fever-mediated 
raphe pallidus neurons (rRPa) and DMH (dorsomedial hypothalamus) neurons. 
Genetic polymorphisms in prostaglandin transporters’ genes (SLC01B1 & 
SLC02A1) may lead to an increase in the expression of prostaglandin transporters 
receptors (influx receptors) in the blood-brain barrier (BBB). This increases the 
uptake of prostaglandin (misoprostol) by the BBB to the hypothalamus. PGE2 
suppresses the GABAergic activity of EP3-expressing neurons, resulting in 
disinhibition and activation of the rRPa and DMH neurons in the hypothalamus, 
leading to thermogenesis (Nakamura et al., 2005) (Figure 15).
This study has highlighted the genetic polymorphisms association between clinical 
phenotype (fever) and misoprostol treatment. It is the first in this subject and may 
show a good example of research into population-based treatment strategies. 
However, further exploration is required using a large sample size and different 
populations. In populations with misoprostol-induced fever, particularly more than 
40°C, the use of misoprostol for PPH may be withheld because of this side effect. 
Genetic testing for individuals’ susceptibility to misoprostol-induced fever is not cost 
effective with the wide use of misoprostol for PPH in some populations. However, 
this may be done based on wide population genetic testing. Samples from populations 
with a high susceptibility to fever can be examined genetically for the presence of 
prostaglandin transporters’ polymorphisms and for populations which show these 
polymorphisms, treatment could be modified in terms of dosages and routes of 
administration while preserving the drug’s efficacy.
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Figure 15. The suggested mechanism of misoprostol-induced fever
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There were several limitations to the study that the genetic association with 
misoprostol-induced fever could be addressed much better with a larger sample size 
from Ecuador and Liverpool populations. First, the Ecuadorian group was part of 
another clinical trial for treatment of PPH where we obtained all the blood samples 
from the women who had been treated with misoprostol and more samples cannot be 
obtained. Second, in Liverpool, there was a big hindrance with recruitment of women 
to the study as they were treated with misoprostol for TOP. The sensitivity of this 
issue made recruitment difficult and complicated. The Bedford Clinic in Liverpool 
has good admission rate per week. However, unexpectedly, the recruitment was very 
difficult, as our study does not involve any aspect of their treatment. In addition, many 
women were unhappy to give a blood sample. We tried to overcome this problem by 
taking the study sample while they were giving blood for the investigations required 
by the hospital on the consultation visit and tracing them on the day of admission to 
fill in the case report form and to measure the temperature. Tracing the women was 
not easy as many of them have been missed due to many reasons. Some women 
cancelled before the day of admission and some of them were rescheduled for 
admission. Registration of the women in the trial took place after signing the consent, 
which took place either on the consultation visit or on the day of admission for 
misoprostol treatment. We recruited 107 women (who signed the consent) and we had 
complete data and blood samples from 93 of them. Also, changes in the Bedford 
Clinic schedule between medical and surgical TOP compromised the recruitment to 
some extent. The genotypic frequencies of the identified polymorphisms were low. 
Although we have included some SNPs with rare alleic frequencies, they were of 
known functional significance and expected to have a large effect.
Our aim was to do a case-control study for the Ecuador and Liverpool populations. 
But, unexpectedly, we found that most of the Ecuadorian women had fever with 
misoprostol (46/50) and there were few controls, and the contrary happened in 
Liverpool population where we had few cases (8/93) and a large number of controls 
(85/93). Therefore, we analysed our data in a single group for each population using 
the analysis of continuous variables (ANOVA). It would be important to compare the 
genetic association of Liverpool and Ecuador populations but this was unfeasible for 
the following reasons. The two populations have different diseases’ phenotype and
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also they have different doses and routes of treatment. The Ecuadorian women had 
600 meg sublingual misoprostol as stated in the protocol of the clinical trial, while 
Liverpool women received 800 meg vaginal misoprostol. Also, those two populations 
included different ethnic groups. The Ecuadorian population was predominantly 
Mestizo, whereas the Liverpool population was mainly white (Caucasian). The 
inconsistency of the doses and routes of administration, the disease phenotype and 
population structure made the comparison impractical. Therefore, we considered each 
population separately when dealing with the data analysis.
The Ecuador population was selected deliberately to be examined because of the high 
incidence of fever and the results may be extrapolated to other populations. However, 
in order to detect a true genetic association we need to perform this study on a larger 
population with clear characterisation of the phenotype and the ethnicity. In this 
study, we had 50 samples from women from Ecuador. The power calculation showed 
that we had a strong chance to find the difference in our sample of 2-3 degrees C for 
all SNPs with the allelic frequency above 20%. Based on the following assumptions: 
Alpha-level=0.002 (0.05/33), mean in wild-type group: 37 degrees, standard 
deviation: 0.85
Minor allele frequency
0.05 0.20 0.40
Difference (degrees) 
between WT group 
and mutant-type
group
1 11% 52% 94%
2 74% 99% 99%
3 99% 99% 99%
The calculations were performed in nquery.
Therefore, we had 99% power to detect the difference of 2 degrees C for SNPs with 
minor allele frequency of 20%. For SNPs with lower frequencies (approx 5%) we had 
99% power to detect the difference of 3 °C. We took into consideration the number of 
SNPs tested (N=33) and corrected for multiple comparisons using Bonferroni 
correction.
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For future case-control study, depending on our findings in this study, the incidence of 
fever > 40 °C was 10%, the allelic frequency of the positive genetic association SNP 
(rs 4149087) was 35%, the sample size for a case control study with 80 % power will 
be 60 case and 60 controls (figure 16). The calculation was done using GPA 
calculator from
http://www.webcitation.org/querv.php?url=http://dceR.cancer.gov/bb/tools/pga&refdoi=l
0.1186/1471-2156-9-36
Rower and Sample Size Curves
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; Sample size, number of cases : ■ ■ " ' ; ;' : v
Figure 16. The sample size calculation curve for a genetic association case control 
study
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6. Conclusion
The incidence of fever has shown clear variations between the Liverpool and Ecuador 
populations in women treated with misoprostol. To our knowledge, this hypothesis 
generating study is the first study to investigate the genetic association between 
polymorphisms in genes encoding prostaglandin transporters and misoprostol-induced 
fever in women treated for PPH.
255
Chapter 5
General discussion and future research
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1. General discussion
The overall work in this thesis aimed to optimise the use of misoprostol for the 
prevention of PPH. The literature review showed the lack of clear evidence for what is 
the most effective and safest dose and route of misoprostol for prevention of PPH. 
Skilled and non-skilled birth attendance tend to use high doses of misoprostol in the 
hope of achieving the strongest effect and this may result in many unwanted adverse 
drug reactions. Therefore, we hypothesised that lower doses of misoprostol may 
achieve a similar effect on the uterine muscle contractility while maintaining a good 
side effects profile.
It is important to reach the best balance between the efficacy and the safety of any 
recommended treatment. The systematic review and the meta-analysis in Chapter 2 
showed that the use of misoprostol was associated with a high incidence of fever 
particularly with high doses of sublingual misoprostol. However, there was wide 
heterogeneity between the trials in this review. This could be explained by the 
shortage of data about the side effects in the clinical trials but might also be related to 
the mixed populations and ethnicity in the studies. Ethnic difference are supported by, 
data from a multi-centre randomised control trial that used 800 meg sublingual 
misoprostol for the treatment of PPH. It found that the incidence of high fever 
(>40°C) in the Ecuador population was significantly higher than the incidence with 
the other populations (Winikoff et al., 2010). This has raised the possibility of a 
genetic association with misoprostol-induced fever. Therefore, a trial was conducted 
to findout the best effective dose of sublingual misoprostol to reduce the incidence of 
fever.
In Chapter 3, the validity of the IlJPCs, which were produced to measure the IUP 
during the first stage of labour, was investigated. Previous studies had been conducted 
using transducer-tipped catheters (Intran plus), but this was unlikely to be accurate 
outside of a closed air or fluid system. The validity of IntranPlus catheter was 
therefore compared with a new balloon catheter (Koala). The study however, showed 
neither of the two types of the IUP catheters (Koala E5000 and Intrans plus) were 
valid outside of a closed pressure system. The Koala was however the most reliable.
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We therefore used the Koala for the clinical trial. We rationalised that we are not 
interested so much in the exact amount of pressure produced, but wished to compare 
the effect of variable doses of sublingual misoprostol on the uterine muscles. The 
study of the effect of misoprostol on postpartum uterine contraction of three 
sublingual doses of misoprostol showed that 200 meg, 400 meg and 600 meg doses of 
sublingual misoprostol had significant effect on the uterine muscle activity but that 
the severity of the side effects was dose dependent. The result of this study provided 
good evidence that lower doses of misoprostol might be effective clinically but with 
fewer side effects. Our findings were supported by a recent randomised clinical trial, 
investigating the effect of 400 meg sublingual misoprostol for prevention of PPH, 
which cited our paper (Chaudhuri, Biswas & Mandal 2012). We expect more 
research using lower doses of misoprostol and the findings of our study will be added 
to the body of evidence supporting a new recommendation of using 400 meg 
sublingual misoprostol for the prevention of PPPI instead of the current 
recommendation, which is 600 meg of oral or sublingual misoprostol (Weeks & 
Faundes 2007).
In Chapter 4, the genetic association with misoprostol induced fever was explored. 
Three single nucleotide polymorphisms (SNPs) in two genes encoding for the 
prostaglandin transporters (SLCOIBI and SLC02A1) were discovered to be 
associated with misoprostol-induced fever in the Ecuadorian population. Although the 
sample size was small, this finding highlighted the possibility of the genetic variation 
as a cause of the high fever in certain population. Physiologically, the presence of 
these SNPs in the prostaglandin transporters, which expressed in the blood brain 
barrier may cause more efflux of misoprostol into the hypothalamus and thus increase 
the thermoregulatory set-point to a higher temperature. Clinically, misoprostol may 
be omitted from the management of PPH in populations where these SNPs are 
common, or the protocol should be tailored towards lower doses. The genetic role 
hypothesis might not be the only mechanism that explains the causes of fever.
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2. Future research
Inevitably, whenever research questions are answered, further questions arise. This 
increases the researchers’ curiosity and may lead them to continue their investigations 
and improve the methodology, or to replicate their previous findings. The work in this 
thesis could open new avenues in several aspects of research around optimising the 
use of misoprostol and understanding its local and systemic effects on the human’s 
body.
Although the use of intrauterine pressure measurements was well established many 
years ago, the uterine activity during the third stage of labour requires more research. 
This may involve research into producing a new catheter with a larger sensitive 
surface area or measuring the effect abdominally using sensitive sensors to detect the 
change in electric myoactivity. The in vitro experiment in Chapter 2 could be 
replicated in vivo in the optimum condition of a post partum uterus and test the 
reliability of the IUP catheters.
The close observation of postpartum women who were treated with misoprostol in 
Libya showed how these side effects are very irritating and unacceptable, even though 
medically they were not very serious. All women after being exhausted in labour and 
delivery are seeking a relaxed and peaceful environment to rest. But severe shivering 
and fever at this time will adversely affect their early postpartum hours. Therefore, 
more research is essential to find a suitable misoprostol dose and route with minimal 
side effects to be used particularly in populations at risk of developing the side effects. 
A multi-centre randomised control trial may provide a good opportunity to document 
the rates of shivering and fever, and to collect blood samples to replicate the genetic 
study in Chapter 4. The data could also increase the evidence towards new 
recommendation of lower doses of misoprostol. Moreover, the use of the misoprostol 
tablet which was produced for swallowing is not practical for the sublingual route. 
After sublingual administration of misoprostol, the unabsorbed vehicle (cellulose) of 
the drug may stay in the mouth for long time and delay the absorption of the active 
ingredients. Producing a new form of misoprostol such as oral lyophilisates (oral 
melt) may provide a good alternative to the current tablets both in practicality and 
speed of absorption.
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The pharmacogenetic study of misoprostol induced fever needs replication using 
samples from a large multi centre randomised control trial comparing high and low 
doses of misoprostol. This could result in many samples from diverse populations and 
adequate power to confirm or refute the genetic findings. Also, it needs to take in 
consideration the characterisation of the selected populations in order to have a good 
powerful association if it has to occur.
Is misoprostol a substrate for the prostaglandin transporters in the brain? How does it 
pass the blood brain barrier? These are some of the questions which need an answer. 
Examination of the movement of misoprostol across a blood brain barrier cell line 
using radio-labelled misoprostol acid may provide us with information that can 
support the genetic hypothesis. It would be even more exciting if we could examine 
and test blood brain barrier cells from people with known genetic variations in genes 
encoding the prostaglandin transporters (SLCOIBI and SLC02A1). This would be 
very ambitious and would require further confirming data regarding the genetic 
variations before it was undertaken.
Prevention of PPH is an important subject and research is going on all over the world 
to improve the current management and medications. Misoprostol is clearly a 
promising drug which can help reducing PPH, particularly in low resource settings. 
The work in this thesis has contributed to the research into misoprostol for the 
prevention of PPH in terms of finding the suitable dose of misoprostol which provides 
the required efficacy while maintaining a good side effect profile. As a result we 
recommend the use of 400 meg sublingual misoprostol for prevention of PPH, a dose 
that balances proven efficacy with an improved side effect profile. This dose may 
need to be reduced further in those populations which have high prevalence of the 
genetic polymorphisms in SLCOIBI and SLC02A1 genes.
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Appendixes
Appendix A. 1. Data Extraction Form
Systematic review of misoprostol induced fever
Data Extraction Template (RCT)
Trial details
Trial methods
Trial ID Extractor Year of publication
Title
Authors
Duration of 
study
Single or 
multicentre study
Method of 
allocation 
generation
Describe
Adequate / unclear / inadequate
Method of 
allocation 
concealment
Describe
Adequate / unclear / inadequate
Loss of 
participants
Describe
<5% 5-10% 10-20% >20%
Blinding Participants yes / no / unclear
Clinician yes / no / unclear
Outcome assessor yes / no / unclear
Intention to treat 
analysis
Describe
Used / unclear / not used
Participants
Study population 
(ethnicity) & 
location (hospital 
or community)
Inclusion criteria
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Exclusion criteria
Intervention
Indication of treatment
Study
medication
Dose Route Pregnancy stage
Experiment 
group 1
Experiment
group2
Experiment
groups
Control
group
Additional information about (fever)
Definition of fever Described Not described
Definition of fever (Categories ) Mild
Moderate
Severe
Method of monitoring fever Reported Not reported
Method of monitoring the temperature is oral axillary
How was fever data collected? Prospective/ routine monitoring
Patient check-list/ questionnaire 
Not describe
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Outcomes
Outcome
measures
Total women =
Intervention group
1 =
Intervention group 
2=
Intervention group 
3=
Control group =
Events incidence Events incidence Events incidence Events incidence
Temp>
Temp>
Temp>
Unspecified
fever
Chills/
Shivering
Chills & 
fever
unspecified
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Appendix A. 2. Characteristics of the included studies
Study Methods Participants Interventio
ns
Outcomes | Notes AUoca
tion
concca
iment
Qualit
>of
report
ing
side
effects
I Randomized Women who had 600 meg The main Intention to B Good
I double blind SVD. The oral outcomes treat
I controlled trial exclusion criteria misoprostol were the analysis
1 using computer were caesarean or 200 meg rates of PPH, with less
I generated list. delivery, methyl- need for than 10%
I The study boxes hypertension. ergometrine therapeutic loss of
I and capsules gestational age oxytocic participants
I were <32 weeks, drugs and to follow
| indistinguishable intrauterine death, side effects. up. TheI uterine study was
malformations, conducted
allergy to in Belgium
prostaglandins or | over 5
alkaloids, months.
inflammatory
bowel disease and
sepsis.
I Randomised Women with 400 meg The primary Intention to A Good
I controlled trial singleton fetus. oral outcome was treat
I using computer cephalic misoprostol a haematocrit analysis
I generated presentation in or 5 IU drop of 10% with no
1 randomisation spontaneous or oxytocin IV. or greater loss of any
9 cards which kept induced labour. over the first of the
1 in sealed. The exclusion 24 hours participants
I opaque, criteria were postpartum. . The study
I sequentially placenta praevia. The was
I numbered abruptio placenta, secondary conducted
I envelopes. coagulation outcomes in Canada
disorders. were over 3 and
unstable asthma, haemoglobin half years.
and caesarean drop of 30
delivery. mg/L or
greater, the
administratio
n of
additional
oxytocic
drugs, an
estimated
_______________ | blood loss>
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Caliska 
n 2002
Caliska 
n 2003
Randomised 
controlled trial 
using computer 
based random 
allocation 
without any 
blocking or 
stratification. 
The list of 
medication was 
printed out and 
put in sealed, 
consecutively 
numbered 
opaque 
envelopes.
Randomised 
controlled trial 
using computer 
based random 
allocation 
without any 
blocking or 
stratification. 
The list of 
medication was 
printed out and 
put in sealed, 
consecutively 
numbered
Women in labour. 
Exclusion criteria 
was caesarean 
delivery 
gestational age 
>32 weeks and 
known
hypersensitivity 
to prostaglandins.
500 meg 
rectal
misoprostol 
and 10 In 
oxytocin 
infusion or 
500 meg 
rectal
misoprostol 
and placebo 
or 10 lu 
oxytocin 
infusion and 
placebo or 
200 meg 
methyl 
ergometrine 
Im and 
oxytocin 10 
IU infusion.
1000 ml, 
manual 
removal of
placenta,
blood
transfusion , 
shivering and 
fever> 38 °C.
The primary Intention to
outcomes treat
were the analysis
incidence of with less
PPH and the than 5%
decrease in loss of
the Hb participants
concentration to follow
.The up. The
secondary study was
outcomes conducted
were the in Turkey
incidence of over 10
severe months.
postpartum 
haemorrhage, 
mean blood 
loss, need for 
additional 
uterotonics 
incidence of
post partum 
blood
transfusion, 
length of the 
third stage of 
labour and 
specific side 
effects.
Women in labour. 600 oral
Exclusion criteria misoprostol
was caesarean and 10 lu
delivery oxytocin
gestational age infusion or
>32 weeks and 600 meg
known oral
hypersensitivity misoprostol
to prostaglandins. and placebo 
or 10 lu 
oxytocin 
infusion and 
placebo or 
200 meg
The primary Intention to
outcomes treat
were the analysis
incidence of with less
PPH and the than 15%
decrease in loss of
the Hb participants
concentration to follow
.The up. The
secondary study was
outcomes conducted
were the in Turkey
incidence of over 10
severe
Good
Good
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Chhabr 
a 2008
Cook
1999
opaque
envelopes.
J-----------—- ----------
methyl 
ergometrine 
Im and 
oxytocin 10 
IU infusion.
postpartum 
haemorrhage, 
mean blood 
loss, need for 
additional 
uterotonics 
incidence of 
post partum 
blood
transfusion, 
length of the 
third stage of 
labour and 
specific side 
effects.
months.
Randomised 
controlled trials 
using random 
number tables in 
group of 100 
each. The 
concealment 
method was not 
reported in the 
paper.
Women with term 
gestation and 
spontaneous onset 
of labour.
Exclusion criteria 
were grand 
multiparity (parity 
>5), multiple 
gestation, 
pregnancy 
induced 
hypertension,
APH, labour 
induction or 
augmentation, 
past or planned 
caesarean section, 
Hb<8gm/Dl or 
obstetrics 
problems and 
known
hypersensitivity 
to prostaglandins.
100 meg 
oral
misoprostol 
or 200 meg 
oral
misoprostol 
or 200 meg 
methyl- 
ergometrine 
IV.
Amount of 
blood loss, 
need for 
additional 
oxytocic, 
third stage 
complication 
and any side 
effects.
Intention to 
treat 
analysis 
with no 
loss of any 
of the
participants 
. The study 
was
conducted 
in India.
B Good
Multicentre Women who Misoprostol Primary Intention to A Poor
randomised trial expecting a 400 meg outcomes. treat
using random vaginal delivery. orally, IM10 uterine blood analysis Definit
number list in Exclusion criteria: IU oxytocin loss, need for with less ion of
blocks of 20 women with or uterine than 10% fever
with a separate known blood syntometrin message, the loss of and
randomisation coagulation e. use of participants metho
for each centre disorders, a additional to follow dof
and sequentially history of asthma, uterotonics, up. The data
numbered sealed heart disease. the need for study was collecti
security opaque severe renal blood conducted on
envelops. disease or transfusion. in were
epilepsy, women Secondary not
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t: w
I-
cfaey 
2000
Enakpc 
ne 2007
undergoing an 
elective caesarean 
section and 
women with 
hypertension.
outcomes,
changes in
temperature,
pulse and
blood
pressure,
vomiting,
diarrhoea,
shivering, Hb
level 24 hrs
postpartum.
Australia. reporte
d
Randomised 
controlled trial 
using computer­
generated block 
randomisation 
with varying 
block size. The 
concealment was 
by opaque, 
sequentially 
numbered sealed 
envelopes
Women who had 
normal vaginal 
delivery. The 
exclusion criteria
were caesarean 
delivery, history 
of bronchial 
asthma and water 
birth.
500 meg 
oral
misoprostol 
or 10 IU 
oxytocin or 
syntometrin 
e or 500 mg 
ergometrine
Incidence of 
PPH and the 
incidence of 
the severity 
of the side 
effect
Intention to 
treat 
analysis 
with less 
than 5% 
loss of 
participants 
. The study 
was
conducted 
in London 
over 24 
months.
A No
clear
deflniti
on.
Routin
e
monito 
ring of 
fever
Randomised 
controlled trial 
using simple 
random 
selection.
Women with 
singleton 
pregnancy, low 
risk pregnancy, 
vertex delivery.
The exclusion 
criteria were the 
presence of 
contraindications 
to the use of 
either misoprostol 
or
methylergometrin 
e such as pre­
eclampsia and 
other
hypertensive 
disease in 
pregnancy, pre­
existing cardiac 
disease, severe 
anaemia, history 
of asthma, renal 
or hepatic 
disorders, allergy 
to prostaglandin 
and presence of
400 meg 
oral
misoprostol 
or 500 meg 
intramuscul 
ar methyl- 
ergometrine
The primary 
outcomes
were
estimated 
blood loss 
during 
delivery and 
within the 
first 24 hours 
postpartum, 
the duration 
of the third 
stage of 
labour, and 
additional 
use of 
oxytocics.
The
secondary
outcomes
were
maternal 
vital signs, 
adverse 
effects such 
as nausea, 
vomiting.
Intention to
treat 
analysis 
with no 
loss of any 
of the
participants 
. The study 
was
conducted 
in Nigeria 
over 1 year.
A Good
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Garg
2005
Gtilmez
oglu
2001
condition 
requiring 
prophylactic 
oxytocin infusion.
headache,
chest pain,
abdominal
cramps,
fever,
shivering.
Randomised 
controlled trial 
using 1:1 ratio 
by random 
number 
sequence.
Women with 
singleton 
pregnancy and 
have SVD.
600 meg 
oral
misoprostol 
or 200 meg 
methylergo 
metrine IV.
Amount of 
blood loss, 
haemoglobin 
concentration 
, duration of 
the third 
stage of 
labour, 
manual 
removal of 
placenta, 
need of 
additional 
oxytocic.
Side effects 
such as 
nausea, 
vomiting, 
diarrhoea, 
headache, 
fever > 38 
°C, shivering 
and vertigo.
Intention to 
treat 
analysis 
with no 
loss of any 
of the
participants 
. The study 
was
conducted 
in India 
over 1 year.
B Poor
The 
metho 
d of 
data 
collecti
on was
not
reporte
d
Multicentre Women in labour. 600 meg The primary Intention to A Good
randomised The exclusion oral outcomes treat
controlled trial criteria were misoprostol were analysis
using computer women with or 10 IU measured with no
regenerated asthma or other oxytocin IV postpartum loss of any
numbers and severe chronic or IM. blood loss of of the
identical allergic 1000 ml or participants
treatment packs. conditions, more and the . The study
sealed and planned caesarean use of was
numbered section, body additional conducted
sequentially and temperature >38 uterotonics. over 1 year
could only be °C. The and 9
taken from the secondary months.
dispenser outcomes
consecutively. were
measured
blood loss
more than
500 ml,
blood
transfusion.
manual
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Harriot 
t 2009
cervical tears
and maternal
admission to
intensive-
care unite.
Double blind Women in labour 600 meg The primary Intention to
randomised pilot rectal outcomes treat
study. misoprostol were the analysis
Randomisation or 10 IU incidence of with less
by using oxytocin PPH and the than 5%
computer decrease in loss of
generated the Hb participants
random tables. concentration to follow
The sealed . The up.
envelope with a secondary
code number outcomes
was opened were the
when vaginal incidence of
delivery is severe
imminent. postpartum
Randomised 
controlled trial 
using computer 
generated block 
randomisation. 
The treatment 
was based on the 
assigned number 
being either IV
Women who is 
expecting to a 
vaginal delivery. 
Exclusion criteria: 
previous PPH, 
hypertensive 
disorders, 
previous
caesarean section,
400 meg 
rectal
misoprostol, 
oxytocin 10 
IU and 0.5 
mg
ergometrine
removal of 
placenta, 
complication 
s such as 
bimanual 
compression, 
hysterectomy 
, suturing of
haemorrhage, 
mean blood 
loss, need for 
additional 
uterotonics, 
need for 
bimanual 
removal of 
placenta, 
length of the 
third stage of 
labour and 
specific side 
effects.
Outcome, 
blood loss, 
additional 
oxytocic 
therapy. Side 
effects.
Intension to 
treat 
analysis 
with less 
than 5% 
loss of 
participants
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syntometrine or intrauterine fetal
rectal death, ant partum
misoprostol. haemorrhage, 
anaemia (Hb<
8g/l)
Hofmey Randomised, Women in labour. 600 meg Primary Intention to
r 2001 placebo- misoprostol outcomes. treat
controlled trial orally or shivering. analysis
using computer placebo. pyrexia > with no
generated 37.8 C and loss of any
random hypertension. of the
sequence, in Secondary' participants
balanced block outcomes.
of 18 and a nausea.
serious of vomiting.
numbered diarrhoea.
opaque test abdominal
tubes. pain, blood 
loss > 1000 
ml,
additional 
use of 
oxytocic, 
manual 
removal of 
placenta and 
blood
transfusion.
Hoj Randomised All women in 600 meg The primary Intention to
2005 double blind labour. sublingual outcome was treat
controlled trial misoprostol postpartum analysis
using a list of or placebo. haemorrhage with no
random numbers of > 500 ml, loss of any
and change in Hb of the
consecutively concentration participants
numbered , the . The study
opaque incidence of was
envelopes. 10% conducted
decrease in in Guinea-
haemoglobin Bissau over
concentration one and
. Side effects
such as
nausea,
diarrhoea,
vomiting,
shivering and
rectal
temperature.
half year.
A
A
Poor
Metho 
d of 
data 
collect! 
on was 
not
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Kuiulod Randomised Women with 400 meg The main Intention to A Good
yiwa controlled trial singleton oral outcome was treat
2001 using computer pregnancy at term misoprostol the incidence analysis
generated (>37 weeks of or 10 IU ofPPH.The with less
numbers using gestation). The oxytocin secondary than 1%
random exclusion criteria IM. outcomes loss of
sequence and were a history of were need for participants
sealed opaque PPH, condition additional to follow
envelopes. causing uterotonics, up. The
disseminated need for study
intravascular blood conducted
coagulation. transfusion. .in
antepartum manual Zimbabwe
haemorrhage. removal of over 5
coagulation placenta. months.
disorders, duration of
operative the third
delivery, multiple stage of
pregnancies, labour, need
history of asthma, for
and known subsequent
allergy to evacuation of
prostaglandin and the uterus.
oxytocin.
Khan Randomised Women with 600 meg The Intention to A Good
2003 controlled trial singleton oral concentration treat
using computer- pregnancy at term misoprostol. of analysis
generated (>37 weeks of 400 meg misoprostol with less
random numbers gestation). rectal free acid The than 1%
with blocked Exclusion criteria misoprostol primary loss of
randomisation. were women with and 600 outcome for participants
consecutively asthma, or other meg rectal the adverse- to follow
numbered sealed chronic misoprostol effect profile up.
opaque conditions, study was
envelopes each cardiac disease. shivering as
contains a fold renal failure, renal experienced
slip of paper or hepatic by the
with the disorders. patient.
treatment written Adverse
on it. effect as
observed by
the birth
attendant.
Oral
measurement
of
temperature.
Lokuga Randomisation Women 500 meg Estimated Intension to A Good
mage using computer- undergoing oral blood loss at treat
2001 generated elective and misoprostol caesarean analysis
random number emergency or 10 IU IV section, drop with less
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and the
concealment was 
by sealed 
opaque 
envelopes.
caesarean section, syntocinon
Exclusion criteria:
two or more
previous sections,
history of rupture
uterus.
in serum 
haemoglobin 
and the need 
for additional 
uterotonics 
agents.
than 5% 
loss of 
participants
Multicentre 
randomised 
controlled trial. 
Method of 
randomisation 
was not
described. 
Concealment by 
using treatment 
packs sealed 
numbered and 
could only taken 
from the 
dispenser 
consecutively.
Exclusion criteria 600 meg 
were women with oral 
asthma, or other misoprostol
severe chronic or, 400 meg
allergic condition, oral 
contraindication misoprostol
to misoprostol or 10 IU
planned caesarean oxytocin 
section. intramuscul
ar.
The
incidence of 
shivering.
Any side 
effects.
Intention to
treat 
analysis 
with less 
than 2% 
loss of 
participants 
to follow 
up.
B Good
Double blind 
randomised 
controlled trial 
using computer 
generated 
randomisation 
list with random 
block size. The 
concealment by 
sealed opaque 
envelopes 
contains either 
active drug or 
placebo.
18 years old, 600 meg
singleton oral
pregnancy, >28 misoprostol
weeks pregnancy, or Zhi Byed
The exclusion 11 a Tibetan
criteria: previous traditional
or planned medicine.
caesarean section,
pre-eclampsia,
severe anaemia,
history of
bleeding
disorders, mental
disability, body
temperature
>38°C, serious
medical illness,
active
haemorrhage st 
the time of 
screening, women 
with asthma or 
glaucoma, women 
with severe labour 
pain (to be 
eligible for 
informed 
consent).
The
incidence of 
PPH,
administratio 
n of
uterotonics 
or maternal 
death.
Intention to 
treat 
analysis 
with less 
than 5% 
patient loss.
A Poor
no
clear 
definiti 
on of 
fever, 
metho 
d of 
data 
collecti
on
about
fever
was
not
describ
ed.
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2009
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Double blind 
randomised 
controlled trial 
using computer­
generated 
random 
allocation 
system and 
sealed opaque 
consecutively 
numbered 
envelopes.
Multicentre 
randomised 
controlled trial. 
Randomisation 
was based on a 
table of 
computer 
generated blocks 
of random 
numbers.
All women who 800 meg of The primary Intention to A Good
have spontaneous rectal outcome is treat
vaginal delivery misoprostol the number analysis
of a live. and placebo of patents with no
singleton neonate. ampoule or estimated to loss of any
and absences of rectal have PPH. of the
any placebo and The participants
contraindications 5IU secondary . The study
for misoprostol or oxytocin outcomes was
oxytocin use. The infusion. were a conducted
exclusion criteria haematocrit in Egypt.
were women who drop of 10%
delivered by or more.
caesarean section. haemoglobin
history of APH or concentration
bleeding , change in
tendency. systolic and
hypertension with diastolic
pregnancy and blood
need for pressure.
anticoagulants. duration of
the third
stage of
labour, need
for manual
removal of
placenta,
nausea.
shivering and
fever > 38°C.
Women who have 600 meg The primary Intention to A Good
singleton oral outcome was treat
pregnancy and misoprostol the amount analysis
vaginal delivery. or 1 of blood loss. with no
Exclusion criteria ampoule The loss of any
were the presence syntometrin secondary of the
of e. outcomes participants
contraindications were change . The study
to misoprostol or in maternal was
syntometrine. haemoglobin. conducted
such as PET, maternal over 1 year.
cardiac disease blood
and asthma of pressure.
presence of pulse and
conditions temperature.. .
requiring occurrence of
prophylactic side effects
oxytocin infusion such as
such as grnd nausea.
multyparity vomiting.
(parity >4), or headache.
presence of chest pain,
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2003
Ng 2007
uterine fibroids 
and women 
receiving 
oxytocin infusion 
during the first 
stage of labour.
fever,
shivering.
Double blind All women 400 meg The primary Intention to
randomised having singleton oral outcome was treat
controlled trial pregnancy >34 misoprostol the change in analysis
using a table of weeks of or 1 haemoglobin with no
computer gestation, low risk ampoule level. The loss of any
generated for PPH and syntometrin secondary of the
random numbers vaginal delivery. e. outcomes participants
and The exclusion were the . The study
consecutively criteria were maternal was
numbered sealed presence of blood conducted
opaque contraindications pressure. in Hong
envelopes. for the use of 
misoprostol or 
syntometrine such 
as PET, cardiac 
disease and 
asthma. The 
presence of 
conditions 
requiring 
prophylactic 
oxytocin infusion 
such as
multiparity (> 4) 
or presence of 
fibroids and 
women received 
oxytocin in the 
first stage of 
labour.
pulse,
temperature.
Side effects
including
nausea,
vomiting,
headache and
shivering.
Kong over
10 months.
Randomised Women with 600 meg The primary Intention to
controlled trial SVD. The oral outcome was treat
using random exclusion criteria misoprostol the incidence analysis
number were women who or 10 IU of PPH. The with no
generated tables had caesarean oxytocin secondary loss of any
and opaque delivery, HB < intramuscul outcomes of the
sealed packets 8g/dl, risk factors ar. were side participants
containing cards for PPH (previous effects . The study
indicating group history of PPH, nausea. was
allocation. multiple
gestation,
polyhydraminos,
grandmultiparity,
induced or
augmented
vomiting, 
shivering and 
elevated 
temperature.
conducted 
over 1 year.
Good
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labour, uterine
leiomyoma and
precipitated
labour.
Parsons Randomized All women 800 meg Postpartum Intention to A Good
2006 placebo presenting in oral haemoglobin treat
controlled trial labour including misoprostol concentration analysis
using computer women at high at the , additional with no
generated risk of PPH. delivery of blood loss. loss of any
randomization the anterior occurrence of of the
and sequentially Exclusion criteria shoulder. shivering, participants
numbered. were any The control temperature
opaque sealed contraindication group >37.5 C
envelops to prostaglandin received 10 Study was
such as known IU IM done in
hypertension, oxytocin. Ghana,
asthma and west
epilepsy. Africa,
over 6
months.
Parsons Multicentre All women 800 meg Subject Intention to B Good
2007 randomised presenting in misoprostol estimation of treat
controlled trial. labour. The only rectally or blood loss. analysis
The exclusion criteria 10 IU change in with less
randomisation were any known oxytocin haemoglobin than 5%
method was contraindication IM. concentration loss of
unclear; using to prostaglandin , occurrence participants
opaque sealed randomisation. of shivering. to follow
envelopes temperature up. The
containing a monitoring. study was
standard data conducted
sheet with a in Ghana
random over 9
assignment to months.
either the control
group and the
treatment group.
Patted Multicentre Pregnant women 600 meg Side effects, Intention to A Definit
2009 randomised anticipated an misoprostol nausea. treat ion of
placebo uncomplicated orally or vomiting. analysis fever
controlled trial vaginal delivery placebo. shivering, with less was
using computer at > 28 weeks. fever. than 1% not
generated diarrhoea. loss of reporte
randomisation Exclusion criteria: participants d
list with a previous or to follow
random block planned caesarean up. The
size and non- section, Hb<8g/L, study was
distinguishable anti-partum conducted
envelops haemorrhage. in India
congaing hypertension, over 3
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misoprostol or multiple years.
placebo. pregnancy, 
history of APH, 
PPH, retained 
placenta, uterine
inversion.
diabetes, heart 
disease, seizures, 
breech, history of
asthma.
Singh Double blind Women with 400 meg Amount of Intention to A Good
2009 randomised trial healthy singleton sublingual blood loss. treat
using computer pregnancy in misoprostol. Maternal analysis
generated spontaneous or 600 meg pulse, blood with no
random number induced labor at sublingual pressure and loss of any
chart and sealed term. Exclusion misoprostol. temperature. of the
and coded drug criteria: known 5 IU participants
packets. hypersensitivity/c oxytocin IV
ontraindication to or 200mcg
prostaglandins. methyl Study was
intrauterine fetal ergometrine done in
demise,
antepartum
haemorrhage,
multiple.
IV. India.
pregnancy,
malpresentation,
cardiac disease,
Rhesus-negative
mother,
hypertensive
disorders and
severe anaemia
(Hb<7 g/dl)
____
Vaid A randomised Pregnant women 400 meg The primary Intention to B Good
2009 controlled trial > 32 weeks with sublingual outcomes treat
using computer spontaneous or misoprostol were, the analysis
generated induced labour. ,200 meg amount of with no
random number. The exclusion IM methyl blood loss, in loss of any
Method of criteria were ergometrine the third of the
allocation grand multi para or 125 meg stage of participants
concealment was (> 5), multiple IM 15 labour, PPH . The study
unclear. gestation, <32 methyl- (blood loss was
weeks of PGF2a. >500 ml). conducted
gestation, HELLP The in India
syndrome. secondary over 10
hydramnios. outcomes month.
known blood were change
coagulation in
disorders, history haemoglobin.
of asthma or drug need for
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2006
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2004
allergy, heart additional
disease, severe oxytocic and
renal disease, 
epilepsy, 
hypertension and 
HB concentration 
< 8 g/dl.
side effects.
A double blind Participants were 400 meg The Intention to B Poor
randomised not described. sublingual outcomes treat
controlled trial. misoprostol were mean analysis Metho
The or methyl blood loss, with no d of
randomisation ergometrine mean loss of any data
and concealment 200 meg difference in of the collecti
were not clearly IM. haemoglobin. participants on was
described. number of . The study not
patients with was reporte
total blood conducted d
loss,
additional 
use of 
oxytocics, 
manual 
removal of 
placenta, 
nausea, 
shivering and 
temperature 
> 38 °C.
in India.
Randomised Pregnant women 400 meg The primary Intention to A Good
controlled trial. at 37 weeks of sublingual outcome was treat
Randomisation gestation with misoprostol the drop in analysis
was done by spontaneous onset or 200 meg haemoglobin with no
opening of labour. of IV concentration loss of any
sequentially Exclusion criteria injection .The of the
numbered sealed were oxytocin methyl secondary participants
envelopes induction or ergometrine outcomes . Study was
prepared using augmentation of were done in
random number labour, caesarean estimated India over
table. delivery, grand blood loss, 4 months.
multipara (parity additional
>5), gestation < use of
37 weeks. uterotonics.
multiple duration of
gestation. the third
pregnancy stage of
induced labour.
hypertension, Hb manual
concentration < removal of
8g/dl and known placenta, side
hypersensitivity effects
including
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2006
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2000
to prostaglandins. nausea,
vomiting, 
giddiness, 
headache, 
shivering and 
elevated
temperature
_________________
>38 °C.
Opened labelled Women at term 400 meg The primary Intention to A Poor
randomised trial (37-40 weeks) sublingual outcomes are treat
using computer gestation misoprostol changes in analysis Definit
generated scheduled for and the haemoglobin with no ion of
random number either elective or control levels after loss of any fever
in sealed opaque emergency lower group delivery. of the and
envelops. segment received 20 estimated participants metho
caesarean section IU oxytocin amount of . Study was d of
under regional as IV blood loss done in data
anaesthesia. infusion. and the need India over collecti
for additional 9 months. on
Exclusion criteria: uterotonics were
any women with therapy. The not
risks to PPH such secondary reporte
as anaemia (Hb outcomes are d
<8g%), multiple the incidence
gestation, APH, of side
polyhydraminos, effects, need
prolonged labour. for blood
(> 12 hours), two transfusion
or more previous and any other
caesarean major
sections, history 
of rupture uterus, 
current or 
previous history 
of heart disease, 
liver, renal 
disorders or 
known
coagulopathy.
complication.
Double blind All women 400 meg Primary Intention to A Good
placebo except, those who oral outcome treat
controlled trial have risk factors misoprostol drop in analysis
using computer for postpartum or 10 IU haemoglobin with less
generated haemorrhage: oxytocin concentration than 2%
random numbers grand IM. . Side effects, loss of
and numbered multipara>5, nausea, participants
opaque packet. multiple vomiting, to follow
Containing a gestation. diarrhoea. up. The
card indicating gestation< 32 shivering and study was
group allocation. weeks, gestational elevated conducted
hypertension with in Ghana
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HELLP
syndrome,
hydramnios,
previous
postpartum
haemorrhage,
caesarean
delivery,
coagulation
abnormalities,
precipitatous
labour (<3 hours),
Chorioamnionitis
and oxytocin
induction or
augmentation,
women with
hypersensitivity
to prostaglandins,
Hb concentration
temperature. over 1 year 
and 3 
months.
Zachari 
ah 2006
<8 g/dl.
Randomised 
controlled trial 
using
randomisation 1 
of the 3 groups 
using computer­
generated 
random 
numbers.
All women with 
SVD. Exclusion 
criteria: bronchial 
asthma, cardiac 
disease, rhesus 
factor
incompatibility,
pregnancy
induced
hypertension,
caesarean
delivery.
400 meg Primary Intention to
oral outcomes: treat
misoprostol mount of analysis
or 10 1U blood with no
oxytocin, loss>500 ml loss of any
IM or 2 mg and 1000 ml. of the
of need for participants
ergometrine additional . The study
IV. oxytocic. was
Secondary conducted
outcomes: in India
duration of over 8
the third months.
stage of There was
labour, need no report
for blood on method
transfusion, of
haematocrit concealmen
fall greater 
than>10%, 
adverse drug 
reactions 
such as 
pyrexia and 
shivering.
t.
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Appendix B. 1. Patient information sheet
UNIVERSITY OF
LIVERPOOL
Participant’s information sheet for the study of
Misoprostol to prevent bleeding after childbirth
You are being invited to take part in a research study. Before you decide whether to 
take part, it is important to understand why the research is being done and what it will 
involve. Please take time to read this information carefully, and ask us if you would 
like more information. You should only agree to take part if you want to - don’t feel 
pressurised into taking part!
What is the purpose of the study?
Bleeding after childbirth is a major problem in the world, but especially in developing 
countries. The chance of bleeding after labour is about 1 in 10, but is halved by the 
use of preventive drugs. These are usually given to all women just after childbirth. 
Misoprostol is a drug that prevents bleeding after birth by making the uterus contract 
strongly. It is cheap, stable in hot climates and can be given orally (rather than 
needing an injection like the alternatives). For most people the treatment is effective 
and produces little or no side effects. However some women have side effects such as 
increased body temperature, diarrhoea or abdominal cramps. These are more common 
at high doses.
The best dose of misoprostol is not known. Although high doses might be more 
effective, they have higher rates of side effects. We therefore want to compare 
different doses to find the lowest effective dose of misoprostol.
Who is organising this research?
The research is being organised by the University of Liveipool and Misurata Teaching 
Hospital in Libya.
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Why have I been chosen?
You have been chosen for the study because you are a healthy woman with a low risk 
of bleeding after labour (we are excluding any woman who has pregnancy 
complications or who has bled after previous deliveries or who has had a caesarean 
section). Your entry into the study will be confirmed after you give birth to make sure 
that you are still fit and well, and happy to take part.
Do I have to take part?
This is a voluntary study, and if you would prefer not to take part your decision will 
be accepted without question and will not affect the standard of care you receive. You 
are free to withdraw from the study at any time without giving a reason.
What will happen to me if I take part?
If you decide to take part in this study, you will receive the usual care ordered by your 
doctor. At delivery you will be given the study treatment which could be misoprostol, 
oxytocin or no treatment. The allocation of treatment will be random. After the 
delivery of the placenta, the study will be conducted by the researcher who is a 
University of Liverpool post graduation student and has a considerable amount of 
training in obstetrics and gynaecology in Libya. The researcher will introduce a small 
catheter connected to a monitor to your uterus to measure the pressure inside the 
uterus before the treatment. For the 2 hours observation in the labour ward you will be 
closely monitored by the investigator who will record your blood pressure, 
temperature and pulse and measure the pressure of the uterus using a computer 
programme. Also, you will be closely observed for the amount of blood loss. During 
this time you will just stay in bed for the 2 hours of the routine observation at the 
labour word and nothing will be required from you. At the end of the two hours 
observation you will be sent to the postnatal word and the treating staff will continue 
the observation for any unusual blood loss.
Are there any risks in taking part?
As with any woman, you might develop bleeding after delivery (this happens to 
around 7 in 100 women despite preventive treatment). This rate is about doubled in
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women not receiving any preventative treatment. If you are in the group that will not 
receive any preventive drugs, then you will be observed closely and the same 
preventative drugs will be given to you at the first sign of any bleeding. Drugs for 
treatment of haemorrhage will be available to all women throughout the study in case 
they need them.
There may be some minor but short-lasting discomfort from having frequent 
monitoring of your blood pressure or from introducing the catheter. There are no side 
effects reported after using this catheter in the similar studies.
Misoprostol may cause diarrhoea which resolves spontaneously within 24 hours, 
abdominal cramps which can be managed with analgesics and misoprostol may also 
cause transient increase in body temperature which can be managed with paracetamol 
and cold sponges.
Are there any benefits in taking part?
Women taking part in this study will have a specialist obstetrician with the throughout 
their time in the study. This may be helpful to you if any complications develop.
The results of this study will not be of a direct benefit to you; however, the treatment 
given is meant to prevent bleeding after you giving birth and you will be closely 
observed and treated for any complications after delivery or any side effects of 
medications. The finding of this study may benefit patients using this treatment in the 
future.
What if I am unhappy or if there is a problem?
If you are unhappy, or if there is a problem, please feel free to let us know as we with 
you all the time from delivery till you transferred to the postnatal ward. Still if you 
have any problem you can contact the researcher Dr Anisa Elati or Prof. Mohammed 
Elmahaishi.
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Will my taking part in this study be kept confidential?
All information collected about you during the course of the research will be kept 
strictly confidential and will not be disclosed to anyone. Any information about you, 
which leaves the research centres taking part, will have your name and address 
removed so that you cannot be recognized from it.
What will happen to the results of the research study?
Results of the project will be published in leading international journals.
What will happen if I want to stop taking part?
You can withdraw at any time without explanation and this will not affect the 
standard care you receive from your treating staff. Any information or data before 
withdrawal will be destroyed and no further use is made of them.
Who can I contact for further questions?
We can be reached on the following points of contact
Prof. Mohammed. S. Elmahaishi 
Email address:
Dr Anisa Elati 
Email address
Phone number, 
elmahaishi@elmahaishi.com 
Phone number, 
elati@liv.ac.uk
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Appendix B. 2. Consent form
UNIVERSITY OF
Patient Identification Number for this trial: LIVERPOOL
CONSENT FORM
Title of Project: Misoprostol for preventing postpartum
haemorrhage
Name of Researchers: Dr. Anisa Elati
Please
initial box
1. I confirm that I have read and understand the information sheet dated (May 2009) 
(version.3) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time
without giving any reason, without my medical care or legal rights being affected.
3. I understand that relevant sections of my medical notes and data collected during 
the study, may be looked at by individuals from The University of Liverpool.
I give permission for these individuals to have access to my records.
4.1 am interested in taking part in the above study.
Name of Patient Date Signature
Name of Person Date
taking consent
Signature
1 copy for the participant 1 copy for the investigators, 1 copy for the
case notes
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Appendix B. 3. Case report for
Optimising the dose of Misoprostol for the 
prevention of postpartum haemorrhage:
a randomised trial
Case Report Form
On admission to the labour word (The initial approach of participants) 
Women will be initially chosen for the study if
They have not had history ofPPH, APH in this pregnancy.............
They have not had history of caesarean section............................
They have not had PROM in this pregnancy...................................
They have not had Pre eclampsia in this pregnancy......................
They have not had history of infection in this pregnancy..............
They have not had history of polyhydraminous in this pregnancy.
They are not anaemic (Hb >10 g/dl)..............................................
They have singleton baby with gestational age > 34 weeks..........
They have 5 or less previous deliveries at over 28 weeks...............
Women should be chosen finally for the study if
• They give informed written consent..............................................
• They were not induced or augmented with any uterotonic drugs.
• They delivered SVD.........................................................................
• They delivered a baby of< 4.00 kg.................................................
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A) Background information
Patients' hospital Number
Patient's name ................
Date of Birth 
OR Age 
Date of Admission 
Time of Admission
/ / (dd/mm/yy)
/ /
Years
(dd/mm/yy)
(24 hrs clock)
Consent for the study Yes| | No | |
Past obstetrics history
No of deliveries beyond 24 weeks (exclude the one just delivered)
This Pregnancy:
LMP / / (dd/mm/yy)
Gestational age Weeks
|- Cd g/dlAnte- partum haemoglobin level
B) Delivery
(Please, do not give oxytocin, syntometrine, methergine after the delivery 
of the baby)
Date of delivery 
Time of delivery 
Birth weight
/ / (dd/mm/yy)
(24 hrs clock)
grams
Time of delivery of the placenta (24 hrs clock)
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Vital signs (after delivery of placenta)
Pulse Diastolic
Temperature (°C)
C) Intrauterine pressure measurements
Insertion of the IUP catheter (Should be with in 1 minute of the delivery of 
the placenta)
Time of insertion (24 hrs clock)
Continuous measurement of IUP starts immediately after it is 
inserted in the uterus (Data is saved in the computer)
Study treatment (envelop No)..............................
(Write the patient No on the envelope and keep (stable) with this form).
Time of treatment (24 hrs clock)
Vital signs at(l) minutes
Pulse
Temperature (C)
sats per minutes BP: Systolic Diastolic
Vital sign at 30 minutes
Pulse
Temperature (C)
beats / minutes BP: Systolic Diastolic
Vital signs at 60 minutes
Pulse
Temperature (C)
beats / minutes BP: Systolic Diastolic
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Vital signs at 90 minutes
Pulse
Temperature (°C)
beats per minutes BP: Systolic
D-D
Diastolic
Vital signs at 120 minutes 
Pulse
Temperature (°C)
beats per minutes BP: Systolic Diastolic
Blood loss from the time of the insertion oflUP until return to the post natal 
word
Unusual blood loss Yes | | No [ | ml
Additional use of other uterotonic drugs to treat patients Yes | | No | |
Treatment given...................................Dose...................................
D) Day after delivery
Postpartum haemoglobin level 
When was the test taken?
g/dl (24 hrs after delivery)
(dd /mm / yy) (24 hrs clock)
Please ask the woman if she experienced any side effects after treatment
Was there any maternal temperature in the first 24 hours?
Note: maternal temperature is defined as two successive reading of above 37.5°C 
taken between 1 and 12 hours apart, or one reading ofover38°C.
Has the patient required blood transfusion since delivery? Yes
If yes, how many unites of blood? Unites
cm
Study treatment given....,........................Dose.....................Route.
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Appendix C. 1. Patient information sheet and consent form
A study of the side effects of misoprostol: a drug to treat
hemorrhage after birth
Bleeding after childbirth occurs in about 1 in 10 women, and can be serious. It is 
usually treated by a drug called oxytocin which is given as an infusion into your aim. 
Recently another drug (misoprostol) has been found to be just as effective as 
oxytocin. Furthermore, it can be taken as tablets placed under the tongue and does not 
need to be kept cold. However, a raised body temperature is seen more commonly 
with misoprostol, affecting about a quarter of those who take it.
Ideally we would like to use a lower dose of the drug to reduce the rate of fever. The 
previous study used 4 tablets under the tongue - we want to use 3 instead and 
compare the effect on bleeding and raised body temperature. The study is being 
conducted at this hospital - Hospital Gineco-Obstetrico Isidro Ayora — in Quito, 
Ecuador. Samples will also be sent to the United Kingdom to test for the possibility of 
genetic reasons of fever after treatment with misoprostol.
If you agree to take part and develop very heavy bleeding after 
delivery, you will be given three pills to hold under your tongue 
to stop the bleeding. Women taking this medicine may 
experience nausea, chills, fever, vomiting, and diarrhoea.
These symptoms occur in about in 1 in 10 people taking the 
drug, are usually not serious and go away in a short time. If 
you continue to bleed you will be given other drugs to stop the 
bleeding, as we would usually do.
If you decide to participate, we will ask you some short questions. You will be also 
asked for a blood sample (about two spoons full) of blood drawn from your arm. This 
blood will be stored at this hospital and then sent to the University of Liverpool in 
The United Kingdom to be studied. The samples will be identified only by a code 
number, and it will not be possible to link you with any results from the blood in the
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future. Your blood sample will be considered a donation to the University of 
Liverpool, and you will not be able to withdraw your blood sample after it has been 
assigned a code number and made not traceable to you. Your blood sample may be 
used in the future for other approved research by doctors at the University of 
Liverpool, but this cannot be traced back to you. The blood sample will not be used 
for commercial purposes.
If you are treated for heavy bleeding, a study nurse will ask you 
some questions about how you are feeling before you leave the 
hospital We will also take another blood sample from your 
finger at this time. We will periodically take your temperature 
to evaluate whether or not you are experiencing a fever. If you 
have a fever, a study nurse will provide medication to lower 
your body temperature and make you feel more comfortable.
You may also be contacted by study staff one-week following 
your discharge.
There are some benefits to participating in this study. Since 
you will have your blood taken, we will be able to give you 
information about you health, for example, if you have anemia.
You will also have your blood loss monitored closely. One risk 
to participating in this study is the possible discomfort from the 
finger prick used to take blood. There is also a small chance 
of bruising and even smaller chance of infection at the site of 
the blood draw.
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Any information you provide during the study will be 
confidential Your name will not appear on any study 
document. Your participation is voluntary and you are free to 
withdraw from the study at any point. If you decide not to 
participate, you will receive standard care and treatment at this 
hospital.
Do you have any questions about the study?
Are you willing to participate?
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Informed Consent, Part 2: Form for participants to sign
Assessment and pharmacogenetics of fever after misoprostol administration for 
the treatment of primary postpartum haemorrhage
Woman’s
Name:....
I have (been) read the information sheet concerning this study and I understand what 
is being asked of me if I participate in the study. All my questions and concerns have 
been addressed to my satisfaction. I understand that I can withdraw from the study at 
any time I wish without giving a reason and this will not affect the normal health care 
I receive.
I agree to take part in this study.
Woman’ ssignature/thumb 
print....................................
Date
Study staff person Signature
If you have any questions regarding your participation in this study, please contact: 
[Insert name and phone number of study staff person / PI]
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Appendix C. 2. Form 6: blood sample / case review form
Woman’s initials: Study staff initials:
Study ID number: - Today’s date: day____/month____/ year_
I. Eligibility & Consent
Did give informed consent and sign form? □ 0 = No □ 1 = Yes
Was the woman diagnosed with PPH and given 
misoprostol treatment? □ 0 = No □ 1 = Yes
Was a blood sample taken? □ 0 = No □ 1 = Yes
II. Participant’s information
4. Woman’s age:______
5. Number of live births (include this one):
6. Self-reported ethnicity:
Add categories per Ecuador census...
7. Is the woman currently taking any medication? 
EH 0 = No EH 1 = Yes
If yes, please 
describe
8. Does the woman have any chronic illness?
EH 0 = No EH 1 = Yes
If yes, please 
describe
9. Woman’s height:
10. Woman’s weight:
III. Blood draw
cm
kg
11. Date/time misoprostol administered:
Day___Month___ Year____ /______ :_
12. Date/time of blood draw:
Day___Month___ Year____ /______ :_
hrs
hrs
13. Any problems collecting blood sample?
EH 0 = No EH 1 = Yes
If yes, please describe_______________
IV. Recorded body temperatures
14. Baseline temperature pre-delivery:______ .___C
15. Temp 60 minutes post-treatment:______.____C
16. Temp 90 minutes post-treatment:______ .____C
17. Did the woman experience fever > 40.0 C at any 
time following treatment with misoprostol?
EH 0 = No EH 1 = Yes
If yes, please specify date/time:
Day____Mo____ Year____ /_______ :_____
hrs
V. Side effects experienced post-treatment
18. Nausea □ 0= No □ 1 = Yes
19. Vomiting □ 0 = No □ 1 = Yes
20. Diarrhea □ 0 = No □ 1 = Yes
21. Shivering/chills □ 0 = No □ 1 = Yes
22. Fever □ 0 = No □ 1 = Yes
23. Fainting □ 0 = No □ 1 = Yes
24. Other □ 0= No □ 1 = Yes
If yes, specify:
25. Additional comments:
Signature of Principal Investigator who reviewed/completed this form:
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Appendix C. 3. Patient information sheet and Consent form
UNIVERSITY OF
LIVERPOOL Liverpool Women's
NHS Foundation Trust
Participant Information Sheet (version 2.1)
Project Title:
Pharmacogenetics of Misoprostol induced fever
What is the purpose of the study using your blood sample?
Misoprostol is widely used nowadays to treat many obstetrics and gynaecological 
problems and for most people the treatment is effective and produces little or no side 
effects. However, in some cases misoprostol can cause an increase in the body 
temperature, which resolves quickly. We do not know why some people develop high 
body temperature while others do not. The purpose of the study is to look for genetic 
markers from your blood that may be related to the increased temperature. In the 
future, this will hopefully allow us to develop a test that can help predict which 
patients are more susceptible to side effects and therefore develop better treatment 
strategies.
Who is organising this research?
The research is being organized by The University of Liverpool.
Why Have I been chosen?
You have been chosen for the study because you are going to have misoprostol as part 
of your treatment.
Do I have to take part?
This is a voluntary project, and if, when you have heard about the study, you would 
prefer not to take part; your decision will be accepted without question and will not
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affect the standard of care you receive. You are free to withdraw from the study at any 
time without giving a reason.
What will happen to me if I take part?
If you decide to take part in this study, you will receive the usual clinical care ordered 
by your
doctor. You will be also asked to donate one sample of 9ml (equivalent to 2 
tablespoons) of blood. Also, you will have your temperature measured before 
treatment and then at 1, 2 and 4 hours after having your treatment.
What if something goes wrong?
Taking your blood sample for the study has mild risk of pain and discomfort which is 
not expected to cause any kind of serious complication. After taking your blood 
sample, you will stay as routinely done by the department as a day case and you will 
be under close observation by the staff nurses. If you have a concern about any aspect 
of the study, you can speak to one of the researchers who will do their best to answer 
your questions.
What will happen to my blood test?
The Blood sample will be stored in this hospital and then sent to the Department of 
Pharmacology & Therapeutics at the University of Liverpool. All samples will be 
identified only by a code number, and so it will not be possible in the future to link 
you with any results from the blood sample. Your blood samples will be considered to 
be a gift to the University of Liverpool, which will act as custodian of all the samples 
obtained as part of this project.
What are the possible disadvantages and risks of taking part?
There may be some minor but short-lasting discomfort from having a blood test. 
Taking part in the study will not affect your current treatment, nor will it affect your 
ability to obtain insurance for health purposes.
What are the possible benefits of taking part?
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The studies will not be of a direct benefit to you; however, it may benefit patients 
using this treatment in the future.
Will my taking part in this study be kept confidential?
As stated above, your samples will be anonymised, and the genetic information 
obtained from the DNA sample will be kept strictly confidential and not be disclosed 
to anyone. All infonnation collected about you during the course of the research will 
be kept strictly confidential. Any information about you, which leaves the research 
centers, will have your name and address removed so that you cannot be recognized 
from it.
What will happen to the results of the research study?
Results of the project will be published in leading international journals.
Who has approved the study?
This research study has been reviewed and approved by Liverpool Adult Research 
Ethics Committee.
Who can I contact for further details or with questions?
We can be reached on the following points of contact.
Dr. Andrew Weeks Tel: 0151 702 4240 email: aweeks@liverpool.ac.uk
Dr. Anisa Elati Tel 01517024109 email: elati@liverpool.ac.uk
Miss. Kay Holland Tel 0151 708 9988 email: kay.holland@lwh.nlis.uk
Ext 1123/1130
Thank you for considering this research*
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Centre Number: 
Study Number: Patient Identification Number for this trial:
CONSENT FORM
Title of Project: Pharmacogenetics of Misoprostol Induced Fever
Name of Researchers: Dr. Andrew Weeks Dr. Anisa Elati
Please initial box
1. I confirm that I have read and understand the information sheet dated March 2009 
(version.2) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time
without giving any reason, without my medical care or legal rights being affected.
3. I understand that relevant sections of my medical notes and data collected during the 
study,
may be looked at by individuals from The University of Liverpool or from the NHS 
T rust,
where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person Date Signature
taking consent
Address of participant (only if she wants a copy of the study results)
7 copy for the participant 1 copy for the investigators, 1 copy for the case notes
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical 
notes
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Appendix C. 4. Case Report Form
PMIF: The Pharmacogenetics of Misoprostol Induced Fever
Patients' Code Number
Patient's name 
Date of Birth 
Date of Admission 
Time of Admission
/ /
/ /
(dd/mm/yy)
(dd/mm/yy)
(24 hrs clock)
Consent for the genetics study Yes [ | | |
1. Background
Obstetrics history No of times pregnant (including this pregnancy) 
No of pregnancy > 24 weeks
Previous termination of pregnancy Yes [ [> | |
If yes, what was the method of termination? Surgical | | Medical | |
If medical, did you take misoprostol? Ye| | No □
If yes, do you have any side effects with misoprostol y| | No | |
If yes, what were the side effects?........................................................ .............
Medical history
Any chronic illness
□ |----- 1No |___ |
If yes,
Current medication
Drug name Dose Frequency
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Gestational age (today) 
Patient's weight
/ 1leks/ days
Kgs patient's height cm
Assessed by (circle): USS/ LMP/PV
2* Observation of temperature
Misoprostol received at 
Temperature is □ C at
(24 hrs clock)
(24 hrs clock)
2 hrs after misoprostol 
4 hrs after misoprostol 
6 hrs after misoprostol
Tempreature (°C) Time taking temperature (24 hrs clock)
no at□
EH at
3. Side effects (Patient complaint) (please complete before discharge)
Coldness yes No
Chills yes No
Fever yes No
Abdominal cramps yes No
Nausea/Vomiting Yes No
Diarrhoea Yes No
Blood sample given Yes| | No | |
CRF completed by
Name ................................ signature............................Date
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Patients self report of ethnicity
I would describe my ethnic origin as (please mark one box only)
White - White British 
White Irish 
Other white background 
Mixed - White and Black Caribbean 
White and Black African 
White and Asian 
Other mixed background
Asian or Asian British - Indian
Pakistani 
Bangladeshi 
Other Asian background 
Black or Black British - Black Caribbean
Black African 
Other black background 
Chinese or other Chinese
ethnic group Other ethnic
back ground
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Appendix C. 5. Sequenom MassArray: iPLEX Protocol
• Reagents and Consumables
• PCR preparation
• Preparation and Addition of SAP Enzyme Solution
• Preparation and Addition of iPLEX Reaction Cocktail Solution
• Cleaning up the iPLEX Reaction Products
• Transfer of the iPLEX Reaction Products onto a SpectroCHIP
• Reading the SpectroCHIP in the MassARRAY READER RT 
instrument
• Analyzing the Data on the MassARRAY TYPER
• Equipment maintainance protocols
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Reagents and Consumables
Plates & Seals:
Description Supplier Item #
384 well Plates, 50 plates ABgene TF-0384
Adhesive PCR- Film, 100 each Abgene AB-0558
96 well Sarstedt- plates, 100 plates Sarstedt 82/1.583
PCR machine:
- G-Storm with 384 well blocks (located in Molecular Lab)
Pipettes:
- Two sets of single channel pipettes (e.g. Eppendorf with 2.5pi, 20pl, 200pl 
and lOOOpl volume) one per PCR and one post PCR set.
- Multichannel pipettes (e.g. Eppendorf with lOpl and 50pl volume)
Tips
Centrifuge:
- Plate centrifuge with at least SOOOrpm
Other components:
- Water system capable of producing at least 18.2 MQ/cm resistivity
- Reaction tubes (500pl - 2000pl)
30pl tips for the Matrix
100% Ethanol (for the nanodispenser)
PCR reagents
■ Hot Star Taq (Qiagen)
■ dNTP mix
■ PCR & Extend Primer
- iPLEX Gold Kit (Sequenom) containing: - SAP- buffer
- SAP- enzyme
- iPLEX- Termination- mix
- iPLEX- buffer
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- iPLEX- enzyme
- Resin (28g)
- 10 x 384 Spectro chips
Primers:
Primers (supplied by Metabion): PCR primer 50jnM each
Extend primer for 36 plex 400jaM each and for 24 plex 300jaM each
Protocol
Preparation of plex primer mix;
For 384-well plate:
• 36-plex: 5pi each Forward primer + 5 pi each Reverse Primer + 140pl 
Nanopure water (500pl total volume)
• 24-plex: 5pl each Forward primer + 5pl each Reverse Primer + 260pl 
Nanopure water (500pl total volume)
PCR preparation:
- Prepare the primer mix for each plex to a working concentration of 0.5pM each 
primer.
Prepare the PCR mix according to Table 1 (volumes for a 384-well Microplate 
include 25% overhang to account for possible pipetting loss).
For plexes >29 the PCR mix for 36-plex should be used- otherwise 24-plex mixed 
should used.
Table 1: PCR mix preparation
Reagent
Volume for
Single Rx
Volume for one 
24-plex
(384 well)
Volume for
Single Rx
Volume for one 
36-plex
(384 well)
Nanopure Water 1.85 pi 888.00 pL 1.85 pi 840.00 pL
PCR Buffer (1 Ox) 0.625 pi 300.00 pL 0.625 pi 300.00 pL
MgCl2 (25mM) 0.325 pi 156.00 pL 0.325 pi 156.00 pL
dNTP mix (25mM) 0.10 pi 48.00 pL 0.10 pi 48.00 pL
primer mix (0.5pM) 1.00 pi 480.00 pL 1.00 pi 480.00 pL
Hot Star Taq 0.10 fil 48.00 pL 0.20 jul 96.00 pL
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(5 U/pl)
Total Volume 4.00 pi 1920.00 pL 4.00 pi 1920.00 pL
DNA (10 ng/pl) 1.0 pi - 1.0 pi -
- Add 4|al PCR mix to each well of the 384 well plate, add 1 pi DNA to each well of 
the 384 well plate.
OR
Add 97pl PCR cocktail to one row of a 96 well plate than add 24.25pl DNA. 
From this mix, dispense 5 pi to a 384 well plate
Seal Microplate with Adhesive PCR Seal (AB-0558)
Cycling: Run G-Storm Thermocycler Program: C\ GStorm\ Users\ Guest\ Scripts 
Sequenom\ PCR IPLEX.scr 
Reaction volume: 5pi 
Approximate running time: 2hrs 30mins
Preparation and Addition of SAP Enzyme Solution
Prepare the SAP Enzyme Solution according to Table 2 (volumes for a 384-well 
Microplate include 38% overhang to account for possible pipetting loss)
Table 2: SAP Enzyme Solution Preparation
Reagent Volume for
Single Rx
Volume for
384-Well MTP
Nanopure Water 1.53 pi 810.78 pi
liME Buffer (lOx) 0.17 pi 90.08 pi
Shrimp alkaline phosphatase (SAP) 0.30 pi 158.98 pi
Total Volume 2.00 pi 1059.84 pi
In a new 96-well, polystyrene microplate, pipette 85 pi of SAP enzyme solution 
into each well HOI “ HI2.
Using a twelve-channel pipettor, draw from the wells in row H and distribute 10 
pi to each well in rows A-G.
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Addition of SAP to 384-well plate using Matrix Liquid handler
Open “ControlMate” software
Select “Open Sequence”- select “maintenance methods”- select “Liquid Handler 
tip wash.cms”
When prompted for password, click “Cancel”
Select “Run” from toolbar
- Repeat “Open Sequence”- select folder “384 methods”- select “iPLE-hME 
Methods”- select “SAP addition (96 to 384).cms”
Check plates are positioned as pop-up diagram shows and close to start- Note: 
384-well plate should always be placed in metal holder provided.
Seal the microplate with AB-0558
Cycling: Run G-Storm Thermocycler Program: C\ GStorm\ Users\ Guest\ Scripts 
-Sequenom\ SAP IPLEX.scr 
Reaction volume: 7pl 
Approximate running time: Ihr
Preparation and Addition of iPLEX Gold Reaction Cocktail
Table 3: Preparation of Extend primer mix for 36-plex reaction using 4-step 
adjustment
Extend Primer 
Group
Final Concentration/ 
primer
Volume/
primer
36-plex (9 primers) 
(total volume)
1 7pM 8.75jul 78.75pl
2 9.3pM 11.63 pi 104.63pl
3 11.66pM 14.58pl 131.22|_il
4 14pM 17.5pl 157.5pl
Nanopure Water 27.9pl (toSOOul)
For <29-plex: same volumes apply but stock primers should be at 300pM not 400pM 
Prepare the Extend primer mix using 4- Step adjustment.
Prepare the iPLEX Reaction Cocktail Solution as described in Table 4 (volumes 
for a 384-well Microplate include 38% overhang to account for possible pipetting 
loss).
Table 4: iPLEX Reaction Cocktail Solution Preparation
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Reagent Volume for Volume for one plex
Single Rx (384 wells)
- H20 0.755 pi 400.10pl
iPLEX-Buffer (lOx) 0.2 pi 105.98pl
iPLEX-Termination mix 0.2 pi 105.98pl
Primer mix 0.804 pi 426.06pl
iPLEX-Enzyme 0.04 pi 21.20pl
Total 2.0 pi 1059.34pl
- In a new 96-well, polystyrene microplate, pipette 85 p,l of iPLEX reaction cocktail 
solution into row H.
Using a twelve-channel pipettor, draw from the wells in row H and distribute 10 
jliI to each well in rows A-G.
Addition of iPLEX reaction mix to 384-well plate usingMatrix Liquid handler
Open “ControlMate” software
Select “Open Sequence”- select “384 methods”- select “iPLEX-hME Methods”- 
select “Cocktail addition (96-384).cms”
When prompted for password, click “Cancel”
Select “Run” from toolbar
Check plates are positioned as pop-up diagram shows and close to start 
Seal the microplate with AB-0558
Cycling: Run G-Storm Thermocycler Program: C\ GStorm\ Users\ Guest\ Scripts 
-Sequenom\ SAP IPLEX.scr 
Reaction volume: 9pi 
Approximate running time: 4hrs
Cleaning up the iPLEX Reaction Products
Apply 2 smalls scoops of CLEAN resin to the left-hand side of the 6mg dispense 
3 84-well dimple plate
Using the beveled Perspex applicator spread the resin into the wells as indicated 
below:
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Any excess unused resin can be returned to the pot for future use
lake the 384-well and invert. Place on directly on top of the resin dimple plate. 
Invert both and tap gently to allow the resin to drop into the wells of the 
thermoplate.
Open “ControlMate” software
- Select “Open Sequence”- select “384 methods”- select “iPLEX-hME Methods”- 
select “16ul water addition.cms”
When prompted for password, click “Cancel”
Select “Run” from toolbar
Check plates are positioned as pop-up diagram shows and close to start 
Seal the microplate with AB-0558
Place the plate between 2 polystyrene blocks and secure in the Heidolph- Reax 2 
rotator and set to level 1. Rotate plate for 10 min.
Centrifuge the sample plate for 5 min at 3000 RPM.
Transfer of the iPLEX Reaction Products onto a SpectroCHIP
On the nanodispenser PC, open the program “Spectropoinf ’
Log-in as User: “Opl” with password “Opl”
Release emergency stop button on the nanodispenser.
Select function “Home machine”
Select function “Pin conditioning” and then “Drain Sonicator”
Refill the sonicator bath with 100% ethanol using a squeezy bottle.
Check the box marked “Main Head” and “Start” Run should take 30mins. 
Repeat process with “Single Head”- this can be stopped after 5mins.
Select “Drain Sonicator” then “Fill Sonicator”
Place the microtiter plate and an old SpectroCHIP on the deck of the 
MassARRAYK Nanodispenser S instrument.
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Before dispensing the Chip, run the volume check to avoid poor dispensing 
quality
Under Load Method go to System change the file type from *.tmf to *.vmf, select 
the file Volume384.vmf.
Run the volume check to adjust the dispense speed.
In the Run Setup tab Load the file iPLEX, change the dispense speed to that speed 
which gave the best results in the volume check.
Replace Chip with new one.
Select the Status tab, click Start.
Using the MassARRAY® Nanodispenser a few nanoliters (approx. 15 nl) of the 
samples are transferred onto a 384 SpectroCHIP.
Add 70 pi calibrant to the calibrant reservoir on the MassARRAY® 
Nanodispenser S instrument.
In the Run Setup tab Load the file Calibrant dispense and select the Start button 
in the Status tab.
When complete, the nanodispenser can be shut down to a sleep mode by running 
the “Clean” function and pushing the red emergency stop button when the pins 
are in the sonicator bath.
Reading the SpectroCHIP in the MassARRAY® READER RT MALDI-TOF 
instrument
On the RT computer make sure FLEXControl and ServerControl are running.
Make sure the correct Method (iPLEX.par) and Sample Carrier 
(SequenomChip3 84C) are loaded in the FLEXControl.
Make sure MassARRAY® CALLER is running.
In the Plate Editor create a chip with assays and samples.
In the MassARRAY Typer folder select ChipLinker.
Connect to your database.
Select the plate you want to analyze.
Select iPLEX
Under Dispenser select Nanodispenser S.
Under Process Method select Genotype.
Enter an Experiment Name (e.g. the chip name entered in the Plate Editor).
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Enter a Chip Barcode.
- Click Add.
Click Create,
Click Done.
In SpectroAQUIRE in the Auto Run Set Up tab under Barcodes for individual 
chips enter the name of the SpectroCHIP plus experiment number you want to 
run (it is recommended do to so with the Copy Paste function) at the position the 
chip is loaded on the Scout Plate.
Make sure that the Parameter file iPLEX is loaded.
Place the Chip on Scout target.
- Introduce target in the MassARRAY® READER with the In/Out function on the 
Autoflex instrument.
In SpectroAQUIRE in the Auto Run Set Up tab 
switch on the high voltage.
Click the Auto Run tab under Run select Start Auto Run.
Analyzing the Data on the MassARRAY® TYPER
In the Typer Analyzer you get a table with the results, can look at the 
corresponding spectra and print out reports with the results and statistics.
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Appendix C. 6. PCR primers, forward primers reversed primers &extension 
primers for the multiplexed assay.
No Type Oligo Name Sequence 5'-3’
1 MTP-96 A-Plex 1 
rs35646917
ACGTTGGAT GT C ACT G AAT GCAGTT CATCC
~2 MTP-96 A-Plex 1 rs3742106 ACGTTGGATGCAACCAAAATGTCAAGTCCG
3 MTP-96 A-Plex 1 rs2253170 ACGTTGGATGGTTTTCCTTCATGCACTTGG
4 MTP-96 A-Plex 1 rs1801253 ACGTTGGATGCCTT C AACCCCAT CAT CT AC
5 MTP-96 A-Plex 1 
rs45439401
ACGTT GG AT GT CT C AAT C AGT AT AC ACC
6 [ MTP-96 A-Plex 1 rs17197 ACGTTGGAT GAAAGT GT CAG AAGGAGCT AC
.7 | MTP-96 A-Plex 1 rs4998 ACGTT GG AT G AGCCTT G AACTT C ACT CCTC
8 MTP-96 A-Plex 1 
rs11045825
ACGTT GG AT G AGG AATTT AGGGT GT GAT GG
9 MTP-96 A-Plex 1 
rs114509093
ACGTTGGAT GAGT GGC AGCGGCGGT ACTT
10 MTP-96 A-Plex 1 
rs34550074
ACGTT GG AT GAT G ATGGT GGT AGCT AT GCG
11 MTP-96 A-Plex 1 rs4149087 ACGTTGGAT GAC AAAC AC AGAGTTT GAAC
mi MTP-96 A-Plex 1 rs2274407 ACGTT GGAT GT AT CT GGTT GACAT CACTGC
MTP-96 A-Plex 1 
rsl 14869610
ACGTTGGAT GAGGGTT CAT AT GGACAGC AC
14 MTP-96 A-Plex 1 rs4148551 ACGTT GGAT GAC AAC AACAAAAACCT GT G
15 MTP-96 A-Plex 1 rs4149085 ACGTTGGAT GGGT GG AAGT AT AAAT AAGCC
16 MTP-96 A-Plex 1 rs708502 ACGTT GGAT GATT AGGGC AGCTT C ATTTT G
17 MTP-96 A-Plex 1 
rs16870224
ACGTT GGAT GGT CT CACT AAAGCAT G AAAT G
18 MTP-96 A-Plex 1 
rs11045879
ACGTTGGATGGGAT CC AGGGTT AAT AT AAC
19 MTP-96 A-Plex 2 rs1042714 ACGTT GGAT GAGACATGACGATGCCCATGC
20 MTP-96 A-Plex 2 
rs72978388
ACGTT GG ATGC AGT GTT GAGT CCT CC ATT G
21 MTP-96 A-Plex 2 
rs16993929
ACGTTGGAT GAT GT GC AACGAGTT ACT GCC
22 MTP-96 A-Plex 2 rs3819783 ACGTTGGAT GTT C AACT AAACTTGCAGCT C
23 MTP-96 A-Plex 2 rs3765534 ACGTT GGAT GTTCCT AAGT ACC AGTT AAG
24 MTP-96 A-Plex 2 rs879894 ACGTTGGATGAGAGCGAGACTCCGTATGAA
25 MTP-96 A-Plex 2 
rs45461592
ACGTT GGAT GTT AAT GAG AATT AACT GCC
26 MTP-96 A-Plex 2 ACGTTGGAT G AC AG AG AACCT GT ATT AGGG
rs76026776
27 MTP-96 A-Plex 2 
rs34671512
ACGTT GGATGGAT ATTTTTT CTT CAT GGC
28 1 MTP-96 A-Plex 2 rs4148553 ACGTTGGATGATGGAAGCCCTTAAAGGTGC
29 MTP-96 A-Plex 2 rs211035 ACGTTGGAT GT GTTTT GTTTT GGACAGGG
30 MTP-96 A-Plex 2 
rs113569514
ACGTTGGATGGAGACTGAGCCAGCGAGTG
31 MTP-96 A-Plex 2 
rs34559063
ACGTT GGAT GGT GAT CAT AAT G AGGTTT G
32 MTP-96 A-Plex 2 rs6439448 ACGTT GGAT GT C AGTT ACT AT AAGGT GT CG
33 MTP-96 A-Plex 2 rs211014 ACGTTGGATGTAGCCTATCTGCAGGCTAAG
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34 | MTP-96 B-Plex 1 
rs35646917
ACGTTGG AT GAG AAGGG AAGGGAGT AAGT G
35 I MTP-96 B-Plex 1 rs3742106 ACGTTGG AT GC AAT GT GGTTT AC AT AGT CC
36 MTP-96 B-Plex 1 rs2253170 ACGTT GG AT GT AGTT CATAACTTTTT ATCC
37 MTP-96 B-Plex 1 rs1801253 ACGTTGGATGAGCCCTGCGCGCGCAGCAGA
38 MTP-96 B-Plex 1 
rs45439401
ACGTT GGAT GT CTT ACCTT CT AT AGGT AGC
39 MTP-96 B-Plex 1 rs17197 ACGTTGG AT GT C AAT GC AGCCGATT GTT CC
40 MTP-96 B-Plex 1 rs4998 ACGTT GGAT GGTGCCCCT ACC AAAGCCAG
41 MTP-96 B-Plex 1 
rs11045825
ACGTT GGAT G AGT GCTTTT GGAT GCAT GGG
42 MTP-96 B-Plex 1 
rs114509093
ACGTTGGAT GCTCCTT ACCGGGGCCT CGC
43 MTP-96 B-Plex 1 
rs34550074
ACGTTGGATGGGATGCTGTTTGGAGGAATC
44 [MTP-96 B-Plex 1 rs4149087 ACGTTGGAT GGT G AGT AAC AG AT ATT ATT G
45 S MTP-96 B-Plex 1 rs2274407 ACGTTGG ATGGGAACTT CT CAG AAT CTT GG
46 MTP-96 B-Plex 1 
rs114869610
ACGTT GGAT GATT ACCTGC ATGCAGGCACC
47 MTP-96 B-Plex 1 rs4148551 ACGTTGGAT GT GT GCCTT AAGAGACT ACAG
48 MTP-96 B-Plex 1 rs4149085 ACGTT GGAT GT GT AAC AAT G AGT ACT CT C
49 MTP-96 B-Plex 1 rs708502 ACGTTGGAT GGC AT CT GG AAG AT C ATTTT G
50 MTP-96 B-Plex 1 
rs16870224
ACGTTGGATGCCTTCTCACAGAGAAGAAA
51 MTP-96 B-Plex 1 
rs11045879
ACGTT GGAT GCTT GAT GGCTT CCAAGTTT C
52 MTP-96 B-Plex 2 rs1042714 ACGTTGGATGAAGCCATGCGCCGGACCA
53 MTP-96 B-Plex 2 
rs72978388
ACGTT GGAT GT CT CT GTTT AGG ATT CCCCC
54 MTP-96 B-Plex 2 
rs16993929
ACGTT GGAT GTT ACT G AGGGAT GCAACCCG
55 MTP-96 B-Plex 2 rs3819783 ACGTTGGAT G AAAGTTTGCT GGCAGATTGG
56 MTP-96 B-Plex 2 rs3765534 ACGTT GGAT GGT C ACT GT AAAT GG AGG AGG
57 MTP-96 B-Plex 2 rs879894 ACGTTGG ATGCCCACT AGGTT GGAGGT G A
58~ MTP-96 B-Plex 2 
rs45461592
ACGTTGGAT GGT GAT CAAG AAGACTTT AGG
59 MTP-96 B-Plex 2 
rs76026776
ACGTT GGAT GT GTT GCTAT AC AT CCC AAAG
60 MTP-96 B-Plex 2 
rs34671512
ACGTT GGATGCTT GGGCTT GT CTT C AAT G
61 MTP-96 B-Plex 2 rs4148553 ACGTT GGAT GACT CT AAAGGAGGATGGACG
62 MTP-96 B-Plex 2 rs211035 ACGTTGGATGGATCACACCACTGCACATTC
63 MTP-96 B-Plex 2 
rs113569514
ACGTT GGATGGG AGAGCGCGTTT CAT CAT C
64 MTP-96 B-Plex 2 
rs34559063
ACGTTGG ATGGT CTTT AACCT C AAAAGT CC
65 MTP-96 B-Plex 2 rs6439448 ACGTTGGATGCCTGGGTAATGAGGCACAGT
66 MTP-96 B-Plex 2 rs211014 ACGTT GGAT GTGGCCT GGCT AAACT CAT AC
67 MTP-96 E-Plex 1 
rs35646917
CAGTT CATCCTCGGCCC
68 MTP-96 E-Plex 1 rs3742106 CCGTT CCG AAGGC ATTT
69 MTP-96 E-Plex 1 rs2253170 ATGC ACTT GGT GAT AAAC
70 MTP-96 E-Plex 1 rs1801253 CTT CCGC AAGGCCTTCCAG
71 MTP-96 E-Plex 1 AAT C AGT AT AC ACC AG AG AT
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rs45439401
MTP-96 E-Plex 1 rs17197 tctCT AC AAAACCT ACCCT CA
MTP-96 E-Plex 1 rs4998 gCCCT CAGTGGT AGT GT CCAG
74 MTP-96 E-Plex 1 
rs11045825
T GAT GGTT AGAAT AGGAG AAT
75 MTP-96 E-Plex 1 
rs114509093
gagaGGCGGTACTTCTACCTGT
76 MTP-96 E-Plex 1 ggGGTAGCTATGCGGGGAATGG
rs34550074
77 | MTP-96 E-Plex 1 rs4149087 AC AC AG AGTTT G AACT AT AAT AC
78 MTP-96 E-Plex 1 rs2274407 ccacAAACCT GT ACT CT CTTT C AG
79 MTP-96 E-Plex 1 
rsl 14869610
ttta AT AT G G AC AG C ACTT AG AT G
80 MTP-96 E-Plex 1 rs4148551 ccacC AAC AAAAACCT GT G AC AACT
81 MTP-96 E-Plex 1 rs4149085 AACTT AT AAT AAAAC AAACT GT AGG
82 MTP-96 E-Plex 1 rs708502 actg AC AC ACT GTTTT C ATTT CTCCA
83 MTP-96 E-Plex 1 
rs16870224
aTTTT ATT GTT GT AC AT ACG ATTT AA
84 MTP-96 E-Plex 1 
rs11045879
agca AGGGTT AAT AT AAC AG AAT C AA
85 MTP-96 E-Plex 2 rs1042714 CCACACCTCGTCCCTTT
86 MTP-96 E-Plex 2 
rs72978388
CT CC ATT G AGG ATGCCC
87 MTP-96 E-Plex 2 
rs16993929
GTT ACT GCCG AT AAT G AAA
88 MTP-96 E-Plex 2 rs3819783 gTTGCAGCT CT GCT GT GTT C
89 MTP-96 E-Plex 2 rs3765534 ACC AGTT AAG AT CT AGCTT CT
90 MTP-96 E-Plex 2 rs879894 TT ACT ACGG AG AAAT AAAC AG
91 MTP-96 E-Plex 2 
rs45461592
cctcATT AACTGCCTT G AGACA
92 MTP-96 E-Plex 2 
rs76026776
gtagT AGGGGT C AGTCCTT GAA
93 MTP-96 E-Plex 2 
rs34671512
g ATTTTTT CTT CAT GGC AT AAAT
94 MTP-96 E-Plex 2 rs4148553 gggg AAGGT GCTTT GAT ACT GAA
95 MTP-96 E-Plex 2 rs211035 ttgtgTTGGACAGGGT CT CGTT CT
96 MTP-96 E-Plex 2 
rs113569514
ccccCTGAGCCAGCGAGTGCGCGCC
97 MTP-96 E-Plex 2 
rs34559063
GT GAT CAT AAT G AGGTTT GTT AAAA
98 MTP-96 E-Plex 2 rs6439448 TT CT G ACT AT AAAT C CT G AAAT AAT G
99 MTP-96 E-Plex 2 rs211014 ggatGGCTAAGGCTCAGCAGTTTGGG
N.B: A- and B- primers are the forward and reverse PCR primers, and E- 
primers are extension primers.
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Misoprostol, although originally introduced as a therapy for 
gastric ulcers, is now widely used in reproductive health. For 
some indications it is now the optimal choice, whilst for others 
it provides an important alternative, especially in low-resource 
settings. The optimal dose varies widely from 20 to 600 meg 
depending on the indication and gestation. Use of the correct 
dose is important, too low a dose will be ineffective and
overdosage can be dangerous for mother and baby. 
Evidence-based information about the safest regimens for 
multiple pregnancy indications are therefore provided in this 
review.
Keywords Misoprostol, low-resource settings, dose, mother, preg­
nancy, safest.
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Misoprostol (15-deoxy-16-hydroxy-16-methyl PGE1) is a 
stable, synthetic form of prostaglandin El analogue. It has 
anti-secretory and mucosal protective properties and was 
originally developed in the 1970s for the prevention of 
nonsteroidal anti-inflammatory drugs (NSAIDS)-induced 
peptic ulcers.1 Its use for that indication however, has 
become limited and it is now used much more widely for 
‘off-label’ indications in obstetrics and gynaecology.
Misoprostol has several properties that make it especially 
suitable for reducing maternal mortality in low-resource 
areas. The tablets are thermo-stable and have a long shelf 
life at room temperature whilst in aluminium blister packets. 
Misoprostol tablets could also be easily administered by 
unskilled attendants or the women themselves thus making 
them available for women giving birth at home or in isolated 
areas. This is in contrast to the alternative uterotonic drugs 
such as oxytocin and prostaglandins which are unstable 
at room temperature and require injection. Initially, miso­
prostol was only commercially available as an oral tablet 
in 100 and 200 /<g strengths. However, the tablets are also 
effective when administered vaginally, rectally, bucally and 
sublingually. The rate of absorption varies considerably 
between routes and care must be taken to use the correct 
dose and frequency for the specified route.
The original pricing of the Cytotec® (Pfizer Inc, New 
York, NY, USA) brand of misoprostol was based on a 6- 
week course of 600 meg daily for gastric ulcer treatment.
This makes the small doses required for reproductive health 
indications very inexpensive, especially when compared 
with the alternatives for labour induction. It is, however, 
currently slightly more expensive than oxytocin (with syr­
inge and needle) for the management of postpartum haem­
orrhage (PPH). Whilst the arrival of new low dose generic 
misoprostol tablets is welcome, the price is likely to be 
higher than for Cytotec!i, and practitioners will need to 
balance the increased cost against the benefits in safety and 
logistics of having an accurately sized formulation.
The slow pace of misoprostol research along with the 
lack of progress in achieving the millennium development 
goal 5 has led to a call to ‘fast track’ the introduction 
of misoprostol without waiting for confirmatory trials.2 
On the premise that in emergencies, policies may be 
implemented based on evidence from good science, but 
not necessarily randomised controlled trials (RCTs), miso­
prostol has now been introduced for PPH management in 
a number of countries including Nigeria, Uganda, Ethiopia, 
Bangladesh, India, Nepal, Tanzania, and Zambia.
The ease with which misoprostol can be used to induce 
abortions has led to a very cautious approach to its introduc­
tion from both the manufacturer and national governments. 
And so, despite the large body of evidence supporting the 
beneficial effects of misoprostol on women’s reproductive 
health, the manufacturers (Searle, now Pfizer) have strongly 
warned obstetricians and physicians that misoprostol should
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not be used in pregnant women.3 The original and most 
widely available preparation of misoprostol (Cytotec®) 
therefore remains off-label for reproductive health uses. 
Despite this, the efficacy and safety of misoprostol for termi­
nation of pregnancy (TOP) has now been acknowledged by 
the US Federal Drug Authority (FDA) by their inclusion of it 
into the mifepristone TOP regimen.3 Furthermore, there is 
also an increasing recognition of the limitations of the drug 
licensing process in pregnancy. The lack of a licence does not 
show a lack of efficacy or safety, but rather demonstrates that 
it is not cost-effective for the pharmaceutical company to 
obtain a licence. This is common in high-risk indications 
(e.g. pregnancy) and with low cost generic drugs. Hence, 
some of the most important drugs in obstetrics (e.g. corticos­
teroids to promote fetal lung maturity and oxytocin 10 IU 
IM for PPH prophylaxis) remain off-label for pregnancy use. 
As if to demonstrate this point, misoprostol is now consid­
ered an ‘essential drug’ by the World Health Organisation 
(WHO) for the induction of labour, medical TOP, and 
incomplete abortion (Table 1).
The lack of a specific licence for Cytotec® has led to a 
number of problems. These include distrust on the part of 
national drug authorities, the lack of a co-ordinated mar­
keting strategy and, perhaps most importantly, confusion 
regarding correct dosaging. For Cytotec®, the package 
insert includes only information about gastric ulcer doses 
and does not include any information about the safe dos­
ages for reproductive health indications. This has led to fre­
quent dosaging errors, with excessive dosages of 
misoprostol being commonly used for the second and third 
trimester indications. The danger of this is uterine rupture, 
and there is a concern that the wide availability of misopr­
ostol in South Africa might have caused an increase in the 
numbers of uterine ruptures. The availability of evidence- 
based information or guidelines about misoprostol uses for 
various reproductive health indications is therefore an 
essential requirement for safe and effective use of misopros­
tol. An expert group convened by WHO met in Bellagio, 
Italy in 2007 to advise on optimal misoprostol dosages (the 
‘Bellagio Expert Group’). The resulting guidelines were 
published in a supplement to the International Journal of 
Gynaecology and Obstetrics in 2007 and are the basis for the 
dosage recommendations included in this review (Figure 1). 
The guidelines are also available on an independent web­
site, http://www.misoprostol.org.
First trimester termination of 
pregnancy (induced abortion)
In the last two decades, medical TOP has become a safe alter­
native to vacuum aspiration and dilatation and curettage 
(D&C). Recently, the mifepristone/misoprostol regimen has 
become more widely available and is now considered to be
the gold standard for early pregnancy termination.4 Further­
more, a recent WHO study has demonstrated that reducing 
the time interval between the mifepristone and misoprostol 
doses from 48 to 24 hours has no effect on efficacy. The 
success rates to achieve complete abortion were 92.4 and 
94.0 at 48 and 24 hours, respectively.5 Increasingly, the 
evidence is pointing towards the use of sublingual or buccal 
misoprostol rather than vaginal: not only are these routes 
more acceptable to women, but they are associated with 
lower infection rates.
The regimen is also very successful when used without 
the mifepristone, achieving complete termination rates of 
80-90%. A recent study compared a single dose of 800 meg 
vaginal misoprostol to suction evacuation under local anaes­
thetic and found the success rate to be similar (94 and 95%, 
respectively), but with fewer side effects in those taking 
misoprostol.6 The route of administration of misoprostol is 
important. Vaginal appears to be the most effective, followed 
by sublingual with oral being the least effective.7,8 Sublingual 
misoprostol needs a more frequent administration, eveiy 
3 hours, to achieve a similar effectiveness to the vaginal 
route, but may be more acceptable to women. Therefore, 
for TOP, misoprostol should be administered vaginally 
unless there are reasons to avoid it. The recommended 
regimen is 800 meg of vaginal misoprostol administered 
every 12 hours for a maximum of three doses.8
Early fetal demise (missed abortion)
The traditional treatment for early fetal demise has been 
suction curettage. However, several studies have shown that 
medical treatment is a safe, effective and acceptable alterna­
tive.9 Both oral and vaginal 800 meg misoprostol are highly 
effective and acceptable for treatment of early fetal loss, 
but the mean time for expulsion is shorter in the vaginal 
group.10 Sublingual misoprostol is also effective, but has 
increased side effects at the same dosage.11 However, a lower 
dosage of 600 meg achieves similar efficacy at 86%.12 It is 
unclear whether the addition of mifepristone gives any added 
benefit.11 Therefore, the currently i*ecommended regimen is 
800 meg vaginal misoprostol every 3 hours (max two doses) 
or 600 meg of sublingual misoprostol every 3 hours (max 
two doses).13 The woman should be reassessed after 14 days 
as it may take this long to be effective.
Incomplete miscarriage (abortion)
A single dose of 600 meg oral misoprostol has been 
shown to be as effective as manual vacuum aspiration 
(MVA) in the management of incomplete miscarriage with 
complete evacuation rates of 95-99% after 1-2 weeks of 
follow-up,14-17 It is also more acceptable to women than 
MVA. The use of double doses of oral 600 meg misoprostol
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Table 1. Summary of recommendations from the World Health Organisation on the use of misoprostol for various reproductive health 
indications
On WHO model list 
of essential medicines62
for this indication? Text of WHO advice
First trimester
Termination of pregnancy (induced abortion) YES
Early fetal demise (missed abortion) NO
Incomplete miscarriage (abortion) YES
Second trimester
Termination of pregnancy (induced abortion) YES
Third trimester
Intrauterine fetal death NO
Induction of labour YES
Prevention of postpartum haemorrhage NO
Treatment of postpartum haemorrhage NO
Gynaecology 
Cervical priming NO
'The following methods are preferred for early abortion:
- Manual or electric vacuum aspiration
- Medical method of abortion - a combination of mifepristone
followed by a prostaglandin such as misoprostol or gemeprost, 
for up to nine completed weeks since last menstrual period. 
Misoprostol is the prostaglandin of choice for most settings 
since it is cheap and does not require refrigeration.'20 
Formal recommendations not available for this indication.
No formal recommendations available for this indication, but 
WHO textbook teaches use of MVA, with misoprostol or 
oxytocin as adjuncts.63
'...the following methods are preferred:
- Dilatation and evacuation (D&E), using vacuum aspiration 
and forceps;
- Mifepristone followed by repeated doses of a prostaglandin 
such as misoprostol or gemeprost;
- Prostaglandins alone (misoprostol or gemeprost), in repeated 
doses.’20
No formal recommendations available for this indication, but 
WHO textbook teaches use of expectant management, 
prostaglandins, misoprostol, oxytocin or transcervical Foley.63 
Formal recommendations not available for this indication, 
but WHO textbook teaches use of oxytocin, prostaglandins 
and transcervical Foley, with misoprostol only in specific 
situations.63
'Skilled attendants should offer oxytocin for prevention of 
PPH in preference to oral misoprostol. Misoprostol can be 
used where no skilled birth attendants are available (without 
the other active management components)'45 
Formal recommendations not available for this indication, 
but WHO textbook only recommends oxytocin ergometrine 
and prostaglandin F2a - misoprostol is not mentioned.63 
Formal WHO guidelines available soon.
Prior to uterine evacuation misoprostol, mifepristone or 
gemeprost are 'recommended for durations of pregnancy 
over nine completed weeks for nulliparous women, for 
women younger than 18 years old and for all women with 
durations of pregnancy over 12 completed weeks'20
increases the rate of side effects without clinical benefits.18 
Misoprostol has recently been added to the WHO model 
essential drugs list for this indication. The recommended 
regimen is a single dose of 600 meg oral misoprostol for 
women with a uterine size equivalent to 12 weeks or less.19 
The single dose should be given between 1 and 2 weeks to 
work.
Second trimester termination of 
pregnancy (TOP, induced abortion)
Surgical termination of early second-trimester pregnancy can 
be performed by D8cC or suction curettage, whereas termina­
tion performed late in the second trimester requires cervical 
dilatation and fetal extraction. This can result in severe
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Figure 1. Recommended doses of misoprostol (IUFD: intrauterine fetal death; IOL: induction of labour; PPH: postpartum haemorrhage. fWhere legal; 
1 included in the WHO Model List of Essential Medicines; * make sure you use the correct dosage - overdose can lead to complications!; s oxytocin 
is first line as it is more effective than misoprostol).
complications including cervical laceration, uterine perfora­
tion and injuries to abdominal organs. Medical TOP is 
potentially safer and provides a good histological specimen 
which is important if the termination is for fetal malforma­
tions. Therefore, medical termination using mifepristone 
followed by a prostaglandin analogue is recommended by 
WHO20 and the Royal College of Obstetricians and Gynae­
cologists.21
Misoprostol appears to be also effective when used 
alone and a variety of regimens with 200-600 meg of 
vaginal misoprostol at different time intervals have shown 
similar effectiveness. A randomised trial of three regimens 
of misoprostol for second trimester induction at 
14-30 weeks showed that 400 meg of vaginal misoprostol 
6 hourly provided the optimal regimen, with a shorter 
delivery interval than the 200 meg dose and fewer side 
effects than the 600 meg dose.22 In balancing efficacy 
and side effects, a regimen of 400 meg vaginal misopros­
tol at 3 hour intervals using a maximum of five doses 
is therefore recommended.23 Higher doses may be 
needed for early second trimester TOP and lower doses
may be sufficient to induce abortion later in the second 
trimester.
Uterine rupture is a rare but serious complication of 
TOP in the second trimester, occurring largely in grand 
multiparous women and those with a previous caesarean 
section. Further research is needed before misoprostol can 
be recommended as the standard method for second 
trimester TOP in women with a previous caesarean section, 
and the Bellagio group recommend caution in these women.
Intrauterine fetal death
There are a wide variety of clinically effective misoprostol 
regimens for the induction of labour following second and 
third trimester intrauterine fetal deaths (IUFDs). The 
required amount of misoprostol not only decreases with 
increasing gestational age, but has also been found to be 
lower in women where the fetus has died in utero.24 
Between the vaginal, sublingual and oral routes, sublingual 
misoprostol has the shortest induction to expulsion inter­
val.23 Oral misoprostol (400 meg) acts more rapidly than
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vaginal misoprostol (200 meg), but has more side effects.26 
However, all completed within 48 hours. The vaginal route 
is therefore recommended for the treatment of IUFD. As 
a result of increasing uterine sensitivity to prostaglandin 
through pregnancy, the recommended doses are variable 
according to gestation.27 From 13 to 17 weeks, 200 meg vagi­
nal misoprostol is required 6 hourly (four doses maxi­
mum), 100 meg of vaginal misoprostol 6 hourly (four 
doses maximum) is recommended for 18-26 weeks and 
25-50 meg eveiy 4 hours (maximum six doses) is used for 
a gestational age of over 27 weeks. If the first dose does 
not produce effective contractions, the second dose can be 
doubled.27 Because of the risk of uterine rupture, it is rec­
ommended that women with a scarred uterus should 
receive lower doses of misoprostol, and not double the 
dose if there is no initial response.
Induction of labour with a live fetus
Induction of labour can be achieved by many medical and 
mechanical methods. Vaginal dinoprostone is the current 
gold standard method for cervical ripening and induction of 
labour, although misoprostol has been used as an alternative 
since 1987. The Cochrane review (70 trials containing over
10 000 women)28 found that vaginal misoprostol Is more 
effective than dinoprostone and oxytocin or oxytocin alone 
for induction, but rates of uterine hyperstimulation and 
meconium stained liquor were increased at doses over 
25 meg. Whether the latter is secondary to uterine hypersti­
mulation or due to a direct effect of misoprostol on the fetal 
bowel is not yet known. Recent pharma-sponsored studies 
have shown that both 25 meg vaginal tablets and a sustained 
release pessary have similar efficacy to dinoprostone.29,30 
Vaginal misoprostol 25 meg given 6 hourly is therefore 
recommended.
Oral misoprostol is also highly effective and has the ben­
efit of a convenient route of administration. Overall, the 
meta-analysis of oral misoprostol trials (56 studies of over
11 000 women) shows it to be more effective than dino­
prostone, but with higher rates of hyperstimulation.31 This 
appears to be due to the doses in many of the trials being 
too high - the same effect is not seen with lower doses. 
Doses of 50 meg orally or less have similar efficacy and 
hyperstimulation rates to dinoprostone.32
Obtaining an accurate dose of 20 or 25 meg misoprostol 
by cutting the 100 meg or the 200 meg tablets can be diffi­
cult and unprecise. Even though misoprostol is evenly 
distributed throughout the tablet, cutting the tablet only 
achieves a dosage within 10% of the planned dosage in 58% 
of the time.33 Although suboptimal, this should be com­
pared with the alternative in low-resource settings which is 
an oxytocin infusion run without an electronic pump where 
dosages obtained are within 10% of planned in only 15% of
observations.3'1 To improve precision, an oral misoprostol 
solution can be made by dissolving one tablet (200 meg) in 
200 ml of tap water. A solution of 20 meg of oral misopros­
tol (i.e. 20 mis of solution) given every 2 hours for a maxi­
mum of 12 doses titrated against individual uterine 
response is associated with a lower incidence of uterine 
hyperstimulation, shorter induction to labour interval and 
lower caesarean section rate than vaginal dinoprostone.31 
Head to head comparisons of low dose oral and vaginal 
misoprostol are few, but one study has shown that 20 meg 
oral misoprostol solution administered 2 hourly is as 
effective as vaginal misoprostol in achieving vaginal 
delivery, but with a much lower rate of uterine hyperstimu­
lation.32
The recommended doses for induction of labour using 
misoprostol are therefore 25 meg vaginal or 50 meg oral 
every 4 hours for a maximum of six doses. Another option 
is 20 meg of oral misoprostol solution 2 hourly for a maxi­
mum of 12 doses.35 There is currently limited evidence 
regarding the safety of misoprostol for the induction in 
women with previous uterine scar. The risk of uterine 
rupture with the use of misoprostol in women attempting 
vaginal birth after caesarean section is reported between 6 
and 12% of women.36,37 Therefore, misoprostol is contrain­
dicated in women who have a uterine scar.
Prevention of postpartum 
haemorrhage
Postpartum haemorrhage is the leading cause of maternal 
mortality in the developing world,38 accounting for about 
25% of all maternal deaths worldwide. Initial small 
randomised trials comparing oral misoprostol to standard 
oxytocic regimens suggested that misoprostol was as 
effective as oxytocic drugs for PPH prevention. However, a 
large multicentre trial of nearly 20 000 women comparing 
600 meg of oral misoprostol with 10IU of oxytocin 
showed that the rate of severe PPH (>1000 mis) was higher 
in the misoprostol group (4 vs 3.0%).39 Oxytocin is there­
fore now recommended over misoprostol as first line for 
PPH prophylaxis as a part of the active management of 
labour.40
The evidence as to whether misoprostol is better than 
placebo is however complex. Although the Cochrane review 
of all RCTs show no overall difference in efficacy,41 misopr­
ostol appears to be beneficial in community settings. Three 
studies have explored this. A double-blind randomised trial 
conducted in The Gambia using 52 traditional birth atten­
dants compared 600 meg of oral misoprostol to 2 mg oral 
ergometrine (used as a placebo). Although there was no 
difference in PPH rate, there were fewer women with a fall 
in Hb >2 g/dl in the misoprostol group.42 A second com­
munity double-blind RCT was undertaken in a primary
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health centre in Guinea-Bissau which demonstrated a 
marked reduction in the rate of severe PPH (>1000 ml) 
with 600 meg sublingual misoprostol.43 And most recently, 
an RCT of 1620 women in India has shown that 600 meg 
oral misoprostol reduced the rate of severe PPH by 50% 
compared with placebo.44 The findings of these three trials 
show the effectiveness of misoprostol in low resource, com­
munity settings, where the PPH rate is very high and where 
there are no alternatives for prophylaxis or treatment. The 
reason for this is unclear but may relate to the differing 
length of the normal third stage in community and hospital 
settings. In hospital settings where active management of 
the third stage is used, there is a tradition of enthusiastic 
early controlled cord traction (CCT) timed to coincide 
with the peak level of oxytocin. If early CCT is used with 
misoprostol, the placental detachment (and haemorrhage) 
will occur before misoprostol is at effective serum levels. 
In community settings, however, the timing of CCT is 
usually later and is likely to coincide with the peak serum 
levels of misoprostol at 20 minutes. This may explain why 
misoprostol appears to be more effective in community 
settings.
Based on the above evidence, WHO currently recom­
mends the use of oxytocin rather than misoprostol for the 
prevention of PPH as part of the active management of the 
third stage of labour.45 However, they recommend the use 
of either oxytocin or misoprostol in settings where active 
management is not being practiced or where no skilled 
birth attendants are available. The dosage recommended by 
the Bellagio expert group is a single dose of 600 meg of 
oral or sublingual misoprostol.46 The dose should not be 
repeated for 2 hours.
Treatment of PPH
For a decade now, studies have generated encouraging evi­
dence on the use of misoprostol as an emergency treatment 
for PPH. Three placebo-controlled RCTs, testing the addi­
tive effect of misoprostol when used in conjunction with 
standard oxytocics to treat PPH, have found favourable 
trends in blood loss reduction in the misoprostol arms.47- 
49 However, a statistically significant reduction of blood 
loss was demonstrated only after conducting a meta-analy­
sis of the combined data from these RCTs testing varying 
regimens of misoprostol (600 to 1000 meg) as an adjunct 
to PPH treatment.49,50 Only one published hospital-based 
RCT has offered evidence on the use of misoprostol as a 
first-line treatment.50 In this open label trial, 64 women 
were randomised to receive either 800 meg misoprostol 
rectally or standard oxytocics as standalone treatment 
for PPH. The results showed dramatic improvements with 
the use of misoprostol, although the study design has been 
criticised as being subject to bias. To date, there is not
enough evidence to recommend replacing injectable 
oxytocics with misoprostol for the first-line treatment of 
primary PPH.51 This appears to be supported by the results 
of two large RCTs which at the time of writing are avail­
able in abstract format only.
Given the wide variety of reported doses and the demon­
strable safety of misoprostol 600 meg orally from the large 
WHO prophylaxis RCT,39 the Bellagio expert group recom­
mended 600 meg of oral or sublingual misoprostol for 
PPH treatment, but not as first-line treatment.52 Again they 
recommend that a second dose should not be repeated 
before 2 hours.
Cervical priming before transcervical 
procedures
Cervical priming refers to the softening or dilation of the 
cervix before transcervical procedures. These include TOP, 
hysteroscopy, D&C, insertion of intrauterine devices, and 
endometrial biopsies. Cervical priming using gemeprost, 
laminaria or mifepristone can facilitate mechanical dilata­
tion, shorten the operation time, reduce blood loss and 
decrease the frequency of complications.53
Misoprostol has also been used effectively for cervical prim­
ing in pregnant women with both oral and vaginal 
misoprostol shown to be useful prior to vacuum aspiration.34 
The dose of 400 meg vaginal misoprostol administrated 
3 hours before the procedures is recommended as an optimal 
dose.55 However, the same regimens using misoprostol either 
orally or sublingually are equally effective54,56 and have the 
advantage of being more convenient and more acceptable to 
women.56 A single dose of 400 meg vaginal or sublingual 
misoprostol 3 hours prior to transcervical procedures has 
been recommended by WHO and the Bellagio expert 
group.20,53
Side effects
Chills and/or fever
Chills and fever are fairly common in association with the 
use of misoprostol but are transient. Typical rates for oral 
misoprostol 600 meg are 28 and 7.5% for shivering and 
temperature over 38°C, respectively.57 Temperatures of 
over 40°C are associated with high doses of misoprostol 
(e.g. 800 meg), shorter intervals and oral or sublingual 
administration. The fever is transient and responds to anti­
pyretics and physical cooling.
Gastrointestinal side effects
Nausea, vomiting and diarrhoea are common adverse 
reactions of misoprostol intake, affecting about 35% of 
women.23 Diarrhoea is the most common side effect and 
it is usually mild and self-limiting within a day; vomiting
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usually resolves in <6 hours. The gastrointestinal side 
effects are more common after oral or sublingual adminis­
tration.58
Abdiominal cramps
Abdominal cramps usually develop within tire first few 
hours and may start as early as 10 minutes after adminis­
tration. NSAIDs can be given for pain relief without 
affecting the effectiveness of misoprostol.59 Higher doses 
of analgesia are required in younger women, those in late 
pregnancy and with multiple doses of misoprostol.60
Uterine hyperstimulation and rupture
Hyperstimulation may result from the use of excessive or 
repeated doses of misoprostol when used for labour induc­
tion. However, with the low misoprostol doses now recom­
mended (25 meg vaginally or 20 meg orally), the incidence 
of hyperstimulation is similar to that of dinoprostone at 
4-12%.28,31
Uterine rupture is another concern with the use of mi­
soprostol, and is discussed in the section of Induction of 
labour with a live fetus.
Fetal abnormalities
A variety of congenital abnormalities have been reported 
after an unsuccessful use of misoprostol for TOP, but 
the most commonly reported are Mobius Syndrome 
(congenital facial paralysis with or without limb defects), 
absence of the fingers, club foot and cranial nerve 
anomalies (affecting nerves V, VI, VII, and XII). How­
ever, the risk of fetal malformation after misoprostol use 
is low with an estimated risk of <1% among exposed 
fetus.61
Conclusion
In settings with lunited access to health care, misoprostol is 
an important intervention that could reduce maternal 
deaths both directly and through the more cost-effective 
use of health services. Misoprostol is, however, a powerful 
drug that needs to be used with care. Evidence-based infor­
mation about the safest regimens should be widely dissemi­
nated so as to prevent its inappropriate use.
Conflict of interest
The authors have no conflicts of interest to declare. AW 
runs the http://www.misoprostol.org website to promote 
the appropriate use of misoprostol, but this does not 
receive any support from the pharmaceutical industry.
Contribution to authorship
AE carried out the literature search and writing of the 
manuscript first draft, AW revised the manuscript. ■
References
1 Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the 
development of misoprostol - from hypothesis to clinical practice. 
Dig Dis Sci 1998;43:447-58.
2 Potts M, Prata N, Walsh J, Grossman A. Parachute approach to evi­
dence based medicine. BM/2006;333:701-703.
3 Hale RW, Zinberg S. Use of misoprostal in pregnancy. N Engl J Med 
2001;344:59-60,
4 KuSier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. 
Medical methods for first trimester abortion. Cochrane Database 
Syst Rev 2004;(2):CD002855.
5 von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, 
Tang OS, et al. Two mifepristone doses and two intervals of 
misoprostol administration for termination of early pregnancy: a 
randomised factorial controlled equivalence trial. BJOG 2009;116: 
381-9,
6 Prasad S, Kumar A, Divya A. Early termination of pregnancy by sin­
gle-dose 800 mug misoprostol compared with surgical evacuation. 
Fertil Steril 2009;91:28-31.
7 Blanchard K, Shochet T, Coyaji K, Thi Nhu Ngoc N, Winikoff B. Mi­
soprostol alone for early abortion: an evaluation of seven potential 
regimens. Contraception 2005;72:91-7.
8 Faundes A, Ftala C, Tang OS, Velasco A. Misoprostol for the termi­
nation of pregnancy up to 12 completed weeks of pregnancy. Int J 
Gynaecol Obstet 2007;99 (Suppl 2):S172-7.
9 Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Man­
agement of miscarriage: expectant, medical, or surgical? Results of 
randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 
2006;332:1235-40.
10 Ngoc NT, Blum J, Westheimer E, Quan TT, Winikoff B. Medical treat­
ment of missed abortion using misoprostol. Int J Gynaecol Obstet 
2004;87:138-42.
11 Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal 
death (less than 24 weeks). Cochrane Database Syst Rev 
2006;(3):CD002253.
12 Sharma D, Singhal SR, Rani XX. Sublingual misoprostol in manage­
ment of missed abortion in India. Trop Doct 2007;37:39-40.
13 Gemzell-Danielsson K, Ho PC, Gomez Ponce de Leon R, Weeks A, 
Winikoff B. Misoprostol to treat missed abortion in the first trimes­
ter. IntJ Gynaecol Obstet 2007;99 (Suppl 2):S182-5,
14 Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, 
Clark W, et al. Misoprostol for treatment of incomplete abortion at 
the regional hospital level: results from Tanzania. BJOG 
2007;114:1363-7.
15 Dao B, Blum J, Thieb B, Raghavan S, Ouedraego M, Lankoande i, 
et al. Is misoprostol a safe, effective and acceptable alternative to 
manual vacuum aspiration for postabortion care? Results from a 
randomised trial in Burkina Faso, West Africa. BJOG 2007;114: 
1368-75.
16 Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, et al. A 
randomized trial of misoprostol compared with manual vacuum aspi­
ration for incomplete abortion. Obstet Gyneco/2005;106:540-7.
17 Gemzell-Danielsson KC, Fiala C, Weeks A. Misoprostol: first-line 
therapy for incomplete miscarriage in the developing world. BJOG 
2007;114:1337-9.
18 Phupong V, Taneepanichskul S, Kriengsinyot R, Sriyirojana N, Blan­
chard K, Winikoff B. Comparative study between single dose 600 
microg and repeated dose of oral misoprostol for treatment of 
incomplete abortion. Contraception 2004;70:307-11.
19 Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R, 
Weeks A, Treatment of incomplete abortion and miscarriage with 
misoprostol. IntJ Gynaecol Obstet 2007;99 (Suppl 2):S186-9.
© 2009 The Authors Journal compilation © RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 67
Elati, Weeks
20 WHO, Safe Abortion: Technical and Policy Guidance for Health 
Systems. Geneva: WHO, 2003.
21 RCOG. The Care of Women Requesting Induced Abortion. London: 
Royal College of Obstetricians and Gynaecologists, 2004.
22 Dickinson JE, Evans SF. The optimization of intravaginal misoprostol 
dosing schedules in second-trimester pregnancy termination. Am J 
Obstet Gynecol 2002;186:470-4.
23 Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de 
Leon R, Mittal S, Tang OS. Misoprostol for the termination of preg­
nancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 
2007;99 (Suppl 2):S178-81.
24 Srisomboon J, Pongpisuttinun S. Efficacy of intracervicovaginal 
misoprostol in second-trimester pregnancy termination: a compari­
son between live and dead fetuses. J Obstet Gynaecol Res 1998;24: 
1-5.
25 Elhassan EM, Abubaker MS, Adam I. Sublingual compared with 
oral and vaginal misoprostol for termination of pregnancy with 
second-trimester fetal demise. Int J Gynaecol Obstet 2008; 100:82- 
3.
26 Chittacharoen A, Herabutya Y, Punyavachira P. A randomized trial 
of oral and vaginal misoprostol to manage delivery in cases of fetal 
death. Obstet Gynecol 2003;101:70-3.
27 Gomez Ponce de Leon R, Wing D, Fiala C. Misoprostol for intrauter­
ine fetal death. International Journal of Gynecology and Obstetrics 
2007;99(Suppl 2):S190-3.
28 Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripen­
ing and induction of labour. Cochrane Database Syst Rev 
2003;(1):CD000941.
29 Calder AA, Loughney AD, Weir CJ, Barber JW. Induction of labour 
in nulliparous and multiparous women: a UK, multicentre, open- 
label study of intravaginal misoprostol in comparison with dinopro- 
stone. BJOG 2008;115:1279-88.
30 Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent 
vaginal administration of misoprostol with continuous dinoprostone 
for cervical ripening and labor induction. Am J Obstet Gynecol 
1997;177:612-8.
31 Alfirevic Z, Weeks A. Oral misoprostol for induction of labour. Coch­
rane Database Syst Rev 2009;(2):CD001338.
32 Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol 
for induction of labor: a systematic review. Obstet Gynecol 
2009;113:374-83.
33 Williams MC, Tsibris JC, Davis G, Baiano J, O'Brien WF. Dose varia­
tion that is associated with approximated one-quarter tablet doses 
of misoprostol. Am J Obstet Gynecol 2002;187:615-9.
34 Crass RE, Vance JR. In vivo accuracy of gravity-flow i.v. infusion sys­
tems. Am J Hosp Pharm 1985;42:328-31.
35 Weeks A, Alfirevic Z, Faundes A, Hofmeyr GJ, Safar P, Wing D. 
Misoprostol for induction of labor with a live fetus. Int J Gynaecol 
Obstet 2007',99 (Suppl 2):S194-7.
36 Piaut MM, Schwartz ML, Lubarsky SL, Uterine rupture associ­
ated with the use of misoprostol in the gravid patient with a 
previous cesarean section. Am J Obstet Gynecol 1999;180:1535- 
42.
37 Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision 
following misoprostol for labor induction in women with previous 
cesarean delivery. Obsfet Gynecol 1998;91:828-30.
38 Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PFA. WHO 
analysis of causes of maternal death: a systematic review. Lancet; 
2006;367:1066-74.
39 Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, 
ef al. WHO multicentre randomised trial of misoprostol in the 
management of the third stage of labour. Lancet 2001;358:689- 
95.
40 National Collaborating Centre for Women's and Children's Health. 
Intrapartum care. Care of healthy women and their babies during 
childbirth. ROCG Presslondon, 2007.
41 Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for 
preventing postpartum haemorrhage. Cochrane Database Syst Rev 
2007;(2):CD000494.
42 Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, 
et al. Misoprostol in the management of the third stage of labour in 
the home delivery setting in rural Gambia: a randomised controlled 
trial. BJOG 2005;112:1277-83.
43 Hoj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of 
sublingual misoprostol on severe postpartum haemorrhage in a pri­
mary health centre in Guinea-Bissau: randomised double blind clini­
cal trial. BMJ 2005;331:723.
44 Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, 
et al. Oral misoprostol in preventing postpartum haemorrhage in 
resource-poor communities: a randomised controlled trial. Lancet 
2006;368:1248-53.
45 WHO. WHO Recommendations for the Prevention of Postpartum 
Haemorrhage. WHO: Geneva, 2006.
46 Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of 
postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 
2007;99 (Suppl 2):S198-201.
47 Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jaffa Z, etal. 
Misoprostol for treating postpartum haemorrhage: a randomized 
controlled trial [ISRCTN72263357], BMC Pregnancy Childbirth 
2D04;4:16.
48 Walraven G, Dampha Y, Bittaye B, Sowe M, Hofmeyr J. Misoprostol 
in the treatment of postpartum haemorrhage in addition to routine 
management: a placebo randomised controlled trial. BJOG 
2004;111:1014-7.
49 Zuberi NF, Durocher J, Sikander R, Baber N, Blum J, Walraven G. Mi­
soprostol in addition to routine treatment of postpartum hemor­
rhage: a hospital-based randomized-controlled trial in Karachi, 
Pakistan. BMC Pregnancy Childbirth 2008;8:40.
50 Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, 
El Refaey H, et al. A randomized study comparing rectally adminis­
tered misoprostol versus Syntometrine combined with an oxytocin 
infusion for the cessation of primary post partum hemorrhage. Acta 
Obstet Gynecol Scand 2001;80:835-9.
51 Mousa HA, Alfirevic Z. Treatment for primary postpartum haemor­
rhage. Cochrane Database Syst Rev 2007;(4):CD003249.
52 Blum J, Alfirevic Z, Walraven G, Weeks A, Winikoff B. Treatment of 
postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 
2007;99 (Suppl 2):S202-5.
53 Fiala C, Gemzell-Danielsson K, Tang OS, von Hertzen H. Cervical 
priming with misoprostol prior to transcervical procedures. Int J 
Gynaecol Obstet 2007;99 (Suppl 2):S168-71.
54 Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for 
pre-operative cen/ical dilatation prior to vacuum aspiration: a ran­
domized trial. Hum Reprod 1999;14:2139-42.
55 Fong YF, Singh K, Prasad RN. A comparative study using two dose 
regimens (200 microg or 400 microg) of vaginal misoprostol for pre­
operative cervical dilatation in first trimester nulliparae. Br J Obstet 
Gynaecol 1998;105:413-7.
56 Tang OS, Mok KH, Ho PC. A randomized study comparing the use 
of sublingual to vaginal misoprostol for pre-operative cervical prim­
ing prior to surgical termination of pregnancy in the first trimester. 
Hum Reprod 2004;19:1101-4.
57 Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misopr­
ostol dose-related shivering and pyrexia in the third stage of labour. 
WHO Collaborative Trial of Misoprostol in the Management of the 
Third Stage of Labour. BrJ Obstet Gynaecol 1999;106:304-8.
68 © 2009 The Authors Journal compilation © RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology

Misoprostol in obstetrics and gynaecology
58 Tang 05, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacoki­
netic profiles, effects on the uterus and side-effects. Int J Gynaecol 
Obstet 2007;99 (Suppl 2):S160-7.
59 Fiala C, Swahn ML, Stephansson 0, Gemzell-Danielsson K. The 
effect of non-steroidal anti-inflammatory drugs on medical abortion 
with mifepristone and misoprostol at 13-22 weeks gestation. Hum 
Reprod 2005;20:3072-7.
60 Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia require­
ments and predictors of analgesia use for women undergoing medical 
abortion up to 22 weeks of gestation. BJOG 2004; 111:996-1000.
61 Philip N, Shannon C, Wintkoff B. Misoprostol and Teratogenicity: 
Reviewing the Evidence. Population Council and Gynuity Health 
Projects. New York, 2002.
62 WHO. WHO Model List of Essential Medicines, 16th edn. WHO: 
Geneva, 2009.
63 WHO. Managing Complications in Pregnancy and Childbirth: A 
Guide for Midwives and Doctors. Geneva: WHO, 2003.
© 2009 The Authors Journal compilation © RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 69
Intrapartum careDOI: 10.1111/j. 1471 -0528.2010.02821 .x www.bjog.org
The effect of misoprostol on postpartum 
contractions: a randomised comparison of three 
sublingual doses
A Elati,3 MS Elmahaishi,b MO Elmahaishi,c OA Elsraiti,c AD Weeks3
a School of Women’s and Children’s Health, Liverpool Women’s Hospital, University of Liverpool, Liverpool, UK b Al Fatah Medical 
University, Tripoli, Libya c Faculty of Medicine, Misurata University, Misurata, Libya
Correspondence: Dr A Weeks, Liverpool Women’s Hospital, Crown Street, Liverpool L8 7SS, UK. Email aweeks@liverpool.ac.uk 
Accepted 1 November 2010. Published Online 24 December 2010.
Objective To compare the postpartum uterine activity and side 
effects of various doses of sublingual misoprostol and 
intramuscular oxytocin.
Design Single centre, randomised trial.
Setting Zliten Teaching Hospital in Libya.
Population Forty-nine women who did not receive oxytocics in 
labour and who delivered vaginally.
Methods Thirty-five women were randomised to receive 200, 400 
or 600 meg of sublingual misoprostol PPH prophylaxis 
immediately following delivery. These were compared with 
14 consecutive women given 10 IU of intramuscular oxytocin. 
Immediately after placental delivery, a Koala intra uterine 
pressure catheter was inserted transcervically into the uterine 
cavity.
Main outcomes measures The uterine pressure (in Montevideo 
units) measured over 120 minutes. Other outcomes included 
temperature and measured blood loss.
Results Women’s age, parity, gestational age and neonatal birth 
weight were not significantly different between the four groups. 
There was no difference in intrauterine pressure between the three 
misoprostol doses. However, the uterine pressure was significantly 
lower than oxytocin with all three doses for the first 10 minutes 
(P < 0.008) and significantly higher than oxytocin from 50 to 
120 minutes (P < 0.008). A dose-related rise in the body 
temperature and chills was observed in the misoprostol groups, 
with 8.3%, 8.3% and 45% of women experiencing a fever >39 °C 
with the 200, 400, and 600 meg doses respectively.
Conclusion Intramuscular oxytocin has the highest immediate 
post partum uterine activity. Lower doses of misoprostol may be 
as effective as high doses and with fewer side effects. Clinical 
outcomes with low-dose misoprostol should be further explored 
(ISRCTN97277056). The study number is for the RCT reported in 
this paper.
Keywords Fever, misoprostol, postpartum haemorrhage, 
sublingual, uterine contraction.
Please cite this paper as: Elati A, Elmahaishi M, Elmahaishi M, Elsraiti O, Weeks A. The effect of misoprostol on postpartum contractions: a randomised 
comparison of three sublingual doses. BJOG 2011;118:466-473.
Introduction
Postpartum haemorrhage (PPH) is the leading cause of 
maternal mortality in the developing world and is responsi­
ble for about 25% of all maternal deaths worldwide.' The 
most common cause of PPH is the failure of the uterus to 
contract after childbirth (atonic PPH) and active manage­
ment of the third stage of labour is recommended to prevent 
this."3 This involves, as a minimum, the administration of a 
uterotonic drug at delivery and controlled cord traction. 
Oxytocin is recommended as the first-line oxytocic for the 
prevention of PPH.3,4 However, oxytocin requires refrigera­
tion because it is unstable when exposed to high ambient
temperatures. Furthermore, this drug must be given paren- 
terally, which requires a skilled birth attendant and a contin­
uous supply of sterile syringes and needles. Both of these are 
frequently unavailable in low-resource settings. About 99% 
of maternal deaths occur in low-resource settings where 
there are poor transportation systems and a lack of skilled 
birth attendants and emergency obstetrics services.5 Hence, a 
major objective for reducing maternal deaths in poor areas 
is to find low-cost, effective ways to prevent and control 
PPH.
Misoprostol is an orally active prostaglandin analogue 
with uterotonic effects, and is an option for PPH preven­
tion in low-resource settings because of its thermostability,
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cost-effectiveness and ease of administration. There have 
been at least 36 trials that have studied misoprostol for 
PPH prevention using doses between 200 and 1000 ng and 
a variety of routes including oral, vaginal, sublingual and 
rectal.6 It is, however, as yet unclear which gives the best 
balance of efficacy and safety. Given the relative ineffective­
ness of misoprostol for PPH, the tendency has been to use 
high doses. There are, however, potential dangers in this. 
Shivering and pyrexia are commonly reported adverse 
effects, and hyperpyrexia of over 40°C has been reported, 
reaching an incidence of 36% in some population groups.7 
A recent systematic review recommends further research to 
find the optimal route and minimum effective dose of 
misoprostol for routine use for the prevention of PPH.8 
The authors suggest that the sublingual route is likely to be 
the most suitable because of rapid uptake, prolonged dura­
tion of action and greater bioavailability.
This study was devised to compare the effects of three 
sublingual misoprostol doses using measurement of post­
partum intrauterine pressure as a surrogate endpoint to 
evaluate the uterine activity of these uterotonics. We also 
compared the adverse effects associated with each treat­
ment. Data from a small cohort of women given intramus­
cular oxytocin prophylaxis are also shown for comparison 
with the misoprostol data. We hypothesised that low doses 
of misoprostol produce a similar strength of myometrial 
contraction to high doses.
Methods
The study population was made up of women who gave 
birth at Zliten Teaching Hospital (in Zliten, Libya) between 
July and December 2009. This is a government-funded, sec­
ondary referral hospital serving a population of 200 000 
people with 4500 deliveries per year. Before the study, a 
small pilot study was conducted in a nearby teaching hos­
pital (in Misurata) to test and perfect the study equipment 
and data acquisition methodology. The data from this pilot 
study were also used to calculate the sample size for the 
main study. At the end of this small pilot study, the 
researcher moved to Zliten Teaching Hospital and the ethi­
cal approval was amended accordingly. During the trial set­
up period for the main study at this new site (pilot data 
analysis, recalculation of samples sizes and development of 
the randomisation schedule and envelopes), 14 women 
were recruited to an observational study at Zliten where 
women were treated with oxytocin alone. Once all the 
study instruments were in place, the main randomised 
study commenced and women entering the delivery suite 
when the researcher was present (usual working hours dur­
ing the week) were invited to participate.
Women who were 18 years old or over, who had a spon­
taneous onset of labour and no risk factors for PPH were
approached upon arrival at hospital in early labour and 
invited to participate in the randomised study. If they 
agreed, informed consent was obtained. Risk factors for 
PPH included a history of PPH in a previous pregnancy, a 
history of antepartum haemorrhage in the current preg­
nancy, a previous caesarean delivery, multiple pregnancy 
and polyhydraminos, Women with anaemia (haemoglo­
bin <10.0 g/dl) or maternal infection were also excluded 
(Figure 1). Intrapartum exclusions were augmentation with 
oxytocin, instrumental delivery or caesarean section.
Women who gave birth to babies weighing >4 kg were 
not randomised. To enable this, the baby was weighed 
immediately after delivery, and the study drug was given 
slightly later than originally described in the protocol so as 
to allow the neonate’s weight to be obtamed. If the birth- 
weight was <4 kg then tire randomisation envelope was 
opened and the study drug was administered. In all women 
the drug was administered within a minute of birth. This 
change to the original protocol, made at the request of the 
local committee, resulted in an inconsistency that required 
both delivery of the study drug at the point of delivery 
and knowledge of the birthweight before randomisation. 
To correct this inconsistency, it was decided to delay the 
drug administration for a maximum of 60 seconds to allow 
rapid weighing and randomisation as described. This was 
done in the knowledge that the main effect of misoprostol 
does not occur until 20-30 minutes after administration so 
the effect of a 1-minute delay was likely to be minimal. 
Furthermore, as the delay occurred in all randomised 
women as well as in the cohort given oxytocin, it would 
have no effect on between-group comparisons.
A commercial randomisation programme was used to 
produce a random list of allocations to three doses of 
misoprostol (www.sealedenvelope.com). The allocations 
were written on cards and placed in consecutively num­
bered sealed opaque envelopes by staff not involved in the 
study. Blinding was not possible because the treatment was 
provided by the researcher who was available at the time of 
the delivery to carry out the final selection of women and 
collection of data.
The delivery of the baby was left entirely to the mid­
wives. Routine practice is to give the uterotonic at the 
delivery of the anterior shoulder and deliver the placenta 
using controlled cord traction. Once the baby is delivered, 
the cord is cut and the baby is weighed immediately. 
All babies are then transferred to the neonatal unit for 
2 hours of observation, even if the birth and immediate 
neonatal period were completely normal. Once the woman 
is transferred to the postnatal ward (after 2 hours of obser­
vation on the labour ward), the baby rejoins her and she is 
then able to start breastfeeding. This routine was not 
changed for women in the study except that the study drug 
was given by the researcher inunediately after the baby was
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Withdrawals = 0
14 women completed 
the study
11 women completed 
the study
12 women completed 
the study
12 women completed 
the study
49 women were eligible to participate
35 women were randomised (after confirming 
that the neonate weighed < 4 kg)
227 women gave their consent to 
participate in the study upon arrival at 
the delivery suite in early labour
14 consecutive women 
received 10 IU IM oxytocin 
before the start of the 
randomised study
178 women were excluded because 
they had an augmented labour, 
caesarean section, or an instrumental 
delivery
12 women allocated 
to receive 200 pg 
misoprostol
12 women allocated 
to receive 400 pg 
misoprostol
11 women allocated 
to receive 600 pg 
misoprostol
Figure 1. Flow diagram of the progress of the study.
weighed (which occurred within seconds of delivery) rather 
than at delivery. For women receiving misoprostol, the 
oxytocin was omitted.
Once the woman was determined as eligible, the next 
successive treatment envelope was opened and the desig­
nated treatment was given. We randomly allocated eligible 
women to 200, 400 or 600 //g sublingual misoprostol 
(Cytotec, Pfizer, Italy). The tablets were moistened with tap 
water before being placed under the tongue. At the same 
time, an ‘under-buttocks drape with fluid-collecting pouch’ 
(Kimberly-Clark, Kent, UK) was placed under the woman’s 
buttocks for collection of any blood over the next 120 min­
utes. Immediately after placental delivery, an intrauterine 
catheter (Koala External Balloon Catheter IPC-5000E; Clin­
ical Innovations, Salt Lake City, UT, USA; Figure 2) was 
inserted manually through the cervix into the uterine cavity 
until the tip of the catheter could be felt to touch the fun­
dus. The catheter was secured in place with tape to the 
mother’s thigh and connected to a Corometrics 118 mater­
nal/fetal monitor (Corometrics Medical Systems Inc., 
Wallingford, CT, USA). The uterine activity was recorded 
and saved over the next 120 minutes. A researcher was with 
the women throughout the 2 hours of observation to 
record maternal temperature, pulse and blood pressure 
before labour, immediately after the delivery and then at 
30, 60, 90 and 120 minutes. The women were closely
Figure 2. Koala External Balloon Catheter IPC-5000E (Clinical 
Innovations, Salt Lake City, UT, USA).
observed for any adverse effects experienced. None of the 
women initiated breastfeeding until 2 hours after delivery, 
when they transferred to the postnatal ward.
The primary outcome was intrauterine pressure over the 
first 10 minutes after delivery. The slight differences in time 
during which the pressure was measured in the first 10 
postnatal minutes (because the catheter was only inserted 
after placental expulsion) meant that the Montevideo 
units (MVU) measurement had to be adjusted for the first
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reading. This was done by adding together the uterine pres­
sures collected in the first 10 minutes after delivery, divid­
ing this by the length of time during which the 
measurements were taken (to get MVU per minute) and 
then multiplying by 10. The difference in means of the pri­
mary outcome was calculated using one way analysis of 
variance. The intrauterine pressures from 20 to 120 min­
utes postpartum were secondary outcomes.
Repeated measures of longitudinal data analysis (repeated 
measures analysis of variance) were used to compare the 
effect of the study treatments over 120 minutes of observa­
tion. Other mean comparisons used the one-way analysis of 
variance with multiple comparisons Bonferroni test. The 
incidence of shivering and fever and other adverse effects 
among the three misoprostol groups were compared using 
chi-square test with Yates’ correction and Fisher exact test 
as appropriate. Statistical analysis was performed using 
Excel and PASW Statistics 17 (Excel, Microsoft Corp., 
Redmond, WA, USA; PASW 17, IBM Corp., Somers, 
New York, NY, USA). The difference between the four 
groups’ parameters was taken as statistically significant 
when P values were <0.05. Based on the primary outcomes 
(mean intrauterine pressure over the first 10 minutes) and 
to detect a significant difference (P = 0.05, two-sided) at 
0.8 power with 50% effect size, we needed a sample size of 
12 in each group. The calculation was performed by 
G*Power 3.0.10 software (G*Power, Dusseldorf, Germany).
The study was approved by the University of Liverpool 
Ethics Committee (RETH000237) and accepted by the local 
hospital committees in Zliten and Misurata Teaching 
Hospitals.
Results
A total of 35 women were randomised out of a planned 
sample of 36. The study was curtailed before the planned
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finish when the investigator had to return to the UK. 
The randomised women were compared with a cohort of 
14 women treated with oxytocin before the start of the 
randomised study. The age, parity, gestational age and 
baby’s birthweight were similar in the four groups (Table 1).
All three doses of sublingual misoprostol produced a 
rapid increase in uterine activity with a peak at 40 minutes 
followed by a gradual decrease over the following 80 min­
utes (Figure 3). Throughout the observations, there was no 
significant difference between the intrauterine pressure in 
the three misoprostol dosage groups (P = 0.8).
The uterine pressure in those receiving oxytocin was 
highest in the immediate postpartum period and declined 
gradually after 40 minutes of administration. In the first 
10 minutes, intrauterine pressures of the three misoprostol 
groups were significantly lower than those of the oxytocin 
group (P = 0.008). Conversely, the uterine pressure over 
the period from 50 to 120 minutes was significantly higher 
in the three misoprostol groups than in the oxytocin group 
(P = 0.008).
All the women were closely observed for adverse effects. 
Women who received intramuscular oxytocin reported no 
adverse effects (Table 2). In the misoprostol groups, the 
two most commonly reported adverse effects were shivering 
and hyperthermia, and a dose-related rise in the body tem­
perature was observed. The incidence of severe hyperther­
mia (>39°C) was higher in the 600-/ig misoprostol group 
than the 200- and 400-/ig misoprostol groups, but this was 
not statistically significant (P = 0.1; Figure 4). Most of the 
women were not aware of the hyperthermia, but com­
plained of coldness and marked shivering. All women in 
the 400- and 600-//g groups had shivering compared with 
75% of the women in the 200-/ig group. The differences 
were statistically significant (P = 0.04).
The blood loss was <500 ml in all women and was nor­
mally distributed. The lowest mean blood loss (±SD) was
Table 1. Basic characteristics of four treatment groups
Oxytocin 10 III IM
200 fig
Sublingual misoprostol
400 fig 600 fig
No. of women recruited 14 12 12 11
Parity, n (%)
0 2 04) 0 1 (8.3) 1 (9)
1 4 (28.5) 3(25) 3(25) 2(18)
2 4 (28.5) 5(41.5) 4 (33.3) 5(45)
>2 4 (28.5) 4 (28.5) 4 (28.5) 3 (27.3)
Age (years) 28.5 ± 6.2 28 .1 ± 5.4 27 ± 3.3 26.3 ± 3.7
Gestational age (weeks) 40.2 ± 1.4 40.1 ± 1.1 40.3 ± 0.8 41 ± 1.1
Birthweight (g) 3350 ± 0.364 3458 ± 0.262 3595 ± 0.397 3522 ± 0.337
Date are mean ± SD unless otherwise stated.
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Figure 3. Line graph of mean postpartum uterine pressure in the 
different treatment groups. Data are presented as Montevideo units 
(MVU; ±SEM). The data in the first 10 minutes are adjusted to correct 
for the timing of placental delivery (MVU per minute).
Table 2. Incidence of adverse effects in the different treatment 
groups, n (%)
Oxytocin 
10IU IM
Sublingual misoprostol
200 fig 400 fig 600 fig
No. of women 14 12 12 11
recruited
Temperature >39°C 0 1 (8.3%) 1 (8.3%) 5 (45%)
Chills 0 9 (75%) 12 (100%) 11 (100%)
Coldness 0 9 (75%) 12 (100%) 11 (100%)
Abdominal pain 0 0 2 (16.6%) 0
requiring analgesia
Nausea and 0 0 2(16.6%) 1 (9%)
vomiting
Skin rash 0 0 0 1 (9%)
observed in women who received 10 IU oxytocin 
(193 ± 35 ml), followed by those who received 200 //g 
sublingual misoprostol (239 ± 46 ml), 600 /<g sublingual 
misoprostol (275 ± 62 ml) and 400 /<g sublingual miso­
prostol (299 ± 60 ml). The difference was statistically sig­
nificant between oxytocin and 400 /tg misoprostol 
(P < 0.001), oxytocin and 600 //g misoprostol (P < 0.001) 
and also between the three misoprostol groups (P = 0.04). 
None of the women received additional uterotonics or 
blood transfusion.
Discussion
This randomised trial was conducted to find out whether 
high-dose misoprostol offered any significant improve-
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Figure 4. The incidence (%) of fever with oxytocin and 200, 400 and 
600 ^9 sublingual misoprostol.
ments in postpartum uterine pressure over low-dose 
misoprostol, and to compare the adverse drug reactions 
associated with each treatment. We also had concurrently 
collected data on intrauterine pressures following oxytocin 
administration, and this allowed us to compare the efficacy 
of these two types of oxytocics.
We used the Koala External Balloon sensor system9’10 to 
measure uterine activity (Figure 2). All previous postpar­
tum intrauterine pressure measurements have been con­
ducted using a Galtec tipped catheter where a small 
pressure sensor is mounted into the tip of the device.11-14 
The Galtec tipped catheter was designed to measure intra­
uterine pressure in the first stage of labour. The pressure 
sensor is located in a recess within the head of the catheter, 
and it detects the myometrial contraction through an 
increase in the pressure of the surrounding amniotic fluid 
within the almost closed cavity. In the third stage of 
labour, however, the uterus is open and the amount of 
fluid is limited because it is squeezed out during each con­
traction. The Galtec tipped catheter therefore functions 
poorly in this situation. For accurate measurements it is 
logical for any measurement device to have a large surface 
area in direct contact with the adjacent uterine wall. The 
Koala catheter has a 3-cm air-filled balloon near its tip that 
connects directly to an external reusable transducer 
mounted into the connecting cable. The balloon sits in 
direct contact with the uterine wall and is compressed 
directly during the contraction.
The mean intrauterine pressure over 120 minutes for the 
intramuscular oxytocin and the three doses of sublingual 
misoprostol are shown in Figure 3. The difference seen in 
speed of onset of action can be explained both by the differ­
ent pharmacokinetics of these drugs and by the different 
routes of administration. The absorption of misoprostol is 
affected by mouth dryness and any surrounding fluid;15,16 
we standardised for this by moistening the tablets with tap 
water before placing them under the tongue. The pharmaco­
kinetics may explain our observation of stronger and more 
frequent initial uterine contractions with intramuscular 
oxytocin than with sublingual misoprostol. The peak of
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uterine contraction for oxytocin was within the first 
10 minutes after administration whereas for sublingual 
misoprostol it was only achieved after 30-40 minutes. This 
mirrors their plasma concentrations.15,17
Most uterine bleeding occurs immediately after placental 
separation.18 At this time, the mean intrauterine pressure 
for intramuscular oxytocin was significantly higher than 
with the three sublingual misoprostol doses. Even though 
the effective action of sublingual misoprostol started late, it 
caused high uterine contractions maintained over a consid­
erable period of time. This may help to prevent steady 
moderate bleeding, which may be unobserved until serious 
hypodynamic manifestations occur.
Very few studies have examined the effect of misoprostol 
on uterine activity during the third stage of labour using 
measurement of intrauterine pressure as an indicator. 
Chong et al, using a Galtec tipped catheter, found no dif­
ference in postpartum uterine pressures between women 
given oral misoprostol and intramuscular syntometrine.11,12 
The readings with this catheter, however, may not be reli­
able for the reasons outlined above.
The mean intrauterine pressure of the three different 
doses of sublingual misoprostol was not significantly differ­
ent over the 2-hour observation period. This is consistent 
with previous research findings. For example, in one previ­
ous study there was no difference in intrauterine pressure 
measurements with five different doses of oral misoprostol, 
although again this used a Galtec tipped catheter.11 
Furthermore, randomised control trials found that both 
600 /rg sublingual and 400 pg oral misoprostol were more 
effective than placebo for the prevention of PPH,19,20 and a 
meta-analysis in which an indirect comparison was made 
between the 400 and 600 [ig oral doses concluded that the 
two were likely to be equally effective.21 As a result of 
adverse effects associated with high doses of sublingual 
misoprostol, some researchers have argued that the dosage 
of misoprostol should be reduced from the 600 and 800 /tg 
doses in common usage today. Our research findings give 
further weight to that argument.
The most commonly observed adverse effects in this 
study were shivering and hyperthermia. Around half of the 
women who received 600 /(g had a temperature >39°C 
whereas the incidence for women who received 400 and 
200 /tg was around 8%. Most of the women were not 
aware of the hyperthermia, but complained of coldness and 
intolerable shivering (all women in the 400 and 600 //g 
groups had shivering). Although there appeared to be clini­
cal differences in the incidence of hyperthermia between 
high and low doses, the difference was not statistically sig­
nificant because the study was not powered enough to 
detect differences in incidence of adverse effects. Shivering 
and hyperthermia have been reported in most of the stud­
ies using misoprostol for different indications and with
variable routes and doses. In a recent multicentre rando­
mised control trial using 800 //g sublingual misoprostol for 
treatment of PPH, the overall incidence of fever (>40°C) 
was 14%. However, the incidence of fever varied between 
different populations with the highest incidence in Ecuador 
(36%) and the lowest (0%) in Egypt.7,22 In our study, the 
incidence of adverse effects appeared to be dose-related. 
Prostaglandins are the principal mediator of fever in the 
brain and can pass the blood-brain barrier to the thermo­
regulation centres in the hypothalamus, causing elevation 
of the thermoregulatory set point. To increase the body 
temperature to the new set point, there are increases in 
heart rate, muscle tone and shivering.23-25
Clinical trials have shown that oxytocin prophylaxis is 
more effective than oral misoprostol for the prevention of 
blood loss >1000 ml.26 Given that most blood is lost 
around the time of placental expulsion during the first 
10 postpartum minutes, it is not surprising that oxytocin is 
the more effective prophylactic.17 It is only after the first 
50 minutes that the uterine contraction strength was higher 
in the misoprostol groups. However, although the effect of 
misoprostol is delayed, it should be eventually as effective 
as oxytocin in preventing massive blood loss through 
atony. There is evidence for this from a Cochrane Review 
in which there are significant differences between oxytocin 
and misoprostol in blood loss >500 and >1000 ml, but no 
difference in need for blood transfusion.6
We acknowledge that this study recruited only low-risk 
women in whom the chance of developing an atonic 
PPH was small. However, even in a study that included 
high-risk women, the majority of women would not 
develop an atonic PPH—and this is the very group for 
which the intervention is designed. However, the area of 
interest in this study is the comparison between drug 
dosages and, as such, it is important to have as homo­
geneous a group of women as possible. This was best 
achieved through the use of a low-risk group. Further­
more, it was considered by the ethical committee to be 
inappropriate to expose women at risk of PPH to misopros­
tol, which has been shown to be less effective for prophy­
laxis than oxytocin.
Conclusion
In conclusion, our results showed that 200, 400 and 600-/(g 
doses of sublingual misoprostol produced similar levels of 
uterine activity, but that the severity of adverse effects was 
dose-related. These findings suggest that lower doses of 
misoprostol may be as effective as high doses. Clinical 
applications of low doses of sublingual misoprostol for the 
prevention of PPH should be further explored by large 
randomised trials comparing the effectiveness and the 
safety of low doses of sublingual misoprostol.
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Discussion points
1. Background: Compare the evidence with regard to therapeutic versus prophylactic use of misoprostol for postpartum 
haemorrhage (PPH). Include in your evaluation data (or arguments) on effectiveness, safety and cost-effectiveness. 
Would your answer be different depending on the population and setting?
2. Methods: Explain why the authors might have been compelled to exclude women at high risk for PPH.
The researchers used a blood-collecting pouch for estimation of blood loss; contrast this to other methods, 
including visual estimation.
What is the Bonferroni method? When is it desirable?
3. Results and implications: Describe the different effects of misoprostol and oxytocin on uterine pressure, with refer­
ence to Figure 3.
Discuss the consequences of misoprostol-induced hyperthermia (Figure 4).
Discuss the external validity (generalisability) of the results; are they likely to stimulate further research, change 
in clinical practice, or both?
4. Publication issues: The authors have reported no conflicts of interest. Discuss the need for such disclosures, particu­
larly for trials of medicinal products, with reference to the Uniform Requirements for Manuscripts Submitted to Bio­
medical Journals, as published by the International Committee of Medical Journal Editors (www.icmje.org/ 
ethical_4conflicts.html. Describe other instances in the research process where such disclosure may be required.
Read the BJOG editorial policy with regard to ethical approval for studies in countries without local ethics committees
or institutional review boards (www.bjog.org/view/O/editorialPolicy.html). How did the authors deal with this issue? Dis­
cuss the advantages and disadvantages of their approach. ■
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EDITORIALS
Misoprostol for the management of postpartum 
haemorrhage
No benefit if oxytocin is available, but useful where no other alternatives exist 
Anisa Elati research fellow, Andrew Weeks senior lecturer in obstetrics
School of Reproductive and Developmental Medicine, University of Liverpool, Liverpool Women’s Hospital, Liverpool L8 7SS, UK
For decades, oxytocin and ergometrine have been the treatments 
of choice for postpartum haemorrhage caused by ineffective 
uterine contraction (uterine atony). Although both drugs are 
effective, oxytocin is more widely used because it has fewer 
side effects and can be used safely in women with hypertension 
and pre-eclampsia. However, in their usual form both drugs can 
be given only by injection, and both require refrigeration. They 
are therefore of limited availability and benefit in low resource 
settings, especially in rural areas. Misoprostol, an orally active 
and heat stable prostaglandin E, analogue, has therefore emerged 
as a popular alternative. Until a year ago, there was limited 
evidence for its ability to treat postpartum haemorrhage.12 
However proponents have argued that it should be “parachuted 
in” to high risk areas despite the lack of evidence.3 This, in part, 
has been responsible for its inclusion in multiple guidelines on 
postpartum haemorrhage both in rich and poor settings (despite 
the call in a systematic review for more studies2).
Since the systematic review of the treatment of postpartum 
haemorrhage was last updated in 2007,2 three large double blind 
randomised trials have been published.4^ Few research teams 
had been able to carry out a randomised trial of treatment for 
this condition, but Gynuity Health Projects and the World Health 
Organization, with backing from the Bill and Melinda Gates 
Foundation, were able to recruit more than 80 000 women in 
14 centres worldwide to three trials to define the role of 
misoprostol. Although these trials are impressive, they have 
gone largely unnoticed by many maternity care workers.
The first compared 800 pg sublingual misoprostol with 40 IU 
oxytocin given in a litre of intravenous solution over 15 minutes 
for the treatment of postpartum haemorrhage in women who 
had not received oxytocin prophylaxis.4 The study recruited 
9348 subjects; 10% of them were diagnosed with postpartum 
haemorrhage (around 700 ml of blood loss) and received the 
study treatments. Further bleeding of at least 300 ml (1 L total) 
occurred in 30% of the women given misoprostol and in only 
17% of women given oxytocin (relative risk 1.78, 95% 
confidence interval 1.40 to 2.26). Misoprostol was associated 
with more side effects—“intolerable shivering” was seen in
aweeks@liverpool.ac.uk
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11% of women receiving misoprostol compared with less than 
1% of women taking oxytocin (55.2, 7.70 to 397).
The second trial used the same protocol but in women who had 
received routine prophylaxis with oxytocin.5 Evidence of the 
benefit of prophylaxis with oxytocin was overwhelming—only 
3% (809/31 055) of women bled compared with 10% in the trial 
above where no prophylaxis was available. In this second trial, 
additional blood loss of 300 ml or more after treatment was 
similar in the two groups (34% v 31 %; 1.12, 0.92 to 1.37), 
whereas blood loss of more than 1 L after treatment occurred 
in 11 (3%) women managed with misoprostol and three (1%) 
women given oxytocin (3.62, 1.02 to 12.89). Intolerable 
shivering occuned in 4% and less than 1% of women treated 
with misoprostol and oxytocin respectively (16.8, 2.25 to 125). 
These findings suggest that 800 pg sublingual misoprostol is a 
possible alternative to 40 IU intravenous oxytocin for the 
management of postpartum haemorrhage after prophylactic 
oxytocin, but that it does have more side effects.
The third study assessed the effect of using misoprostol in 
addition to conventional injectable uterotonics to treat 
postpartum haemorrhage.6 The study compared 600 pg 
sublingual misoprostol to placebo in 1422 women who were 
being treated with 10 IU intramuscular or slow intravenous 
oxytocin for the treatment of postpartum haemorrhage. The 
study found no significant difference between the two treatment 
groups in the proportion with blood loss of 500 ml or more 
within 60 minutes (14% in both treatment groups; 1.02, 0.79 to 
1.32) or blood loss greater than 1000 ml (1% in both treatment 
groups; 1.02,0.41 to 2.55). Consistent with the other trials, side 
effects were more common with misoprostol than with placebo.
Following on from WHO studies nearly 10 years ago showing 
that misoprostol was less effective than oxytocin for 
prophylaxis,7 the results of these studies were disappointing for 
misoprostol enthusiasts. Not only is it less effective than 
oxytocin, but it has more side effects and no adjunctive effect 
if the woman has already been given oxytocin. The only comfort 
is that detailed examination of the data, along with the excellent 
outcomes for the participants, suggests that misoprostol is better 
than nothing.
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So is there any remaining role for misoprostol in the 
management of postpartum haemorrhage? In settings where 
oxytocin is freely available it should be used instead of 
misoprostol for prophylaxis. And although the two drugs have 
similar efficacy after oxytocin prophylaxis, there is no benefit 
of providing a second drug that is commonly more expensive, 
has more side effects, and has no additional effect.
In rural low resource settings, however, where injectable 
oxytocics are rarely available, misoprostol is an important 
weapon in the fight against postpartum haemorrhage related 
mortality. Its heat stability and ease of use mean that all 
midwives and doctors in these settings should carry a stock. 
Furthermore, recent observational studies in women having 
home births in Nepal and Afghanistan suggest that giving 
misoprostol to women antenatally for self administration 
immediately after delivery may be a safe and effective 
strategy.*’11 A large placebo controlled randomised trial is now 
under way to test this hypothesis. If true, this would provide an 
effective self administered treatment for the first time to those 
women most at risk of death from postpartum haemorrhage, 
and it could help reduce maternal mortality worldwide.
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Obtaining informed consent for clinical trials involving the 
management of intrapartum complications is complex. This 
article describes the strategies used to obtain consent over the 
last 60 years using data from the Cochrane Library. Of 138 
intrapartum randomised studies, 37% had no record of the 
consent procedures. Of the remainder, 74% sought consent only 
when the complication developed, 11% sought consent from all
women in early labour, and 13% gave all women antenatal 
information and then sought written consent when the 
complication arose. Despite the existence of ethics guidelines for 
intrapartum consent, many studies fail to follow their advice.
Keywords Clinical trials, Cochrane Library, intrapartum research, 
informed consent.
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Introduction
Informed consent has been described as being at the ‘heart 
of ethical research’.1 For consent to be valid, three critical 
factors need to be present: the individual needs to be well 
informed, be ‘competent’ enough to give their agreement 
to participate, and not be coerced. Meeting these criteria in 
labouring women who have developed an intrapartum 
complication is challenging. Not only is a woman likely to 
be anxious and distressed from labour pains, but there is 
often little time to provide detailed information about the 
trial. There is also a risk of coercion as women may fear 
being treated poorly or being abandoned should they refuse 
participation.2 For these reasons, it has been suggested that 
all potentially eligible women should be approached ante- 
natally and the consent procedures should be completed at 
that time, even though only a small percentage of them will 
end up eligible for inclusion. Consumer groups, however, 
have expressed concern that detailed discussions antenatally 
about rare complications could cause anxiety and medica- 
lise completely normal pregnancies.1 Striking the right bal­
ance between these two strategies is a major problem for 
those conducting intrapartum research.
There is very little information on women’s preferences 
in this situation. An insight can be obtained from those hav­
ing epidural analgesia as a clinical intervention, and whether 
they feel able to understand the risks before giving consent. 
In one study, the majority of the women wanted to hear 
about all the potential epidural risks and for these risks to 
be discussed with them before the onset of labour.3 They 
also found that the labouring woman’s pain and anxiety lev­
els (including several other factors such as age, education 
level and opioid premedication) did not correlate with her 
ability to understand information. Although there have been 
no direct examinations of intrapartum consent strategies, 
women in the USA entering a 21-year cohort study were 
asked about the collection of data and samples during 
labour.4 They expressed concern about the level of intrusive­
ness caused by researchers collecting data during labour and 
wished to minimise intrapartum contact with researchers.
Children were previously thought to be the ‘therapeutic 
orphans’ when it came to clinical research. However, with 
recent legislation and guidance many would now agree that 
pregnant women are the new ‘therapeutic orphan’ subgroup. 
Despite research bodies and regulators acknowledging the 
need for research in this group, there remains a paucity of
©2011 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2011 RCOG 361
Patel et al.
specific guidance. Perinatal researchers have looked towards 
guidance available for ‘vulnerable populations’, but this is 
not particularly suitable because pregnant women do not 
strictly fall under this definition. Instead, the regulations 
pertaining to emergency care may be more appropriate. 
Good ethical research practices for pregnant women fall 
somewhere between the regulations and guidance for vul­
nerable populations and emergency research, but neither are 
currently suitable.
Until recently, there has been little ethical advice avail­
able for researchers conducting intrapartum research. In 
1997, two consumer groups [the Association for Improve­
ment in tire Midwifery Services (AIMS) and the National 
Childbirth Trust (NCT)] published their Charter for Ethical 
Research in Maternity Care.1 They recommend the distribu­
tion of information to all women antenatally with signed 
consent only once the complication develops. Recently, the 
Royal College of Obstetricians and Gynaecologists 
(RCOG)5 has published advice on how to obtain valid 
intrapartum consent for research. They agree with the 
AIMS/NCT system, although they recommend varying the 
method according to the nature of the study and likelihood 
of the event occurring. With a high risk of occurrence 
(10-100%, e.g. perineal tears), they suggest that full 
informed consent should be gained from all potentially eli­
gible women antenatally and confirmed at the time of the 
complication for those who develop it.5 With rarer compli­
cations (1-10%, e.g. retained placenta) they recommend 
that women should receive outline trial information ante­
natally, but then obtain full information and provide 
signed consent only once the woman becomes eligible dur­
ing labour. For very rare complications (<1%, e.g. shoulder 
dystocia) it is appropriate to provide information only 
once the event occurs or when the suspected risk exceeds 
the background risk of 1 in 100.
Many women in labour have a heightened sense of emo­
tion and some may feel veiy vulnerable. To make a clumsy 
approach to them at this time to participate in a research 
project may result in anxiety, confusion and distraction, 
and may threaten the crucial bond of trust that develops 
between a labouring woman and her carers. The guidelines 
from the RCOG are therefore welcome as a way of avoid- 
ing this situation, but it is not known how frequently they 
are currently used.
This study examines the approaches to obtaining 
informed consent that researchers have used over the past 
five decades, and describes the current frequency of differ­
ent consent strategies.
Methods
The Cochrane Database of Clinical Trials was searched and 
15 reviews (see Table SI) were identified that examined
therapies for the management of intrapartum complications 
(i.e. those that arose for the first time in labour and could 
not be predicted previously). The Cochrane search method 
is described elsewhere6 but includes weekly searches of 
MEDLINE and hand searches of 30 journals as well as the 
proceedings of major conferences.
All randomised controlled trials within these reviews (i.e. 
those involving the management of intrapartum complica­
tions) were included for analysis. Duplicates, studies avail­
able in abstract form only, those not in English, trials 
involving the study of prophylactic interventions, unpub­
lished trials and those studying non-obstetric emergencies 
were excluded. Studies that fulfilled the criteria were exam­
ined and information from these studies was entered into 
an electronic proforma. The consent methods were classi­
fied into nine separate categories: consent not needed (no 
consent required by the ethics committee), unclear method 
(method of consent unclear from the published 
manuscript), no data (no evidence within the published 
manuscript of any consent having been taken), post-event 
(no consent taken at tune of recruitment, but consent was 
obtained post-event), proxy (no personal consent, consent 
from proxy only), consent at complication (consent at time 
of complication with no previous information provided), 
antenatal information with consent at complication (antena­
tal information in groups, leaflets or individually with for­
mal consent sought at the time of complication), early 
labour (consent from all women during early labour), and 
AN (consent from all pregnant women during the antenatal 
period). Information on the consent approach used in the 
trial was examined and classified independently by two 
independent investigators (DP and NS) and checked by a 
third (AE, GV or ADW). The final classification was con­
firmed through majority agreement.
The results were analysed according to decade of publi­
cation and stage of labour at which the complication 
occurred.
Results
Three hundred references were retrieved from the 15 Coch­
rane reviews, but only 138 met the inclusion criteria (see 
Figure SI for flow chart). Of these, 37% had no clear 
record of the consent procedures. Of the remainder, 74% 
sought consent for the first time at recruitment when the 
complication developed, 11% sought consent from all 
women in early labour so that consent for the trial was 
obtained in advance for those who developed the complica­
tion and 13% gave all women antenatal information and 
then sought consent only when the complication arose. In 
one study the researchers obtained consent from all women 
in the antenatal period, and in another the ethics commit­
tee did not deem it necessaiy to obtain written consent.
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The standard of reporting changed through the decades 
(Figure 1). None of the eight studies conducted before 
1980 recorded any evidence of consent having been taken, 
but by the 2000s 86% of studies had clear descriptions of 
consent procedures. Between 1980 and 2010 a variety of 
consent methods were used, with antenatal information­
giving (and consent at the time of complication) and con­
sent from all women in early labour becoming increasingly 
common. In the 1980s and 1990s, 23% and 59% of studies, 
respectively, obtained consent from women at the time of 
the complication. In the 2000s the level fell with only 45% 
of researchers obtaining consent in this way. A variety of 
other methods were used instead: 20% of researchers 
obtained consent from the total population during admis­
sion to the labour ward and 18% provided antenatal infor­
mation and then obtained consent at the time of the 
complication.
In those studies in which consent procedures are 
described, taking consent from women when complications 
arise is by far the most common method for consent in 
the first and second stages of labour (79% and 82%, 
respectively, see Figure S2). For third-stage complications,
however, only 38% of studies sought consent using this 
process; 46% sought consent from all women in early 
labour and 15% gave all women information antenatally 
and then sought formal consent at the time of the compli­
cation.
Discussion
Although there are a variety of methods described for 
obtaining informed consent in the 138 studies discussed in 
this review, most researchers simply sought consent at the 
time of complication. However, the method of obtaining 
consent appears to have been improving since the 1980s, 
with the introduction of novel methods of obtaining 
informed consent. Deficiencies remain. In the decade since 
2000, only 18% of studies used the method advised by the 
consumer groups, and 11% of studies did not provide any 
information at all about their method of obtaining 
informed consent in the published manuscript. These sta­
tistics are disappointing and suggest that researchers need 
to be made more aware of the current intrapartum consent 
guidelines provided by consumer groups and, more
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Figure 1. Consent approach according to decade of the trial. Definitions: Not needed, no consent required by ethics committee; Unclear, method of 
consent unclear; No data, no evidence of consent recorded; Post-event, no consent at time of recruitment, obtained post-event; Proxy, no personal 
consent, consent from proxy only; Comp, consent at time of complication with no other information provided; AN info & comp, antenatal 
information in groups, leaflets or individually with formal consent sought at the time of complication; Early lab. consent from all labourers during 
early labour; AN, consent from all pregnant women during the antenatal period.
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recently, by the RCOG. Although following these guidelines 
would require some additional resources, the use of these 
consent guidelines would provide researchers with an ethi­
cally and legally respected methodology. The simplest 
method of enforcing their use would be through the ethics 
research committees.
To our knowledge this is the first published review of 
historical intrapartum research consent methodology. Its 
strength is that it examined every published English lan­
guage randomised trial on the management of intrapartum 
complications in great detail. This was ensured by the use 
of the robust study identification methodology of the 
Cochrane Libraiy database and the use of triple review for 
each manuscript. However, this study did not examine all 
the randomised controlled trials on the management of 
intrapartum complications. Studies published in abstract 
form only or not in English were excluded. This may have 
led to an over-optimistic view of the global nature of con­
sent methodology over the last 60 years. Furthermore, this 
review has not examined research on trials of intrapartum 
analgesia, because pain was not considered to be a compli­
cation of labour. This has meant that a number of studies 
on epidural analgesia have not been included for analysis.
The ability of any individual to take in new information 
and make informed decision choices while in labour can 
vary hugely. Dorantes et al.7 found that 41% of women 
refused participation in an anaesthesia trial simply because 
they felt the discomfort of labour pains hindered their abil­
ity to understand the trial information. Conversely, 59% 
believed that the discomfort did not hinder their ability to 
take part. The nature of the complication also determines 
the speed with which consent needs to be obtained. For 
example, obtaining consent for a study of the treatment of 
postpartum haemorrhage would have much less time than 
for a study of a therapy for delay in the first stage of labour 
in women with epidural analgesia. It could be argued 
therefore that a single consent process for all women is 
inappropriate. Vernon et al.8 attempt to address this by the 
use of the midwife or doctor as a ‘gatekeeper’ to assess the 
emotional and physical state of the labouring woman and 
therefore determine whether she is ‘competent’ to give 
informed consent to the researchers. They also argue that 
large amounts of antenatal information should be provided 
in a variety of formats, and then each woman can access it 
to a degree appropriate to her needs.8 This advice has since 
been incorporated into the RCOG guidelines.5 However, 
despite arguments questioning the competency of labouring 
women, there is evidence that some of the events of labour 
may not interfere with a woman’s capacity. Jackson et al.3 
found that none of the anticipated variables (including 
pain, anxiety and opiate use) correlated with the labouring 
woman’s ability to understand epidural risks. They con­
cluded that women in labour are just as capable to give
informed consent as at other times. However, when evalu­
ating epidural risks, the woman is also anticipating a major 
benefit (pain relief), which may act as a positive pressure 
for the woman to provide consent.
In this study we also examined how consent approaches 
varied with the stage of labour. In most first-stage and sec­
ond-stage trials, consent was usually sought at the time of 
the obstetric complication development, van Lier and 
Roberts2 recommended that consent could be sought in 
early labour (<4 cm dilatation) because most women are 
relatively comfortable during this stage and the intervals 
between contractions do allow for adequate explanation 
and discussion. In contrast, the second stage of labour may 
be characterised by considerable pain and exhaustion. All 
the randomised trials for second stage complications in this 
review were comparing operative delivery methods for 
failed progress in labour. This time is especially difficult 
because the situation is rapidly evolving, the mother is 
exhausted and there is often concern about fetal wellbeing. 
Despite this, most studies still used consent at the time of 
complication. The degree to which consent could be seen 
to be valid in this situation would be questioned by many 
of today’s ethics committees.
In the third stage of labour a variety of research methods 
have been used, to some extent reflecting the conditions 
the studies are concerned with. In studies of postpartum 
haemorrhage treatments there was no time to take consent, 
and studies obtained consent from all potentially eligible 
women in early labour. In contrast, in the event of a peri­
neal tear or retained placenta there is a little more time to 
discuss consent and so researchers sought consent at the 
time of the complication.
A major factor affecting the consent method is the year 
in which the research was conducted, with this review find­
ing major changes over time. There have been numerous 
drivers for this including the increased use of ethics com­
mittees. In the UK, for example, although research ethics 
committees were established in the NHS in the mid-1960s, 
reporting to them was initially voluntary. In the early 
1990s it became a requirement for all proposed clinical 
studies to obtain approval from an ethics committee, a fac­
tor that will have increased the use of formal and ethical 
consent procedures. The requirement for formal approved 
processes increased further with the European Union Clini­
cal Trials Directive and the Research Governance Frame­
work for Health and Social Care. This increase in UK 
research governance has not been seen in all countries, and 
the stringency and demands of ethics committees now vaiy 
widely between countries.
The seeking of consent from all eligible women in early 
labour, and the provision of antenatal information with 
consent at the time of complication are the fastest emerg- 
ing strategies for intrapartum consent. The latter strategy is
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in line with the recommendations of AIMS,1 the North- 
West Clinical Trials Network8 and the recent RCOG guide­
lines (which more specifically tailor the degree of antenatal 
information provision to the incidence of the complica­
tion).5 The benefits of this strategy have not however been 
formally assessed and qualitative research into women’s 
preferences for intrapartum research consent methods are 
urgently needed. Research consent strategies have never 
been subject to debate outside the narrow confines of intra­
partum research groups. Although limited attempts have 
been made to address this question in emergency medi­
cine,9 none have examined intrapartum consent. If we are 
to identify a strategy that is safe, respectful of women’s 
autonomy and which allows intrapartum research to con­
tinue, then it will be necessary to initiate a public debate 
involving women, ethicists, researchers and consumer 
groups, and not just take it for granted that the profession­
als know best.
Disclosure of interests
None.
Contribution to authorship
ADW had the original idea for the study and assisted with 
data analysis and writing of the paper. He is the guarantor 
of the paper. DP and SN collected the data, conducted the 
primary analysis and wrote the first draft of the paper. AE 
and GV assisted with the analysis and reviewed the drafts 
of the manuscript. All authors approved the final version 
of the manuscript before publication.
Details of ethics approval
Not required.
Funding
None.
Acknowledgements
Thanks to Jill Hampson and colleagues at the Cochrane 
Pregnancy and Childbirth Centre in Liverpool Women’s 
Hospital for providing us with copies of all the manuscripts 
in this study.
Figure SI. Flow chart showing how studies were 
excluded from analysis.
Figure S2. Chart showing the consent approaches in 
relation to the stage of labour.
Table Si. Cochrane database reviews of treatment for 
intrapartum complications that were examined in this 
review.
Please note: Wiley-Blackwell are not responsible for the 
content or functionality of any supporting information 
supplied by the authors. Any queries (other than missing 
material) should be directed to the corresponding 
author. ■
References
1 Association for Improvements in the Maternity Services, The National 
Childbirth Trust. A Charter for Ethical Research in Maternity Care. 
London: AIMS/NCT, 1997.
2 van Lier DJ, Roberts JE. Promoting informed consent of women in 
labor. J Obstet Gynecol Neonatal Nurs 1986;15:419-22.
3 Jackson A, Henry R, Avery N, Van Den Kerkhof E, Milne B. Informed 
consent for labour epidurals: what labouring women want to know. 
Can JAnesth 2000;47:1068-73.
4 Lakes KD, Vayghan E, Jones M, Burke W, Baker D, Swanson JM. 
Diverse perceptions of the informed consent process: implications for 
the recruitment and participation of diverse communities in the 
National Children's Study. Am J Community Psychol 2011; DOI 
10,1007/si 0464-011 -9450-1.
5 Royal College of Obstetricians and Gynaecologists. Obtaining Valid 
Consent to Participate in Research While in Labour. Clinical Gover­
nance Advice No. 6a. London: RCOG, 2010 [www.rcog.org.uk/ 
obtaining-valid-consent-participate-research-while-labour]. Last accessed 
31 October 2011.
6 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 [updated March 2011], The 
Cochrane Collaboration, 2011, Available from www.cochrane-hand 
book.org. Last accessed 31 October 2011.
7 Dorantes DM, Tait AR, Naughton NN. Informed consent for obstetric 
anesthesia research: factors that influence parturients' decisions to 
participate. Anesth Analg 2000;91:369-73.
8 Vernon GH, Alfirevic Z, Weeks AD. Issues of informed consent for in­
trapartum trial: a suggested consent pathway from the experience of 
the Release Trial. Trials 2006;7:13.
9 Lecouturier J, Rodgers H, Ford GA, Rapley T, Stobbart L, Louw SJ, 
et al. Clinical research without consent in adults in the emergency 
setting: a review of patient and public views. BMC Med Ethics 
2008;29;9.
Supporting Information
Additional Supporting Information may be foimd in the 
online version of this article:
© 2011 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2011 RCOG 365


